{"text":"Cardiac events occurred after posaconazole administration , incriminating posaconazole use , alone or in combination with voriconazole , as the culpable agent .","paragraph":"<h3><u>Long QT Syndrome Leading to Multiple Cardiac Arrests After Posaconazole Administration in an Immune-Compromised Patient with Sepsis: An Unusual Case Report.</u></h3>We present the case of a septic patient with severe immunodeficiency, who developed QT interval prolongation followed by episodes of lethal cardiac arrhythmia. <b style='color:DodgerBlue;'><i>Cardiac</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>occurred</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>posaconazole</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>incriminating</i></b> <b style='color:MediumOrchid;'><i>posaconazole</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>voriconazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>culpable</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Case Report A 26-year-old female patient underwent orthopedic surgery to remove ectopic calcifications in her left hip joint. On the first post-operative day she became septic due to a surgical wound infection. Despite being treated according to the therapeutic protocols for sepsis, no clinical improvement was noticed and further assessment revealed an underlying immunodeficiency. Considering the underlying immunodeficiency and to that point poor clinical response, an antifungal agent was added to the antibiotic regiment. Following discontinuation of multiple antifungal agents due to adverse effects, <b style='color:Tomato;'><i>posaconazole</i></b> was administered. <b style='color:Tomato;'><i>posaconazole</i></b> oral intake was followed by episodes of bradycardia and QT interval prolongation. The patient suffered continuous incidents of cardiac arrest due to polymorphic ventricular tachycardia (torsades des pointes) that degenerated to lethal ventricular fibrillation. <b style='color:Tomato;'><i>posaconazole</i></b> was immediately discontinued and a temporary pacemaker was installed. The patient finally recovered without any neurological deficit, and was discharged in a good clinical status. ### conclusions Close cardiac monitoring is recommended in cases where <b style='color:Tomato;'><i>posaconazole</i></b> administration is combined with coexisting risk factors, as they may lead to severe ECG abnormalities and cardiac arrhythmias such as long QT interval syndrome and torsades de pointes. <b style='color:Tomato;'><i>posaconazole</i></b> interactions with medications metabolized via the CYP3A4 pathway should be considered an additional risk factor for lethal cardiac incidents.","tokens":[{"text":"Cardiac","start":0,"end":7,"id":0,"ws":true},{"text":"events","start":8,"end":14,"id":1,"ws":true},{"text":"occurred","start":15,"end":23,"id":2,"ws":true},{"text":"after","start":24,"end":29,"id":3,"ws":true},{"text":"posaconazole","start":30,"end":42,"id":4,"ws":true},{"text":"administration","start":43,"end":57,"id":5,"ws":true},{"text":",","start":58,"end":59,"id":6,"ws":true},{"text":"incriminating","start":60,"end":73,"id":7,"ws":true},{"text":"posaconazole","start":74,"end":86,"id":8,"ws":true},{"text":"use","start":87,"end":90,"id":9,"ws":true},{"text":",","start":91,"end":92,"id":10,"ws":true},{"text":"alone","start":93,"end":98,"id":11,"ws":true},{"text":"or","start":99,"end":101,"id":12,"ws":true},{"text":"in","start":102,"end":104,"id":13,"ws":true},{"text":"combination","start":105,"end":116,"id":14,"ws":true},{"text":"with","start":117,"end":121,"id":15,"ws":true},{"text":"voriconazole","start":122,"end":134,"id":16,"ws":true},{"text":",","start":135,"end":136,"id":17,"ws":true},{"text":"as","start":137,"end":139,"id":18,"ws":true},{"text":"the","start":140,"end":143,"id":19,"ws":true},{"text":"culpable","start":144,"end":152,"id":20,"ws":true},{"text":"agent","start":153,"end":158,"id":21,"ws":true},{"text":".","start":159,"end":160,"id":22,"ws":false}],"spans":[{"start":30,"end":42,"token_start":4,"token_end":4,"label":"DRUG"},{"start":74,"end":86,"token_start":8,"token_end":8,"label":"DRUG"},{"start":122,"end":134,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27125217/","_input_hash":-9132301,"_task_hash":-1195455115,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":8,"child":16,"head_span":{"start":74,"end":86,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":122,"end":134,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"Prognostic value of expression of Kit67 , p53 , TopoIIa and GSTP1 for curatively resected advanced gastric cancer patients receiving adjuvant paclitaxel plus capecitabine chemotherapy .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Prognostic</i></b> <b style='color:DodgerBlue;'><i>value</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Kit67</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>p53</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>TopoIIa</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>GSTP1</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>curatively</i></b> <b style='color:DodgerBlue;'><i>resected</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>gastric</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>To investigate the role of Kit67, p53, topoisomerase II (TopoII) and glutathione S-transferase P1 (GSTP1) in predicting clinical outcome of advanced gastric cancer patients receiving <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> chemotherapy. ### methodology The clinical data and tissue samples from 136 curatively resected advanced gastric cancer patients receiving <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> in the third affiliated hospital of Kunming medical university from January 2005 to December 2007 were retrospectively collected and analyzed for Kit67, p53, TopoIIa and GSTP1 expressions by immunohistochemistry. The relationships between expressions of the biomarkers and survival were analyzed. ### results p53 expression were associated with the significantly shorter disease-free survival (DFS) (p<0.001) and overall survival (OS) (p=0.012) in the curatively resected advanced gastric cancer patients receiving <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b>. Kit67, TopoIIa and GSTP1 expressions were not related to DFS and OS. ### conclusions p53 expression positive might predict prognosis in gastric cancer patients who underwent curative surgery followed by adjuvant <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> chemotherapy. A favorable effect of <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> might therefore be expected in patients that do not express p53.","tokens":[{"text":"Prognostic","start":0,"end":10,"id":0,"ws":true},{"text":"value","start":11,"end":16,"id":1,"ws":true},{"text":"of","start":17,"end":19,"id":2,"ws":true},{"text":"expression","start":20,"end":30,"id":3,"ws":true},{"text":"of","start":31,"end":33,"id":4,"ws":true},{"text":"Kit67","start":34,"end":39,"id":5,"ws":true},{"text":",","start":40,"end":41,"id":6,"ws":true},{"text":"p53","start":42,"end":45,"id":7,"ws":true},{"text":",","start":46,"end":47,"id":8,"ws":true},{"text":"TopoIIa","start":48,"end":55,"id":9,"ws":true},{"text":"and","start":56,"end":59,"id":10,"ws":true},{"text":"GSTP1","start":60,"end":65,"id":11,"ws":true},{"text":"for","start":66,"end":69,"id":12,"ws":true},{"text":"curatively","start":70,"end":80,"id":13,"ws":true},{"text":"resected","start":81,"end":89,"id":14,"ws":true},{"text":"advanced","start":90,"end":98,"id":15,"ws":true},{"text":"gastric","start":99,"end":106,"id":16,"ws":true},{"text":"cancer","start":107,"end":113,"id":17,"ws":true},{"text":"patients","start":114,"end":122,"id":18,"ws":true},{"text":"receiving","start":123,"end":132,"id":19,"ws":true},{"text":"adjuvant","start":133,"end":141,"id":20,"ws":true},{"text":"paclitaxel","start":142,"end":152,"id":21,"ws":true},{"text":"plus","start":153,"end":157,"id":22,"ws":true},{"text":"capecitabine","start":158,"end":170,"id":23,"ws":true},{"text":"chemotherapy","start":171,"end":183,"id":24,"ws":true},{"text":".","start":184,"end":185,"id":25,"ws":false}],"spans":[{"start":142,"end":152,"token_start":21,"token_end":21,"label":"DRUG"},{"start":158,"end":170,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22534478/","_input_hash":-1836483379,"_task_hash":-417698877,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":21,"child":23,"head_span":{"start":142,"end":152,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":158,"end":170,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin ( FL ) .","paragraph":"<h3><u>Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>colon</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>oxaliplatin</i></b> improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b> in the postoperative adjuvant setting. ### methods We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to receive FL alone or with <b style='color:Tomato;'><i>oxaliplatin</i></b> for six months. The primary end point was disease-free survival. ### results A total of 1123 patients were randomly assigned to each group. After a median follow-up of 37.9 months, 237 patients in the group given FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b> had had a cancer-related event, as compared with 293 patients in the FL group (21.1 percent vs. 26.1 percent; hazard ratio for recurrence, 0.77; P=0.002). The rate of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in the group given FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b> and 72.9 percent (95 percent confidence interval, 70.2 to 75.7) in the FL group (P=0.002 by the stratified log-rank test). In the group given FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b>, the incidence of febrile neutropenia was 1.8 percent, the incidence of gastrointestinal adverse effects was low, and the incidence of grade 3 sensory neuropathy was 12.4 percent during treatment, decreasing to 1.1 percent at one year of follow-up. Six patients in each group died during treatment (death rate, 0.5 percent). ### conclusions Adding <b style='color:Tomato;'><i>oxaliplatin</i></b> to a regimen of <b style='color:Tomato;'><i>fluorouracil</i></b> and <b style='color:Tomato;'><i>leucovorin</i></b> improves the adjuvant treatment of colon cancer.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"standard","start":4,"end":12,"id":1,"ws":true},{"text":"adjuvant","start":13,"end":21,"id":2,"ws":true},{"text":"treatment","start":22,"end":31,"id":3,"ws":true},{"text":"of","start":32,"end":34,"id":4,"ws":true},{"text":"colon","start":35,"end":40,"id":5,"ws":true},{"text":"cancer","start":41,"end":47,"id":6,"ws":true},{"text":"is","start":48,"end":50,"id":7,"ws":true},{"text":"fluorouracil","start":51,"end":63,"id":8,"ws":true},{"text":"plus","start":64,"end":68,"id":9,"ws":true},{"text":"leucovorin","start":69,"end":79,"id":10,"ws":true},{"text":"(","start":80,"end":81,"id":11,"ws":true},{"text":"FL","start":82,"end":84,"id":12,"ws":true},{"text":")","start":85,"end":86,"id":13,"ws":true},{"text":".","start":87,"end":88,"id":14,"ws":false}],"spans":[{"start":51,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},{"start":69,"end":79,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15175436/","_input_hash":312360282,"_task_hash":409765963,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":51,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":69,"end":79,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Effects of ultrasound were similar at baseline and after propranolol but increased after phenylephrine .","paragraph":"<h3><u>Alteration of left ventricular endocardial function by intracavitary high-power ultrasound interacts with volume, inotropic state, and alpha 1-adrenergic stimulation.</u></h3>High-power intracavitary ultrasound abbreviates left ventricular (LV) ejection duration, thereby decreasing mechanical LV performance, presumably by selective impairment of endocardial endothelial function. ### Methods And Results Effects of ultrasound were evaluated in the ejecting LV of anesthetized, open-chest dogs under different conditions of LV volume and contractile state and after mild selective alpha 1-adrenergic stimulation. LV pressures, left atrial pressures, and regional segment lengths were measured in anterior and posterior midwall. A cylindrical ultrasound probe (0.9 MHz, 25 W) mounted on a catheter was inserted into the LV cavity through the apex and was activated for 4 minutes in each condition. In protocol A (n = 7), LV volume was altered with caval vein occlusion and intravenous dextran infusion. The ultrasound probe was activated at low (4.1 +/- 0.9 mm Hg), mid (10.6 +/- 1.5 mm Hg), and high (17.9 +/- 1.8 mm Hg) LV end-diastolic pressure (EDP). Effects of ultrasound were less pronounced at higher EDP. For example, the time interval from end-diastole to peak (-)dP/dt decreased by 7.5 +/- 2.3% at low, 4.4 +/- 2.2% at mid, and 1.9 +/- 1.6% at high LVEDP (p < 0.001). In protocol B (n = 7), LV inotropic state was altered by slow intravenous infusion of low-dose calcium. The ultrasound probe was activated before and after calcium. Effects of ultrasound were less pronounced after calcium. Time from end-diastole to peak (-)dP/dt decreased by 8.4 +/- 3.1% at baseline and by 3.5 +/- 2.1% after calcium (p < 0.001). In protocol C (n = 7), activation of the ultrasound probe was performed at baseline and after mild selective alpha 1-adrenergic stimulation (<b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>phenylephrine</i></b>). <b style='color:DodgerBlue;'><i>Effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ultrasound</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>baseline</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>phenylephrine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Time from end-diastole to peak (-)dP/dt decreased by 5.2 +/- 2.4% at baseline, by 5.3 +/- 1.9% after <b style='color:Tomato;'><i>propranolol</i></b>, and by 8.9 +/- 3.2% after <b style='color:Tomato;'><i>phenylephrine</i></b> (p < 0.05). ### conclusions Effects of intracavitary ultrasound, which are presumably mediated through modulation of endocardial endothelial function, were more important at low volume, lower calcium, and under mild selective alpha 1-adrenergic stimulation.","tokens":[{"text":"Effects","start":0,"end":7,"id":0,"ws":true},{"text":"of","start":8,"end":10,"id":1,"ws":true},{"text":"ultrasound","start":11,"end":21,"id":2,"ws":true},{"text":"were","start":22,"end":26,"id":3,"ws":true},{"text":"similar","start":27,"end":34,"id":4,"ws":true},{"text":"at","start":35,"end":37,"id":5,"ws":true},{"text":"baseline","start":38,"end":46,"id":6,"ws":true},{"text":"and","start":47,"end":50,"id":7,"ws":true},{"text":"after","start":51,"end":56,"id":8,"ws":true},{"text":"propranolol","start":57,"end":68,"id":9,"ws":true},{"text":"but","start":69,"end":72,"id":10,"ws":true},{"text":"increased","start":73,"end":82,"id":11,"ws":true},{"text":"after","start":83,"end":88,"id":12,"ws":true},{"text":"phenylephrine","start":89,"end":102,"id":13,"ws":true},{"text":".","start":103,"end":104,"id":14,"ws":false}],"spans":[{"start":57,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},{"start":89,"end":102,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7681734/","_input_hash":-1194206629,"_task_hash":325387940,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Thirty-four patients ( 4 patients with stage IIIb , 30 patients in stage IV ) , with median age 66 and performance status 0 - 1 , were administered paclitaxel , 175 mg/m(2 ) in a 3-h infusion rate on day 1 and vinorelbine , 25 mg/m(2 ) in a 10-min infusion rate on days 1 , and 8 with G-CSF and EPO support .","paragraph":"<h3><u>A phase II study of non-platinum based chemotherapy with paclitaxel and vinorelbine in non-small cell lung cancer.</u></h3><b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> combination in previous untreated patients with stage IIIb-IV non-small cell lung cancer (NSCLC) as a phase II study. ### Patients And Methods <b style='color:DodgerBlue;'><i>Thirty-four</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IIIb</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>age</i></b> <b style='color:DodgerBlue;'><i>66</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>performance</i></b> <b style='color:DodgerBlue;'><i>status</i></b> <b style='color:DodgerBlue;'><i>0</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>175</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>3-h</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>10-min</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>G-CSF</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>EPO</i></b> <b style='color:DodgerBlue;'><i>support</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Among our 33 evaluable patients for toxicity 16 patients (48.4%) presented leukopenia and 15 patients (45.4%) presented anemia despite G-CSF and EPO administration. Two patients (6%) presented Grade III-IV peripheral neuropathy. The overall response rate was 67.7%; 5 patients (16.1%) showed complete response (2 patients stage IIIb) and 16 patients (51.6%) showed partial response (1 patient stage IIIb). The overall median survival time was 10 months (range 3-18 months) and the median disease-free survival was 9 months (range 3-15 months) with an 1-year survival time of 45.1% (14 patients). ### conclusion The results of the combination as 1st line treatment for patients with non-operable NSCLC are promising and should be further investigated.","tokens":[{"text":"Thirty-four","start":0,"end":11,"id":0,"ws":true},{"text":"patients","start":12,"end":20,"id":1,"ws":true},{"text":"(","start":21,"end":22,"id":2,"ws":true},{"text":"4","start":23,"end":24,"id":3,"ws":true},{"text":"patients","start":25,"end":33,"id":4,"ws":true},{"text":"with","start":34,"end":38,"id":5,"ws":true},{"text":"stage","start":39,"end":44,"id":6,"ws":true},{"text":"IIIb","start":45,"end":49,"id":7,"ws":true},{"text":",","start":50,"end":51,"id":8,"ws":true},{"text":"30","start":52,"end":54,"id":9,"ws":true},{"text":"patients","start":55,"end":63,"id":10,"ws":true},{"text":"in","start":64,"end":66,"id":11,"ws":true},{"text":"stage","start":67,"end":72,"id":12,"ws":true},{"text":"IV","start":73,"end":75,"id":13,"ws":true},{"text":")","start":76,"end":77,"id":14,"ws":true},{"text":",","start":78,"end":79,"id":15,"ws":true},{"text":"with","start":80,"end":84,"id":16,"ws":true},{"text":"median","start":85,"end":91,"id":17,"ws":true},{"text":"age","start":92,"end":95,"id":18,"ws":true},{"text":"66","start":96,"end":98,"id":19,"ws":true},{"text":"and","start":99,"end":102,"id":20,"ws":true},{"text":"performance","start":103,"end":114,"id":21,"ws":true},{"text":"status","start":115,"end":121,"id":22,"ws":true},{"text":"0","start":122,"end":123,"id":23,"ws":true},{"text":"-","start":124,"end":125,"id":24,"ws":true},{"text":"1","start":126,"end":127,"id":25,"ws":true},{"text":",","start":128,"end":129,"id":26,"ws":true},{"text":"were","start":130,"end":134,"id":27,"ws":true},{"text":"administered","start":135,"end":147,"id":28,"ws":true},{"text":"paclitaxel","start":148,"end":158,"id":29,"ws":true},{"text":",","start":159,"end":160,"id":30,"ws":true},{"text":"175","start":161,"end":164,"id":31,"ws":true},{"text":"mg/m(2","start":165,"end":171,"id":32,"ws":true},{"text":")","start":172,"end":173,"id":33,"ws":true},{"text":"in","start":174,"end":176,"id":34,"ws":true},{"text":"a","start":177,"end":178,"id":35,"ws":true},{"text":"3-h","start":179,"end":182,"id":36,"ws":true},{"text":"infusion","start":183,"end":191,"id":37,"ws":true},{"text":"rate","start":192,"end":196,"id":38,"ws":true},{"text":"on","start":197,"end":199,"id":39,"ws":true},{"text":"day","start":200,"end":203,"id":40,"ws":true},{"text":"1","start":204,"end":205,"id":41,"ws":true},{"text":"and","start":206,"end":209,"id":42,"ws":true},{"text":"vinorelbine","start":210,"end":221,"id":43,"ws":true},{"text":",","start":222,"end":223,"id":44,"ws":true},{"text":"25","start":224,"end":226,"id":45,"ws":true},{"text":"mg/m(2","start":227,"end":233,"id":46,"ws":true},{"text":")","start":234,"end":235,"id":47,"ws":true},{"text":"in","start":236,"end":238,"id":48,"ws":true},{"text":"a","start":239,"end":240,"id":49,"ws":true},{"text":"10-min","start":241,"end":247,"id":50,"ws":true},{"text":"infusion","start":248,"end":256,"id":51,"ws":true},{"text":"rate","start":257,"end":261,"id":52,"ws":true},{"text":"on","start":262,"end":264,"id":53,"ws":true},{"text":"days","start":265,"end":269,"id":54,"ws":true},{"text":"1","start":270,"end":271,"id":55,"ws":true},{"text":",","start":272,"end":273,"id":56,"ws":true},{"text":"and","start":274,"end":277,"id":57,"ws":true},{"text":"8","start":278,"end":279,"id":58,"ws":true},{"text":"with","start":280,"end":284,"id":59,"ws":true},{"text":"G-CSF","start":285,"end":290,"id":60,"ws":true},{"text":"and","start":291,"end":294,"id":61,"ws":true},{"text":"EPO","start":295,"end":298,"id":62,"ws":true},{"text":"support","start":299,"end":306,"id":63,"ws":true},{"text":".","start":307,"end":308,"id":64,"ws":false}],"spans":[{"start":148,"end":158,"token_start":29,"token_end":29,"label":"DRUG"},{"start":210,"end":221,"token_start":43,"token_end":43,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12399133/","_input_hash":1446922198,"_task_hash":1350048234,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":29,"child":43,"head_span":{"start":148,"end":158,"token_start":29,"token_end":29,"label":"DRUG"},"child_span":{"start":210,"end":221,"token_start":43,"token_end":43,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>I</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>decitabine</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>valproic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>myeloid</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>To determine an optimal biologic dose (OBD) of <b style='color:Tomato;'><i>decitabine</i></b> as a single agent and then the maximum-tolerated dose (MTD) of <b style='color:Tomato;'><i>valproic</i></b> acid (VA) combined with <b style='color:Tomato;'><i>decitabine</i></b> in acute myeloid leukemia (AML). ### Patients And Methods Twenty-five patients (median age, 70 years) were enrolled; 12 were untreated and 13 had relapsed AML. To determine an OBD (based on a gene re-expression end point), 14 patients received <b style='color:Tomato;'><i>decitabine</i></b> alone for 10 days. To determine the MTD, 11 patients received <b style='color:Tomato;'><i>decitabine</i></b> (at OBD, days 1 through 10) plus dose-escalating VA (days 5 through 21). ### results The OBD of <b style='color:Tomato;'><i>decitabine</i></b> was 20 mg/m(2)/d intravenously, with limited nonhematologic toxicity. In patients treated with <b style='color:Tomato;'><i>decitabine</i></b> plus VA, dose-limiting encephalopathy occurred in two of two patients at VA 25 mg/kg/d and one of six patients at VA 20 mg/kg/d. Drug-induced re-expression of estrogen receptor (ER) was associated with clinical response (P < or = .05). ER promoter demethylation, global DNA hypomethylation, depletion of DNA methyltransferase enzyme, and histone hyperacetylation were also observed. In an intent-to-treat analysis, the response rate was 44% (11 of 25). Of 21 assessable patients, 11 (52%) responded: four with morphologic and cytogenetic complete remission (CR; each had complex karyotype), four with incomplete CR, and three with partial remission. In untreated AML, four of nine assessable patients achieved CR. Clinical responses appeared similar for <b style='color:Tomato;'><i>decitabine</i></b> alone or with VA. ### conclusion Low-dose <b style='color:Tomato;'><i>decitabine</i></b> was safe and showed encouraging clinical and biologic activity in AML, but the addition of VA led to encephalopathy at relatively low doses. On the basis of these results, additional studies of <b style='color:Tomato;'><i>decitabine</i></b> (20 mg/m(2)/d for 10 days) alone or with an alternative deacetylating agent are warranted.","tokens":[{"text":"Phase","start":0,"end":5,"id":0,"ws":true},{"text":"I","start":6,"end":7,"id":1,"ws":true},{"text":"study","start":8,"end":13,"id":2,"ws":true},{"text":"of","start":14,"end":16,"id":3,"ws":true},{"text":"decitabine","start":17,"end":27,"id":4,"ws":true},{"text":"alone","start":28,"end":33,"id":5,"ws":true},{"text":"or","start":34,"end":36,"id":6,"ws":true},{"text":"in","start":37,"end":39,"id":7,"ws":true},{"text":"combination","start":40,"end":51,"id":8,"ws":true},{"text":"with","start":52,"end":56,"id":9,"ws":true},{"text":"valproic","start":57,"end":65,"id":10,"ws":true},{"text":"acid","start":66,"end":70,"id":11,"ws":true},{"text":"in","start":71,"end":73,"id":12,"ws":true},{"text":"acute","start":74,"end":79,"id":13,"ws":true},{"text":"myeloid","start":80,"end":87,"id":14,"ws":true},{"text":"leukemia","start":88,"end":96,"id":15,"ws":true},{"text":".","start":97,"end":98,"id":16,"ws":false}],"spans":[{"start":17,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},{"start":57,"end":65,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17679729/","_input_hash":741112160,"_task_hash":-528000752,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":4,"child":10,"head_span":{"start":17,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":57,"end":65,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Early discontinuation of clopidogrel results in a transient rebound increase in risk of recurrence in acute coronary syndromes , but there are no published data on any similar rebound effect in patients with TIA or stroke that might inform the design of clinical trials of aspirin and clopidogrel in the acute phase .","paragraph":"<h3><u>Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke.</u></h3>The combination of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke. <b style='color:DodgerBlue;'><i>Early</i></b> <b style='color:DodgerBlue;'><i>discontinuation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>transient</i></b> <b style='color:DodgerBlue;'><i>rebound</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>recurrence</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>coronary</i></b> <b style='color:DodgerBlue;'><i>syndromes</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>there</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>published</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>any</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>rebound</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>TIA</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>stroke</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>inform</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>design</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A 30-day course of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> (both 75 mg daily) was given to high-risk patients with TIA or minor ischemic stroke seen acutely in the EXPRESS study clinic from April 1, 2002, to March 31, 2009. <b style='color:Tomato;'><i>clopidogrel</i></b> was stopped after 30 days and <b style='color:Tomato;'><i>aspirin</i></b> continued. Recurrent events were ascertained at face-to-face follow-up. ### results A total of 320 patients were prescribed a 30-day course of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> acutely after TIA or minor stroke. There were 5 recurrent ischemic strokes and 7 TIAs during the <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> treatment period, but no strokes and 4 TIAs during the 30 days after stopping <b style='color:Tomato;'><i>clopidogrel</i></b>. A similar temporal trend in stroke risk was seen in the 487 patients prescribed <b style='color:Tomato;'><i>aspirin</i></b> alone in the acute phase, with 12 and 5 strokes in the equivalent time periods. The upper 95% confidence intervals of the observed 0% risk of stroke during the 30 days after stopping <b style='color:Tomato;'><i>clopidogrel</i></b> was 1.15% overall. ### conclusion Although larger studies are required, our findings suggest there is unlikely to be a large rebound effect after discontinuation of a 30-day course of <b style='color:Tomato;'><i>clopidogrel</i></b> in acute TIA and minor ischemic stroke. However, planned trials of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> in the acute phase after TIA or stroke should still follow-up beyond the cessation of <b style='color:Tomato;'><i>clopidogrel</i></b> treatment.","tokens":[{"text":"Early","start":0,"end":5,"id":0,"ws":true},{"text":"discontinuation","start":6,"end":21,"id":1,"ws":true},{"text":"of","start":22,"end":24,"id":2,"ws":true},{"text":"clopidogrel","start":25,"end":36,"id":3,"ws":true},{"text":"results","start":37,"end":44,"id":4,"ws":true},{"text":"in","start":45,"end":47,"id":5,"ws":true},{"text":"a","start":48,"end":49,"id":6,"ws":true},{"text":"transient","start":50,"end":59,"id":7,"ws":true},{"text":"rebound","start":60,"end":67,"id":8,"ws":true},{"text":"increase","start":68,"end":76,"id":9,"ws":true},{"text":"in","start":77,"end":79,"id":10,"ws":true},{"text":"risk","start":80,"end":84,"id":11,"ws":true},{"text":"of","start":85,"end":87,"id":12,"ws":true},{"text":"recurrence","start":88,"end":98,"id":13,"ws":true},{"text":"in","start":99,"end":101,"id":14,"ws":true},{"text":"acute","start":102,"end":107,"id":15,"ws":true},{"text":"coronary","start":108,"end":116,"id":16,"ws":true},{"text":"syndromes","start":117,"end":126,"id":17,"ws":true},{"text":",","start":127,"end":128,"id":18,"ws":true},{"text":"but","start":129,"end":132,"id":19,"ws":true},{"text":"there","start":133,"end":138,"id":20,"ws":true},{"text":"are","start":139,"end":142,"id":21,"ws":true},{"text":"no","start":143,"end":145,"id":22,"ws":true},{"text":"published","start":146,"end":155,"id":23,"ws":true},{"text":"data","start":156,"end":160,"id":24,"ws":true},{"text":"on","start":161,"end":163,"id":25,"ws":true},{"text":"any","start":164,"end":167,"id":26,"ws":true},{"text":"similar","start":168,"end":175,"id":27,"ws":true},{"text":"rebound","start":176,"end":183,"id":28,"ws":true},{"text":"effect","start":184,"end":190,"id":29,"ws":true},{"text":"in","start":191,"end":193,"id":30,"ws":true},{"text":"patients","start":194,"end":202,"id":31,"ws":true},{"text":"with","start":203,"end":207,"id":32,"ws":true},{"text":"TIA","start":208,"end":211,"id":33,"ws":true},{"text":"or","start":212,"end":214,"id":34,"ws":true},{"text":"stroke","start":215,"end":221,"id":35,"ws":true},{"text":"that","start":222,"end":226,"id":36,"ws":true},{"text":"might","start":227,"end":232,"id":37,"ws":true},{"text":"inform","start":233,"end":239,"id":38,"ws":true},{"text":"the","start":240,"end":243,"id":39,"ws":true},{"text":"design","start":244,"end":250,"id":40,"ws":true},{"text":"of","start":251,"end":253,"id":41,"ws":true},{"text":"clinical","start":254,"end":262,"id":42,"ws":true},{"text":"trials","start":263,"end":269,"id":43,"ws":true},{"text":"of","start":270,"end":272,"id":44,"ws":true},{"text":"aspirin","start":273,"end":280,"id":45,"ws":true},{"text":"and","start":281,"end":284,"id":46,"ws":true},{"text":"clopidogrel","start":285,"end":296,"id":47,"ws":true},{"text":"in","start":297,"end":299,"id":48,"ws":true},{"text":"the","start":300,"end":303,"id":49,"ws":true},{"text":"acute","start":304,"end":309,"id":50,"ws":true},{"text":"phase","start":310,"end":315,"id":51,"ws":true},{"text":".","start":316,"end":317,"id":52,"ws":false}],"spans":[{"start":25,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},{"start":273,"end":280,"token_start":45,"token_end":45,"label":"DRUG"},{"start":285,"end":296,"token_start":47,"token_end":47,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20530325/","_input_hash":779656601,"_task_hash":1542041114,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Patients received docetaxel 35 mg/m(2 ) and irinotecan 60 mg/m(2 ) , intravenously , on Days 1 and 8 , every 21 days , until disease progression .","paragraph":"<h3><u>Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.</u></h3><b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b> have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). The authors sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN. ### methods Eligibility criteria included recurrent or metastatic SCCHN with measurable disease, good performance status, and adequate laboratory parameters. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>Days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>until</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The authors assessed UGT1A1 genotype, vascular endothelial growth factor (VEGF) in serum, and cyclooxygenase-2 and VEGF in baseline tumor tissue. ### results Fifty-two patients were analyzable: 20 chemotherapy naive (Group A) and 32 previously treated with 1 chemotherapy regimen (Group B); 73% of patients had distant metastasis, and 60% were <b style='color:Tomato;'><i>paclitaxel</i></b>-exposed. In Group A, 3 (15%) patients achieved a partial response; in Group B, 1 (3%) patient achieved a partial response. Median progression-free survival (PFS) and overall survival were 3.3 and 8.2 months in Group A and 1.9 and 5.0 months in Group B, respectively. Common serious toxicities were diarrhea, fatigue, and anorexia. Patients with high serum VEGF had a median PFS of 2.8 months versus 1.7 months for patients with low VEGF (P = .085). ### conclusions <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b> had acceptable toxicities, but efficacy results in unselected patients with recurrent or metastatic SCCHN did not suggest an advantage over <b style='color:Tomato;'><i>docetaxel</i></b> alone or platinum-based regimens.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"received","start":9,"end":17,"id":1,"ws":true},{"text":"docetaxel","start":18,"end":27,"id":2,"ws":true},{"text":"35","start":28,"end":30,"id":3,"ws":true},{"text":"mg/m(2","start":31,"end":37,"id":4,"ws":true},{"text":")","start":38,"end":39,"id":5,"ws":true},{"text":"and","start":40,"end":43,"id":6,"ws":true},{"text":"irinotecan","start":44,"end":54,"id":7,"ws":true},{"text":"60","start":55,"end":57,"id":8,"ws":true},{"text":"mg/m(2","start":58,"end":64,"id":9,"ws":true},{"text":")","start":65,"end":66,"id":10,"ws":true},{"text":",","start":67,"end":68,"id":11,"ws":true},{"text":"intravenously","start":69,"end":82,"id":12,"ws":true},{"text":",","start":83,"end":84,"id":13,"ws":true},{"text":"on","start":85,"end":87,"id":14,"ws":true},{"text":"Days","start":88,"end":92,"id":15,"ws":true},{"text":"1","start":93,"end":94,"id":16,"ws":true},{"text":"and","start":95,"end":98,"id":17,"ws":true},{"text":"8","start":99,"end":100,"id":18,"ws":true},{"text":",","start":101,"end":102,"id":19,"ws":true},{"text":"every","start":103,"end":108,"id":20,"ws":true},{"text":"21","start":109,"end":111,"id":21,"ws":true},{"text":"days","start":112,"end":116,"id":22,"ws":true},{"text":",","start":117,"end":118,"id":23,"ws":true},{"text":"until","start":119,"end":124,"id":24,"ws":true},{"text":"disease","start":125,"end":132,"id":25,"ws":true},{"text":"progression","start":133,"end":144,"id":26,"ws":true},{"text":".","start":145,"end":146,"id":27,"ws":false}],"spans":[{"start":18,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},{"start":44,"end":54,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19634157/","_input_hash":-1994564215,"_task_hash":-1898193515,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":2,"child":7,"head_span":{"start":18,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":44,"end":54,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Most patients with advanced ovarian cancer achieve a clinical complete remission following cytoreductive surgery and chemotherapy with paclitaxel plus carboplatin .","paragraph":"<h3><u>Gemcitabine and carboplatin in second-line ovarian cancer.</u></h3> <b style='color:DodgerBlue;'><i>Most</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>remission</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>cytoreductive</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, a majority of these patients will ultimately recur, and second-line treatment for this group of patients is an important aspect of management of this disease as well as an area of active clinical investigation. Until recently, for patients with platinum-sensitive ovarian cancer (more than 6-month disease-free interval), chemotherapy with single-agent <b style='color:Tomato;'><i>carboplatin</i></b> was frequently recommended. However, two recent prospective randomized trials have shown that combination chemotherapy produces higher response rates and improvement in progression-free survival compared with treatment with single-agent <b style='color:Tomato;'><i>carboplatin</i></b>. One trial compared treatment with <b style='color:Tomato;'><i>paclitaxel</i></b> plus a platinum compound with re-treatment with platinum, and a second trial compared <b style='color:Tomato;'><i>carboplatin</i></b> plus <b style='color:Tomato;'><i>gemcitabine</i></b> re-treatment against <b style='color:Tomato;'><i>carboplatin</i></b> in patients with platinum-sensitive recurrent ovarian cancer. Both trials showed a 3-month improvement in progression-free survival in patients treated with the combination, as well as acceptable toxicity. In the absence of a prospective randomized trial comparing these two regimens in patients with platinum-sensitive recurrent ovarian cancer, the choice of which combination to use may depend on toxicity considerations.","tokens":[{"text":"Most","start":0,"end":4,"id":0,"ws":true},{"text":"patients","start":5,"end":13,"id":1,"ws":true},{"text":"with","start":14,"end":18,"id":2,"ws":true},{"text":"advanced","start":19,"end":27,"id":3,"ws":true},{"text":"ovarian","start":28,"end":35,"id":4,"ws":true},{"text":"cancer","start":36,"end":42,"id":5,"ws":true},{"text":"achieve","start":43,"end":50,"id":6,"ws":true},{"text":"a","start":51,"end":52,"id":7,"ws":true},{"text":"clinical","start":53,"end":61,"id":8,"ws":true},{"text":"complete","start":62,"end":70,"id":9,"ws":true},{"text":"remission","start":71,"end":80,"id":10,"ws":true},{"text":"following","start":81,"end":90,"id":11,"ws":true},{"text":"cytoreductive","start":91,"end":104,"id":12,"ws":true},{"text":"surgery","start":105,"end":112,"id":13,"ws":true},{"text":"and","start":113,"end":116,"id":14,"ws":true},{"text":"chemotherapy","start":117,"end":129,"id":15,"ws":true},{"text":"with","start":130,"end":134,"id":16,"ws":true},{"text":"paclitaxel","start":135,"end":145,"id":17,"ws":true},{"text":"plus","start":146,"end":150,"id":18,"ws":true},{"text":"carboplatin","start":151,"end":162,"id":19,"ws":true},{"text":".","start":163,"end":164,"id":20,"ws":false}],"spans":[{"start":135,"end":145,"token_start":17,"token_end":17,"label":"DRUG"},{"start":151,"end":162,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16143161/","_input_hash":-848463825,"_task_hash":1187260872,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":17,"child":19,"head_span":{"start":135,"end":145,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":151,"end":162,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Patients were assigned to receive either oxaliplatin ( 100 mg/m(2 ) ) in the SOX arm or docetaxel ( 40 mg/m(2 ) ) in the mDS arm on day 1 of every 3-week cycle .","paragraph":"<h3><u>Low-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma.</u></h3>Platinum-fluoropyrimidine combinations are the preferred first-line options for advanced gastric cancer (AGC) in East Asia. On the other hand, <b style='color:Tomato;'><i>docetaxel</i></b>-containing regimens without platinum have demonstrated promising activity in AGC. However, dose-related toxicity of <b style='color:Tomato;'><i>docetaxel</i></b> has limited its clinical adoption. This study compared the efficacy and safety of a modified low-dosed <b style='color:Tomato;'><i>docetaxel</i></b> plus S-1 (mDS) with <b style='color:Tomato;'><i>oxaliplatin</i></b> plus S-1 (SOX) in Chinese patients with AGC. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>SOX</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mDS</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3-week</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>.</i></b> S-1 80-120 mg/day was administered orally on days 1-14 in the 3-week cycle in both groups. One hundred and eighty-eight patients (mDS regimen 101; SOX 87) showed similar overall survival (OS; 13.1 vs 12.8 months, P = 0.878), progression-free survival (PFS; 5.8 vs 5.5 months, P = 0.924), and overall response rate (39.7 vs 44.2%, P = 0.569) in the mDS and SOX arms, respectively. mDS was associated with significantly less grade 3/4 toxicities in thrombocytopenia (5.9 vs 16.1%) and gastrointestinal disturbances (1.0 vs 8.0%). Furthermore, in patients who had ever received <b style='color:Tomato;'><i>oxaliplatin</i></b>-based adjuvant chemotherapy (N = 40), mDS resulted in significantly superior OS (17.8 vs 9.5 months, P = 0.015) and PFS (7.0 vs 4.2 months, P = 0.008) compared with SOX. In conclusion, mDS was as effective as SOX in Chinese patients with AGC, but it resulted in a significantly improved tolerability. In patients who received <b style='color:Tomato;'><i>oxaliplatin</i></b>-based adjuvant chemotherapy before, mDS was associated with improved efficacy in the first-line setting.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"were","start":9,"end":13,"id":1,"ws":true},{"text":"assigned","start":14,"end":22,"id":2,"ws":true},{"text":"to","start":23,"end":25,"id":3,"ws":true},{"text":"receive","start":26,"end":33,"id":4,"ws":true},{"text":"either","start":34,"end":40,"id":5,"ws":true},{"text":"oxaliplatin","start":41,"end":52,"id":6,"ws":true},{"text":"(","start":53,"end":54,"id":7,"ws":true},{"text":"100","start":55,"end":58,"id":8,"ws":true},{"text":"mg/m(2","start":59,"end":65,"id":9,"ws":true},{"text":")","start":66,"end":67,"id":10,"ws":true},{"text":")","start":68,"end":69,"id":11,"ws":true},{"text":"in","start":70,"end":72,"id":12,"ws":true},{"text":"the","start":73,"end":76,"id":13,"ws":true},{"text":"SOX","start":77,"end":80,"id":14,"ws":true},{"text":"arm","start":81,"end":84,"id":15,"ws":true},{"text":"or","start":85,"end":87,"id":16,"ws":true},{"text":"docetaxel","start":88,"end":97,"id":17,"ws":true},{"text":"(","start":98,"end":99,"id":18,"ws":true},{"text":"40","start":100,"end":102,"id":19,"ws":true},{"text":"mg/m(2","start":103,"end":109,"id":20,"ws":true},{"text":")","start":110,"end":111,"id":21,"ws":true},{"text":")","start":112,"end":113,"id":22,"ws":true},{"text":"in","start":114,"end":116,"id":23,"ws":true},{"text":"the","start":117,"end":120,"id":24,"ws":true},{"text":"mDS","start":121,"end":124,"id":25,"ws":true},{"text":"arm","start":125,"end":128,"id":26,"ws":true},{"text":"on","start":129,"end":131,"id":27,"ws":true},{"text":"day","start":132,"end":135,"id":28,"ws":true},{"text":"1","start":136,"end":137,"id":29,"ws":true},{"text":"of","start":138,"end":140,"id":30,"ws":true},{"text":"every","start":141,"end":146,"id":31,"ws":true},{"text":"3-week","start":147,"end":153,"id":32,"ws":true},{"text":"cycle","start":154,"end":159,"id":33,"ws":true},{"text":".","start":160,"end":161,"id":34,"ws":false}],"spans":[{"start":41,"end":52,"token_start":6,"token_end":6,"label":"DRUG"},{"start":88,"end":97,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26268397/","_input_hash":258919544,"_task_hash":389632687,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Agents in clinical trials for subsets of MDS include luspatercept , antibodies targeting CD33 , isocitrate dehydrogenase inhibitors , deacetylase inhibitors , venetoclax , and immunotherapies designed to overcome immune checkpoint inhibition .","paragraph":"<h3><u>Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches.</u></h3>It has been more than 10 years since any new disease-modifying therapies have received regulatory approval for indications related to myelodysplastic syndromes (MDS). Advances in our collective biological understanding of MDS in the last decade, however, have made it possible to hope that effective therapeutics can be designed to improve MDS-associated cytopenias and patients' quality of life, and perhaps even delay clonal progression and extend survival. Classes of MDS-associated mutations and disordered biological pathways targeted by developmental therapeutics include the following: aberrant messenger RNA splicing, neomorphic enzymes in the citric acid cycle with oncogenic activity, overactivated tyrosine and serine-threonine kinases, epigenetic and chromatin remodeling alterations, abnormal telomere dynamics, and failed protection of DNA integrity. At present, treatments for MDS are usually administered as sequential monotherapy, but there is a trend toward clinical trials of combination therapies-in which new agents are added to a DNA hypomethylating agent backbone-for both upfront treatment and the treatment of relapsed/refractory disease. <b style='color:DodgerBlue;'><i>Agents</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>subsets</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>MDS</i></b> <b style='color:DodgerBlue;'><i>include</i></b> <b style='color:MediumOrchid;'><i>luspatercept</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>antibodies</i></b> <b style='color:DodgerBlue;'><i>targeting</i></b> <b style='color:DodgerBlue;'><i>CD33</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>isocitrate</i></b> <b style='color:DodgerBlue;'><i>dehydrogenase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>deacetylase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>venetoclax</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>immunotherapies</i></b> <b style='color:DodgerBlue;'><i>designed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>overcome</i></b> <b style='color:DodgerBlue;'><i>immune</i></b> <b style='color:DodgerBlue;'><i>checkpoint</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These biologically based therapeutics, as well as the encouraging precedent of 7 new approvals by the US Food and Drug Administration in 2017 for the treatment of acute leukemia, offer the prospect that 10 more years will not elapse before another new therapy is approved for MDS.","tokens":[{"text":"Agents","start":0,"end":6,"id":0,"ws":true},{"text":"in","start":7,"end":9,"id":1,"ws":true},{"text":"clinical","start":10,"end":18,"id":2,"ws":true},{"text":"trials","start":19,"end":25,"id":3,"ws":true},{"text":"for","start":26,"end":29,"id":4,"ws":true},{"text":"subsets","start":30,"end":37,"id":5,"ws":true},{"text":"of","start":38,"end":40,"id":6,"ws":true},{"text":"MDS","start":41,"end":44,"id":7,"ws":true},{"text":"include","start":45,"end":52,"id":8,"ws":true},{"text":"luspatercept","start":53,"end":65,"id":9,"ws":true},{"text":",","start":66,"end":67,"id":10,"ws":true},{"text":"antibodies","start":68,"end":78,"id":11,"ws":true},{"text":"targeting","start":79,"end":88,"id":12,"ws":true},{"text":"CD33","start":89,"end":93,"id":13,"ws":true},{"text":",","start":94,"end":95,"id":14,"ws":true},{"text":"isocitrate","start":96,"end":106,"id":15,"ws":true},{"text":"dehydrogenase","start":107,"end":120,"id":16,"ws":true},{"text":"inhibitors","start":121,"end":131,"id":17,"ws":true},{"text":",","start":132,"end":133,"id":18,"ws":true},{"text":"deacetylase","start":134,"end":145,"id":19,"ws":true},{"text":"inhibitors","start":146,"end":156,"id":20,"ws":true},{"text":",","start":157,"end":158,"id":21,"ws":true},{"text":"venetoclax","start":159,"end":169,"id":22,"ws":true},{"text":",","start":170,"end":171,"id":23,"ws":true},{"text":"and","start":172,"end":175,"id":24,"ws":true},{"text":"immunotherapies","start":176,"end":191,"id":25,"ws":true},{"text":"designed","start":192,"end":200,"id":26,"ws":true},{"text":"to","start":201,"end":203,"id":27,"ws":true},{"text":"overcome","start":204,"end":212,"id":28,"ws":true},{"text":"immune","start":213,"end":219,"id":29,"ws":true},{"text":"checkpoint","start":220,"end":230,"id":30,"ws":true},{"text":"inhibition","start":231,"end":241,"id":31,"ws":true},{"text":".","start":242,"end":243,"id":32,"ws":false}],"spans":[{"start":53,"end":65,"token_start":9,"token_end":9,"label":"DRUG"},{"start":159,"end":169,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29741506/","_input_hash":85053744,"_task_hash":1768436942,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Possible differences between enalapril and captopril .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Possible</i></b> <b style='color:DodgerBlue;'><i>differences</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:MediumOrchid;'><i>enalapril</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>captopril</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Inhibitors of angiotensin converting enzyme block the conversion of angiotensin I to angiotensin II, the active hormone of the renin-angiotensin system. This inhibition leads to a reduction in angiotensin-mediated vasoconstriction and aldosterone production. Although converting enzyme inhibitors have other potential metabolic effects, their beneficial effects in hypertension and congestive heart failure appear to be, in large part, related to their ability to reduce angiotensin II. This causes an increase in plasma renin levels and a fall in plasma and urine aldosterone, which can be sustained for many years. As a consequence, converting enzyme inhibitors produce mild natriuresis and positive potassium balance. At conventionally used doses, <b style='color:Tomato;'><i>enalapril</i></b> more completely prevents posture-induced increases in aldosterone than does <b style='color:Tomato;'><i>captopril</i></b>, probably reflecting more complete inhibition of angiotensin II formation in vivo.","tokens":[{"text":"Possible","start":0,"end":8,"id":0,"ws":true},{"text":"differences","start":9,"end":20,"id":1,"ws":true},{"text":"between","start":21,"end":28,"id":2,"ws":true},{"text":"enalapril","start":29,"end":38,"id":3,"ws":true},{"text":"and","start":39,"end":42,"id":4,"ws":true},{"text":"captopril","start":43,"end":52,"id":5,"ws":true},{"text":".","start":53,"end":54,"id":6,"ws":false}],"spans":[{"start":29,"end":38,"token_start":3,"token_end":3,"label":"DRUG"},{"start":43,"end":52,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6089554/","_input_hash":-1441819874,"_task_hash":198220139,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Exposure of the saphenous veins to imipenem or imipenem combined with amphotericin B had no adverse effects on the viability of the endothelial cells with 12 h exposure .","paragraph":"<h3><u>Effects of antibiotics on the endothelium of fresh and cryopreserved canine saphenous veins.</u></h3>To determine if antibiotic solutions for potential use in antimicrobial treatment of tissues were detrimental to cell viability, canine saphenous veins were exposed to three different antibiotic solutions at 37 degrees C for 12 h. Viability was determined by tissue culture, utilizing a limiting dilution assay. The antibiotic series included two formulations currently used for the preservation of heart valves and a new formulation containing <b style='color:Tomato;'><i>imipenem</i></b>, a broad spectrum beta-lactam. Currently used antibiotic regimes and <b style='color:Tomato;'><i>imipenem</i></b> with <b style='color:Tomato;'><i>gentamicin</i></b> resulted in a decrease of 30 to 50% of the viable endothelial cells within 12 h. <b style='color:DodgerBlue;'><i>Exposure</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>saphenous</i></b> <b style='color:DodgerBlue;'><i>veins</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>imipenem</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>imipenem</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>viability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>endothelial</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>exposure</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, veins exposed to <b style='color:Tomato;'><i>amphotericin</i></b> B were more susceptible to subsequent damage during freezing and thawing than veins frozen after incubation with either <b style='color:Tomato;'><i>imipenem</i></b> alone or <b style='color:Tomato;'><i>imipenem</i></b> combined with <b style='color:Tomato;'><i>flucytosine</i></b>. These studies indicate that <b style='color:Tomato;'><i>imipenem</i></b> combined with <b style='color:Tomato;'><i>flucytosine</i></b> is suitable for use with vein grafts.","tokens":[{"text":"Exposure","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"saphenous","start":16,"end":25,"id":3,"ws":true},{"text":"veins","start":26,"end":31,"id":4,"ws":true},{"text":"to","start":32,"end":34,"id":5,"ws":true},{"text":"imipenem","start":35,"end":43,"id":6,"ws":true},{"text":"or","start":44,"end":46,"id":7,"ws":true},{"text":"imipenem","start":47,"end":55,"id":8,"ws":true},{"text":"combined","start":56,"end":64,"id":9,"ws":true},{"text":"with","start":65,"end":69,"id":10,"ws":true},{"text":"amphotericin","start":70,"end":82,"id":11,"ws":true},{"text":"B","start":83,"end":84,"id":12,"ws":true},{"text":"had","start":85,"end":88,"id":13,"ws":true},{"text":"no","start":89,"end":91,"id":14,"ws":true},{"text":"adverse","start":92,"end":99,"id":15,"ws":true},{"text":"effects","start":100,"end":107,"id":16,"ws":true},{"text":"on","start":108,"end":110,"id":17,"ws":true},{"text":"the","start":111,"end":114,"id":18,"ws":true},{"text":"viability","start":115,"end":124,"id":19,"ws":true},{"text":"of","start":125,"end":127,"id":20,"ws":true},{"text":"the","start":128,"end":131,"id":21,"ws":true},{"text":"endothelial","start":132,"end":143,"id":22,"ws":true},{"text":"cells","start":144,"end":149,"id":23,"ws":true},{"text":"with","start":150,"end":154,"id":24,"ws":true},{"text":"12","start":155,"end":157,"id":25,"ws":true},{"text":"h","start":158,"end":159,"id":26,"ws":true},{"text":"exposure","start":160,"end":168,"id":27,"ws":true},{"text":".","start":169,"end":170,"id":28,"ws":false}],"spans":[{"start":35,"end":43,"token_start":6,"token_end":6,"label":"DRUG"},{"start":47,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},{"start":70,"end":82,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8319486/","_input_hash":-1861796111,"_task_hash":1320881043,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"First-line chemotherapy was either R-CHOP ( rituximab , cyclophosphamide , doxorubicin , vincristine and prednisolone ) or CHOP-like-based regimen .","paragraph":"<h3><u>[Primary testicular non-Hodgkin's lymphoma: clinical analysis of 21 cases].</u></h3>To explore the clinical characteristics and prognosis of patients with primary testicular non-Hodgkin's lymphoma. ### methods The clinical profiles and prognostic factors of 21 cases newly diagnosed as primary testicular non-Hodgkin's lymphoma at Peking University Cancer Hospital from January 2005 to December 2012 were retrospectively analyzed. ### results Their median age was 59 (34-86) years. And they were classified as Ann Arbor stage I (n = 8), stage II (n = 2) and stage IV (n = 11). There were B symptoms (n = 4), extranodal involvement outside testis (n = 12) and elevated lactate dehydrogenase (LDH) at diagnosis (n = 6). The scores of international prognostic index (IPI) were 0-1 point (n = 10), 3 points (n = 10) and 4 points (n = 1). The regimens included orchidectomy as the initial treatment (n = 15), chemotherapy followed by radiotherapy (n = 7) and CNS prophylaxis during treatment (n = 15). All patients were pathologically diagnosed as diffuse large B-cell lymphoma. And 11 cases belonged to the non-germinal center B cell-like subgroup. <b style='color:DodgerBlue;'><i>First-line</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>R-CHOP</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>CHOP-like-based</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Complete response was achieved in 85.7% of patients. The median follow-up period was 18 (6-58) months. The 1, 2 and 3-year survival rates were 100%, 80% and 60% respectively. Statistical analysis showed that the first-line chemotherapy with <b style='color:Tomato;'><i>rituximab</i></b> was a prognostic factor (P = 0.038).Other factors included stage (P = 0.275), LDH level (P = 0.179) , \u03b22-microglobulin level (P = 0.229) and IPI (P = 0.275) . ### conclusions The prognosis of primary testicular non-Hodgkin's lymphoma is usually poor. The first-line chemotherapy with <b style='color:Tomato;'><i>rituximab</i></b> is a prognostic factor.","tokens":[{"text":"First-line","start":0,"end":10,"id":0,"ws":true},{"text":"chemotherapy","start":11,"end":23,"id":1,"ws":true},{"text":"was","start":24,"end":27,"id":2,"ws":true},{"text":"either","start":28,"end":34,"id":3,"ws":true},{"text":"R-CHOP","start":35,"end":41,"id":4,"ws":true},{"text":"(","start":42,"end":43,"id":5,"ws":true},{"text":"rituximab","start":44,"end":53,"id":6,"ws":true},{"text":",","start":54,"end":55,"id":7,"ws":true},{"text":"cyclophosphamide","start":56,"end":72,"id":8,"ws":true},{"text":",","start":73,"end":74,"id":9,"ws":true},{"text":"doxorubicin","start":75,"end":86,"id":10,"ws":true},{"text":",","start":87,"end":88,"id":11,"ws":true},{"text":"vincristine","start":89,"end":100,"id":12,"ws":true},{"text":"and","start":101,"end":104,"id":13,"ws":true},{"text":"prednisolone","start":105,"end":117,"id":14,"ws":true},{"text":")","start":118,"end":119,"id":15,"ws":true},{"text":"or","start":120,"end":122,"id":16,"ws":true},{"text":"CHOP-like-based","start":123,"end":138,"id":17,"ws":true},{"text":"regimen","start":139,"end":146,"id":18,"ws":true},{"text":".","start":147,"end":148,"id":19,"ws":false}],"spans":[{"start":44,"end":53,"token_start":6,"token_end":6,"label":"DRUG"},{"start":56,"end":72,"token_start":8,"token_end":8,"label":"DRUG"},{"start":75,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},{"start":89,"end":100,"token_start":12,"token_end":12,"label":"DRUG"},{"start":105,"end":117,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24169330/","_input_hash":1227589076,"_task_hash":-754511544,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":44,"end":53,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":56,"end":72,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":8,"child":10,"head_span":{"start":56,"end":72,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":75,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":10,"child":12,"head_span":{"start":75,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":89,"end":100,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":12,"child":14,"head_span":{"start":89,"end":100,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":105,"end":117,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The combination of rituximab with vincristine and 5-day cyclophosphamide is able to produce CR in patients with advanced follicular lymphoma , even in patients resistant to third-generation regimens .","paragraph":"<h3><u>Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma.</u></h3>Therapeutic options for relapsed or refractory follicular lymphoma include combination chemotherapy, immunotherapy and, for selected patients, autotransplant. Because of the different mechanisms of action and non-overlapping toxicities, combination of <b style='color:Tomato;'><i>rituximab</i></b> with chemotherapy is a rational approach. ### methods 30 patients with follicular non-Hodgkin's lymphoma with advanced-stage disease were treated with four cycles of immunochemotherapy with <b style='color:Tomato;'><i>rituximab</i></b> 375 mg/m2 on day 1, <b style='color:Tomato;'><i>vincristine</i></b> 2 mg i.v. on day 2 and <b style='color:Tomato;'><i>cyclophosphamide</i></b> 400 mg/m2 i.v. from days 2 to 6, repeated at 3-week intervals. All patients had received multiple lines of therapy (median 3); 9 (30%) had relapses (2 after high-dose therapy with autologous transplant), and 21 (70%) were in relapse and refractory to salvage treatment (with an anthracycline-containing regimen in 19). ### results Of 29 patients evaluable for response, 16 (55 %) obtained a complete response (CR) and 3 (10%) a partial response (PR), with an overall response rate of 65% (19/29); 10 patients (35%) achieved less than PR. The median event-free survival was 16.1 months for all patients, being 22.8 months for responders. After a median follow-up of 2 years from the start of therapy (range 6 months to 3.8 years), of 16 patients who achieved CR, 10 remain free of disease. ### conclusion <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5-day</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>able</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>CR</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>follicular</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>even</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>third-generation</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The regimen designed on the basis of pharmacokinetics of the chimeric antibody seemed important for the clinical efficacy of the combination.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"combination","start":4,"end":15,"id":1,"ws":true},{"text":"of","start":16,"end":18,"id":2,"ws":true},{"text":"rituximab","start":19,"end":28,"id":3,"ws":true},{"text":"with","start":29,"end":33,"id":4,"ws":true},{"text":"vincristine","start":34,"end":45,"id":5,"ws":true},{"text":"and","start":46,"end":49,"id":6,"ws":true},{"text":"5-day","start":50,"end":55,"id":7,"ws":true},{"text":"cyclophosphamide","start":56,"end":72,"id":8,"ws":true},{"text":"is","start":73,"end":75,"id":9,"ws":true},{"text":"able","start":76,"end":80,"id":10,"ws":true},{"text":"to","start":81,"end":83,"id":11,"ws":true},{"text":"produce","start":84,"end":91,"id":12,"ws":true},{"text":"CR","start":92,"end":94,"id":13,"ws":true},{"text":"in","start":95,"end":97,"id":14,"ws":true},{"text":"patients","start":98,"end":106,"id":15,"ws":true},{"text":"with","start":107,"end":111,"id":16,"ws":true},{"text":"advanced","start":112,"end":120,"id":17,"ws":true},{"text":"follicular","start":121,"end":131,"id":18,"ws":true},{"text":"lymphoma","start":132,"end":140,"id":19,"ws":true},{"text":",","start":141,"end":142,"id":20,"ws":true},{"text":"even","start":143,"end":147,"id":21,"ws":true},{"text":"in","start":148,"end":150,"id":22,"ws":true},{"text":"patients","start":151,"end":159,"id":23,"ws":true},{"text":"resistant","start":160,"end":169,"id":24,"ws":true},{"text":"to","start":170,"end":172,"id":25,"ws":true},{"text":"third-generation","start":173,"end":189,"id":26,"ws":true},{"text":"regimens","start":190,"end":198,"id":27,"ws":true},{"text":".","start":199,"end":200,"id":28,"ws":false}],"spans":[{"start":19,"end":28,"token_start":3,"token_end":3,"label":"DRUG"},{"start":34,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},{"start":56,"end":72,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16006752/","_input_hash":-1125996466,"_task_hash":-1111940363,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":19,"end":28,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":34,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":8,"head_span":{"start":34,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":56,"end":72,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The results showed that lamotrigine did not produce any change in cognitive function , while carbamazepine produced cognitive dysfunction .","paragraph":"<h3><u>Effect of carbamazepine and lamotrigine on cognitive function and oxidative stress in brain during chemical epileptogenesis in rats.</u></h3>The present study assessed the effect of <b style='color:Tomato;'><i>carbamazepine</i></b> and <b style='color:Tomato;'><i>lamotrigine</i></b> on cognitive function and oxidative stress in brain during chemically induced epileptogenesis in rats. Epileptogenesis was induced by administration of pentylenetetrazole (30 mg/kg, s.c.) on alternate days (three times/week) for 9-11 weeks or until stage 4 of seizure score was achieved. The neurobehavioural parameters used for cognitive assessment were step-down latency in continuous avoidance apparatus and transfer latency in elevated plus maze test paradigm. <b style='color:Tomato;'><i>carbamazepine</i></b> and <b style='color:Tomato;'><i>lamotrigine</i></b> were administered intraperitoneally in doses of 60 mg/kg and 25 mg/kg, respectively, according to the groups, once a day for 11 weeks. Oxidative stress was assessed in isolated homogenized whole brain samples and estimated for the levels of malondialdehyde, reduced glutathione, catalase and superoxide dismutase. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>lamotrigine</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>any</i></b> <b style='color:DodgerBlue;'><i>change</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cognitive</i></b> <b style='color:DodgerBlue;'><i>function</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:MediumOrchid;'><i>carbamazepine</i></b> <b style='color:DodgerBlue;'><i>produced</i></b> <b style='color:DodgerBlue;'><i>cognitive</i></b> <b style='color:DodgerBlue;'><i>dysfunction</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Cognitive decline seen in the <b style='color:Tomato;'><i>carbamazepine</i></b>-treated pentylenetetrazole-kindled group was also associated with increased oxidative stress. <b style='color:Tomato;'><i>lamotrigine</i></b> treatment had no effect on oxidative stress parameters alone, while it significantly decreased oxidative stress in the pentylenetetrazole-kindled group as compared to the pentylenetetrazole-kindled <b style='color:Tomato;'><i>carbamazepine</i></b>-treated group.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"results","start":4,"end":11,"id":1,"ws":true},{"text":"showed","start":12,"end":18,"id":2,"ws":true},{"text":"that","start":19,"end":23,"id":3,"ws":true},{"text":"lamotrigine","start":24,"end":35,"id":4,"ws":true},{"text":"did","start":36,"end":39,"id":5,"ws":true},{"text":"not","start":40,"end":43,"id":6,"ws":true},{"text":"produce","start":44,"end":51,"id":7,"ws":true},{"text":"any","start":52,"end":55,"id":8,"ws":true},{"text":"change","start":56,"end":62,"id":9,"ws":true},{"text":"in","start":63,"end":65,"id":10,"ws":true},{"text":"cognitive","start":66,"end":75,"id":11,"ws":true},{"text":"function","start":76,"end":84,"id":12,"ws":true},{"text":",","start":85,"end":86,"id":13,"ws":true},{"text":"while","start":87,"end":92,"id":14,"ws":true},{"text":"carbamazepine","start":93,"end":106,"id":15,"ws":true},{"text":"produced","start":107,"end":115,"id":16,"ws":true},{"text":"cognitive","start":116,"end":125,"id":17,"ws":true},{"text":"dysfunction","start":126,"end":137,"id":18,"ws":true},{"text":".","start":138,"end":139,"id":19,"ws":false}],"spans":[{"start":24,"end":35,"token_start":4,"token_end":4,"label":"DRUG"},{"start":93,"end":106,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20002063/","_input_hash":1266528498,"_task_hash":-276814944,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"These results confirm that sequential decitabine and carboplatin requires further investigation as a combination treatment for melanoma .","paragraph":"<h3><u>Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.</u></h3>Melanoma has two key features, an over-representation of UV-induced mutations and resistance to DNA damaging chemotherapy agents. Both of these features may result from dysfunction of the nucleotide excision repair pathway, in particular the DNA damage detection branch, global genome repair (GGR). The key GGR component XPC does not respond to DNA damage in melanoma, the cause of this lack of response has not been investigated. In this study, we investigated the role of methylation in reduced XPC in melanoma. ### methods To reduce methylation and induce DNA-damage, melanoma cell lines were treated with <b style='color:Tomato;'><i>decitabine</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b>, individually and sequentially. Global DNA methylation levels, XPC mRNA and protein expression and methylation of the XPC promoter were examined. Apoptosis, cell proliferation and senescence were also quantified. XPC siRNA was used to determine that the responses seen were reliant on XPC induction. ### results Treatment with high-dose <b style='color:Tomato;'><i>decitabine</i></b> resulted in global demethylation, including the the shores of the XPC CpG island and significantly increased XPC mRNA expression. Lower, clinically relevant dose of <b style='color:Tomato;'><i>decitabine</i></b> also resulted in global demethylation including the CpG island shores and induced XPC in 50% of cell lines. <b style='color:Tomato;'><i>decitabine</i></b> followed by DNA-damaging <b style='color:Tomato;'><i>carboplatin</i></b> treatment led to significantly higher XPC expression in 75% of melanoma cell lines tested. Combined sequential treatment also resulted in a greater apoptotic response in 75% of cell lines compared to <b style='color:Tomato;'><i>carboplatin</i></b> alone, and significantly slowed cell proliferation, with some melanoma cell lines going into senescence. Inhibiting the increased XPC using siRNA had a small but significant negative effect, indicating that XPC plays a partial role in the response to sequential <b style='color:Tomato;'><i>decitabine</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b>. ### conclusions Demethylation using <b style='color:Tomato;'><i>decitabine</i></b> increased XPC and apoptosis after sequential <b style='color:Tomato;'><i>carboplatin</i></b>. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>confirm</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:MediumOrchid;'><i>decitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>requires</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>investigation</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"results","start":6,"end":13,"id":1,"ws":true},{"text":"confirm","start":14,"end":21,"id":2,"ws":true},{"text":"that","start":22,"end":26,"id":3,"ws":true},{"text":"sequential","start":27,"end":37,"id":4,"ws":true},{"text":"decitabine","start":38,"end":48,"id":5,"ws":true},{"text":"and","start":49,"end":52,"id":6,"ws":true},{"text":"carboplatin","start":53,"end":64,"id":7,"ws":true},{"text":"requires","start":65,"end":73,"id":8,"ws":true},{"text":"further","start":74,"end":81,"id":9,"ws":true},{"text":"investigation","start":82,"end":95,"id":10,"ws":true},{"text":"as","start":96,"end":98,"id":11,"ws":true},{"text":"a","start":99,"end":100,"id":12,"ws":true},{"text":"combination","start":101,"end":112,"id":13,"ws":true},{"text":"treatment","start":113,"end":122,"id":14,"ws":true},{"text":"for","start":123,"end":126,"id":15,"ws":true},{"text":"melanoma","start":127,"end":135,"id":16,"ws":true},{"text":".","start":136,"end":137,"id":17,"ws":false}],"spans":[{"start":38,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},{"start":53,"end":64,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29373959/","_input_hash":329451074,"_task_hash":947957786,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":5,"child":7,"head_span":{"start":38,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":53,"end":64,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"[ Rhabdomyosarcoma of the urinary bladder : complete remission induced by vinblastine , cis-platinum , and bleomycin ] .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>Rhabdomyosarcoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>urinary</i></b> <b style='color:DodgerBlue;'><i>bladder</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>remission</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cis-platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bleomycin</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Combination therapy consisting of <b style='color:Tomato;'><i>vincristine</i></b>, actinomycin-D, and <b style='color:Tomato;'><i>cyclophosphamide</i></b> with or without adriamycin is the most common chemotherapy for rhabdomyosarcoma in childhood. But the effective chemotherapy for rhabdomyosarcoma resistant to these four drugs has not been established. We report a case with rhabdomyosarcoma, which was resistant to these four drugs but responded completely to three drug combination chemotherapy consisting of <b style='color:Tomato;'><i>vinblastine</i></b>, cis-platinum, and <b style='color:Tomato;'><i>bleomycin</i></b> (VPB therapy). A 11-months-old boy was referred to us because of giant abdominal tumor. Postoperative diagnosis was Group III embryonal rhabdomyosarcoma of the urinary bladder. Partial resection was followed by <b style='color:Tomato;'><i>vincristine</i></b>, actinomycin-D, <b style='color:Tomato;'><i>cyclophosphamide</i></b>, and adriamycin, but his residual tumor was growing. Then VPB therapy was administered and the first course of the chemotherapy reduced the size of tumor. After three courses of VPB therapy the second-look operation was performed. At operation no residual tumor was found and a complete remission was confirmed. During the course of VPB therapy no severe adverse effect was detectable.","tokens":[{"text":"[","start":0,"end":1,"id":0,"ws":true},{"text":"Rhabdomyosarcoma","start":2,"end":18,"id":1,"ws":true},{"text":"of","start":19,"end":21,"id":2,"ws":true},{"text":"the","start":22,"end":25,"id":3,"ws":true},{"text":"urinary","start":26,"end":33,"id":4,"ws":true},{"text":"bladder","start":34,"end":41,"id":5,"ws":true},{"text":":","start":42,"end":43,"id":6,"ws":true},{"text":"complete","start":44,"end":52,"id":7,"ws":true},{"text":"remission","start":53,"end":62,"id":8,"ws":true},{"text":"induced","start":63,"end":70,"id":9,"ws":true},{"text":"by","start":71,"end":73,"id":10,"ws":true},{"text":"vinblastine","start":74,"end":85,"id":11,"ws":true},{"text":",","start":86,"end":87,"id":12,"ws":true},{"text":"cis-platinum","start":88,"end":100,"id":13,"ws":true},{"text":",","start":101,"end":102,"id":14,"ws":true},{"text":"and","start":103,"end":106,"id":15,"ws":true},{"text":"bleomycin","start":107,"end":116,"id":16,"ws":true},{"text":"]","start":117,"end":118,"id":17,"ws":true},{"text":".","start":119,"end":120,"id":18,"ws":false}],"spans":[{"start":74,"end":85,"token_start":11,"token_end":11,"label":"DRUG"},{"start":107,"end":116,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6191695/","_input_hash":1763146291,"_task_hash":228955403,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":11,"child":13,"head_span":{"start":74,"end":85,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":88,"end":100,"token_start":13,"token_end":13,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":13,"child":16,"head_span":{"start":88,"end":100,"token_start":13,"token_end":13,"label":null},"child_span":{"start":107,"end":116,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Recent comparative studies suggest that atenolol ( 200 mg daily ) , metoprolol ( 200 mg daily ) ; acebutolol ( 400 mg daily ) , oxprenolol ( 160 mg daily ) , nadolol ( 80 mg daily ) and timolol ( 20 mg daily ) produce a beneficial clinical response equal to that seen with propranolol ( 160 mg daily ) .","paragraph":"<h3><u>Use of beta-adrenoceptor blocking drugs in hyperthyroidism.</u></h3>There is an increasing use and variety of beta-adrenoceptor blocking agents (beta-blockers) available for the treatment of hyperthyroidism. <b style='color:DodgerBlue;'><i>Recent</i></b> <b style='color:DodgerBlue;'><i>comparative</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>atenolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>metoprolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:MediumOrchid;'><i>acebutolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>400</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>oxprenolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>160</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>nadolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>timolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>beneficial</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>equal</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>seen</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>160</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Most beta-blockers reduce resting heart rate by approximately 25 to 30 beats/min, although a lesser reduction is seen with those possessing intrinsic sympathomimetic activity such as <b style='color:Tomato;'><i>oxprenolol</i></b> and <b style='color:Tomato;'><i>pindolol</i></b>. While earlier studies employing large doses of intravenous <b style='color:Tomato;'><i>propranolol</i></b> concluded that beta-blockade reduced myocardial contractility, more recent non-invasive studies suggest that the predominant cardiac effect is on heart rate. In patients with cardiac failure, beta-blockers may, however, produce a profound fall in cardiac output. Nevertheless, in combination with <b style='color:Tomato;'><i>digoxin</i></b> they may be useful in controlling the atrial fibrillation of thyrocardiac disease. beta-Blockers improve nervousness and tremor (although to a lesser extent with cardioselective agents) and severe myopathy, and they also reduce the frequency of paralysis in patients with thyrotoxic periodic paralysis. There is often subjective improvement in sweating but usually no major effect on eye signs. Recent studies show a 10% reduction in oxygen consumption/basal metabolic rate with long term oral use of selective or nonselective beta-blockers. In addition, many agents (<b style='color:Tomato;'><i>propranolol</i></b>, <b style='color:Tomato;'><i>metoprolol</i></b>, <b style='color:Tomato;'><i>nadolol</i></b> and <b style='color:Tomato;'><i>sotalol</i></b> but not <b style='color:Tomato;'><i>acebutolol</i></b>, <b style='color:Tomato;'><i>atenolol</i></b> or <b style='color:Tomato;'><i>oxprenolol</i></b>) reduce circulating tri-iodothyronine (T3) concentration by between 10 and 40%, although the clinical significance of this effect (if any) is not established. beta-Blockers may also have endocrinological effects on gastrin, cyclic AMP, catecholamines and other hormone levels. Given in adequate dosage, <b style='color:Tomato;'><i>propranolol</i></b> has been shown to control thyrotoxic hypercalcaemia. Minor side effects (nausea, headaches, tiredness, etc.) are quite common but overall beta-blockers are well tolerated by the thyrotoxic patient. The major use of these drugs is in symptomatic control while awaiting definitive diagnosis or treatment. As an adjunct to antithyroid drugs or radioactive iodine, beta-blockers will produce a satisfactory clinical response in the weeks to months before these forms of therapy produce a euthyroid state. beta-Blockers are more convenient than antithyroid drugs in the control of patients receiving therapeutic radioiodine, in that continuous therapy and assessment of biochemical response is possible.(ABSTRACT TRUNCATED AT 400 WORDS)","tokens":[{"text":"Recent","start":0,"end":6,"id":0,"ws":true},{"text":"comparative","start":7,"end":18,"id":1,"ws":true},{"text":"studies","start":19,"end":26,"id":2,"ws":true},{"text":"suggest","start":27,"end":34,"id":3,"ws":true},{"text":"that","start":35,"end":39,"id":4,"ws":true},{"text":"atenolol","start":40,"end":48,"id":5,"ws":true},{"text":"(","start":49,"end":50,"id":6,"ws":true},{"text":"200","start":51,"end":54,"id":7,"ws":true},{"text":"mg","start":55,"end":57,"id":8,"ws":true},{"text":"daily","start":58,"end":63,"id":9,"ws":true},{"text":")","start":64,"end":65,"id":10,"ws":true},{"text":",","start":66,"end":67,"id":11,"ws":true},{"text":"metoprolol","start":68,"end":78,"id":12,"ws":true},{"text":"(","start":79,"end":80,"id":13,"ws":true},{"text":"200","start":81,"end":84,"id":14,"ws":true},{"text":"mg","start":85,"end":87,"id":15,"ws":true},{"text":"daily","start":88,"end":93,"id":16,"ws":true},{"text":")","start":94,"end":95,"id":17,"ws":true},{"text":";","start":96,"end":97,"id":18,"ws":true},{"text":"acebutolol","start":98,"end":108,"id":19,"ws":true},{"text":"(","start":109,"end":110,"id":20,"ws":true},{"text":"400","start":111,"end":114,"id":21,"ws":true},{"text":"mg","start":115,"end":117,"id":22,"ws":true},{"text":"daily","start":118,"end":123,"id":23,"ws":true},{"text":")","start":124,"end":125,"id":24,"ws":true},{"text":",","start":126,"end":127,"id":25,"ws":true},{"text":"oxprenolol","start":128,"end":138,"id":26,"ws":true},{"text":"(","start":139,"end":140,"id":27,"ws":true},{"text":"160","start":141,"end":144,"id":28,"ws":true},{"text":"mg","start":145,"end":147,"id":29,"ws":true},{"text":"daily","start":148,"end":153,"id":30,"ws":true},{"text":")","start":154,"end":155,"id":31,"ws":true},{"text":",","start":156,"end":157,"id":32,"ws":true},{"text":"nadolol","start":158,"end":165,"id":33,"ws":true},{"text":"(","start":166,"end":167,"id":34,"ws":true},{"text":"80","start":168,"end":170,"id":35,"ws":true},{"text":"mg","start":171,"end":173,"id":36,"ws":true},{"text":"daily","start":174,"end":179,"id":37,"ws":true},{"text":")","start":180,"end":181,"id":38,"ws":true},{"text":"and","start":182,"end":185,"id":39,"ws":true},{"text":"timolol","start":186,"end":193,"id":40,"ws":true},{"text":"(","start":194,"end":195,"id":41,"ws":true},{"text":"20","start":196,"end":198,"id":42,"ws":true},{"text":"mg","start":199,"end":201,"id":43,"ws":true},{"text":"daily","start":202,"end":207,"id":44,"ws":true},{"text":")","start":208,"end":209,"id":45,"ws":true},{"text":"produce","start":210,"end":217,"id":46,"ws":true},{"text":"a","start":218,"end":219,"id":47,"ws":true},{"text":"beneficial","start":220,"end":230,"id":48,"ws":true},{"text":"clinical","start":231,"end":239,"id":49,"ws":true},{"text":"response","start":240,"end":248,"id":50,"ws":true},{"text":"equal","start":249,"end":254,"id":51,"ws":true},{"text":"to","start":255,"end":257,"id":52,"ws":true},{"text":"that","start":258,"end":262,"id":53,"ws":true},{"text":"seen","start":263,"end":267,"id":54,"ws":true},{"text":"with","start":268,"end":272,"id":55,"ws":true},{"text":"propranolol","start":273,"end":284,"id":56,"ws":true},{"text":"(","start":285,"end":286,"id":57,"ws":true},{"text":"160","start":287,"end":290,"id":58,"ws":true},{"text":"mg","start":291,"end":293,"id":59,"ws":true},{"text":"daily","start":294,"end":299,"id":60,"ws":true},{"text":")","start":300,"end":301,"id":61,"ws":true},{"text":".","start":302,"end":303,"id":62,"ws":false}],"spans":[{"start":40,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},{"start":68,"end":78,"token_start":12,"token_end":12,"label":"DRUG"},{"start":98,"end":108,"token_start":19,"token_end":19,"label":"DRUG"},{"start":128,"end":138,"token_start":26,"token_end":26,"label":"DRUG"},{"start":158,"end":165,"token_start":33,"token_end":33,"label":"DRUG"},{"start":186,"end":193,"token_start":40,"token_end":40,"label":"DRUG"},{"start":273,"end":284,"token_start":56,"token_end":56,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6144501/","_input_hash":990193972,"_task_hash":-9132630,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":5,"child":12,"head_span":{"start":40,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":68,"end":78,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":12,"child":19,"head_span":{"start":68,"end":78,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":98,"end":108,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":19,"child":26,"head_span":{"start":98,"end":108,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":128,"end":138,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":26,"child":33,"head_span":{"start":128,"end":138,"token_start":26,"token_end":26,"label":"DRUG"},"child_span":{"start":158,"end":165,"token_start":33,"token_end":33,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":33,"child":40,"head_span":{"start":158,"end":165,"token_start":33,"token_end":33,"label":"DRUG"},"child_span":{"start":186,"end":193,"token_start":40,"token_end":40,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"All the animals in the placebo group had tumors in each lobe compared with only 43 % each in the dorsolateral ( DLP ) and anterior prostate ( AP ) of the animals treated with raloxifene ( 10 mg/kg/day ) plus nimesulide .","paragraph":"<h3><u>Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.</u></h3>The chemopreventive efficacies of <b style='color:Tomato;'><i>raloxifene</i></b> and <b style='color:Tomato;'><i>nimesulide</i></b>, an anti-estrogen but with anti-androgen action and a cyclooxygenase-2 (COX-2) selective inhibitor, respectively, were evaluated in probasin/SV40 T antigen (Tag) transgenic (TG) rats. The treatment groups were placebo, <b style='color:Tomato;'><i>nimesulide</i></b> (400 p.p.m. in basal diet p.o.), <b style='color:Tomato;'><i>raloxifene</i></b> (slow-release pellets implanted s.c., 5 mg/kg/day), <b style='color:Tomato;'><i>raloxifene</i></b> (5 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> (400 p.p.m.), and <b style='color:Tomato;'><i>raloxifene</i></b> (10 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> (400 p.p.m.). Animals were killed at 17 weeks of age, and prostate tissues were harvested and weighed by lobes. Tissues were evaluated by histology, immunohistochemistry, and western blot analyses and blood was collected to measure the testosterone levels. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>animals</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>lobe</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>43</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsolateral</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>DLP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anterior</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>animals</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>raloxifene</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg/kg/day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>nimesulide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The total prostate weights and adenocarcinoma portions were significantly reduced in the three <b style='color:Tomato;'><i>raloxifene</i></b>-treated groups, whereas atrophic glands were increased. There were no significant differences between the <b style='color:Tomato;'><i>nimesulide</i></b> alone and placebo groups or between the <b style='color:Tomato;'><i>raloxifene</i></b> (5 mg/kg/day) alone and <b style='color:Tomato;'><i>raloxifene</i></b> (5 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> group, suggesting a lack of cancer preventive effects of the COX-2 inhibitor in this animal model. PCNA positive rates in ventral prostate (VP) and DLP, and androgen receptor (AR) levels in VP were significantly reduced in the three <b style='color:Tomato;'><i>raloxifene</i></b>-treated groups. Furthermore, circulating testosterone was decreased after <b style='color:Tomato;'><i>raloxifene</i></b> (10 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> treatment. These results demonstrate that <b style='color:Tomato;'><i>raloxifene</i></b>, but not <b style='color:Tomato;'><i>nimesulide</i></b>, inhibits prostate carcinogenesis in SV40 Tag TG rats associated with a decline in circulating testosterone levels and a loss of AR expression, as well as an inhibition of cell proliferation.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"the","start":4,"end":7,"id":1,"ws":true},{"text":"animals","start":8,"end":15,"id":2,"ws":true},{"text":"in","start":16,"end":18,"id":3,"ws":true},{"text":"the","start":19,"end":22,"id":4,"ws":true},{"text":"placebo","start":23,"end":30,"id":5,"ws":true},{"text":"group","start":31,"end":36,"id":6,"ws":true},{"text":"had","start":37,"end":40,"id":7,"ws":true},{"text":"tumors","start":41,"end":47,"id":8,"ws":true},{"text":"in","start":48,"end":50,"id":9,"ws":true},{"text":"each","start":51,"end":55,"id":10,"ws":true},{"text":"lobe","start":56,"end":60,"id":11,"ws":true},{"text":"compared","start":61,"end":69,"id":12,"ws":true},{"text":"with","start":70,"end":74,"id":13,"ws":true},{"text":"only","start":75,"end":79,"id":14,"ws":true},{"text":"43","start":80,"end":82,"id":15,"ws":true},{"text":"%","start":83,"end":84,"id":16,"ws":true},{"text":"each","start":85,"end":89,"id":17,"ws":true},{"text":"in","start":90,"end":92,"id":18,"ws":true},{"text":"the","start":93,"end":96,"id":19,"ws":true},{"text":"dorsolateral","start":97,"end":109,"id":20,"ws":true},{"text":"(","start":110,"end":111,"id":21,"ws":true},{"text":"DLP","start":112,"end":115,"id":22,"ws":true},{"text":")","start":116,"end":117,"id":23,"ws":true},{"text":"and","start":118,"end":121,"id":24,"ws":true},{"text":"anterior","start":122,"end":130,"id":25,"ws":true},{"text":"prostate","start":131,"end":139,"id":26,"ws":true},{"text":"(","start":140,"end":141,"id":27,"ws":true},{"text":"AP","start":142,"end":144,"id":28,"ws":true},{"text":")","start":145,"end":146,"id":29,"ws":true},{"text":"of","start":147,"end":149,"id":30,"ws":true},{"text":"the","start":150,"end":153,"id":31,"ws":true},{"text":"animals","start":154,"end":161,"id":32,"ws":true},{"text":"treated","start":162,"end":169,"id":33,"ws":true},{"text":"with","start":170,"end":174,"id":34,"ws":true},{"text":"raloxifene","start":175,"end":185,"id":35,"ws":true},{"text":"(","start":186,"end":187,"id":36,"ws":true},{"text":"10","start":188,"end":190,"id":37,"ws":true},{"text":"mg/kg/day","start":191,"end":200,"id":38,"ws":true},{"text":")","start":201,"end":202,"id":39,"ws":true},{"text":"plus","start":203,"end":207,"id":40,"ws":true},{"text":"nimesulide","start":208,"end":218,"id":41,"ws":true},{"text":".","start":219,"end":220,"id":42,"ws":false}],"spans":[{"start":175,"end":185,"token_start":35,"token_end":35,"label":"DRUG"},{"start":208,"end":218,"token_start":41,"token_end":41,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15731164/","_input_hash":-1074706345,"_task_hash":911107500,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":35,"child":41,"head_span":{"start":175,"end":185,"token_start":35,"token_end":35,"label":"DRUG"},"child_span":{"start":208,"end":218,"token_start":41,"token_end":41,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Overdose of dolutegravir in combination with tenofovir disaproxil fumarate/emtricitabine in suicide attempt in a 21-year old patient .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Overdose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>dolutegravir</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tenofovir</i></b> <b style='color:DodgerBlue;'><i>disaproxil</i></b> <b style='color:DodgerBlue;'><i>fumarate/emtricitabine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>suicide</i></b> <b style='color:DodgerBlue;'><i>attempt</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>21-year</i></b> <b style='color:DodgerBlue;'><i>old</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>A 21\u00a0year old MSM patient with newly diagnosed HIV infection was hospitalized in our department after ingestion of an overdose of his antiretroviral therapy (ART) comprising <b style='color:Tomato;'><i>dolutegravir</i></b> (DTG - Tivicay\u00ae) and <b style='color:Tomato;'><i>tenofovir</i></b> disaproxil fumarate/<b style='color:Tomato;'><i>emtricitabine</i></b> (Truvada\u00ae) in suicidal intention. On admission, the patient did not show any clinical signs of intoxication and laboratory findings were unremarkable. After 6\u00a0hours of intensive care monitoring, the patient was referred to a psychiatric clinic. 5\u00a0days after the day of intoxication, serum creatinine levels increased to high normal values (1.2\u00a0mg/dl). However, levels never exceeded the upper threshold. 8 and 12\u00a0weeks later, serum creatinine normalized to levels measured prior to the intoxication. No other adverse events occurred, and the patient does not suffer from permanent impairments.","tokens":[{"text":"Overdose","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"dolutegravir","start":12,"end":24,"id":2,"ws":true},{"text":"in","start":25,"end":27,"id":3,"ws":true},{"text":"combination","start":28,"end":39,"id":4,"ws":true},{"text":"with","start":40,"end":44,"id":5,"ws":true},{"text":"tenofovir","start":45,"end":54,"id":6,"ws":true},{"text":"disaproxil","start":55,"end":65,"id":7,"ws":true},{"text":"fumarate/emtricitabine","start":66,"end":88,"id":8,"ws":true},{"text":"in","start":89,"end":91,"id":9,"ws":true},{"text":"suicide","start":92,"end":99,"id":10,"ws":true},{"text":"attempt","start":100,"end":107,"id":11,"ws":true},{"text":"in","start":108,"end":110,"id":12,"ws":true},{"text":"a","start":111,"end":112,"id":13,"ws":true},{"text":"21-year","start":113,"end":120,"id":14,"ws":true},{"text":"old","start":121,"end":124,"id":15,"ws":true},{"text":"patient","start":125,"end":132,"id":16,"ws":true},{"text":".","start":133,"end":134,"id":17,"ws":false}],"spans":[{"start":12,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},{"start":45,"end":54,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26045712/","_input_hash":-247737991,"_task_hash":-854886939,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer : a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes .","paragraph":"<h3><u><b style='color:MediumOrchid;'><i>Abiraterone</i></b> <b style='color:DodgerBlue;'><i>acetate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pre-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>post-docetaxel</i></b> <b style='color:DodgerBlue;'><i>setting</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>mono-institutional</i></b> <b style='color:DodgerBlue;'><i>experience</i></b> <b style='color:DodgerBlue;'><i>focused</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>cardiovascular</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>impact</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>outcomes</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The aim of this work was to to evaluate the incidence and risk factors of adverse events (AEs), focusing on cardiovascular events (CVEs) and hypokalemia, in patients treated with <b style='color:Tomato;'><i>abiraterone</i></b> acetate (AA) and <b style='color:Tomato;'><i>prednisone</i></b> (PDN) outside clinical trials, and their association with survival outcomes. ### methods This was a retrospective cohort study of 105 patients treated from 2011 to 2016. Incidence of AEs was descriptively summarized in the whole cohort and by subgroup (pre- ### results Overall, median PFS and OS were 14.9 and 24.6 months, respectively. Prostate-specific antigen (PSA) \u2a7e 10 ng/ml ( ### conclusions Median PFS and OS estimates and incidence of CVEs and hypokalemia in our series are consistent with those of pivotal trials of AA plus PDN, confirming the efficacy and safety of this regimen also in the real-world setting. Elderly patients have higher odds of developing/worsening CVEs. However, regardless of age, CVEs were not associated with worse outcomes. Treatment-related hypokalemia seemed to be associated with longer OS, albeit this finding needs confirmation within larger, prospective series.","tokens":[{"text":"Abiraterone","start":0,"end":11,"id":0,"ws":true},{"text":"acetate","start":12,"end":19,"id":1,"ws":true},{"text":"and","start":20,"end":23,"id":2,"ws":true},{"text":"prednisone","start":24,"end":34,"id":3,"ws":true},{"text":"in","start":35,"end":37,"id":4,"ws":true},{"text":"the","start":38,"end":41,"id":5,"ws":true},{"text":"pre-","start":42,"end":46,"id":6,"ws":true},{"text":"and","start":47,"end":50,"id":7,"ws":true},{"text":"post-docetaxel","start":51,"end":65,"id":8,"ws":true},{"text":"setting","start":66,"end":73,"id":9,"ws":true},{"text":"for","start":74,"end":77,"id":10,"ws":true},{"text":"metastatic","start":78,"end":88,"id":11,"ws":true},{"text":"castration-resistant","start":89,"end":109,"id":12,"ws":true},{"text":"prostate","start":110,"end":118,"id":13,"ws":true},{"text":"cancer","start":119,"end":125,"id":14,"ws":true},{"text":":","start":126,"end":127,"id":15,"ws":true},{"text":"a","start":128,"end":129,"id":16,"ws":true},{"text":"mono-institutional","start":130,"end":148,"id":17,"ws":true},{"text":"experience","start":149,"end":159,"id":18,"ws":true},{"text":"focused","start":160,"end":167,"id":19,"ws":true},{"text":"on","start":168,"end":170,"id":20,"ws":true},{"text":"cardiovascular","start":171,"end":185,"id":21,"ws":true},{"text":"events","start":186,"end":192,"id":22,"ws":true},{"text":"and","start":193,"end":196,"id":23,"ws":true},{"text":"their","start":197,"end":202,"id":24,"ws":true},{"text":"impact","start":203,"end":209,"id":25,"ws":true},{"text":"on","start":210,"end":212,"id":26,"ws":true},{"text":"clinical","start":213,"end":221,"id":27,"ws":true},{"text":"outcomes","start":222,"end":230,"id":28,"ws":true},{"text":".","start":231,"end":232,"id":29,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":24,"end":34,"token_start":3,"token_end":3,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29383035/","_input_hash":-1606804744,"_task_hash":761335342,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":0,"child":3,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":24,"end":34,"token_start":3,"token_end":3,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Nivolumab plus ipilimumab combined therapy is among the most effective therapies for advanced melanoma .","paragraph":"<h3><u>Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma.</u></h3> <b style='color:MediumOrchid;'><i>Nivolumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>among</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, this therapy is also associated with a high frequency of immune-related adverse events (irAEs). To avoid such severe irAEs caused by additional administration of anti-CTLA4 antibodies, biomarkers to distinguish responders from non-responders among patients treated with anti-PD1 antibodies are important. The purpose of this study is to evaluate the increased serum levels of CCL11, CCL24, and CCL26 as a predictive biomarker for the efficacy of anti-PD1 antibodies in advanced cutaneous melanoma patients. This study analyzed increased serum levels of CCL11, CCL24, and CCL26 in 46 cases of advanced cutaneous melanoma treated with anti-PD1 antibodies. Serum levels on day 42 were compared to baseline (day 0) and analyzed statistically. Receiver operating characteristic curves were established to evaluate the correlation between serum levels of CCL11, CCL24, and CCL26 and efficacy of anti-PD1 antibodies. Increased serum levels of CCL26 correlated significantly with the efficacy of anti-PD1 antibodies. In contrast, no significant correlations were seen between increased serum levels of CCL11 and CCL24 and efficacy of anti-PD1 antibodies. Increased serum levels of CCL26 may be a useful biomarker for identifying those patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.","tokens":[{"text":"Nivolumab","start":0,"end":9,"id":0,"ws":true},{"text":"plus","start":10,"end":14,"id":1,"ws":true},{"text":"ipilimumab","start":15,"end":25,"id":2,"ws":true},{"text":"combined","start":26,"end":34,"id":3,"ws":true},{"text":"therapy","start":35,"end":42,"id":4,"ws":true},{"text":"is","start":43,"end":45,"id":5,"ws":true},{"text":"among","start":46,"end":51,"id":6,"ws":true},{"text":"the","start":52,"end":55,"id":7,"ws":true},{"text":"most","start":56,"end":60,"id":8,"ws":true},{"text":"effective","start":61,"end":70,"id":9,"ws":true},{"text":"therapies","start":71,"end":80,"id":10,"ws":true},{"text":"for","start":81,"end":84,"id":11,"ws":true},{"text":"advanced","start":85,"end":93,"id":12,"ws":true},{"text":"melanoma","start":94,"end":102,"id":13,"ws":true},{"text":".","start":103,"end":104,"id":14,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":15,"end":25,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32658051/","_input_hash":238886149,"_task_hash":2049657732,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":15,"end":25,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Cells that were sequentially exposed to rapamycin and topotecan had significantly higher levels of cleaved caspase-8 , -3 , and PARP compared to those treated with topotecan alone .","paragraph":"<h3><u>Rapamycin-topotecan combination exhibited enhanced antitumor efficacy compared to topotecan used alone in cisplatin-resistant ovarian cancer cells.</u></h3>The present study aimed to investigate the antitumor efficacy of combination of <b style='color:Tomato;'><i>topotecan</i></b> with <b style='color:Tomato;'><i>rapamycin</i></b>, a\u00a0mTOR inhibitor, in <b style='color:Tomato;'><i>cisplatin</i></b>-resistant ovarian cancer cells A2780cis and COC1/DDP. Expressions of mTOR and its target molecules p70S6K and 4E-BP1 were determined in A2780cis and COC1/DDP and the parental cells A2780 and COC1 that are sensitive to <b style='color:Tomato;'><i>cisplatin</i></b> using Western blotting. Cell proliferation was examined using MTT assay in vitro and a\u00a0nude mouse model in vivo, respectively. Cell apoptosis and the relevant proteins were determined by flow cytometry and Western blotting. We found that the levels of phosphorylated mTOR, p70S6K, and 4E-BP1 were obviously higher in A2780cis and COC1/DDP cells than that in A2780 and COC1 cells. Pretreatment with <b style='color:Tomato;'><i>rapamycin</i></b> significantly enhanced the effects of <b style='color:Tomato;'><i>topotecan</i></b> in suppressing cell proliferation and soliciting cell apoptosis in A2780cis and COC1/DDP cells. <b style='color:DodgerBlue;'><i>Cells</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>sequentially</i></b> <b style='color:DodgerBlue;'><i>exposed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cleaved</i></b> <b style='color:DodgerBlue;'><i>caspase-8</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>-3</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>PARP</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Mice co-administered <b style='color:Tomato;'><i>rapamycin</i></b> and <b style='color:Tomato;'><i>topotecan</i></b> had significantly decreased terminal tumor burden without additional loss of bodyweight compared to the mice received <b style='color:Tomato;'><i>topotecan</i></b> alone. The results suggested that <b style='color:Tomato;'><i>rapamycin</i></b> sensitized A2780cis and COC1/DDP cells to <b style='color:Tomato;'><i>topotecan</i></b>-induced apoptosis and <b style='color:Tomato;'><i>rapamycin</i></b>-<b style='color:Tomato;'><i>topotecan</i></b> combination might have a\u00a0value in treatment of <b style='color:Tomato;'><i>cisplatin</i></b>-resistant ovarian cancer.","tokens":[{"text":"Cells","start":0,"end":5,"id":0,"ws":true},{"text":"that","start":6,"end":10,"id":1,"ws":true},{"text":"were","start":11,"end":15,"id":2,"ws":true},{"text":"sequentially","start":16,"end":28,"id":3,"ws":true},{"text":"exposed","start":29,"end":36,"id":4,"ws":true},{"text":"to","start":37,"end":39,"id":5,"ws":true},{"text":"rapamycin","start":40,"end":49,"id":6,"ws":true},{"text":"and","start":50,"end":53,"id":7,"ws":true},{"text":"topotecan","start":54,"end":63,"id":8,"ws":true},{"text":"had","start":64,"end":67,"id":9,"ws":true},{"text":"significantly","start":68,"end":81,"id":10,"ws":true},{"text":"higher","start":82,"end":88,"id":11,"ws":true},{"text":"levels","start":89,"end":95,"id":12,"ws":true},{"text":"of","start":96,"end":98,"id":13,"ws":true},{"text":"cleaved","start":99,"end":106,"id":14,"ws":true},{"text":"caspase-8","start":107,"end":116,"id":15,"ws":true},{"text":",","start":117,"end":118,"id":16,"ws":true},{"text":"-3","start":119,"end":121,"id":17,"ws":true},{"text":",","start":122,"end":123,"id":18,"ws":true},{"text":"and","start":124,"end":127,"id":19,"ws":true},{"text":"PARP","start":128,"end":132,"id":20,"ws":true},{"text":"compared","start":133,"end":141,"id":21,"ws":true},{"text":"to","start":142,"end":144,"id":22,"ws":true},{"text":"those","start":145,"end":150,"id":23,"ws":true},{"text":"treated","start":151,"end":158,"id":24,"ws":true},{"text":"with","start":159,"end":163,"id":25,"ws":true},{"text":"topotecan","start":164,"end":173,"id":26,"ws":true},{"text":"alone","start":174,"end":179,"id":27,"ws":true},{"text":".","start":180,"end":181,"id":28,"ws":false}],"spans":[{"start":40,"end":49,"token_start":6,"token_end":6,"label":"DRUG"},{"start":54,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},{"start":164,"end":173,"token_start":26,"token_end":26,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26278147/","_input_hash":1375843614,"_task_hash":-289441407,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":40,"end":49,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":54,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"No cross-resistance was found with conventional drugs , being PNU-159548 active also in cells resistant to doxorubicin and with a multidrug resistance phenotype ( associated with MDR1 gene/P-glycoprotein overexpression ) , as well as in cells resistant to methotrexate or to cisplatin .","paragraph":"<h3><u>4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.</u></h3>The effectiveness of the alkycycline 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-<b style='color:Tomato;'><i>daunorubicin</i></b> (PNU-159548, ladirubicin), a new drug with high antitumour activity against a broad range of neoplasms, was evaluated by using a panel of 32 human osteosarcoma cell lines, including cell lines resistant to <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, or <b style='color:Tomato;'><i>cisplatin</i></b>. PNU-159548 resulted to be highly active in all cell lines. <b style='color:DodgerBlue;'><i>No</i></b> <b style='color:DodgerBlue;'><i>cross-resistance</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>conventional</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>being</i></b> <b style='color:DodgerBlue;'><i>PNU-159548</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multidrug</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>phenotype</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MDR1</i></b> <b style='color:DodgerBlue;'><i>gene/P-glycoprotein</i></b> <b style='color:DodgerBlue;'><i>overexpression</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Analysis of drug-drug interactions showed that PNU-159548 could be successfully used in combination with all the most important drugs currently used in OS chemotherapy. In fact, the simultaneous administration of PNU-159548 and <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, or <b style='color:Tomato;'><i>cisplatin</i></b> produced mostly additive or synergistic effects. Sequential exposure to PNU-159548 followed immediately by <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, or <b style='color:Tomato;'><i>cisplatin</i></b> was the most effective sequence of administration, invariably resulting in additive or synergistic effects in both drug-sensitive and drug-resistant osteosarcoma cell lines. In conclusion, the high in vitro effectiveness, the absence of cross-resistance with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, or <b style='color:Tomato;'><i>cisplatin</i></b> and the possibility to be successfully used in combination with these drugs indicate PNU-159548 as a promising candidate to be considered for planning new therapeutic regimens for osteosarcoma patients, who show a decreased response to conventional chemotherapy.","tokens":[{"text":"No","start":0,"end":2,"id":0,"ws":true},{"text":"cross-resistance","start":3,"end":19,"id":1,"ws":true},{"text":"was","start":20,"end":23,"id":2,"ws":true},{"text":"found","start":24,"end":29,"id":3,"ws":true},{"text":"with","start":30,"end":34,"id":4,"ws":true},{"text":"conventional","start":35,"end":47,"id":5,"ws":true},{"text":"drugs","start":48,"end":53,"id":6,"ws":true},{"text":",","start":54,"end":55,"id":7,"ws":true},{"text":"being","start":56,"end":61,"id":8,"ws":true},{"text":"PNU-159548","start":62,"end":72,"id":9,"ws":true},{"text":"active","start":73,"end":79,"id":10,"ws":true},{"text":"also","start":80,"end":84,"id":11,"ws":true},{"text":"in","start":85,"end":87,"id":12,"ws":true},{"text":"cells","start":88,"end":93,"id":13,"ws":true},{"text":"resistant","start":94,"end":103,"id":14,"ws":true},{"text":"to","start":104,"end":106,"id":15,"ws":true},{"text":"doxorubicin","start":107,"end":118,"id":16,"ws":true},{"text":"and","start":119,"end":122,"id":17,"ws":true},{"text":"with","start":123,"end":127,"id":18,"ws":true},{"text":"a","start":128,"end":129,"id":19,"ws":true},{"text":"multidrug","start":130,"end":139,"id":20,"ws":true},{"text":"resistance","start":140,"end":150,"id":21,"ws":true},{"text":"phenotype","start":151,"end":160,"id":22,"ws":true},{"text":"(","start":161,"end":162,"id":23,"ws":true},{"text":"associated","start":163,"end":173,"id":24,"ws":true},{"text":"with","start":174,"end":178,"id":25,"ws":true},{"text":"MDR1","start":179,"end":183,"id":26,"ws":true},{"text":"gene/P-glycoprotein","start":184,"end":203,"id":27,"ws":true},{"text":"overexpression","start":204,"end":218,"id":28,"ws":true},{"text":")","start":219,"end":220,"id":29,"ws":true},{"text":",","start":221,"end":222,"id":30,"ws":true},{"text":"as","start":223,"end":225,"id":31,"ws":true},{"text":"well","start":226,"end":230,"id":32,"ws":true},{"text":"as","start":231,"end":233,"id":33,"ws":true},{"text":"in","start":234,"end":236,"id":34,"ws":true},{"text":"cells","start":237,"end":242,"id":35,"ws":true},{"text":"resistant","start":243,"end":252,"id":36,"ws":true},{"text":"to","start":253,"end":255,"id":37,"ws":true},{"text":"methotrexate","start":256,"end":268,"id":38,"ws":true},{"text":"or","start":269,"end":271,"id":39,"ws":true},{"text":"to","start":272,"end":274,"id":40,"ws":true},{"text":"cisplatin","start":275,"end":284,"id":41,"ws":true},{"text":".","start":285,"end":286,"id":42,"ws":false}],"spans":[{"start":62,"end":72,"token_start":9,"token_end":9,"label":"DRUG"},{"start":107,"end":118,"token_start":16,"token_end":16,"label":"DRUG"},{"start":256,"end":268,"token_start":38,"token_end":38,"label":"DRUG"},{"start":275,"end":284,"token_start":41,"token_end":41,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16140527/","_input_hash":-1391381095,"_task_hash":-2089933908,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Synergistic cytotoxic effects of recombinant human tumor necrosis factor and Etoposide ( VP16 ) or Doxorubicin on A2774 human epithelial ovarian cancer cell line .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Synergistic</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>recombinant</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>necrosis</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VP16</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>Doxorubicin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>A2774</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>epithelial</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>line</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Recombinant human tumor necrosis factor (rHuTNF) is a cytokine, with some antitumor activity, released by stimulated monocytes-macrophages. In vivo and in vitro cytotoxicity studies testing the effectiveness of rHuTNF alone or in combination with chemotherapeutic agents have been carried out. We have evaluated the direct cytotoxic effect of rHuTNF on a human epithelial ovarian cancer cell line in vitro (A2774), alone or in combination with <b style='color:Tomato;'><i>etoposide</i></b> (VP16) or <b style='color:Tomato;'><i>doxorubicin</i></b> (Doxo), some topoisomerase II (Topo II) targeted drugs, or in combination with <b style='color:Tomato;'><i>cisplatin</i></b> (CDDP), a not Topo II interactive drug. Our results suggest that rHuTNF is directly cytotoxic and that it is also able to induce a potentiation of VP16- or Doxo-cytotoxicity, but it is unable to potentiate CDDP-cytotoxicity. These data represent a reasonable basis for combining rHuTNF with Topo II inhibitors within phase I studies. The combination regimen could be tested in ovarian cancer patients.","tokens":[{"text":"Synergistic","start":0,"end":11,"id":0,"ws":true},{"text":"cytotoxic","start":12,"end":21,"id":1,"ws":true},{"text":"effects","start":22,"end":29,"id":2,"ws":true},{"text":"of","start":30,"end":32,"id":3,"ws":true},{"text":"recombinant","start":33,"end":44,"id":4,"ws":true},{"text":"human","start":45,"end":50,"id":5,"ws":true},{"text":"tumor","start":51,"end":56,"id":6,"ws":true},{"text":"necrosis","start":57,"end":65,"id":7,"ws":true},{"text":"factor","start":66,"end":72,"id":8,"ws":true},{"text":"and","start":73,"end":76,"id":9,"ws":true},{"text":"Etoposide","start":77,"end":86,"id":10,"ws":true},{"text":"(","start":87,"end":88,"id":11,"ws":true},{"text":"VP16","start":89,"end":93,"id":12,"ws":true},{"text":")","start":94,"end":95,"id":13,"ws":true},{"text":"or","start":96,"end":98,"id":14,"ws":true},{"text":"Doxorubicin","start":99,"end":110,"id":15,"ws":true},{"text":"on","start":111,"end":113,"id":16,"ws":true},{"text":"A2774","start":114,"end":119,"id":17,"ws":true},{"text":"human","start":120,"end":125,"id":18,"ws":true},{"text":"epithelial","start":126,"end":136,"id":19,"ws":true},{"text":"ovarian","start":137,"end":144,"id":20,"ws":true},{"text":"cancer","start":145,"end":151,"id":21,"ws":true},{"text":"cell","start":152,"end":156,"id":22,"ws":true},{"text":"line","start":157,"end":161,"id":23,"ws":true},{"text":".","start":162,"end":163,"id":24,"ws":false}],"spans":[{"start":45,"end":72,"token_start":5,"token_end":8,"label":"DRUG"},{"start":77,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},{"start":99,"end":110,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11576250/","_input_hash":464556084,"_task_hash":-284315972,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":45,"end":72,"token_start":5,"token_end":8,"label":"DRUG"},"child_span":{"start":77,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":8,"child":15,"head_span":{"start":45,"end":72,"token_start":5,"token_end":8,"label":"DRUG"},"child_span":{"start":99,"end":110,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"Many ESBL-producing E. coli had significantly lower susceptibility to gentamicin ( p \uff1c 0.0001 ) and the quinolones nalidixic acid ( p\uff1d0.004 ) and ciprofloxacin ( p \uff1c 0.0001 ) than non-producers .","paragraph":"<h3><u>Antibiotic Susceptibilities and Genetic Characteristics of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates from Stools of Pediatric Diarrhea Patients in Surabaya, Indonesia.</u></h3>The purpose of this study was to investigate extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolates from pediatric (aged 0 to 3 years) diarrhea patients in Surabaya, Indonesia, where this kind of survey is rare; our study included assessment of their antibiotic susceptibilities, as well as ESBL typing, multilocus sequence typing (MLST), and diarrheagenic E. coli (DEC)-typing. ESBL-producing E. coli were detected in 18.8% of all the samples. <b style='color:DodgerBlue;'><i>Many</i></b> <b style='color:DodgerBlue;'><i>ESBL-producing</i></b> <b style='color:DodgerBlue;'><i>E.</i></b> <b style='color:DodgerBlue;'><i>coli</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>susceptibility</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>\uff1c</i></b> <b style='color:DodgerBlue;'><i>0.0001</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>quinolones</i></b> <b style='color:MediumOrchid;'><i>nalidixic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p\uff1d0.004</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ciprofloxacin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>\uff1c</i></b> <b style='color:DodgerBlue;'><i>0.0001</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>non-producers</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In ESBL-producing E. coli, 84.0% of strains expressed CTX-M-15 alone or in combination with other ESBL types. MLST revealed that 24.0% of ESBL-producers had sequence type 617, all of which expressed the CTX-M-15 gene; we also detected expression of 3 DEC-related genes: 2 enteroaggregative E. coli genes and 1 enteropathogenic E. coli gene. In conclusion, CTX-M-15-type ESBL-producing E. coli ST617 appear to have spread to Indonesia.","tokens":[{"text":"Many","start":0,"end":4,"id":0,"ws":true},{"text":"ESBL-producing","start":5,"end":19,"id":1,"ws":true},{"text":"E.","start":20,"end":22,"id":2,"ws":true},{"text":"coli","start":23,"end":27,"id":3,"ws":true},{"text":"had","start":28,"end":31,"id":4,"ws":true},{"text":"significantly","start":32,"end":45,"id":5,"ws":true},{"text":"lower","start":46,"end":51,"id":6,"ws":true},{"text":"susceptibility","start":52,"end":66,"id":7,"ws":true},{"text":"to","start":67,"end":69,"id":8,"ws":true},{"text":"gentamicin","start":70,"end":80,"id":9,"ws":true},{"text":"(","start":81,"end":82,"id":10,"ws":true},{"text":"p","start":83,"end":84,"id":11,"ws":true},{"text":"\uff1c","start":85,"end":86,"id":12,"ws":true},{"text":"0.0001","start":87,"end":93,"id":13,"ws":true},{"text":")","start":94,"end":95,"id":14,"ws":true},{"text":"and","start":96,"end":99,"id":15,"ws":true},{"text":"the","start":100,"end":103,"id":16,"ws":true},{"text":"quinolones","start":104,"end":114,"id":17,"ws":true},{"text":"nalidixic","start":115,"end":124,"id":18,"ws":true},{"text":"acid","start":125,"end":129,"id":19,"ws":true},{"text":"(","start":130,"end":131,"id":20,"ws":true},{"text":"p\uff1d0.004","start":132,"end":139,"id":21,"ws":true},{"text":")","start":140,"end":141,"id":22,"ws":true},{"text":"and","start":142,"end":145,"id":23,"ws":true},{"text":"ciprofloxacin","start":146,"end":159,"id":24,"ws":true},{"text":"(","start":160,"end":161,"id":25,"ws":true},{"text":"p","start":162,"end":163,"id":26,"ws":true},{"text":"\uff1c","start":164,"end":165,"id":27,"ws":true},{"text":"0.0001","start":166,"end":172,"id":28,"ws":true},{"text":")","start":173,"end":174,"id":29,"ws":true},{"text":"than","start":175,"end":179,"id":30,"ws":true},{"text":"non-producers","start":180,"end":193,"id":31,"ws":true},{"text":".","start":194,"end":195,"id":32,"ws":false}],"spans":[{"start":70,"end":80,"token_start":9,"token_end":9,"label":"DRUG"},{"start":115,"end":124,"token_start":18,"token_end":18,"label":"DRUG"},{"start":146,"end":159,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/28003592/","_input_hash":-959830506,"_task_hash":1562370820,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The resistance of topotecan in MDR HL-60 cells was potently reversed by the addition of amlodipine .","paragraph":"<h3><u>Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.</u></h3>Multidrug resistance (MDR) is a major obstacle to successful cancer chemotherapy as the over-expressed MDR protein acts as an efflux pump, which leads to a reduction in the uptake of the anticancer agent by tumour cells. We combined <b style='color:Tomato;'><i>topotecan</i></b> and <b style='color:Tomato;'><i>amlodipine</i></b> together into the stealthy liposomes, in which <b style='color:Tomato;'><i>amlodipine</i></b> was applied as a MDR reversing agent to overcome the resistance. ### Materials And Methods Cytotoxicity, apoptosis and the signalling pathway assays were performed on human chronic myelogenous leukaemia K562, promyelocytic leukaemia HL-60 and MDR HL-60 cells, respectively. Pharmacokinetics and antitumour activity studies were performed on normal Kunming mice and female BALB/c nude mice with MDR HL-60 xenografts, respectively. ### results <b style='color:Tomato;'><i>topotecan</i></b> alone was effective in inhibiting the growth of non-resistant leukaemia cells, K562 and HL-60 cells but not the growth of MDR HL-60 cells. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>MDR</i></b> <b style='color:DodgerBlue;'><i>HL-60</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>potently</i></b> <b style='color:DodgerBlue;'><i>reversed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amlodipine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Moreover, <b style='color:Tomato;'><i>amlodipine</i></b> enhanced the apoptosis-inducing effect of <b style='color:Tomato;'><i>topotecan</i></b> synergistically. Apoptosis was through activating caspases in a cascade: first, the initiator caspase 8 and then effectors caspase 3/7 (total activity of caspases 3 and 7) were activated. Being encapsulated into the stealthy liposomes with an acidic internal medium, <b style='color:Tomato;'><i>topotecan</i></b> existed dominantly in an active lactone species, which was reversibly changed from an inactive carboxylate form via a pH-dependent reaction. After administration of stealthy liposomes to mice, the blood exposure of the lactone form was evidently increased and extended. The antitumour effects in the MDR HL-60 xenografted tumour were stealthy liposomal <b style='color:Tomato;'><i>topotecan</i></b> (SLT) plus <b style='color:Tomato;'><i>amlodipine</i></b> > SLT > un-encapsulated <b style='color:Tomato;'><i>topotecan</i></b> > blank control. ### conclusions The enhanced antitumour activity in the MDR HL-60 cells by the SLT plus <b style='color:Tomato;'><i>amlodipine</i></b> could be owing to multiple reasons: (a) synergistic apoptosis inducing effect, (b) reversing MDR by <b style='color:Tomato;'><i>amlodipine</i></b> and (c) increasing the availability of active lactone of <b style='color:Tomato;'><i>topotecan</i></b> by the stealthy liposomes. The apoptosis induced by <b style='color:Tomato;'><i>amlodipine</i></b> is through caspase 8 and then the 3/7 signalling pathway.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"resistance","start":4,"end":14,"id":1,"ws":true},{"text":"of","start":15,"end":17,"id":2,"ws":true},{"text":"topotecan","start":18,"end":27,"id":3,"ws":true},{"text":"in","start":28,"end":30,"id":4,"ws":true},{"text":"MDR","start":31,"end":34,"id":5,"ws":true},{"text":"HL-60","start":35,"end":40,"id":6,"ws":true},{"text":"cells","start":41,"end":46,"id":7,"ws":true},{"text":"was","start":47,"end":50,"id":8,"ws":true},{"text":"potently","start":51,"end":59,"id":9,"ws":true},{"text":"reversed","start":60,"end":68,"id":10,"ws":true},{"text":"by","start":69,"end":71,"id":11,"ws":true},{"text":"the","start":72,"end":75,"id":12,"ws":true},{"text":"addition","start":76,"end":84,"id":13,"ws":true},{"text":"of","start":85,"end":87,"id":14,"ws":true},{"text":"amlodipine","start":88,"end":98,"id":15,"ws":true},{"text":".","start":99,"end":100,"id":16,"ws":false}],"spans":[{"start":18,"end":27,"token_start":3,"token_end":3,"label":"DRUG"},{"start":88,"end":98,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16684125/","_input_hash":920981054,"_task_hash":947211331,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":3,"child":15,"head_span":{"start":18,"end":27,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":88,"end":98,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"In separate studies , the electrocardiogram ( ECG ) and cardiovascular effects of loratadine ( 30 and 100 mg/kg , i.v . ) , terfenadine ( 10 mg/kg , i.v . ) , promethazine ( 5 mg/kg , i.v . ) and diphenhydramine ( 20 mg/kg , i.v . ) were evaluated .","paragraph":"<h3><u>Antihistamine activity, central nervous system and cardiovascular profiles of histamine H1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea-pigs.</u></h3>Sedation limits the clinical utility of classical H1 antihistamines, while newer antihistamines such as <b style='color:Tomato;'><i>loratadine</i></b> and <b style='color:Tomato;'><i>terfenadine</i></b> are non-sedating. However, clinical use of the <b style='color:Tomato;'><i>terfenadine</i></b> has been associated with rare but severe cardiac arrhythmias, in particular torsades de pointes. ### objective To establish a quantitative experimental model for assessing the sedating and cardiotoxicity potential of non-sedating and sedating antihistamines. ### methods Drugs were administered intravenously and the integrated amplitude of the cortical electroencephalogram (EEG) signal was recorded. The threshold dose that depressed EEG activity was compared with the dose required to inhibit by 50% the peripheral bronchospasm elicited by 10 micrograms/kg i.v., of histamine. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>separate</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>electrocardiogram</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ECG</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cardiovascular</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>loratadine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>terfenadine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>promethazine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>diphenhydramine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results The sedating antihistamines, <b style='color:Tomato;'><i>diphenhydramine</i></b> and <b style='color:Tomato;'><i>promethazine</i></b>, depressed the integrated EEG at doses between 0.6 and 2.0 times their peripheral antihistamine doses. <b style='color:Tomato;'><i>loratadine</i></b> had no EEG depressant activity at 100 mg/kg, i.v., a dose more than 170 times its ED50 (0.58 mg/kg, i.v.) against histamine bronchospasm. We were unable to evaluate the EEG effects of <b style='color:Tomato;'><i>terfenadine</i></b>, because it produced cardiovascular collapse at 10 mg/kg, i.v. <b style='color:Tomato;'><i>loratadine</i></b> and <b style='color:Tomato;'><i>promethazine</i></b> did not produce adverse cardiovascular effects, nor did they alter normal ECG activity. <b style='color:Tomato;'><i>diphenhydramine</i></b> produced bradycardia followed by a transient hypertensive phase without affecting the QTc interval. In contrast, <b style='color:Tomato;'><i>terfenadine</i></b> elicited hypotension, bradycardia and significant arrhythmogenic activity, causing a prolongation of the QTc interval and a torsades de pointes--like ventricular arrhythmia. Pharmacokinetic studies after i.v. administration of <b style='color:Tomato;'><i>loratadine</i></b> (30 and 100 mg/kg) demonstrated plasma levels of <b style='color:Tomato;'><i>loratadine</i></b> and its major metabolite descarboethoxy<b style='color:Tomato;'><i>loratadine</i></b> to be several orders of magnitude greater than levels found in humans at the clinical dose of 10 mg. ### conclusion The CNS depressant effects of H1 antihistamines are <b style='color:Tomato;'><i>promethazine</i></b> approximately <b style='color:Tomato;'><i>diphenhydramine</i></b> >> <b style='color:Tomato;'><i>loratadine</i></b> = placebo. Of the non-sedating antihistamines, <b style='color:Tomato;'><i>loratadine</i></b> was devoid of adverse cardiovascular effects whereas <b style='color:Tomato;'><i>terfenadine</i></b> caused a pronounced disruption of the normal ECG, characterized by a torsades de pointes-like effect.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"separate","start":3,"end":11,"id":1,"ws":true},{"text":"studies","start":12,"end":19,"id":2,"ws":true},{"text":",","start":20,"end":21,"id":3,"ws":true},{"text":"the","start":22,"end":25,"id":4,"ws":true},{"text":"electrocardiogram","start":26,"end":43,"id":5,"ws":true},{"text":"(","start":44,"end":45,"id":6,"ws":true},{"text":"ECG","start":46,"end":49,"id":7,"ws":true},{"text":")","start":50,"end":51,"id":8,"ws":true},{"text":"and","start":52,"end":55,"id":9,"ws":true},{"text":"cardiovascular","start":56,"end":70,"id":10,"ws":true},{"text":"effects","start":71,"end":78,"id":11,"ws":true},{"text":"of","start":79,"end":81,"id":12,"ws":true},{"text":"loratadine","start":82,"end":92,"id":13,"ws":true},{"text":"(","start":93,"end":94,"id":14,"ws":true},{"text":"30","start":95,"end":97,"id":15,"ws":true},{"text":"and","start":98,"end":101,"id":16,"ws":true},{"text":"100","start":102,"end":105,"id":17,"ws":true},{"text":"mg/kg","start":106,"end":111,"id":18,"ws":true},{"text":",","start":112,"end":113,"id":19,"ws":true},{"text":"i.v","start":114,"end":117,"id":20,"ws":true},{"text":".","start":118,"end":119,"id":21,"ws":true},{"text":")","start":120,"end":121,"id":22,"ws":true},{"text":",","start":122,"end":123,"id":23,"ws":true},{"text":"terfenadine","start":124,"end":135,"id":24,"ws":true},{"text":"(","start":136,"end":137,"id":25,"ws":true},{"text":"10","start":138,"end":140,"id":26,"ws":true},{"text":"mg/kg","start":141,"end":146,"id":27,"ws":true},{"text":",","start":147,"end":148,"id":28,"ws":true},{"text":"i.v","start":149,"end":152,"id":29,"ws":true},{"text":".","start":153,"end":154,"id":30,"ws":true},{"text":")","start":155,"end":156,"id":31,"ws":true},{"text":",","start":157,"end":158,"id":32,"ws":true},{"text":"promethazine","start":159,"end":171,"id":33,"ws":true},{"text":"(","start":172,"end":173,"id":34,"ws":true},{"text":"5","start":174,"end":175,"id":35,"ws":true},{"text":"mg/kg","start":176,"end":181,"id":36,"ws":true},{"text":",","start":182,"end":183,"id":37,"ws":true},{"text":"i.v","start":184,"end":187,"id":38,"ws":true},{"text":".","start":188,"end":189,"id":39,"ws":true},{"text":")","start":190,"end":191,"id":40,"ws":true},{"text":"and","start":192,"end":195,"id":41,"ws":true},{"text":"diphenhydramine","start":196,"end":211,"id":42,"ws":true},{"text":"(","start":212,"end":213,"id":43,"ws":true},{"text":"20","start":214,"end":216,"id":44,"ws":true},{"text":"mg/kg","start":217,"end":222,"id":45,"ws":true},{"text":",","start":223,"end":224,"id":46,"ws":true},{"text":"i.v","start":225,"end":228,"id":47,"ws":true},{"text":".","start":229,"end":230,"id":48,"ws":true},{"text":")","start":231,"end":232,"id":49,"ws":true},{"text":"were","start":233,"end":237,"id":50,"ws":true},{"text":"evaluated","start":238,"end":247,"id":51,"ws":true},{"text":".","start":248,"end":249,"id":52,"ws":false}],"spans":[{"start":82,"end":92,"token_start":13,"token_end":13,"label":"DRUG"},{"start":124,"end":135,"token_start":24,"token_end":24,"label":"DRUG"},{"start":159,"end":171,"token_start":33,"token_end":33,"label":"DRUG"},{"start":196,"end":211,"token_start":42,"token_end":42,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8556569/","_input_hash":1378418684,"_task_hash":-1885246676,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"[ Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer -- comparative study of treatment with 2 and 4 cycles ] .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>Clinical</i></b> <b style='color:DodgerBlue;'><i>evaluation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>neoadjuvant</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cases</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>locally</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>--</i></b> <b style='color:DodgerBlue;'><i>comparative</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Neoadjuvant chemotherapy of <b style='color:Tomato;'><i>epirubicin</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> was administered to 75 patients (including a 2-cycle group of 39 patients and a 4-cycle group of 36 patients) with locally advanced breast cancer (35 cases of stage IIb, 28 of stage IIIa, 12 of stage IIIb) to compare efficacy and toxicity of 2 cycle and 4 cycle regimens. All patients were female. They were treated with <b style='color:Tomato;'><i>epirubicin</i></b> 60 mg/m2, on day 1, by i.v., followed by <b style='color:Tomato;'><i>paclitaxel</i></b> 150 mg/m2, by 3 hour continuous infusion on day 2 repeated every 3 weeks. Premedication with <b style='color:Tomato;'><i>dexamethasone</i></b>, <b style='color:Tomato;'><i>ondansetron</i></b>, <b style='color:Tomato;'><i>diphenhydramine</i></b> and <b style='color:Tomato;'><i>cimetidine</i></b> were administered to prevent gastroenteritic and allergic reactions before chemotherapy. Thirty-nine patients were given 2 cycles and thirty-six were given 4 cycles of this regimen. One of 39 patients had complete response, 28 had partial response and 10 had no change in the 2-cycle group. In addition, 21 of 36 patients had complete response (including 9 who had pathologic complete response), 13 had partial response and 2 had no change. The response rates were 74% (29/39) in the 2-cycle group and 94% (34/36) in the 4-cycle group. There were no progressive disease in these 2 groups. However a higher proportion of PR was observed in stage II patients than in stage III patients. Twelve of 36 patients underwent breast conserving surgery, as tumor size had become smaller and down-staging was realized after neoadjuvant chemotherapy. In addition, axillary lymph nodes were palpable in all 75 patients before neoadjuvant chemotherapy with the ET regimen. But 46% (18/39) in the 2-cycle group and 75% (27/36) in the 4-cycle group became impalpable. Conversely, major toxicities (including leukopenia and gastroenteric reactions) were similar in both groups, but myalgia, arthralgia, neurotoxicity and alopecia were more severe in the 4-cycle group than in the 2-cycle group. In the present study, neoadjuvant chemotherapy with a 4-cycle ET regimen was more effective than with a 2-cycle regimen in down staging locally advanced breast cancer. Although major toxicities were more severe in the 4-cycle group than in the 2-cycle group, the regimen was tolerable and safe.","tokens":[{"text":"[","start":0,"end":1,"id":0,"ws":true},{"text":"Clinical","start":2,"end":10,"id":1,"ws":true},{"text":"evaluation","start":11,"end":21,"id":2,"ws":true},{"text":"of","start":22,"end":24,"id":3,"ws":true},{"text":"effects","start":25,"end":32,"id":4,"ws":true},{"text":"from","start":33,"end":37,"id":5,"ws":true},{"text":"neoadjuvant","start":38,"end":49,"id":6,"ws":true},{"text":"chemotherapy","start":50,"end":62,"id":7,"ws":true},{"text":"with","start":63,"end":67,"id":8,"ws":true},{"text":"epirubicin","start":68,"end":78,"id":9,"ws":true},{"text":"plus","start":79,"end":83,"id":10,"ws":true},{"text":"paclitaxel","start":84,"end":94,"id":11,"ws":true},{"text":"in","start":95,"end":97,"id":12,"ws":true},{"text":"cases","start":98,"end":103,"id":13,"ws":true},{"text":"of","start":104,"end":106,"id":14,"ws":true},{"text":"locally","start":107,"end":114,"id":15,"ws":true},{"text":"advanced","start":115,"end":123,"id":16,"ws":true},{"text":"breast","start":124,"end":130,"id":17,"ws":true},{"text":"cancer","start":131,"end":137,"id":18,"ws":true},{"text":"--","start":138,"end":140,"id":19,"ws":true},{"text":"comparative","start":141,"end":152,"id":20,"ws":true},{"text":"study","start":153,"end":158,"id":21,"ws":true},{"text":"of","start":159,"end":161,"id":22,"ws":true},{"text":"treatment","start":162,"end":171,"id":23,"ws":true},{"text":"with","start":172,"end":176,"id":24,"ws":true},{"text":"2","start":177,"end":178,"id":25,"ws":true},{"text":"and","start":179,"end":182,"id":26,"ws":true},{"text":"4","start":183,"end":184,"id":27,"ws":true},{"text":"cycles","start":185,"end":191,"id":28,"ws":true},{"text":"]","start":192,"end":193,"id":29,"ws":true},{"text":".","start":194,"end":195,"id":30,"ws":false}],"spans":[{"start":68,"end":78,"token_start":9,"token_end":9,"label":"DRUG"},{"start":84,"end":94,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/14997752/","_input_hash":-2122849102,"_task_hash":1304982906,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":68,"end":78,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":84,"end":94,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"When systemically active chemotherapy doses were reached , further dose escalation was discontinued , and a phase II dose-range was established ( pemetrexed 500 mg/m(2 ) and carboplatin AUC = 5 - 6 ) .","paragraph":"<h3><u>A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.</u></h3>The primary objective of this phase I study was to determine the maximum tolerated dose for <b style='color:Tomato;'><i>pemetrexed</i></b>, alone and in combination with <b style='color:Tomato;'><i>carboplatin</i></b>, with concurrent radiotherapy. ### Experimental Design Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) or esophageal cancer were treated every 21 days for two cycles. Regimen 1 was <b style='color:Tomato;'><i>pemetrexed</i></b> (200-600 mg/m(2)); regimen 2 was <b style='color:Tomato;'><i>pemetrexed</i></b> (500 mg/m(2)) with escalating <b style='color:Tomato;'><i>carboplatin</i></b> doses (AUC = 4-6). Both regimens included concurrent radiation (40-66 Gy; palliative-intent doses were lower). ### results Thirty patients (18 locally advanced and 12 metastatic with dominant local symptoms) were enrolled, with an Eastern Cooperative Oncology Group performance status of 0/1/2 (n = 8/21/1). All dose levels were tolerable for regimen 1 (n = 18: 15 NSCLC and 3 esophageal cancers) and regimen 2 (n = 12: all NSCLC). In regimen 1, one dose-limiting toxicity (grade 4 esophagitis/anorexia) occurred (500 mg/m(2)). Grade 3 neutropenia (3 of 18 patients) was the main hematologic toxicity. In regimen 2, one dose-limiting toxicity (grade 3 esophagitis) occurred (500 mg/m(2); AUC = 6); grade 3/4 leukopenia (4 of 12 patients) was the main hematologic toxicity. Four complete responses (2 pathology proven) and eight partial responses were observed. <b style='color:DodgerBlue;'><i>When</i></b> <b style='color:DodgerBlue;'><i>systemically</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>reached</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>escalation</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>discontinued</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>dose-range</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>established</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>500</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions The combination of <b style='color:Tomato;'><i>pemetrexed</i></b> (500 mg/m(2)) and <b style='color:Tomato;'><i>carboplatin</i></b> (AUC = 5 or 6) with concurrent radiation is well tolerated, allows for the administration of systemically active chemotherapy doses, and shows signs of activity. To further determine efficacy, safety profile, and optimal dosing, the Cancer and Leukemia Group B study 30407 is currently evaluating this regimen in patients with unresectable stage III NSCLC.","tokens":[{"text":"When","start":0,"end":4,"id":0,"ws":true},{"text":"systemically","start":5,"end":17,"id":1,"ws":true},{"text":"active","start":18,"end":24,"id":2,"ws":true},{"text":"chemotherapy","start":25,"end":37,"id":3,"ws":true},{"text":"doses","start":38,"end":43,"id":4,"ws":true},{"text":"were","start":44,"end":48,"id":5,"ws":true},{"text":"reached","start":49,"end":56,"id":6,"ws":true},{"text":",","start":57,"end":58,"id":7,"ws":true},{"text":"further","start":59,"end":66,"id":8,"ws":true},{"text":"dose","start":67,"end":71,"id":9,"ws":true},{"text":"escalation","start":72,"end":82,"id":10,"ws":true},{"text":"was","start":83,"end":86,"id":11,"ws":true},{"text":"discontinued","start":87,"end":99,"id":12,"ws":true},{"text":",","start":100,"end":101,"id":13,"ws":true},{"text":"and","start":102,"end":105,"id":14,"ws":true},{"text":"a","start":106,"end":107,"id":15,"ws":true},{"text":"phase","start":108,"end":113,"id":16,"ws":true},{"text":"II","start":114,"end":116,"id":17,"ws":true},{"text":"dose-range","start":117,"end":127,"id":18,"ws":true},{"text":"was","start":128,"end":131,"id":19,"ws":true},{"text":"established","start":132,"end":143,"id":20,"ws":true},{"text":"(","start":144,"end":145,"id":21,"ws":true},{"text":"pemetrexed","start":146,"end":156,"id":22,"ws":true},{"text":"500","start":157,"end":160,"id":23,"ws":true},{"text":"mg/m(2","start":161,"end":167,"id":24,"ws":true},{"text":")","start":168,"end":169,"id":25,"ws":true},{"text":"and","start":170,"end":173,"id":26,"ws":true},{"text":"carboplatin","start":174,"end":185,"id":27,"ws":true},{"text":"AUC","start":186,"end":189,"id":28,"ws":true},{"text":"=","start":190,"end":191,"id":29,"ws":true},{"text":"5","start":192,"end":193,"id":30,"ws":true},{"text":"-","start":194,"end":195,"id":31,"ws":true},{"text":"6","start":196,"end":197,"id":32,"ws":true},{"text":")","start":198,"end":199,"id":33,"ws":true},{"text":".","start":200,"end":201,"id":34,"ws":false}],"spans":[{"start":146,"end":156,"token_start":22,"token_end":22,"label":"DRUG"},{"start":174,"end":185,"token_start":27,"token_end":27,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17255273/","_input_hash":1071410750,"_task_hash":1537762818,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":22,"child":27,"head_span":{"start":146,"end":156,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":174,"end":185,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Increased dose density is feasible : a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel , at 10- or 11-day intervals with filgrastim support in women with breast cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Increased</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>density</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>feasible</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>pilot</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>10-</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>11-day</i></b> <b style='color:DodgerBlue;'><i>intervals</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>filgrastim</i></b> <b style='color:DodgerBlue;'><i>support</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Because Cancer and Leukemia Group B 9741 trial showed a benefit for every 14-day administration of chemotherapy compared with every 21-day treatment, we hypothesized that even greater dose density would be more effective. We conducted a pilot trial to assess the feasibility of dose-dense chemotherapy consisting of a standard regime at 10- to 11-day intervals in the adjuvant/neoadjuvant setting. A 2-day window was allowed for scheduling logistics. ### Experimental Design Thirty-nine women with early-stage breast carcinoma were accrued from April 2004 to October 2004. Median age was 47 years (range, 26-67 years). Patients received therapy with 100 mg/m(2) <b style='color:Tomato;'><i>epirubicin</i></b> and 600 mg/m(2) <b style='color:Tomato;'><i>cyclophosphamide</i></b> (EC) q 10 to 11 days for four cycles followed by 175 mg/m(2) <b style='color:Tomato;'><i>paclitaxel</i></b> q 10 to 11 days for four cycles, all with <b style='color:Tomato;'><i>filgrastim</i></b> support (300 microg s.c. daily) from day 2 to 24 h before the next treatment. ### results Thirty-five (90%) patients completed all planned therapy. The median intertreatment interval was 10 days (range, 8-28 days). Cycles (80.7%) were delivered at no more than 10- to 11-day intervals. There were five dose reductions of 25% for grade 3 nonhematologic toxicity in five patients. Six (16%) patients developed febrile neutropenia defined as temperature >38 degrees C with absolute neutrophil count <1,000/microL. All febrile neutropenia was during therapy with EC. Other grade 3 toxicities included bone pain, hand and foot syndrome, neuropathy, mucositis, nausea, and vomiting. ### conclusions Therapy with EC for four cycles followed by <b style='color:Tomato;'><i>paclitaxel</i></b> for four cycles at 10- to 11-day intervals is feasible. The approximately 30% reduction in intertreatment interval compared with every 14-day treatment could increase the efficacy of adjuvant chemotherapy.","tokens":[{"text":"Increased","start":0,"end":9,"id":0,"ws":true},{"text":"dose","start":10,"end":14,"id":1,"ws":true},{"text":"density","start":15,"end":22,"id":2,"ws":true},{"text":"is","start":23,"end":25,"id":3,"ws":true},{"text":"feasible","start":26,"end":34,"id":4,"ws":true},{"text":":","start":35,"end":36,"id":5,"ws":true},{"text":"a","start":37,"end":38,"id":6,"ws":true},{"text":"pilot","start":39,"end":44,"id":7,"ws":true},{"text":"study","start":45,"end":50,"id":8,"ws":true},{"text":"of","start":51,"end":53,"id":9,"ws":true},{"text":"adjuvant","start":54,"end":62,"id":10,"ws":true},{"text":"epirubicin","start":63,"end":73,"id":11,"ws":true},{"text":"and","start":74,"end":77,"id":12,"ws":true},{"text":"cyclophosphamide","start":78,"end":94,"id":13,"ws":true},{"text":"followed","start":95,"end":103,"id":14,"ws":true},{"text":"by","start":104,"end":106,"id":15,"ws":true},{"text":"paclitaxel","start":107,"end":117,"id":16,"ws":true},{"text":",","start":118,"end":119,"id":17,"ws":true},{"text":"at","start":120,"end":122,"id":18,"ws":true},{"text":"10-","start":123,"end":126,"id":19,"ws":true},{"text":"or","start":127,"end":129,"id":20,"ws":true},{"text":"11-day","start":130,"end":136,"id":21,"ws":true},{"text":"intervals","start":137,"end":146,"id":22,"ws":true},{"text":"with","start":147,"end":151,"id":23,"ws":true},{"text":"filgrastim","start":152,"end":162,"id":24,"ws":true},{"text":"support","start":163,"end":170,"id":25,"ws":true},{"text":"in","start":171,"end":173,"id":26,"ws":true},{"text":"women","start":174,"end":179,"id":27,"ws":true},{"text":"with","start":180,"end":184,"id":28,"ws":true},{"text":"breast","start":185,"end":191,"id":29,"ws":true},{"text":"cancer","start":192,"end":198,"id":30,"ws":true},{"text":".","start":199,"end":200,"id":31,"ws":false}],"spans":[{"start":63,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},{"start":78,"end":94,"token_start":13,"token_end":13,"label":"DRUG"},{"start":107,"end":117,"token_start":16,"token_end":16,"label":"DRUG"},{"start":152,"end":162,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17200358/","_input_hash":939881528,"_task_hash":2125935323,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":11,"child":13,"head_span":{"start":63,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":78,"end":94,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":16,"child":24,"head_span":{"start":107,"end":117,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":152,"end":162,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS21"],"answer":"accept"}
{"text":"Those who test positive are treated with combinations of the following agents : omeprazole , clarithromycin , amoxicillin , tetracycline , and metronidazole .","paragraph":"<h3><u>Pharmacist-managed Helicobacter pylori clinic.</u></h3>A pharmacist-managed Helicobacter pylori assessment clinic for ambulatory patients is described. The pharmacy service at a 400-bed Veterans Affairs Medical Center established a pharmacist-managed clinic to assess patients who were receiving long-term acid-suppressive medications (histamine H2-receptor antagonists, <b style='color:Tomato;'><i>sucralfate</i></b>, or <b style='color:Tomato;'><i>omeprazole</i></b>). Patients with active ulcer disease and those receiving ulcer prophylaxis are screened for the presence of H. pylori. <b style='color:DodgerBlue;'><i>Those</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>test</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>tetracycline</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metronidazole</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The pharmacist also may adjust or discontinue acid-suppressive drug regimens. The pharmacist is responsible for ordering all appropriate laboratory tests, monitoring patients for adverse effects, collecting data on patient outcomes, and providing patient education. The clinic provides opportunities for pharmacists to study the clinical effectiveness and pharmacoeconomics of various regimens for treating H. pylori-associated disease and for pharmacy students and residents to interact with patients. As of fall 1994, 20 patients had been evaluated at the clinic: 12 tested positive for H. pylori and were treated with antimicrobials and all were pain-free without medication at the end of treatment. An H. pylori assessment clinic enabled pharmacists to assume a primary care role, document improvement in patient outcomes, and study the effectiveness of various antimicrobial regimens.","tokens":[{"text":"Those","start":0,"end":5,"id":0,"ws":true},{"text":"who","start":6,"end":9,"id":1,"ws":true},{"text":"test","start":10,"end":14,"id":2,"ws":true},{"text":"positive","start":15,"end":23,"id":3,"ws":true},{"text":"are","start":24,"end":27,"id":4,"ws":true},{"text":"treated","start":28,"end":35,"id":5,"ws":true},{"text":"with","start":36,"end":40,"id":6,"ws":true},{"text":"combinations","start":41,"end":53,"id":7,"ws":true},{"text":"of","start":54,"end":56,"id":8,"ws":true},{"text":"the","start":57,"end":60,"id":9,"ws":true},{"text":"following","start":61,"end":70,"id":10,"ws":true},{"text":"agents","start":71,"end":77,"id":11,"ws":true},{"text":":","start":78,"end":79,"id":12,"ws":true},{"text":"omeprazole","start":80,"end":90,"id":13,"ws":true},{"text":",","start":91,"end":92,"id":14,"ws":true},{"text":"clarithromycin","start":93,"end":107,"id":15,"ws":true},{"text":",","start":108,"end":109,"id":16,"ws":true},{"text":"amoxicillin","start":110,"end":121,"id":17,"ws":true},{"text":",","start":122,"end":123,"id":18,"ws":true},{"text":"tetracycline","start":124,"end":136,"id":19,"ws":true},{"text":",","start":137,"end":138,"id":20,"ws":true},{"text":"and","start":139,"end":142,"id":21,"ws":true},{"text":"metronidazole","start":143,"end":156,"id":22,"ws":true},{"text":".","start":157,"end":158,"id":23,"ws":false}],"spans":[{"start":80,"end":90,"token_start":13,"token_end":13,"label":"DRUG"},{"start":93,"end":107,"token_start":15,"token_end":15,"label":"DRUG"},{"start":110,"end":121,"token_start":17,"token_end":17,"label":"DRUG"},{"start":124,"end":136,"token_start":19,"token_end":19,"label":"DRUG"},{"start":143,"end":156,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12879545/","_input_hash":-1629384935,"_task_hash":-792898755,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":80,"end":90,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":93,"end":107,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":15,"child":17,"head_span":{"start":93,"end":107,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":110,"end":121,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":17,"child":19,"head_span":{"start":110,"end":121,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":124,"end":136,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":19,"child":22,"head_span":{"start":124,"end":136,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":143,"end":156,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Patients can be treatment-na\u00efve for mCRPC or on first-line androgen receptor-targeted therapy for mCRPC ( ie , abiraterone or enzalutamide ) without evidence of progression at enrolment , and with no prior chemotherapy for mCRPC .","paragraph":"<h3><u>Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.</u></h3>Preliminary evidence supports the beneficial role of physical activity on prostate cancer outcomes. This phase III randomised controlled trial (RCT) is designed to determine if supervised high-intensity aerobic and resistance exercise increases overall survival (OS) in patients with metastatic castrate-resistant prostate cancer (mCRPC). ### Methods And Analysis Participants (n=866) must have histologically documented metastatic prostate cancer with evidence of progressive disease on androgen deprivation therapy (defined as mCRPC). <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>treatment-na\u00efve</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>mCRPC</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>androgen</i></b> <b style='color:DodgerBlue;'><i>receptor-targeted</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>mCRPC</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ie</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>abiraterone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>evidence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>enrolment</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>prior</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>mCRPC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Patients will receive psychosocial support and will be randomly assigned (1:1) to either supervised exercise (high-intensity aerobic and resistance training) or self-directed exercise (provision of guidelines), stratified by treatment status and site. Exercise prescriptions will be tailored to each participant's fitness and morbidities. The primary endpoint is OS. Secondary endpoints include time to disease progression, occurrence of a skeletal-related event or progression of pain, and degree of pain, opiate use, physical and emotional quality of life, and changes in metabolic biomarkers. An assessment of whether immune function, inflammation, dysregulation of insulin and energy metabolism, and androgen biomarkers are associated with OS will be performed, and whether they mediate the primary association between exercise and OS will also be investigated. This study will also establish a biobank for future biomarker discovery or validation. ### Ethics And Dissemination Validation of exercise as medicine and its mechanisms of action will create evidence to change clinical practice. Accordingly, outcomes of this RCT will be published in international, peer-reviewed journals, and presented at national and international conferences. Ethics approval was first obtained at Edith Cowan University (ID: 13236 NEWTON), with a further 10 investigator sites since receiving ethics approval, prior to activation. ### Trial Registration Number NCT02730338.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"can","start":9,"end":12,"id":1,"ws":true},{"text":"be","start":13,"end":15,"id":2,"ws":true},{"text":"treatment-na\u00efve","start":16,"end":31,"id":3,"ws":true},{"text":"for","start":32,"end":35,"id":4,"ws":true},{"text":"mCRPC","start":36,"end":41,"id":5,"ws":true},{"text":"or","start":42,"end":44,"id":6,"ws":true},{"text":"on","start":45,"end":47,"id":7,"ws":true},{"text":"first-line","start":48,"end":58,"id":8,"ws":true},{"text":"androgen","start":59,"end":67,"id":9,"ws":true},{"text":"receptor-targeted","start":68,"end":85,"id":10,"ws":true},{"text":"therapy","start":86,"end":93,"id":11,"ws":true},{"text":"for","start":94,"end":97,"id":12,"ws":true},{"text":"mCRPC","start":98,"end":103,"id":13,"ws":true},{"text":"(","start":104,"end":105,"id":14,"ws":true},{"text":"ie","start":106,"end":108,"id":15,"ws":true},{"text":",","start":109,"end":110,"id":16,"ws":true},{"text":"abiraterone","start":111,"end":122,"id":17,"ws":true},{"text":"or","start":123,"end":125,"id":18,"ws":true},{"text":"enzalutamide","start":126,"end":138,"id":19,"ws":true},{"text":")","start":139,"end":140,"id":20,"ws":true},{"text":"without","start":141,"end":148,"id":21,"ws":true},{"text":"evidence","start":149,"end":157,"id":22,"ws":true},{"text":"of","start":158,"end":160,"id":23,"ws":true},{"text":"progression","start":161,"end":172,"id":24,"ws":true},{"text":"at","start":173,"end":175,"id":25,"ws":true},{"text":"enrolment","start":176,"end":185,"id":26,"ws":true},{"text":",","start":186,"end":187,"id":27,"ws":true},{"text":"and","start":188,"end":191,"id":28,"ws":true},{"text":"with","start":192,"end":196,"id":29,"ws":true},{"text":"no","start":197,"end":199,"id":30,"ws":true},{"text":"prior","start":200,"end":205,"id":31,"ws":true},{"text":"chemotherapy","start":206,"end":218,"id":32,"ws":true},{"text":"for","start":219,"end":222,"id":33,"ws":true},{"text":"mCRPC","start":223,"end":228,"id":34,"ws":true},{"text":".","start":229,"end":230,"id":35,"ws":false}],"spans":[{"start":111,"end":122,"token_start":17,"token_end":17,"label":"DRUG"},{"start":126,"end":138,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29764892/","_input_hash":-196170261,"_task_hash":1174955668,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"CYP2D6 metabolizes other opioid analgesics , including tramadol , dihydrocodeine , oxycodone and hydrocodone , although they have been less systematically studied .","paragraph":"<h3><u>Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.</u></h3><b style='color:Tomato;'><i>codeine</i></b> is metabolized by the cytochrome P450 2D6 (CYP2D6) to morphine. <b style='color:Tomato;'><i>codeine</i></b> is a much weaker agonist at mu opioid receptors than morphine. Therefore, <b style='color:Tomato;'><i>codeine</i></b> analgesia is highly dependent on CYP2D6 activity. Large prospective studies in the clinical environment do not exist, but it appears reasonable to avoid <b style='color:Tomato;'><i>codeine</i></b> use in CYP2D6 poor metabolizers (PMs). <b style='color:DodgerBlue;'><i>CYP2D6</i></b> <b style='color:DodgerBlue;'><i>metabolizes</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>opioid</i></b> <b style='color:DodgerBlue;'><i>analgesics</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>tramadol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>dihydrocodeine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>oxycodone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>hydrocodone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>although</i></b> <b style='color:DodgerBlue;'><i>they</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>less</i></b> <b style='color:DodgerBlue;'><i>systematically</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>.</i></b> It is unclear whether these other pro-drugs may be as completely dependent on CYP2D6 for their analgesia as <b style='color:Tomato;'><i>codeine</i></b>. We describe a patient identified as a CYP2D6 PM with a history of problems with opioid analgesics. The patient was an 85-year-old female Caucasian who had hip surgery. The patient had a long-standing intolerance to <b style='color:Tomato;'><i>codeine</i></b>. In her first admission, she couldn't tolerate the regimen of oxycodone combined with <b style='color:Tomato;'><i>tramadol</i></b> prns (as needed). She was genotyped as a CYP2D6 PM and after the information was provided to the treating physician in her second admission, she seemed to have a better response to <b style='color:Tomato;'><i>hydrocodone</i></b>. Large case-control naturalistic studies followed by randomized trials in patients taking opioid analgesics may be needed to definitively establish that CYP2D6 genotyping has clinical relevance in the use of several opioid analgesics.","tokens":[{"text":"CYP2D6","start":0,"end":6,"id":0,"ws":true},{"text":"metabolizes","start":7,"end":18,"id":1,"ws":true},{"text":"other","start":19,"end":24,"id":2,"ws":true},{"text":"opioid","start":25,"end":31,"id":3,"ws":true},{"text":"analgesics","start":32,"end":42,"id":4,"ws":true},{"text":",","start":43,"end":44,"id":5,"ws":true},{"text":"including","start":45,"end":54,"id":6,"ws":true},{"text":"tramadol","start":55,"end":63,"id":7,"ws":true},{"text":",","start":64,"end":65,"id":8,"ws":true},{"text":"dihydrocodeine","start":66,"end":80,"id":9,"ws":true},{"text":",","start":81,"end":82,"id":10,"ws":true},{"text":"oxycodone","start":83,"end":92,"id":11,"ws":true},{"text":"and","start":93,"end":96,"id":12,"ws":true},{"text":"hydrocodone","start":97,"end":108,"id":13,"ws":true},{"text":",","start":109,"end":110,"id":14,"ws":true},{"text":"although","start":111,"end":119,"id":15,"ws":true},{"text":"they","start":120,"end":124,"id":16,"ws":true},{"text":"have","start":125,"end":129,"id":17,"ws":true},{"text":"been","start":130,"end":134,"id":18,"ws":true},{"text":"less","start":135,"end":139,"id":19,"ws":true},{"text":"systematically","start":140,"end":154,"id":20,"ws":true},{"text":"studied","start":155,"end":162,"id":21,"ws":true},{"text":".","start":163,"end":164,"id":22,"ws":false}],"spans":[{"start":55,"end":63,"token_start":7,"token_end":7,"label":"DRUG"},{"start":97,"end":108,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16631290/","_input_hash":180518504,"_task_hash":386885726,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Atracurium or vecuronium was given for intubation .","paragraph":"<h3><u>Prediction of oculocardiac reflex in strabismus surgery using neural networks.</u></h3>Successfully predicting an oculocardiac reflex (OCR) is difficult to achieve despite various proposed maneuvers. The aim of this study was to test the models built up by neural networks to predict the occurrence of OCR during strabismus surgery in children. Premedication was not given. <b style='color:Tomato;'><i>atropine</i></b> 0.01 mg/kg was medicated just before induction. Induction was performed with fentanyl or <b style='color:Tomato;'><i>ketorolac</i></b>, followed by <b style='color:Tomato;'><i>propofol</i></b>. <b style='color:MediumOrchid;'><i>Atracurium</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>vecuronium</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>intubation</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Anesthesia was maintained with O2-N2O with continuous <b style='color:Tomato;'><i>propofol</i></b> infusion. Chi-square test was performed for induction agents, gender, weight, muscle blockade, repaired muscle, number of repaired muscles, duration of operation to detect any association between the occurrence of OCR and to develop the model of neural networks. The multi-layer perceptron, radial basis function and Bayesian backpropagation network were tested. The occurrence of OCR was significantly associated with gender and repaired muscle (p < 0.05). Gender, repaired muscle and age were considered as input for the multi-layer perceptron, radial basis function and Bayesian backpropagation network. Three neural networks had predicted the same correction rate in the occurrence of OCR as being 87.5% overall among 16 patients' records tested. These models are conceptually different in predicting compared to conventional maneuvers, and have the advantage of testing individually and foretelling the propensity. By comparison neural networks use grouped experiential data and predict OCR by the learning rule. Neural networks require a relatively abundant number of experienced and homogenous patients' records to establish an accurate model. The multi-layer perceptron, radial basis function and Bayesian backpropagation modeling network may be an alternative way, and preferable to vagal tone maneuvers if the associated relationships to the occurrence of OCR are more clearly defined.","tokens":[{"text":"Atracurium","start":0,"end":10,"id":0,"ws":true},{"text":"or","start":11,"end":13,"id":1,"ws":true},{"text":"vecuronium","start":14,"end":24,"id":2,"ws":true},{"text":"was","start":25,"end":28,"id":3,"ws":true},{"text":"given","start":29,"end":34,"id":4,"ws":true},{"text":"for","start":35,"end":38,"id":5,"ws":true},{"text":"intubation","start":39,"end":49,"id":6,"ws":true},{"text":".","start":50,"end":51,"id":7,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":14,"end":24,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10412336/","_input_hash":1481785694,"_task_hash":868944343,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The data show that knockdown of Rad51 or BRCA2 greatly sensitizes cells to DSBs and the induction of cell death following temozolomide and nimustine ( ACNU ) .","paragraph":"<h3><u>Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs.</u></h3>First line chemotherapeutics for brain tumors (malignant gliomas) are alkylating agents such as <b style='color:Tomato;'><i>temozolomide</i></b> and <b style='color:Tomato;'><i>nimustine</i></b>. Despite growing knowledge of how these agents work, patients suffering from this malignancy still face a dismal prognosis. Alkylating agents target DNA, forming the killing lesion O(6)-alkylguanine, which is converted into DNA double-strand breaks (DSBs) that trigger apoptosis. Here we assessed whether inhibiting repair of DSBs by homologous recombination (HR) or non-homologous end joining (NHEJ) is a reasonable strategy for sensitizing glioma cells to alkylating agents. For down-regulation of HR in glioma cells, we used an interference RNA (iRNA) approach targeting Rad51 and BRCA2, and for NHEJ we employed the DNA-PK inhibitor NU7026. We also assessed whether inhibition of poly(ADP)ribosyltransferase (PARP) by <b style='color:Tomato;'><i>olaparib</i></b> would enhance the killing effect. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>show</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>knockdown</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Rad51</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>BRCA2</i></b> <b style='color:DodgerBlue;'><i>greatly</i></b> <b style='color:DodgerBlue;'><i>sensitizes</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>DSBs</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>death</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>nimustine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ACNU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> It did not sensitize to ionizing radiation (IR). The expression of O(6)-methylguanine-DNA methyltransferase (MGMT) abolished all these effects, indicating that O(6)-alkylguanine induced by these drugs is the primary lesion responsible for the formation of DSBs and increased sensitivity of glioma cells following knockdown of Rad51 and BRCA2. Inhibition of DNA-PK only slightly sensitized to <b style='color:Tomato;'><i>temozolomide</i></b> whereas a significant effect was observed with IR. A triple strategy including siRNA and the PARP inhibitor <b style='color:Tomato;'><i>olaparib</i></b> further improved the killing effect of <b style='color:Tomato;'><i>temozolomide</i></b>. The data provides evidence that down-regulation of Rad51 or BRCA2 is a reasonable strategy for sensitizing glioma cells to killing by O(6)-alkylating anti-cancer drugs. The data also provide proof of principle that a triple strategy involving down-regulation of HR, PARP inhibition and MGMT depletion may greatly enhance the therapeutic effect of <b style='color:Tomato;'><i>temozolomide</i></b>.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"data","start":4,"end":8,"id":1,"ws":true},{"text":"show","start":9,"end":13,"id":2,"ws":true},{"text":"that","start":14,"end":18,"id":3,"ws":true},{"text":"knockdown","start":19,"end":28,"id":4,"ws":true},{"text":"of","start":29,"end":31,"id":5,"ws":true},{"text":"Rad51","start":32,"end":37,"id":6,"ws":true},{"text":"or","start":38,"end":40,"id":7,"ws":true},{"text":"BRCA2","start":41,"end":46,"id":8,"ws":true},{"text":"greatly","start":47,"end":54,"id":9,"ws":true},{"text":"sensitizes","start":55,"end":65,"id":10,"ws":true},{"text":"cells","start":66,"end":71,"id":11,"ws":true},{"text":"to","start":72,"end":74,"id":12,"ws":true},{"text":"DSBs","start":75,"end":79,"id":13,"ws":true},{"text":"and","start":80,"end":83,"id":14,"ws":true},{"text":"the","start":84,"end":87,"id":15,"ws":true},{"text":"induction","start":88,"end":97,"id":16,"ws":true},{"text":"of","start":98,"end":100,"id":17,"ws":true},{"text":"cell","start":101,"end":105,"id":18,"ws":true},{"text":"death","start":106,"end":111,"id":19,"ws":true},{"text":"following","start":112,"end":121,"id":20,"ws":true},{"text":"temozolomide","start":122,"end":134,"id":21,"ws":true},{"text":"and","start":135,"end":138,"id":22,"ws":true},{"text":"nimustine","start":139,"end":148,"id":23,"ws":true},{"text":"(","start":149,"end":150,"id":24,"ws":true},{"text":"ACNU","start":151,"end":155,"id":25,"ws":true},{"text":")","start":156,"end":157,"id":26,"ws":true},{"text":".","start":158,"end":159,"id":27,"ws":false}],"spans":[{"start":122,"end":134,"token_start":21,"token_end":21,"label":"DRUG"},{"start":139,"end":148,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22073281/","_input_hash":-1385267655,"_task_hash":1362201328,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The systemic treatment in both studies consisted of a four-drug-regimen ( VACA = vincristine , actinomycin D , cyclophosphamide , and adriamycin ; or VAIA = vincristine , actinomycin D , ifosfamide , and adriamycin ) and a total number of four courses , each lasting nine weeks , was recommended by the protocol .","paragraph":"<h3><u>Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.</u></h3>During recent years, more intensified systemic and local treatment regimens have increased the 5-year survival figures in localized Ewing's sarcoma to more than 60%. There is, however, concern about the risk of second malignancies (SM) in long-term survivors. We have analyzed the second malignancies in patients treated in the German Ewing's Sarcoma Studies CESS 81 and CESS 86. ### Materials And Methods From January 1981 through June 1991, 674 patients were registered in the two sequential multicentric Ewing's sarcoma trials CESS 81 (recruitment period 1981-1985) and CESS 86 (1986-1991). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>consisted</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>four-drug-regimen</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VACA</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin</i></b> <b style='color:DodgerBlue;'><i>D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>VAIA</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin</i></b> <b style='color:DodgerBlue;'><i>D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>number</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>courses</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>lasting</i></b> <b style='color:DodgerBlue;'><i>nine</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Local therapy in curative patients was either complete surgery (n = 162), surgery plus postoperative radiotherapy with 36-46Gy (n = 274), or definitive radiotherapy with 46-60Gy (n = 212). The median follow-up at the time of this analysis was 5.1 years, the maximum follow-up 16.5 years. ### results The overall survival of all patients including metastatic patients was 55% after 5 years, 48% after 10 years, and 37% after 15 years. Eight out of 674 patients (1.2%) developed a SM. Five of these were acute myelogenic leukemias (n = 4) or MDS (n = 1), and three were sarcomas. The interval between diagnosis of Ewing's sarcoma and the diagnosis of the SM was 17-78 months for the four AMLs, 96 months for the MDS and 82-136 months for the three sarcomas. The cumulative risk of an SM was 0.7% after 5 years, 2.9% after 10 years, and 4.7% after 15 years. Out of five patients with AML/MDS, three died of rapid AML-progression, and two are living with disease. Local therapy (surgery vs. surgery plus postoperative irradiation vs. definitive radiotherapy) had no impact on the frequency of AML/MDS, but local therapy did influence the risk of secondary sarcomas. All three patients with secondary sarcomas had received radiotherapy; however, all three sarcomas were salvaged by subsequent treatment and are in clinical remission with a follow-up of 1 month, 4.3 years, and 7.5 years after the diagnosis of the secondary sarcoma. Thus far, SM contributed to less than 1 % (3/328) of all deaths in the CESS-studies. ### conclusions The risk of leukemia after treatment for Ewing's sarcoma is probably in the range of 2%. The risk of solid tumors also seems to be low within the first 10 years after treatment and remains in the range of 5 % after 15 years. In the CESS-studies, less than 1% of all deaths within the first 10 years after diagnosis were caused by SM. Effective salvage therapy for secondary sarcomas is feasible.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"systemic","start":4,"end":12,"id":1,"ws":true},{"text":"treatment","start":13,"end":22,"id":2,"ws":true},{"text":"in","start":23,"end":25,"id":3,"ws":true},{"text":"both","start":26,"end":30,"id":4,"ws":true},{"text":"studies","start":31,"end":38,"id":5,"ws":true},{"text":"consisted","start":39,"end":48,"id":6,"ws":true},{"text":"of","start":49,"end":51,"id":7,"ws":true},{"text":"a","start":52,"end":53,"id":8,"ws":true},{"text":"four-drug-regimen","start":54,"end":71,"id":9,"ws":true},{"text":"(","start":72,"end":73,"id":10,"ws":true},{"text":"VACA","start":74,"end":78,"id":11,"ws":true},{"text":"=","start":79,"end":80,"id":12,"ws":true},{"text":"vincristine","start":81,"end":92,"id":13,"ws":true},{"text":",","start":93,"end":94,"id":14,"ws":true},{"text":"actinomycin","start":95,"end":106,"id":15,"ws":true},{"text":"D","start":107,"end":108,"id":16,"ws":true},{"text":",","start":109,"end":110,"id":17,"ws":true},{"text":"cyclophosphamide","start":111,"end":127,"id":18,"ws":true},{"text":",","start":128,"end":129,"id":19,"ws":true},{"text":"and","start":130,"end":133,"id":20,"ws":true},{"text":"adriamycin","start":134,"end":144,"id":21,"ws":true},{"text":";","start":145,"end":146,"id":22,"ws":true},{"text":"or","start":147,"end":149,"id":23,"ws":true},{"text":"VAIA","start":150,"end":154,"id":24,"ws":true},{"text":"=","start":155,"end":156,"id":25,"ws":true},{"text":"vincristine","start":157,"end":168,"id":26,"ws":true},{"text":",","start":169,"end":170,"id":27,"ws":true},{"text":"actinomycin","start":171,"end":182,"id":28,"ws":true},{"text":"D","start":183,"end":184,"id":29,"ws":true},{"text":",","start":185,"end":186,"id":30,"ws":true},{"text":"ifosfamide","start":187,"end":197,"id":31,"ws":true},{"text":",","start":198,"end":199,"id":32,"ws":true},{"text":"and","start":200,"end":203,"id":33,"ws":true},{"text":"adriamycin","start":204,"end":214,"id":34,"ws":true},{"text":")","start":215,"end":216,"id":35,"ws":true},{"text":"and","start":217,"end":220,"id":36,"ws":true},{"text":"a","start":221,"end":222,"id":37,"ws":true},{"text":"total","start":223,"end":228,"id":38,"ws":true},{"text":"number","start":229,"end":235,"id":39,"ws":true},{"text":"of","start":236,"end":238,"id":40,"ws":true},{"text":"four","start":239,"end":243,"id":41,"ws":true},{"text":"courses","start":244,"end":251,"id":42,"ws":true},{"text":",","start":252,"end":253,"id":43,"ws":true},{"text":"each","start":254,"end":258,"id":44,"ws":true},{"text":"lasting","start":259,"end":266,"id":45,"ws":true},{"text":"nine","start":267,"end":271,"id":46,"ws":true},{"text":"weeks","start":272,"end":277,"id":47,"ws":true},{"text":",","start":278,"end":279,"id":48,"ws":true},{"text":"was","start":280,"end":283,"id":49,"ws":true},{"text":"recommended","start":284,"end":295,"id":50,"ws":true},{"text":"by","start":296,"end":298,"id":51,"ws":true},{"text":"the","start":299,"end":302,"id":52,"ws":true},{"text":"protocol","start":303,"end":311,"id":53,"ws":true},{"text":".","start":312,"end":313,"id":54,"ws":false}],"spans":[{"start":81,"end":92,"token_start":13,"token_end":13,"label":"DRUG"},{"start":95,"end":106,"token_start":15,"token_end":15,"label":"DRUG"},{"start":111,"end":127,"token_start":18,"token_end":18,"label":"DRUG"},{"start":134,"end":144,"token_start":21,"token_end":21,"label":"DRUG"},{"start":157,"end":168,"token_start":26,"token_end":26,"label":"DRUG"},{"start":171,"end":182,"token_start":28,"token_end":28,"label":"DRUG"},{"start":187,"end":197,"token_start":31,"token_end":31,"label":"DRUG"},{"start":204,"end":214,"token_start":34,"token_end":34,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9788419/","_input_hash":261521970,"_task_hash":456606957,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":81,"end":92,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":95,"end":106,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":15,"child":18,"head_span":{"start":95,"end":106,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":111,"end":127,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":18,"child":21,"head_span":{"start":111,"end":127,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":134,"end":144,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":26,"child":28,"head_span":{"start":157,"end":168,"token_start":26,"token_end":26,"label":"DRUG"},"child_span":{"start":171,"end":182,"token_start":28,"token_end":28,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":28,"child":31,"head_span":{"start":171,"end":182,"token_start":28,"token_end":28,"label":"DRUG"},"child_span":{"start":187,"end":197,"token_start":31,"token_end":31,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":31,"child":34,"head_span":{"start":187,"end":197,"token_start":31,"token_end":31,"label":"DRUG"},"child_span":{"start":204,"end":214,"token_start":34,"token_end":34,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":[],"answer":"accept"}
{"text":"Rationale , design , and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive , nonhypercholesterolemic subjects with microalbuminuria ( the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [ PREVEND IT ] ) .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Rationale</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>design</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>baseline</i></b> <b style='color:DodgerBlue;'><i>characteristics</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>prevention</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cardiovascular</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>fosinopril</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>pravastatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>nonhypertensive</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>nonhypercholesterolemic</i></b> <b style='color:DodgerBlue;'><i>subjects</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>microalbuminuria</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Prevention</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>REnal</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Vascular</i></b> <b style='color:DodgerBlue;'><i>ENdstage</i></b> <b style='color:DodgerBlue;'><i>Disease</i></b> <b style='color:DodgerBlue;'><i>Intervention</i></b> <b style='color:DodgerBlue;'><i>Trial</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>PREVEND</i></b> <b style='color:DodgerBlue;'><i>IT</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>This study describes the rationale, design, and baseline characteristics of a trial to determine whether treatment with <b style='color:Tomato;'><i>fosinopril</i></b> 20 mg/day and/or <b style='color:Tomato;'><i>pravastatin</i></b> 40 mg/ day will prevent cardiovascular and renal disease in nonhypertensive (RR <160/100 mm Hg and not using antihypertensive medication) and nonhypercholesterolemic (total cholesterol <8.0 or <5.0 mmol/L in case of previous myocardial infarction and not using lipid lowering medication) men and women with persistent microalbuminuria (urinary albumin excretion >10 mg/L once in an early morning spot urine and 15 to 300 mg/24-hour at least once in two 24-hour urine collections). The Prevention of REnal and Vascular ENdstage Disease Intervention Trial is a single-center, double-blind, randomized, placebo-controlled trial with a 2 x 2 factorial design. The 864 randomized subjects will be monitored for a minimum of 4 years and a maximum of 5 years. The primary efficacy parameter is defined as the combined incidence of all-cause mortality or hospital admission for documented (1) nonfatal myocardial infarction, (2) myocardial ischemia, (3) heart failure, (4) peripheral vascular disease, (5) cerebrovascular accident and/or (6) end-stage renal disease.","tokens":[{"text":"Rationale","start":0,"end":9,"id":0,"ws":true},{"text":",","start":10,"end":11,"id":1,"ws":true},{"text":"design","start":12,"end":18,"id":2,"ws":true},{"text":",","start":19,"end":20,"id":3,"ws":true},{"text":"and","start":21,"end":24,"id":4,"ws":true},{"text":"baseline","start":25,"end":33,"id":5,"ws":true},{"text":"characteristics","start":34,"end":49,"id":6,"ws":true},{"text":"of","start":50,"end":52,"id":7,"ws":true},{"text":"a","start":53,"end":54,"id":8,"ws":true},{"text":"trial","start":55,"end":60,"id":9,"ws":true},{"text":"of","start":61,"end":63,"id":10,"ws":true},{"text":"prevention","start":64,"end":74,"id":11,"ws":true},{"text":"of","start":75,"end":77,"id":12,"ws":true},{"text":"cardiovascular","start":78,"end":92,"id":13,"ws":true},{"text":"and","start":93,"end":96,"id":14,"ws":true},{"text":"renal","start":97,"end":102,"id":15,"ws":true},{"text":"disease","start":103,"end":110,"id":16,"ws":true},{"text":"with","start":111,"end":115,"id":17,"ws":true},{"text":"fosinopril","start":116,"end":126,"id":18,"ws":true},{"text":"and","start":127,"end":130,"id":19,"ws":true},{"text":"pravastatin","start":131,"end":142,"id":20,"ws":true},{"text":"in","start":143,"end":145,"id":21,"ws":true},{"text":"nonhypertensive","start":146,"end":161,"id":22,"ws":true},{"text":",","start":162,"end":163,"id":23,"ws":true},{"text":"nonhypercholesterolemic","start":164,"end":187,"id":24,"ws":true},{"text":"subjects","start":188,"end":196,"id":25,"ws":true},{"text":"with","start":197,"end":201,"id":26,"ws":true},{"text":"microalbuminuria","start":202,"end":218,"id":27,"ws":true},{"text":"(","start":219,"end":220,"id":28,"ws":true},{"text":"the","start":221,"end":224,"id":29,"ws":true},{"text":"Prevention","start":225,"end":235,"id":30,"ws":true},{"text":"of","start":236,"end":238,"id":31,"ws":true},{"text":"REnal","start":239,"end":244,"id":32,"ws":true},{"text":"and","start":245,"end":248,"id":33,"ws":true},{"text":"Vascular","start":249,"end":257,"id":34,"ws":true},{"text":"ENdstage","start":258,"end":266,"id":35,"ws":true},{"text":"Disease","start":267,"end":274,"id":36,"ws":true},{"text":"Intervention","start":275,"end":287,"id":37,"ws":true},{"text":"Trial","start":288,"end":293,"id":38,"ws":true},{"text":"[","start":294,"end":295,"id":39,"ws":true},{"text":"PREVEND","start":296,"end":303,"id":40,"ws":true},{"text":"IT","start":304,"end":306,"id":41,"ws":true},{"text":"]","start":307,"end":308,"id":42,"ws":true},{"text":")","start":309,"end":310,"id":43,"ws":true},{"text":".","start":311,"end":312,"id":44,"ws":false}],"spans":[{"start":116,"end":126,"token_start":18,"token_end":18,"label":"DRUG"},{"start":131,"end":142,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10980214/","_input_hash":-1982290624,"_task_hash":1322187593,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In the present study , rabbits prepared with chronic vascular cannulae were used to study the effects of nicotine administration on plasma corticosterone , catecholamine ( epinephrine , norepinephrine and dopamine ) and glucose responses to physical restraint stress .","paragraph":"<h3><u>Neuroendocrine responses to nicotine and stress: enhancement of peripheral stress responses by the administration of nicotine.</u></h3>Habitual smokers frequently report that when they are stressed smoking helps them to relax. One potential explanation for the reported stress ameliorating effect of smoking is that cigarette consumption (<b style='color:Tomato;'><i>nicotine</i></b> self-administration) may decrease the sympathetic autonomic nervous system activity which is associated with the stress response. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>rabbits</i></b> <b style='color:DodgerBlue;'><i>prepared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>cannulae</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>nicotine</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>corticosterone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>catecholamine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>epinephrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>norepinephrine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>dopamine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>glucose</i></b> <b style='color:DodgerBlue;'><i>responses</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>physical</i></b> <b style='color:DodgerBlue;'><i>restraint</i></b> <b style='color:DodgerBlue;'><i>stress</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>nicotine</i></b> (0.025, 0.05 or 0.10 mg <b style='color:Tomato;'><i>nicotine</i></b> base/kg body weight) was administered for 10 days prior to the \"stress test\" to allow for the development of habituation/tolerance to its acute toxic effects. Independent administration of <b style='color:Tomato;'><i>nicotine</i></b>, or the application of the physical restraint stressor, resulted in increases in the plasma concentrations of corticosterone, <b style='color:Tomato;'><i>epinephrine</i></b>, nor<b style='color:Tomato;'><i>epinephrine</i></b>, and glucose. <b style='color:Tomato;'><i>nicotine</i></b> administration during restraint stress enhanced the increase in plasma corticosterone and <b style='color:Tomato;'><i>epinephrine</i></b>, as compared to the responses induced by either factor alone. The results suggest that the stress ameliorating effect of continued cigarette smoking, as reported by habitual smokers, is not due to a reduction in the activity of the peripheral sympathetic autonomic nervous system.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"present","start":7,"end":14,"id":2,"ws":true},{"text":"study","start":15,"end":20,"id":3,"ws":true},{"text":",","start":21,"end":22,"id":4,"ws":true},{"text":"rabbits","start":23,"end":30,"id":5,"ws":true},{"text":"prepared","start":31,"end":39,"id":6,"ws":true},{"text":"with","start":40,"end":44,"id":7,"ws":true},{"text":"chronic","start":45,"end":52,"id":8,"ws":true},{"text":"vascular","start":53,"end":61,"id":9,"ws":true},{"text":"cannulae","start":62,"end":70,"id":10,"ws":true},{"text":"were","start":71,"end":75,"id":11,"ws":true},{"text":"used","start":76,"end":80,"id":12,"ws":true},{"text":"to","start":81,"end":83,"id":13,"ws":true},{"text":"study","start":84,"end":89,"id":14,"ws":true},{"text":"the","start":90,"end":93,"id":15,"ws":true},{"text":"effects","start":94,"end":101,"id":16,"ws":true},{"text":"of","start":102,"end":104,"id":17,"ws":true},{"text":"nicotine","start":105,"end":113,"id":18,"ws":true},{"text":"administration","start":114,"end":128,"id":19,"ws":true},{"text":"on","start":129,"end":131,"id":20,"ws":true},{"text":"plasma","start":132,"end":138,"id":21,"ws":true},{"text":"corticosterone","start":139,"end":153,"id":22,"ws":true},{"text":",","start":154,"end":155,"id":23,"ws":true},{"text":"catecholamine","start":156,"end":169,"id":24,"ws":true},{"text":"(","start":170,"end":171,"id":25,"ws":true},{"text":"epinephrine","start":172,"end":183,"id":26,"ws":true},{"text":",","start":184,"end":185,"id":27,"ws":true},{"text":"norepinephrine","start":186,"end":200,"id":28,"ws":true},{"text":"and","start":201,"end":204,"id":29,"ws":true},{"text":"dopamine","start":205,"end":213,"id":30,"ws":true},{"text":")","start":214,"end":215,"id":31,"ws":true},{"text":"and","start":216,"end":219,"id":32,"ws":true},{"text":"glucose","start":220,"end":227,"id":33,"ws":true},{"text":"responses","start":228,"end":237,"id":34,"ws":true},{"text":"to","start":238,"end":240,"id":35,"ws":true},{"text":"physical","start":241,"end":249,"id":36,"ws":true},{"text":"restraint","start":250,"end":259,"id":37,"ws":true},{"text":"stress","start":260,"end":266,"id":38,"ws":true},{"text":".","start":267,"end":268,"id":39,"ws":false}],"spans":[{"start":105,"end":113,"token_start":18,"token_end":18,"label":"DRUG"},{"start":172,"end":183,"token_start":26,"token_end":26,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2505296/","_input_hash":-1406796643,"_task_hash":386005025,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Phase III , randomized , double-blind , multicenter trial comparing orteronel ( TAK-700 ) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy : ELM-PC 5 .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>multicenter</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:DodgerBlue;'><i>orteronel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>TAK-700</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>progressed</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>docetaxel-based</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>ELM-PC</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Orteronel (<b style='color:Tomato;'><i>tak-700</i></b>) is an investigational, nonsteroidal, reversible, selective 17,20-lyase inhibitor. This study examined orteronel in patients with metastatic castration-resistant prostate cancer that progressed after <b style='color:Tomato;'><i>docetaxel</i></b> therapy. ### Patients And Methods In our study, 1,099 men were randomly assigned in a 2:1 schedule to receive orteronel 400 mg plus <b style='color:Tomato;'><i>prednisone</i></b> 5 mg twice daily or placebo plus <b style='color:Tomato;'><i>prednisone</i></b> 5 mg twice daily, stratified by region (Europe, North America [NA], and non-Europe/NA) and Brief Pain Inventory-Short Form worst pain score. Primary end point was overall survival (OS). Key secondary end points (radiographic progression-free survival [rPFS], \u2265 50% decrease of prostate-specific antigen [PSA50], and pain response at 12 weeks) were to undergo statistical testing only if the primary end point analysis was significant. ### results The study was unblinded after crossing a prespecified OS futility boundary. The median OS was 17.0 months versus 15.2 months with orteronel-<b style='color:Tomato;'><i>prednisone</i></b> versus placebo-<b style='color:Tomato;'><i>prednisone</i></b> (hazard ratio [HR], 0.886; 95% CI, 0.739 to 1.062; P = .190). Improved rPFS was observed with orteronel-<b style='color:Tomato;'><i>prednisone</i></b> (median, 8.3 v 5.7 months; HR, 0.760; 95% CI, 0.653 to 0.885; P < .001). Orteronel-<b style='color:Tomato;'><i>prednisone</i></b> showed advantages over placebo-<b style='color:Tomato;'><i>prednisone</i></b> in PSA50 rate (25% v 10%, P < .001) and time to PSA progression (median, 5.5 v 2.9 months, P < .001) but not pain response rate (12% v 9%; P = .128). Adverse events (all grades) were generally more frequent with orteronel-<b style='color:Tomato;'><i>prednisone</i></b>, including nausea (42% v 26%), vomiting (36% v 17%), fatigue (29% v 23%), and increased amylase (14% v 2%). ### conclusion Our study did not meet the primary end point of OS. Longer rPFS and a higher PSA50 rate with orteronel-<b style='color:Tomato;'><i>prednisone</i></b> indicate antitumor activity.","tokens":[{"text":"Phase","start":0,"end":5,"id":0,"ws":true},{"text":"III","start":6,"end":9,"id":1,"ws":true},{"text":",","start":10,"end":11,"id":2,"ws":true},{"text":"randomized","start":12,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"double-blind","start":25,"end":37,"id":5,"ws":true},{"text":",","start":38,"end":39,"id":6,"ws":true},{"text":"multicenter","start":40,"end":51,"id":7,"ws":true},{"text":"trial","start":52,"end":57,"id":8,"ws":true},{"text":"comparing","start":58,"end":67,"id":9,"ws":true},{"text":"orteronel","start":68,"end":77,"id":10,"ws":true},{"text":"(","start":78,"end":79,"id":11,"ws":true},{"text":"TAK-700","start":80,"end":87,"id":12,"ws":true},{"text":")","start":88,"end":89,"id":13,"ws":true},{"text":"plus","start":90,"end":94,"id":14,"ws":true},{"text":"prednisone","start":95,"end":105,"id":15,"ws":true},{"text":"with","start":106,"end":110,"id":16,"ws":true},{"text":"placebo","start":111,"end":118,"id":17,"ws":true},{"text":"plus","start":119,"end":123,"id":18,"ws":true},{"text":"prednisone","start":124,"end":134,"id":19,"ws":true},{"text":"in","start":135,"end":137,"id":20,"ws":true},{"text":"patients","start":138,"end":146,"id":21,"ws":true},{"text":"with","start":147,"end":151,"id":22,"ws":true},{"text":"metastatic","start":152,"end":162,"id":23,"ws":true},{"text":"castration-resistant","start":163,"end":183,"id":24,"ws":true},{"text":"prostate","start":184,"end":192,"id":25,"ws":true},{"text":"cancer","start":193,"end":199,"id":26,"ws":true},{"text":"that","start":200,"end":204,"id":27,"ws":true},{"text":"has","start":205,"end":208,"id":28,"ws":true},{"text":"progressed","start":209,"end":219,"id":29,"ws":true},{"text":"during","start":220,"end":226,"id":30,"ws":true},{"text":"or","start":227,"end":229,"id":31,"ws":true},{"text":"after","start":230,"end":235,"id":32,"ws":true},{"text":"docetaxel-based","start":236,"end":251,"id":33,"ws":true},{"text":"therapy","start":252,"end":259,"id":34,"ws":true},{"text":":","start":260,"end":261,"id":35,"ws":true},{"text":"ELM-PC","start":262,"end":268,"id":36,"ws":true},{"text":"5","start":269,"end":270,"id":37,"ws":true},{"text":".","start":271,"end":272,"id":38,"ws":false}],"spans":[{"start":80,"end":87,"token_start":12,"token_end":12,"label":"DRUG"},{"start":95,"end":105,"token_start":15,"token_end":15,"label":"DRUG"},{"start":124,"end":134,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25624429/","_input_hash":-1244978902,"_task_hash":632074452,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Five clinical trials with temozolomide or dacarbazine have been performed in metastatic colorectal cancer ( mCRC ) with selection based on methyl-specific PCR ( MSP ) testing with modest results .","paragraph":"<h3><u>Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in\u00a0metastatic colorectal cancer patients.</u></h3>O(6)-methylguanine-DNA-methyltransferase (MGMT) is a repair protein, and its deficiency makes tumours more susceptible to the cytotoxic effect of alkylating agents. <b style='color:DodgerBlue;'><i>Five</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mCRC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selection</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>methyl-specific</i></b> <b style='color:DodgerBlue;'><i>PCR</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MSP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>testing</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>modest</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We hypothesised that mitigated results are consequences of unspecific patient selection and that alternative methodologies for MGMT testing such as immunohistochemistry (IHC) and digital polymerase chain reaction (PCR) could enhance patient enrolment. ### Patients And Methods Formalin-fixed paraffin embedded archival tumour tissue samples from four phase II studies of <b style='color:Tomato;'><i>temozolomide</i></b> or <b style='color:Tomato;'><i>dacarbazine</i></b> in MGMT MSP-positive mCRCs were analysed by IHC for MGMT protein expression and by methyl-BEAMing (MB) for percentage of promoter methylation. Pooled data were then retrospectively analysed according to objective response rate, progression-free survival (PFS) and overall survival (OS). ### results One hundred and five patients were included in the study. Twelve had achieved partial response (PR) (11.4%), 24 stable disease (SD; 22.9%) and 69 progressive disease (PD; 65.7%). Patients with PR/SD had lower IHC scores and higher MB levels than those with PD. MGMT expression by IHC was negatively and MB levels positively associated with PFS (p\u00a0<\u00a00.001 and 0.004, respectively), but not with OS. By combining both assays, IHC low/MB high patients displayed an 87% reduction in the hazard of progression (p\u00a0<\u00a00.001) and a 77% in the hazard for death (p\u00a0=\u00a00.001). ### conclusion In mCRC selected for MGMT deficiency by MSP, IHC and MB testing improve clinical outcome to alkylating agents. Their combination could enhance patient selection in this setting.","tokens":[{"text":"Five","start":0,"end":4,"id":0,"ws":true},{"text":"clinical","start":5,"end":13,"id":1,"ws":true},{"text":"trials","start":14,"end":20,"id":2,"ws":true},{"text":"with","start":21,"end":25,"id":3,"ws":true},{"text":"temozolomide","start":26,"end":38,"id":4,"ws":true},{"text":"or","start":39,"end":41,"id":5,"ws":true},{"text":"dacarbazine","start":42,"end":53,"id":6,"ws":true},{"text":"have","start":54,"end":58,"id":7,"ws":true},{"text":"been","start":59,"end":63,"id":8,"ws":true},{"text":"performed","start":64,"end":73,"id":9,"ws":true},{"text":"in","start":74,"end":76,"id":10,"ws":true},{"text":"metastatic","start":77,"end":87,"id":11,"ws":true},{"text":"colorectal","start":88,"end":98,"id":12,"ws":true},{"text":"cancer","start":99,"end":105,"id":13,"ws":true},{"text":"(","start":106,"end":107,"id":14,"ws":true},{"text":"mCRC","start":108,"end":112,"id":15,"ws":true},{"text":")","start":113,"end":114,"id":16,"ws":true},{"text":"with","start":115,"end":119,"id":17,"ws":true},{"text":"selection","start":120,"end":129,"id":18,"ws":true},{"text":"based","start":130,"end":135,"id":19,"ws":true},{"text":"on","start":136,"end":138,"id":20,"ws":true},{"text":"methyl-specific","start":139,"end":154,"id":21,"ws":true},{"text":"PCR","start":155,"end":158,"id":22,"ws":true},{"text":"(","start":159,"end":160,"id":23,"ws":true},{"text":"MSP","start":161,"end":164,"id":24,"ws":true},{"text":")","start":165,"end":166,"id":25,"ws":true},{"text":"testing","start":167,"end":174,"id":26,"ws":true},{"text":"with","start":175,"end":179,"id":27,"ws":true},{"text":"modest","start":180,"end":186,"id":28,"ws":true},{"text":"results","start":187,"end":194,"id":29,"ws":true},{"text":".","start":195,"end":196,"id":30,"ws":false}],"spans":[{"start":26,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},{"start":42,"end":53,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27997874/","_input_hash":-261435108,"_task_hash":-743889492,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Heparin infusion , followed by oral warfarin , is indicated for symptomatic thromboembolic disease as well as for asymptomatic patients with substantial proximal deep venous thrombosis or large pulmonary emboli .","paragraph":"<h3><u>Therapy for postoperative thromboembolic disease:  indications and treatment.</u></h3>Postarthroplasty patients develop venous thromboembolic disease because of venous stasis, hypercoaguability, and vessel wall injury.  However, most venous thrombi are nonocclusive or small and elicit few symptoms; pulmonary emboli also tend to be asymptomatic.  Noninvasive techniques to detect deep vein thrombosis do not appear to be reliable in this population, so venography may be required.  Postoperative perfusion lung scans, with comparison to preoperative perfusion scans, are the best screen for asymptomatic pulmonary emboli. <b style='color:MediumOrchid;'><i>Heparin</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>warfarin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>indicated</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>symptomatic</i></b> <b style='color:DodgerBlue;'><i>thromboembolic</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>asymptomatic</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>substantial</i></b> <b style='color:DodgerBlue;'><i>proximal</i></b> <b style='color:DodgerBlue;'><i>deep</i></b> <b style='color:DodgerBlue;'><i>venous</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>large</i></b> <b style='color:DodgerBlue;'><i>pulmonary</i></b> <b style='color:DodgerBlue;'><i>emboli</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Heparin","start":0,"end":7,"id":0,"ws":true},{"text":"infusion","start":8,"end":16,"id":1,"ws":true},{"text":",","start":17,"end":18,"id":2,"ws":true},{"text":"followed","start":19,"end":27,"id":3,"ws":true},{"text":"by","start":28,"end":30,"id":4,"ws":true},{"text":"oral","start":31,"end":35,"id":5,"ws":true},{"text":"warfarin","start":36,"end":44,"id":6,"ws":true},{"text":",","start":45,"end":46,"id":7,"ws":true},{"text":"is","start":47,"end":49,"id":8,"ws":true},{"text":"indicated","start":50,"end":59,"id":9,"ws":true},{"text":"for","start":60,"end":63,"id":10,"ws":true},{"text":"symptomatic","start":64,"end":75,"id":11,"ws":true},{"text":"thromboembolic","start":76,"end":90,"id":12,"ws":true},{"text":"disease","start":91,"end":98,"id":13,"ws":true},{"text":"as","start":99,"end":101,"id":14,"ws":true},{"text":"well","start":102,"end":106,"id":15,"ws":true},{"text":"as","start":107,"end":109,"id":16,"ws":true},{"text":"for","start":110,"end":113,"id":17,"ws":true},{"text":"asymptomatic","start":114,"end":126,"id":18,"ws":true},{"text":"patients","start":127,"end":135,"id":19,"ws":true},{"text":"with","start":136,"end":140,"id":20,"ws":true},{"text":"substantial","start":141,"end":152,"id":21,"ws":true},{"text":"proximal","start":153,"end":161,"id":22,"ws":true},{"text":"deep","start":162,"end":166,"id":23,"ws":true},{"text":"venous","start":167,"end":173,"id":24,"ws":true},{"text":"thrombosis","start":174,"end":184,"id":25,"ws":true},{"text":"or","start":185,"end":187,"id":26,"ws":true},{"text":"large","start":188,"end":193,"id":27,"ws":true},{"text":"pulmonary","start":194,"end":203,"id":28,"ws":true},{"text":"emboli","start":204,"end":210,"id":29,"ws":true},{"text":".","start":211,"end":212,"id":30,"ws":false}],"spans":[{"start":0,"end":7,"token_start":0,"token_end":0,"label":"DRUG"},{"start":36,"end":44,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10147578/","_input_hash":630344348,"_task_hash":-1639191693,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":0,"child":6,"head_span":{"start":0,"end":7,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":36,"end":44,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Fluoxetine and paroxetine are potent inhibitors of CYP2D6 and administration of these SSRIs reduces the clinical benefit of an anticancer drug , such as tamoxifen , by decreasing the formation of active metabolites of this drug .","paragraph":"<h3><u>Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract.</u></h3>Different antidepressant drugs are currently used for the treatment of depression in cancer patients, such as second-generation antidepressants and, recently, the extracts of Hypericum perforatum. These agents are susceptible to metabolically-based drug interactions with anticancer drugs. The aim of the present article is to provide an updated review of clinically relevant metabolic drug interactions between selected anticancer drugs and antidepressants, focusing on selective serotonin reuptake inhibitors (SSRIs) and Hypericum extract. SSRIs can cause pharmacokinetic interactions through their in vitro ability to inhibit one or more cytochrome P450 isoenzymes (CYPs). SSRIs differ in their potential for metabolic drug interactions with anticancer drugs. <b style='color:MediumOrchid;'><i>Fluoxetine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paroxetine</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>potent</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>CYP2D6</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>SSRIs</i></b> <b style='color:DodgerBlue;'><i>reduces</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticancer</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>decreasing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>formation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>metabolites</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Women with breast cancer who receive <b style='color:Tomato;'><i>paroxetine</i></b> in combination with <b style='color:Tomato;'><i>tamoxifen</i></b> are at increased risk for death. Other SSRIs, including <b style='color:Tomato;'><i>citalopram</i></b>, es<b style='color:Tomato;'><i>citalopram</i></b>, are weak or negligible inhibitors of CYP2D6 and are less likely to interact with anticancer drugs, while <b style='color:Tomato;'><i>sertraline</i></b> causes significant inhibition of this isoform only at high doses. Hypericum extract, by inducing both the CYP3A4 and the P-glycoprotein (P-gp), can reduce the plasma concentrations of different antineoplastic agents such as <b style='color:Tomato;'><i>imatinib</i></b>, <b style='color:Tomato;'><i>irinotecan</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b>, thus reducing the clinical efficacy of these drugs. Although these interactions are often predictable, the use of <b style='color:Tomato;'><i>fluoxetine</i></b>, <b style='color:Tomato;'><i>paroxetine</i></b> and Hypericum extract should be avoided in cancer patients.","tokens":[{"text":"Fluoxetine","start":0,"end":10,"id":0,"ws":true},{"text":"and","start":11,"end":14,"id":1,"ws":true},{"text":"paroxetine","start":15,"end":25,"id":2,"ws":true},{"text":"are","start":26,"end":29,"id":3,"ws":true},{"text":"potent","start":30,"end":36,"id":4,"ws":true},{"text":"inhibitors","start":37,"end":47,"id":5,"ws":true},{"text":"of","start":48,"end":50,"id":6,"ws":true},{"text":"CYP2D6","start":51,"end":57,"id":7,"ws":true},{"text":"and","start":58,"end":61,"id":8,"ws":true},{"text":"administration","start":62,"end":76,"id":9,"ws":true},{"text":"of","start":77,"end":79,"id":10,"ws":true},{"text":"these","start":80,"end":85,"id":11,"ws":true},{"text":"SSRIs","start":86,"end":91,"id":12,"ws":true},{"text":"reduces","start":92,"end":99,"id":13,"ws":true},{"text":"the","start":100,"end":103,"id":14,"ws":true},{"text":"clinical","start":104,"end":112,"id":15,"ws":true},{"text":"benefit","start":113,"end":120,"id":16,"ws":true},{"text":"of","start":121,"end":123,"id":17,"ws":true},{"text":"an","start":124,"end":126,"id":18,"ws":true},{"text":"anticancer","start":127,"end":137,"id":19,"ws":true},{"text":"drug","start":138,"end":142,"id":20,"ws":true},{"text":",","start":143,"end":144,"id":21,"ws":true},{"text":"such","start":145,"end":149,"id":22,"ws":true},{"text":"as","start":150,"end":152,"id":23,"ws":true},{"text":"tamoxifen","start":153,"end":162,"id":24,"ws":true},{"text":",","start":163,"end":164,"id":25,"ws":true},{"text":"by","start":165,"end":167,"id":26,"ws":true},{"text":"decreasing","start":168,"end":178,"id":27,"ws":true},{"text":"the","start":179,"end":182,"id":28,"ws":true},{"text":"formation","start":183,"end":192,"id":29,"ws":true},{"text":"of","start":193,"end":195,"id":30,"ws":true},{"text":"active","start":196,"end":202,"id":31,"ws":true},{"text":"metabolites","start":203,"end":214,"id":32,"ws":true},{"text":"of","start":215,"end":217,"id":33,"ws":true},{"text":"this","start":218,"end":222,"id":34,"ws":true},{"text":"drug","start":223,"end":227,"id":35,"ws":true},{"text":".","start":228,"end":229,"id":36,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":15,"end":25,"token_start":2,"token_end":2,"label":"DRUG"},{"start":153,"end":162,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21395523/","_input_hash":-1272081112,"_task_hash":-110484064,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":2,"child":24,"head_span":{"start":15,"end":25,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":153,"end":162,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":0,"child":24,"head_span":{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":153,"end":162,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#ffdaf9","label":"NEG2"}],"radio":["NEG10","NEG20"],"answer":"accept"}
{"text":"Epirubicin is an anthracyclin , analogous to doxorubicin , with a different toxicologic pattern .","paragraph":"<h3><u>A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.</u></h3>Few chemotherapeutic agents have demonstrated their efficacy in malignant mesothelioma. The <b style='color:Tomato;'><i>cisplatin</i></b> plus <b style='color:Tomato;'><i>doxorubicin</i></b> combination has one of the highest response rates. <b style='color:MediumOrchid;'><i>Epirubicin</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anthracyclin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>analogous</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>toxicologic</i></b> <b style='color:DodgerBlue;'><i>pattern</i></b> <b style='color:DodgerBlue;'><i>.</i></b> As there are no data on the activity of the combination <b style='color:Tomato;'><i>cisplatin</i></b> plus <b style='color:Tomato;'><i>epirubicin</i></b> in malignant mesothelioma, the European Lung Cancer Working Party (ELCWP) designed a phase II study with response rate as primary objective. Sixty-nine eligible patients with malignant pleural mesothelioma were centrally registered. The majority of the patients were male (n=59), had a Karnofsky performance status of 80 or more (n=62) and presented with an epithelial histologic subtype (n=43). Median age was 62 years. In nine patients, metastases were documented at the initial work-up, mainly in bone, lung and skin. Three hundred and twenty-four cycles of chemotherapy were administered. The main toxicities were nausea and vomiting, neutropenia and alopecia. Among 63 assessable patients, response rate was 19.0% (95% confidence interval [CI] 9-29%). Median survival was 13.3 months. In multivariate analysis, poor prognostic factors for survival were neutrophil count and CALGB groups 4-6. In conclusion, <b style='color:Tomato;'><i>cisplatin</i></b> plus <b style='color:Tomato;'><i>epirubicin</i></b> appears as an effective regimen in malignant mesothelioma, with a favourable toxicity profile. However, it does not demonstrate superior activity to other active regimens in this disease.","tokens":[{"text":"Epirubicin","start":0,"end":10,"id":0,"ws":true},{"text":"is","start":11,"end":13,"id":1,"ws":true},{"text":"an","start":14,"end":16,"id":2,"ws":true},{"text":"anthracyclin","start":17,"end":29,"id":3,"ws":true},{"text":",","start":30,"end":31,"id":4,"ws":true},{"text":"analogous","start":32,"end":41,"id":5,"ws":true},{"text":"to","start":42,"end":44,"id":6,"ws":true},{"text":"doxorubicin","start":45,"end":56,"id":7,"ws":true},{"text":",","start":57,"end":58,"id":8,"ws":true},{"text":"with","start":59,"end":63,"id":9,"ws":true},{"text":"a","start":64,"end":65,"id":10,"ws":true},{"text":"different","start":66,"end":75,"id":11,"ws":true},{"text":"toxicologic","start":76,"end":87,"id":12,"ws":true},{"text":"pattern","start":88,"end":95,"id":13,"ws":true},{"text":".","start":96,"end":97,"id":14,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":45,"end":56,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16005104/","_input_hash":-1375944148,"_task_hash":-1600740243,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"A total of 460 patients were randomized into four 10-day therapeutic schemes ( 115 patients per group ): ( i ) standard OCA , omeprazole , clarithromycin and amoxicillin ; ( ii ) triple OLA , omeprazole , levofloxacin and amoxicillin ; ( iii ) sequential OACM , omeprazole plus amoxicillin for 5 days , followed by omeprazole plus clarithromycin plus metronidazole for 5 days ; and ( iv ) modified sequential OALM , using levofloxacin instead of clarithromycin .","paragraph":"<h3><u>Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.</u></h3>Helicobacter pylori eradication rates with standard triple therapy have declined to unacceptable levels. ### aim To compare <b style='color:Tomato;'><i>clarithromycin</i></b> and <b style='color:Tomato;'><i>levofloxacin</i></b> in triple and sequential first-line regimens. ### methods <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>460</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>10-day</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>schemes</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>115</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>):</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>OCA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ii</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>triple</i></b> <b style='color:DodgerBlue;'><i>OLA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>iii</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>OACM</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>metronidazole</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>iv</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>modified</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>OALM</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>instead</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Eradication was confirmed by 13C-urea breath test. Adverse effects and compliance were assessed by a questionnaire. ### results Per protocol cure rates were: OCA (66%; 95% CI: 57-74%), OLA (82.6%; 75-89%), OACM (80.8%; 73-88%) and OALM (85.2%; 78-91%). Intention-to-treat cure rates were: OCA (64%; 55-73%), OLA (80.8%; 73-88%), OACM (76.5%; 69-85%) and OALM (82.5%; 75-89%). Eradication rates were lower with OCA than with all the other regimens (P < 0.05). No differences in compliance or adverse effects were demonstrated among treatments. ### conclusions <b style='color:Tomato;'><i>levofloxacin</i></b>-based and sequential therapy are superior to standard triple scheme as first-line regimens in a setting with high <b style='color:Tomato;'><i>clarithromycin</i></b> resistance. However, all of these therapies still have a 20% failure rate.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"total","start":2,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"460","start":11,"end":14,"id":3,"ws":true},{"text":"patients","start":15,"end":23,"id":4,"ws":true},{"text":"were","start":24,"end":28,"id":5,"ws":true},{"text":"randomized","start":29,"end":39,"id":6,"ws":true},{"text":"into","start":40,"end":44,"id":7,"ws":true},{"text":"four","start":45,"end":49,"id":8,"ws":true},{"text":"10-day","start":50,"end":56,"id":9,"ws":true},{"text":"therapeutic","start":57,"end":68,"id":10,"ws":true},{"text":"schemes","start":69,"end":76,"id":11,"ws":true},{"text":"(","start":77,"end":78,"id":12,"ws":true},{"text":"115","start":79,"end":82,"id":13,"ws":true},{"text":"patients","start":83,"end":91,"id":14,"ws":true},{"text":"per","start":92,"end":95,"id":15,"ws":true},{"text":"group","start":96,"end":101,"id":16,"ws":true},{"text":"):","start":102,"end":104,"id":17,"ws":true},{"text":"(","start":105,"end":106,"id":18,"ws":true},{"text":"i","start":107,"end":108,"id":19,"ws":true},{"text":")","start":109,"end":110,"id":20,"ws":true},{"text":"standard","start":111,"end":119,"id":21,"ws":true},{"text":"OCA","start":120,"end":123,"id":22,"ws":true},{"text":",","start":124,"end":125,"id":23,"ws":true},{"text":"omeprazole","start":126,"end":136,"id":24,"ws":true},{"text":",","start":137,"end":138,"id":25,"ws":true},{"text":"clarithromycin","start":139,"end":153,"id":26,"ws":true},{"text":"and","start":154,"end":157,"id":27,"ws":true},{"text":"amoxicillin","start":158,"end":169,"id":28,"ws":true},{"text":";","start":170,"end":171,"id":29,"ws":true},{"text":"(","start":172,"end":173,"id":30,"ws":true},{"text":"ii","start":174,"end":176,"id":31,"ws":true},{"text":")","start":177,"end":178,"id":32,"ws":true},{"text":"triple","start":179,"end":185,"id":33,"ws":true},{"text":"OLA","start":186,"end":189,"id":34,"ws":true},{"text":",","start":190,"end":191,"id":35,"ws":true},{"text":"omeprazole","start":192,"end":202,"id":36,"ws":true},{"text":",","start":203,"end":204,"id":37,"ws":true},{"text":"levofloxacin","start":205,"end":217,"id":38,"ws":true},{"text":"and","start":218,"end":221,"id":39,"ws":true},{"text":"amoxicillin","start":222,"end":233,"id":40,"ws":true},{"text":";","start":234,"end":235,"id":41,"ws":true},{"text":"(","start":236,"end":237,"id":42,"ws":true},{"text":"iii","start":238,"end":241,"id":43,"ws":true},{"text":")","start":242,"end":243,"id":44,"ws":true},{"text":"sequential","start":244,"end":254,"id":45,"ws":true},{"text":"OACM","start":255,"end":259,"id":46,"ws":true},{"text":",","start":260,"end":261,"id":47,"ws":true},{"text":"omeprazole","start":262,"end":272,"id":48,"ws":true},{"text":"plus","start":273,"end":277,"id":49,"ws":true},{"text":"amoxicillin","start":278,"end":289,"id":50,"ws":true},{"text":"for","start":290,"end":293,"id":51,"ws":true},{"text":"5","start":294,"end":295,"id":52,"ws":true},{"text":"days","start":296,"end":300,"id":53,"ws":true},{"text":",","start":301,"end":302,"id":54,"ws":true},{"text":"followed","start":303,"end":311,"id":55,"ws":true},{"text":"by","start":312,"end":314,"id":56,"ws":true},{"text":"omeprazole","start":315,"end":325,"id":57,"ws":true},{"text":"plus","start":326,"end":330,"id":58,"ws":true},{"text":"clarithromycin","start":331,"end":345,"id":59,"ws":true},{"text":"plus","start":346,"end":350,"id":60,"ws":true},{"text":"metronidazole","start":351,"end":364,"id":61,"ws":true},{"text":"for","start":365,"end":368,"id":62,"ws":true},{"text":"5","start":369,"end":370,"id":63,"ws":true},{"text":"days","start":371,"end":375,"id":64,"ws":true},{"text":";","start":376,"end":377,"id":65,"ws":true},{"text":"and","start":378,"end":381,"id":66,"ws":true},{"text":"(","start":382,"end":383,"id":67,"ws":true},{"text":"iv","start":384,"end":386,"id":68,"ws":true},{"text":")","start":387,"end":388,"id":69,"ws":true},{"text":"modified","start":389,"end":397,"id":70,"ws":true},{"text":"sequential","start":398,"end":408,"id":71,"ws":true},{"text":"OALM","start":409,"end":413,"id":72,"ws":true},{"text":",","start":414,"end":415,"id":73,"ws":true},{"text":"using","start":416,"end":421,"id":74,"ws":true},{"text":"levofloxacin","start":422,"end":434,"id":75,"ws":true},{"text":"instead","start":435,"end":442,"id":76,"ws":true},{"text":"of","start":443,"end":445,"id":77,"ws":true},{"text":"clarithromycin","start":446,"end":460,"id":78,"ws":true},{"text":".","start":461,"end":462,"id":79,"ws":false}],"spans":[{"start":126,"end":136,"token_start":24,"token_end":24,"label":"DRUG"},{"start":139,"end":153,"token_start":26,"token_end":26,"label":"DRUG"},{"start":158,"end":169,"token_start":28,"token_end":28,"label":"DRUG"},{"start":192,"end":202,"token_start":36,"token_end":36,"label":"DRUG"},{"start":205,"end":217,"token_start":38,"token_end":38,"label":"DRUG"},{"start":222,"end":233,"token_start":40,"token_end":40,"label":"DRUG"},{"start":262,"end":272,"token_start":48,"token_end":48,"label":"DRUG"},{"start":278,"end":289,"token_start":50,"token_end":50,"label":"DRUG"},{"start":315,"end":325,"token_start":57,"token_end":57,"label":"DRUG"},{"start":331,"end":345,"token_start":59,"token_end":59,"label":"DRUG"},{"start":351,"end":364,"token_start":61,"token_end":61,"label":"DRUG"},{"start":422,"end":434,"token_start":75,"token_end":75,"label":"DRUG"},{"start":446,"end":460,"token_start":78,"token_end":78,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20180787/","_input_hash":1528379475,"_task_hash":831950146,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":36,"child":38,"head_span":{"start":192,"end":202,"token_start":36,"token_end":36,"label":"DRUG"},"child_span":{"start":205,"end":217,"token_start":38,"token_end":38,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":38,"child":40,"head_span":{"start":205,"end":217,"token_start":38,"token_end":38,"label":"DRUG"},"child_span":{"start":222,"end":233,"token_start":40,"token_end":40,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Captopril in combination with HYZ significantly reduced BP compared with controls but T replacement increased BP and coronary collagen deposition in spite of HYZ and captopril treatment .","paragraph":"<h3><u>Testosterone increases blood pressure and cardiovascular and renal pathology in spontaneously hypertensive rats.</u></h3>The objective of this paper was to test the hypothesis that testosterone (T) raises blood pressure (BP), which is associated with increased coronary adventitial collagen, whereas the hemodynamic force of BP increases the coronary media:lumen ratio. Five treatment groups of spontaneously hypertensive rat (SHR) were established (n = 8-10 per group): controls; <b style='color:Tomato;'><i>hydralazine</i></b> (HYZ); castration; castration + HYZ; and castration + HYZ + T + <b style='color:Tomato;'><i>captopril</i></b>. At 12 weeks of age, the castrate + HYZ group was divided so that the mean BP was the same in both groups (162 mmHg). Both groups continued to receive HYZ treatment; however one group received T implants. Also, at 12 weeks of age the castrate + HYZ + T + <b style='color:Tomato;'><i>captopril</i></b> group received T implants. BP in the HYZ group was reduced compared with controls (192 mmHg vs 218 mmHg, p < 0.01). Castration lowered BP to 170 mmHg (p < 0.01) compared with controls. However, T implants increased BP by 15 mmHg (p < 0.02) in the castrate + HYZ group and by 44 mmHg in the castrate + HYZ + <b style='color:Tomato;'><i>captopril</i></b> group (p < 0.01). <b style='color:MediumOrchid;'><i>Captopril</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HYZ</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>BP</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>controls</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>T</i></b> <b style='color:DodgerBlue;'><i>replacement</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>BP</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>coronary</i></b> <b style='color:DodgerBlue;'><i>collagen</i></b> <b style='color:DodgerBlue;'><i>deposition</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>spite</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>HYZ</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>captopril</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Captopril","start":0,"end":9,"id":0,"ws":true},{"text":"in","start":10,"end":12,"id":1,"ws":true},{"text":"combination","start":13,"end":24,"id":2,"ws":true},{"text":"with","start":25,"end":29,"id":3,"ws":true},{"text":"HYZ","start":30,"end":33,"id":4,"ws":true},{"text":"significantly","start":34,"end":47,"id":5,"ws":true},{"text":"reduced","start":48,"end":55,"id":6,"ws":true},{"text":"BP","start":56,"end":58,"id":7,"ws":true},{"text":"compared","start":59,"end":67,"id":8,"ws":true},{"text":"with","start":68,"end":72,"id":9,"ws":true},{"text":"controls","start":73,"end":81,"id":10,"ws":true},{"text":"but","start":82,"end":85,"id":11,"ws":true},{"text":"T","start":86,"end":87,"id":12,"ws":true},{"text":"replacement","start":88,"end":99,"id":13,"ws":true},{"text":"increased","start":100,"end":109,"id":14,"ws":true},{"text":"BP","start":110,"end":112,"id":15,"ws":true},{"text":"and","start":113,"end":116,"id":16,"ws":true},{"text":"coronary","start":117,"end":125,"id":17,"ws":true},{"text":"collagen","start":126,"end":134,"id":18,"ws":true},{"text":"deposition","start":135,"end":145,"id":19,"ws":true},{"text":"in","start":146,"end":148,"id":20,"ws":true},{"text":"spite","start":149,"end":154,"id":21,"ws":true},{"text":"of","start":155,"end":157,"id":22,"ws":true},{"text":"HYZ","start":158,"end":161,"id":23,"ws":true},{"text":"and","start":162,"end":165,"id":24,"ws":true},{"text":"captopril","start":166,"end":175,"id":25,"ws":true},{"text":"treatment","start":176,"end":185,"id":26,"ws":true},{"text":".","start":186,"end":187,"id":27,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":30,"end":33,"token_start":4,"token_end":4,"label":"DRUG"},{"start":166,"end":175,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11055476/","_input_hash":-1679930929,"_task_hash":983882790,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":0,"child":4,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":30,"end":33,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Targeted therapy was administered to match the P1K3CA , c-MET , and SPARC and COX2 aberrations with sirolimus+ crizotinib and abraxane+ celecoxib .","paragraph":"<h3><u>Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.</u></h3>Despite advances in molecular medicine over recent decades, there has been little advancement in the treatment of osteosarcoma. We performed comprehensive molecular profiling in two cases of metastatic and chemotherapy-refractory osteosarcoma to guide molecularly targeted therapy. ### Patients And Methods Hybridization capture of >300 cancer-related genes plus introns from 28 genes often rearranged or altered in cancer was applied to >50 ng of DNA extracted from tumor samples from two patients with recurrent, metastatic osteosarcoma. The DNA from each sample was sequenced to high, uniform coverage. Immunohistochemical probes and morphoproteomics analysis were performed, in addition to fluorescence in situ hybridization. All analyses were performed in CLIA-certified laboratories. Molecularly targeted therapy based on the resulting profiles was offered to the patients. Biomedical analytics were performed using QIAGEN's Ingenuity\u00ae Pathway Analysis. ### results In Patient #1, comprehensive next-generation exome sequencing showed MET amplification, PIK3CA mutation, CCNE1 amplification, and PTPRD mutation. Immunohistochemistry-based morphoproteomic analysis revealed c-Met expression [(p)-c-Met (Tyr1234/1235)] and activation of mTOR/AKT pathway [IGF-1R (Tyr1165/1166), p-mTOR [Ser2448], p-Akt (Ser473)] and expression of SPARC and COX2. <b style='color:DodgerBlue;'><i>Targeted</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>match</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>P1K3CA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>c-MET</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>SPARC</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>COX2</i></b> <b style='color:DodgerBlue;'><i>aberrations</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>sirolimus+</i></b> <b style='color:MediumOrchid;'><i>crizotinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>abraxane+</i></b> <b style='color:MediumOrchid;'><i>celecoxib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In Patient #2, aberrations included NF2 loss in exons 2-16, PDGFR\u03b1 amplification, and TP53 mutation. This patient was enrolled on a clinical trial combining targeted agents tem<b style='color:Tomato;'><i>sirolimus</i></b>, <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b>, to match NF2, PDGFR\u03b1 and TP53 aberrations. Both the patients did not benefit from matched therapy. ### conclusions Relapsed osteosarcoma is characterized by complex signaling and drug resistance pathways. Comprehensive molecular profiling holds great promise for tailoring personalized therapies for cancer. Methods for such profiling are evolving and need to be refined to better assist clinicians in making treatment decisions based on the large amount of data that results from this type of testing. Further research in this area is warranted.","tokens":[{"text":"Targeted","start":0,"end":8,"id":0,"ws":true},{"text":"therapy","start":9,"end":16,"id":1,"ws":true},{"text":"was","start":17,"end":20,"id":2,"ws":true},{"text":"administered","start":21,"end":33,"id":3,"ws":true},{"text":"to","start":34,"end":36,"id":4,"ws":true},{"text":"match","start":37,"end":42,"id":5,"ws":true},{"text":"the","start":43,"end":46,"id":6,"ws":true},{"text":"P1K3CA","start":47,"end":53,"id":7,"ws":true},{"text":",","start":54,"end":55,"id":8,"ws":true},{"text":"c-MET","start":56,"end":61,"id":9,"ws":true},{"text":",","start":62,"end":63,"id":10,"ws":true},{"text":"and","start":64,"end":67,"id":11,"ws":true},{"text":"SPARC","start":68,"end":73,"id":12,"ws":true},{"text":"and","start":74,"end":77,"id":13,"ws":true},{"text":"COX2","start":78,"end":82,"id":14,"ws":true},{"text":"aberrations","start":83,"end":94,"id":15,"ws":true},{"text":"with","start":95,"end":99,"id":16,"ws":true},{"text":"sirolimus+","start":100,"end":110,"id":17,"ws":true},{"text":"crizotinib","start":111,"end":121,"id":18,"ws":true},{"text":"and","start":122,"end":125,"id":19,"ws":true},{"text":"abraxane+","start":126,"end":135,"id":20,"ws":true},{"text":"celecoxib","start":136,"end":145,"id":21,"ws":true},{"text":".","start":146,"end":147,"id":22,"ws":false}],"spans":[{"start":100,"end":110,"token_start":17,"token_end":17,"label":"DRUG"},{"start":111,"end":121,"token_start":18,"token_end":18,"label":"DRUG"},{"start":126,"end":135,"token_start":20,"token_end":20,"label":"DRUG"},{"start":136,"end":145,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26510912/","_input_hash":84312616,"_task_hash":1485475965,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":17,"child":18,"head_span":{"start":100,"end":110,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":111,"end":121,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":20,"child":21,"head_span":{"start":126,"end":135,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":136,"end":145,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#ffdaf9","label":"NEG2"}],"radio":["NEG11","NEG21"],"answer":"accept"}
{"text":"Aspirin in antiinflammatory doses has been associated with gastrointestinal bleeding , and the bleeding potential of even 75 mg aspirin has been established .","paragraph":"<h3><u>Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis.</u></h3>Low-dose <b style='color:Tomato;'><i>aspirin</i></b> has been recommended for primary and secondary prevention of myocardial infarction and for the maintenance of aortocoronary bypass patency. Doses as low as 75 mg/day significantly lessen the risk of stroke or death in patients who experience cerebrovascular and ischemic events. <b style='color:MediumOrchid;'><i>Aspirin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>antiinflammatory</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>gastrointestinal</i></b> <b style='color:DodgerBlue;'><i>bleeding</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>bleeding</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>even</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>established</i></b> <b style='color:DodgerBlue;'><i>.</i></b> I assessed the role of low-dose <b style='color:Tomato;'><i>aspirin</i></b> in gastrointestinal bleeding by combining the results of nine studies that dealt with the prevention of ischemic, thromboembolic, or cerebrovascular events. The combination of the results showed that the occurrence of bleeding was 1.5 times higher in patients treated with low-dose <b style='color:Tomato;'><i>aspirin</i></b> in doses of 75-325 mg/day as compared with placebo (odds ratio 1.52; 95% CI 1.32-1.75). The monthly probability of gastrointestinal bleeding per 1,000 patients treated with low-dose <b style='color:Tomato;'><i>aspirin</i></b> ranged between 0 and 2.1.","tokens":[{"text":"Aspirin","start":0,"end":7,"id":0,"ws":true},{"text":"in","start":8,"end":10,"id":1,"ws":true},{"text":"antiinflammatory","start":11,"end":27,"id":2,"ws":true},{"text":"doses","start":28,"end":33,"id":3,"ws":true},{"text":"has","start":34,"end":37,"id":4,"ws":true},{"text":"been","start":38,"end":42,"id":5,"ws":true},{"text":"associated","start":43,"end":53,"id":6,"ws":true},{"text":"with","start":54,"end":58,"id":7,"ws":true},{"text":"gastrointestinal","start":59,"end":75,"id":8,"ws":true},{"text":"bleeding","start":76,"end":84,"id":9,"ws":true},{"text":",","start":85,"end":86,"id":10,"ws":true},{"text":"and","start":87,"end":90,"id":11,"ws":true},{"text":"the","start":91,"end":94,"id":12,"ws":true},{"text":"bleeding","start":95,"end":103,"id":13,"ws":true},{"text":"potential","start":104,"end":113,"id":14,"ws":true},{"text":"of","start":114,"end":116,"id":15,"ws":true},{"text":"even","start":117,"end":121,"id":16,"ws":true},{"text":"75","start":122,"end":124,"id":17,"ws":true},{"text":"mg","start":125,"end":127,"id":18,"ws":true},{"text":"aspirin","start":128,"end":135,"id":19,"ws":true},{"text":"has","start":136,"end":139,"id":20,"ws":true},{"text":"been","start":140,"end":144,"id":21,"ws":true},{"text":"established","start":145,"end":156,"id":22,"ws":true},{"text":".","start":157,"end":158,"id":23,"ws":false}],"spans":[{"start":0,"end":7,"token_start":0,"token_end":0,"label":"DRUG"},{"start":128,"end":135,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7560825/","_input_hash":-1674945343,"_task_hash":1558867634,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"EURAMOS-1 results do not support the addition of ifosfamide and etoposide to postoperative chemotherapy in patients with poorly responding osteosarcoma because its administration was associated with increased toxicity without improving event-free survival .","paragraph":"<h3><u>Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.</u></h3>We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (\u226510% viable tumour) improved event-free survival in patients with high-grade osteosarcoma. ### methods EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation. Patients were randomly assigned (1:1) to receive either postoperative <b style='color:Tomato;'><i>cisplatin</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, and <b style='color:Tomato;'><i>methotrexate</i></b> (MAP) or MAP plus <b style='color:Tomato;'><i>ifosfamide</i></b> and <b style='color:Tomato;'><i>etoposide</i></b> (MAPIE) using concealed permuted blocks with three stratification factors: trial group; location of tumour (proximal femur or proximal humerus vs other limb vs axial skeleton); and presence of metastases (no vs yes or possible). The MAP regimen consisted of <b style='color:Tomato;'><i>cisplatin</i></b> 120 mg/m ### findings Between April 14, 2005, and June 30, 2011, 2260 patients were registered from 325 sites in 17 countries. 618 patients with poor response were randomly assigned; 310 to receive MAP and 308 to receive MAPIE. Median follow-up was 62\u00b71 months (IQR 46\u00b76-76\u00b76); 62\u00b73 months (IQR 46\u00b79-77\u00b71) for the MAP group and 61\u00b71 months (IQR 46\u00b75-75\u00b73) for the MAPIE group. 307 event-free survival events were reported (153 in the MAP group vs 154 in the MAPIE group). 193 deaths were reported (101 in the MAP group vs 92 in the MAPIE group). Event-free survival did not differ between treatment groups (hazard ratio [HR] 0\u00b798 [95% CI 0\u00b778-1\u00b723]); hazards were non-proportional (p=0\u00b70003). The most common grade 3-4 adverse events were neutropenia (268 [89%] patients in MAP vs 268 [90%] in MAPIE), thrombocytopenia (231 [78% in MAP vs 248 [83%] in MAPIE), and febrile neutropenia without documented infection (149 [50%] in MAP vs 217 [73%] in MAPIE). MAPIE was associated with more frequent grade 4 non-haematological toxicity than MAP (35 [12%] of 301 in the MAP group vs 71 [24%] of 298 in the MAPIE group). Two patients died during postoperative therapy, one from infection (although their absolute neutrophil count was normal), which was definitely related to their MAP treatment (specifically <b style='color:Tomato;'><i>doxorubicin</i></b> and <b style='color:Tomato;'><i>cisplatin</i></b>), and one from left ventricular systolic dysfunction, which was probably related to MAPIE treatment (specifically <b style='color:Tomato;'><i>doxorubicin</i></b>). One suspected unexpected serious adverse reaction was reported in the MAP group: bone marrow infarction due to <b style='color:Tomato;'><i>methotrexate</i></b>. ### interpretation <b style='color:DodgerBlue;'><i>EURAMOS-1</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>do</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>support</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>postoperative</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>poorly</i></b> <b style='color:DodgerBlue;'><i>responding</i></b> <b style='color:DodgerBlue;'><i>osteosarcoma</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>improving</i></b> <b style='color:DodgerBlue;'><i>event-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The results define standard of care for this population. New strategies are required to improve outcomes in this setting. ### funding UK Medical Research Council, National Cancer Institute, European Science Foundation, St Anna Kinderkrebsforschung, Fonds National de la Recherche Scientifique, Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, Parents Organization, Danish Medical Research Council, Academy of Finland, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Federal Ministry of Education and Research, Semmelweis Foundation, ZonMw (Council for Medical Research), Research Council of Norway, Scandinavian Sarcoma Group, Swiss Paediatric Oncology Group, Cancer Research UK, National Institute for Health Research, University College London Hospitals, and Biomedical Research Centre.","tokens":[{"text":"EURAMOS-1","start":0,"end":9,"id":0,"ws":true},{"text":"results","start":10,"end":17,"id":1,"ws":true},{"text":"do","start":18,"end":20,"id":2,"ws":true},{"text":"not","start":21,"end":24,"id":3,"ws":true},{"text":"support","start":25,"end":32,"id":4,"ws":true},{"text":"the","start":33,"end":36,"id":5,"ws":true},{"text":"addition","start":37,"end":45,"id":6,"ws":true},{"text":"of","start":46,"end":48,"id":7,"ws":true},{"text":"ifosfamide","start":49,"end":59,"id":8,"ws":true},{"text":"and","start":60,"end":63,"id":9,"ws":true},{"text":"etoposide","start":64,"end":73,"id":10,"ws":true},{"text":"to","start":74,"end":76,"id":11,"ws":true},{"text":"postoperative","start":77,"end":90,"id":12,"ws":true},{"text":"chemotherapy","start":91,"end":103,"id":13,"ws":true},{"text":"in","start":104,"end":106,"id":14,"ws":true},{"text":"patients","start":107,"end":115,"id":15,"ws":true},{"text":"with","start":116,"end":120,"id":16,"ws":true},{"text":"poorly","start":121,"end":127,"id":17,"ws":true},{"text":"responding","start":128,"end":138,"id":18,"ws":true},{"text":"osteosarcoma","start":139,"end":151,"id":19,"ws":true},{"text":"because","start":152,"end":159,"id":20,"ws":true},{"text":"its","start":160,"end":163,"id":21,"ws":true},{"text":"administration","start":164,"end":178,"id":22,"ws":true},{"text":"was","start":179,"end":182,"id":23,"ws":true},{"text":"associated","start":183,"end":193,"id":24,"ws":true},{"text":"with","start":194,"end":198,"id":25,"ws":true},{"text":"increased","start":199,"end":208,"id":26,"ws":true},{"text":"toxicity","start":209,"end":217,"id":27,"ws":true},{"text":"without","start":218,"end":225,"id":28,"ws":true},{"text":"improving","start":226,"end":235,"id":29,"ws":true},{"text":"event-free","start":236,"end":246,"id":30,"ws":true},{"text":"survival","start":247,"end":255,"id":31,"ws":true},{"text":".","start":256,"end":257,"id":32,"ws":false}],"spans":[{"start":49,"end":59,"token_start":8,"token_end":8,"label":"DRUG"},{"start":64,"end":73,"token_start":10,"token_end":10,"label":"DRUG"},{"start":77,"end":103,"token_start":12,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27569442/","_input_hash":1532611365,"_task_hash":-785120694,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":10,"child":13,"head_span":{"start":64,"end":73,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":77,"end":103,"token_start":12,"token_end":13,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":8,"child":13,"head_span":{"start":49,"end":59,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":77,"end":103,"token_start":12,"token_end":13,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"The focus of this study is to investigate , whether altered expression levels of potentially relevant microRNAs ( miRs ) in serum are associated with response to trastuzumab or lapatinib .","paragraph":"<h3><u>Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.</u></h3><b style='color:Tomato;'><i>trastuzumab</i></b> and <b style='color:Tomato;'><i>lapatinib</i></b> are established treatments for patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer with different mechanisms of action. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>focus</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>whether</i></b> <b style='color:DodgerBlue;'><i>altered</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>potentially</i></b> <b style='color:DodgerBlue;'><i>relevant</i></b> <b style='color:DodgerBlue;'><i>microRNAs</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>miRs</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lapatinib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Circulating miR-21, miR-210, and miR-373 were quantified with TaqMan MicroRNA assays in serum of 127 HER2-postive breast cancer patients before and after neoadjuvant therapy and in 19 healthy controls. Patients received chemotherapy combined with either <b style='color:Tomato;'><i>trastuzumab</i></b> or <b style='color:Tomato;'><i>lapatinib</i></b> within the prospectively randomized Geparquinto trial. The association between miR levels and pathological response (pCR) to therapy and type of therapy was examined. Serum levels of miR-21 (p\u00a0=\u00a05.04e-08, p\u00a0=\u00a01.43e-10), miR-210 (p\u00a0=\u00a00.00151, p\u00a0=\u00a01.6e-05), and miR-373 (p\u00a0=\u00a07.87e-06, p\u00a0=\u00a01.75e-07) were significantly higher in patients before and after chemotherapy than in healthy women. Concentrations of miR-21 (p\u00a0=\u00a05.73e-08), miR-210 (p\u00a0=\u00a00.000724), and miR-373 (p\u00a0=\u00a00.00209) increased further after chemotherapy. A significant association of higher serum levels of miR-373 with advanced clinical tumor stage could be detected (p\u00a0<\u00a00.002). An association of miR-21 levels before (p\u00a0=\u00a00.0091) and after (p\u00a0=\u00a00.037) chemotherapy with overall survival of the patients could be detected, independent of type of anti-HER2 therapy. No association of circulating miRs with pCR was found. Our findings demonstrate a specific influence of neoadjuvant therapy on the serum levels of miR-21, miR-210, and miR-373 in breast cancer patients together with a prognostic value of miR-21.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"focus","start":4,"end":9,"id":1,"ws":true},{"text":"of","start":10,"end":12,"id":2,"ws":true},{"text":"this","start":13,"end":17,"id":3,"ws":true},{"text":"study","start":18,"end":23,"id":4,"ws":true},{"text":"is","start":24,"end":26,"id":5,"ws":true},{"text":"to","start":27,"end":29,"id":6,"ws":true},{"text":"investigate","start":30,"end":41,"id":7,"ws":true},{"text":",","start":42,"end":43,"id":8,"ws":true},{"text":"whether","start":44,"end":51,"id":9,"ws":true},{"text":"altered","start":52,"end":59,"id":10,"ws":true},{"text":"expression","start":60,"end":70,"id":11,"ws":true},{"text":"levels","start":71,"end":77,"id":12,"ws":true},{"text":"of","start":78,"end":80,"id":13,"ws":true},{"text":"potentially","start":81,"end":92,"id":14,"ws":true},{"text":"relevant","start":93,"end":101,"id":15,"ws":true},{"text":"microRNAs","start":102,"end":111,"id":16,"ws":true},{"text":"(","start":112,"end":113,"id":17,"ws":true},{"text":"miRs","start":114,"end":118,"id":18,"ws":true},{"text":")","start":119,"end":120,"id":19,"ws":true},{"text":"in","start":121,"end":123,"id":20,"ws":true},{"text":"serum","start":124,"end":129,"id":21,"ws":true},{"text":"are","start":130,"end":133,"id":22,"ws":true},{"text":"associated","start":134,"end":144,"id":23,"ws":true},{"text":"with","start":145,"end":149,"id":24,"ws":true},{"text":"response","start":150,"end":158,"id":25,"ws":true},{"text":"to","start":159,"end":161,"id":26,"ws":true},{"text":"trastuzumab","start":162,"end":173,"id":27,"ws":true},{"text":"or","start":174,"end":176,"id":28,"ws":true},{"text":"lapatinib","start":177,"end":186,"id":29,"ws":true},{"text":".","start":187,"end":188,"id":30,"ws":false}],"spans":[{"start":162,"end":173,"token_start":27,"token_end":27,"label":"DRUG"},{"start":177,"end":186,"token_start":29,"token_end":29,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25086636/","_input_hash":1312052038,"_task_hash":391736444,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"These results suggest that the addition of intravenous ceftriaxone during the first 3 days of hospitalization does not improve the cost-efficacy of oral norfloxacin in the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding and high risk of infection .","paragraph":"<h3><u>Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding.</u></h3>Selective intestinal decontamination with <b style='color:Tomato;'><i>norfloxacin</i></b> is useful in the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding. However, bleeding cirrhotic patients with ascites, encephalopathy, or shock are at high risk to develop bacterial infections in spite of prophylactic <b style='color:Tomato;'><i>norfloxacin</i></b>. The aim of this study was to assess whether the addition of intravenous <b style='color:Tomato;'><i>ceftriaxone</i></b> could improve the efficacy of prophylaxis with <b style='color:Tomato;'><i>norfloxacin</i></b> in these patients. ### methods Fifty-six cirrhotic patients with gastrointestinal hemorrhage and ascites, encephalopathy, or shock were randomized into two groups: Group 1 (n = 28) received oral <b style='color:Tomato;'><i>norfloxacin</i></b> 400 mg/12 h for 7 days, and group 2 (n = 28) received <b style='color:Tomato;'><i>norfloxacin</i></b> plus intravenous <b style='color:Tomato;'><i>ceftriaxone</i></b> 2 g daily during the first 3 days of admission. ### results Ten patients were excluded because of community-acquired infection, surgery, or death within the first 24 h. The incidence of bacterial infections during hospitalization was 18.1% in group 1 and 12.5% in group 2 (p = NS). The incidence of severe infections (spontaneous bacterial peritonitis, bacteremia, or pneumonia) was also similar in both groups: 9% in group 1 versus 8.3% in group 2 (p = NS). There were no statistical differences between the two groups with respect to duration of hospitalization or mortality. The cost of antibiotic therapy (including prophylaxis and treatment of infections) was significantly higher in group 2. ### conclusion <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>ceftriaxone</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>hospitalization</i></b> <b style='color:DodgerBlue;'><i>does</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>improve</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cost-efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>norfloxacin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>prevention</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>bacterial</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cirrhotic</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>gastrointestinal</i></b> <b style='color:DodgerBlue;'><i>bleeding</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"results","start":6,"end":13,"id":1,"ws":true},{"text":"suggest","start":14,"end":21,"id":2,"ws":true},{"text":"that","start":22,"end":26,"id":3,"ws":true},{"text":"the","start":27,"end":30,"id":4,"ws":true},{"text":"addition","start":31,"end":39,"id":5,"ws":true},{"text":"of","start":40,"end":42,"id":6,"ws":true},{"text":"intravenous","start":43,"end":54,"id":7,"ws":true},{"text":"ceftriaxone","start":55,"end":66,"id":8,"ws":true},{"text":"during","start":67,"end":73,"id":9,"ws":true},{"text":"the","start":74,"end":77,"id":10,"ws":true},{"text":"first","start":78,"end":83,"id":11,"ws":true},{"text":"3","start":84,"end":85,"id":12,"ws":true},{"text":"days","start":86,"end":90,"id":13,"ws":true},{"text":"of","start":91,"end":93,"id":14,"ws":true},{"text":"hospitalization","start":94,"end":109,"id":15,"ws":true},{"text":"does","start":110,"end":114,"id":16,"ws":true},{"text":"not","start":115,"end":118,"id":17,"ws":true},{"text":"improve","start":119,"end":126,"id":18,"ws":true},{"text":"the","start":127,"end":130,"id":19,"ws":true},{"text":"cost-efficacy","start":131,"end":144,"id":20,"ws":true},{"text":"of","start":145,"end":147,"id":21,"ws":true},{"text":"oral","start":148,"end":152,"id":22,"ws":true},{"text":"norfloxacin","start":153,"end":164,"id":23,"ws":true},{"text":"in","start":165,"end":167,"id":24,"ws":true},{"text":"the","start":168,"end":171,"id":25,"ws":true},{"text":"prevention","start":172,"end":182,"id":26,"ws":true},{"text":"of","start":183,"end":185,"id":27,"ws":true},{"text":"bacterial","start":186,"end":195,"id":28,"ws":true},{"text":"infections","start":196,"end":206,"id":29,"ws":true},{"text":"in","start":207,"end":209,"id":30,"ws":true},{"text":"cirrhotic","start":210,"end":219,"id":31,"ws":true},{"text":"patients","start":220,"end":228,"id":32,"ws":true},{"text":"with","start":229,"end":233,"id":33,"ws":true},{"text":"gastrointestinal","start":234,"end":250,"id":34,"ws":true},{"text":"bleeding","start":251,"end":259,"id":35,"ws":true},{"text":"and","start":260,"end":263,"id":36,"ws":true},{"text":"high","start":264,"end":268,"id":37,"ws":true},{"text":"risk","start":269,"end":273,"id":38,"ws":true},{"text":"of","start":274,"end":276,"id":39,"ws":true},{"text":"infection","start":277,"end":286,"id":40,"ws":true},{"text":".","start":287,"end":288,"id":41,"ws":false}],"spans":[{"start":55,"end":66,"token_start":8,"token_end":8,"label":"DRUG"},{"start":153,"end":164,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9860409/","_input_hash":-1538837134,"_task_hash":-782081798,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":8,"child":23,"head_span":{"start":55,"end":66,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":153,"end":164,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"However , clindamycin possesses only one of the two mechanisms of lincomycin action , which is bacteriostatic , against Escherichia coli .","paragraph":"<h3><u>Microbial kinetics of drug action against gram-positive and gram-negative organisms. III: Effect of lincomycin and clindamycin combinations on Staphylococcus aureus and Escherichia coli.</u></h3>The functional dependencies of apparent first-order generation rate constants kapp, of drug-affected cultures on drug concentrations indicate that <b style='color:Tomato;'><i>lincomycin</i></b> and <b style='color:Tomato;'><i>clindamycin</i></b> possess the same mechanism of action, which is bacteriostatic, against Staphylococcus aureus. <b style='color:Tomato;'><i>clindamycin</i></b> also possesses another mechanism of action, which is bactericidal, at high concentration levels. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clindamycin</i></b> <b style='color:DodgerBlue;'><i>possesses</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>mechanisms</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>lincomycin</i></b> <b style='color:DodgerBlue;'><i>action</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>bacteriostatic</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>Escherichia</i></b> <b style='color:DodgerBlue;'><i>coli</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The relative potency of action of a <b style='color:Tomato;'><i>clindamycin</i></b>-<b style='color:Tomato;'><i>lincomycin</i></b> combination against Staph. aureus is variable, and the effective ratio ranges between 5:1 and 9:1; the effective ratio against E. coli is fixed at 6:1 over a wide concentration range. This difference is attributed to differences in bioavailability and/or binding characteristics of the drugs for bioreceptors, as a consequence of structural modifications in the drug molecules, and to differences in modes of action in the respective organisms. Mixtures containing equipotent fractions of <b style='color:Tomato;'><i>clindamycin</i></b> and <b style='color:Tomato;'><i>lincomycin</i></b> show \"equivalence\" or \"indifference\" of effects on Staph. aureus. The combined action of the mixtures can be quantitatively predicted from the separate dose-response curves of either component drug alone. Therefore, it is concluded that <b style='color:Tomato;'><i>clindamycin</i></b> and <b style='color:Tomato;'><i>lincomycin</i></b> may bind to the same receptor site that is engaged in microbial protein synthesis to inhibit the generation of Staph. aureus. However, combinations of <b style='color:Tomato;'><i>clindamycin</i></b> and <b style='color:Tomato;'><i>lincomycin</i></b> are less active than the a priori equipotent concentration of either drug alone in their action against E. coli, demonstrating unequivocally an antagonism of effects. Furthermore, the degree of antagonism is dependent on the order of addition of the drugs, which is attributed to the possibility that <b style='color:Tomato;'><i>clindamycin</i></b> and <b style='color:Tomato;'><i>lincomycin</i></b> bind differently on active and allosteric loci of the same receptor site functionally engaged in protein synthesis in E. coli. A rational approach to the quantification and prediction of combined antibiotic action must, therefore, be based not only on the kinetics and mechanisms of action as well as on the dose-response relationship over a wide concentration range for the separate antibiotics but also on the strain and species of the test organism.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"clindamycin","start":10,"end":21,"id":2,"ws":true},{"text":"possesses","start":22,"end":31,"id":3,"ws":true},{"text":"only","start":32,"end":36,"id":4,"ws":true},{"text":"one","start":37,"end":40,"id":5,"ws":true},{"text":"of","start":41,"end":43,"id":6,"ws":true},{"text":"the","start":44,"end":47,"id":7,"ws":true},{"text":"two","start":48,"end":51,"id":8,"ws":true},{"text":"mechanisms","start":52,"end":62,"id":9,"ws":true},{"text":"of","start":63,"end":65,"id":10,"ws":true},{"text":"lincomycin","start":66,"end":76,"id":11,"ws":true},{"text":"action","start":77,"end":83,"id":12,"ws":true},{"text":",","start":84,"end":85,"id":13,"ws":true},{"text":"which","start":86,"end":91,"id":14,"ws":true},{"text":"is","start":92,"end":94,"id":15,"ws":true},{"text":"bacteriostatic","start":95,"end":109,"id":16,"ws":true},{"text":",","start":110,"end":111,"id":17,"ws":true},{"text":"against","start":112,"end":119,"id":18,"ws":true},{"text":"Escherichia","start":120,"end":131,"id":19,"ws":true},{"text":"coli","start":132,"end":136,"id":20,"ws":true},{"text":".","start":137,"end":138,"id":21,"ws":false}],"spans":[{"start":10,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":66,"end":76,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/1102659/","_input_hash":1108803543,"_task_hash":557502043,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We conducted a multicenter , retrospective study to evaluate the efficacy and safety of combination nivolumab plus ipilimumab ( NIVO+IPI ) in 35 patients with advanced or metastatic renal cell carcinoma ( mRCC ) .","paragraph":"<h3><u>Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multicenter</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>retrospective</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NIVO+IPI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mRCC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, we focused on patients who received NIVO+IPI and were stratified into intermediate- or poor-risk disease according to the International Metastatic Renal Cell Carcinoma Database Consortium model at five institutions in Japan. The primary endpoint was overall survival (OS). Secondary endpoints were disease control rate (DCR), best overall response (BOR), objective response rate (ORR), and progression-free survival (PFS). In addition, we evaluated the role of inflammatory cell ratios, namely neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), as predictive biomarkers in patients with mRCC. The median follow-up period was 1 year, and the 1-year OS rate was 95.8%. The ORR and DCR were 34.3% and 80.0%, respectively. According to BOR, four patients (11.4%) achieved complete response. According to NLR stratification, the 1-year PFS rates were 82.6% and 23.7% when the NLR was \u22644.6 and >4.6, respectively (","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"conducted","start":3,"end":12,"id":1,"ws":true},{"text":"a","start":13,"end":14,"id":2,"ws":true},{"text":"multicenter","start":15,"end":26,"id":3,"ws":true},{"text":",","start":27,"end":28,"id":4,"ws":true},{"text":"retrospective","start":29,"end":42,"id":5,"ws":true},{"text":"study","start":43,"end":48,"id":6,"ws":true},{"text":"to","start":49,"end":51,"id":7,"ws":true},{"text":"evaluate","start":52,"end":60,"id":8,"ws":true},{"text":"the","start":61,"end":64,"id":9,"ws":true},{"text":"efficacy","start":65,"end":73,"id":10,"ws":true},{"text":"and","start":74,"end":77,"id":11,"ws":true},{"text":"safety","start":78,"end":84,"id":12,"ws":true},{"text":"of","start":85,"end":87,"id":13,"ws":true},{"text":"combination","start":88,"end":99,"id":14,"ws":true},{"text":"nivolumab","start":100,"end":109,"id":15,"ws":true},{"text":"plus","start":110,"end":114,"id":16,"ws":true},{"text":"ipilimumab","start":115,"end":125,"id":17,"ws":true},{"text":"(","start":126,"end":127,"id":18,"ws":true},{"text":"NIVO+IPI","start":128,"end":136,"id":19,"ws":true},{"text":")","start":137,"end":138,"id":20,"ws":true},{"text":"in","start":139,"end":141,"id":21,"ws":true},{"text":"35","start":142,"end":144,"id":22,"ws":true},{"text":"patients","start":145,"end":153,"id":23,"ws":true},{"text":"with","start":154,"end":158,"id":24,"ws":true},{"text":"advanced","start":159,"end":167,"id":25,"ws":true},{"text":"or","start":168,"end":170,"id":26,"ws":true},{"text":"metastatic","start":171,"end":181,"id":27,"ws":true},{"text":"renal","start":182,"end":187,"id":28,"ws":true},{"text":"cell","start":188,"end":192,"id":29,"ws":true},{"text":"carcinoma","start":193,"end":202,"id":30,"ws":true},{"text":"(","start":203,"end":204,"id":31,"ws":true},{"text":"mRCC","start":205,"end":209,"id":32,"ws":true},{"text":")","start":210,"end":211,"id":33,"ws":true},{"text":".","start":212,"end":213,"id":34,"ws":false}],"spans":[{"start":100,"end":109,"token_start":15,"token_end":15,"label":"DRUG"},{"start":115,"end":125,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33916792/","_input_hash":-66354120,"_task_hash":-648982159,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":15,"child":17,"head_span":{"start":100,"end":109,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":115,"end":125,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"This study evaluated the response rate of the combination therapy of aprinocarsen , gemcitabine , and carboplatin in previously untreated patients with advanced non-small cell lung cancer ( NSCLC ) .","paragraph":"<h3><u>Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.</u></h3>The antisense oligonucleotide aprinocarsen specifically inhibits the transcription of protein kinase C-alpha. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>aprinocarsen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>non-small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Secondary objectives included the measurement of time-to-event efficacy parameters and toxicity. Patients with stage IV or stage IIIB disease (N(3) and/or pleural/pericardial effusion) were treated with <b style='color:Tomato;'><i>gemcitabine</i></b> 1,250 mg/m(2) on days 1 and 8 and <b style='color:Tomato;'><i>carboplatin</i></b> AUC 5 on day 1 every 21 days. Aprinocarsen was administered as 2mg/kg/day continuous iv infusion on the first 14 days of each cycle, following the <b style='color:Tomato;'><i>carboplatin</i></b> treatment. A total of 36 patients received a median of 3 treatment cycles, with 10 patients completing 6 cycles. No complete response was observed, while partial response was seen in 25% of patients. Stable disease and progressive disease was observed in 36.1% and 22.2% of patients. The median overall survival was 8.3 months, and the median duration of progression-free survival was 5.7 months (95% CI, 3.2-7.1 months). Thrombocytopenia (78%) and neutropenia (50%) were the major grade 3/4 toxicities. Enrollment for this study was stopped and the study was terminated in March 2003 due to the results of a large phase III study, which suggested that aprinocarsen did not improve response or add survival benefit to chemotherapy in advanced NSCLC. The addition of aprinocarsen to <b style='color:Tomato;'><i>gemcitabine</i></b>+<b style='color:Tomato;'><i>carboplatin</i></b> therapy in patients with NSCLC showed moderate activity. However, this combination resulted in severe thrombocytopenia in the majority of patients.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"study","start":5,"end":10,"id":1,"ws":true},{"text":"evaluated","start":11,"end":20,"id":2,"ws":true},{"text":"the","start":21,"end":24,"id":3,"ws":true},{"text":"response","start":25,"end":33,"id":4,"ws":true},{"text":"rate","start":34,"end":38,"id":5,"ws":true},{"text":"of","start":39,"end":41,"id":6,"ws":true},{"text":"the","start":42,"end":45,"id":7,"ws":true},{"text":"combination","start":46,"end":57,"id":8,"ws":true},{"text":"therapy","start":58,"end":65,"id":9,"ws":true},{"text":"of","start":66,"end":68,"id":10,"ws":true},{"text":"aprinocarsen","start":69,"end":81,"id":11,"ws":true},{"text":",","start":82,"end":83,"id":12,"ws":true},{"text":"gemcitabine","start":84,"end":95,"id":13,"ws":true},{"text":",","start":96,"end":97,"id":14,"ws":true},{"text":"and","start":98,"end":101,"id":15,"ws":true},{"text":"carboplatin","start":102,"end":113,"id":16,"ws":true},{"text":"in","start":114,"end":116,"id":17,"ws":true},{"text":"previously","start":117,"end":127,"id":18,"ws":true},{"text":"untreated","start":128,"end":137,"id":19,"ws":true},{"text":"patients","start":138,"end":146,"id":20,"ws":true},{"text":"with","start":147,"end":151,"id":21,"ws":true},{"text":"advanced","start":152,"end":160,"id":22,"ws":true},{"text":"non-small","start":161,"end":170,"id":23,"ws":true},{"text":"cell","start":171,"end":175,"id":24,"ws":true},{"text":"lung","start":176,"end":180,"id":25,"ws":true},{"text":"cancer","start":181,"end":187,"id":26,"ws":true},{"text":"(","start":188,"end":189,"id":27,"ws":true},{"text":"NSCLC","start":190,"end":195,"id":28,"ws":true},{"text":")","start":196,"end":197,"id":29,"ws":true},{"text":".","start":198,"end":199,"id":30,"ws":false}],"spans":[{"start":69,"end":81,"token_start":11,"token_end":11,"label":"DRUG"},{"start":84,"end":95,"token_start":13,"token_end":13,"label":"DRUG"},{"start":102,"end":113,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16507327/","_input_hash":-1769105221,"_task_hash":-1161201303,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":11,"child":13,"head_span":{"start":69,"end":81,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":84,"end":95,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":13,"child":16,"head_span":{"start":84,"end":95,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":102,"end":113,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"All patients were treated by surgical debridement followed by a combination of antibiotics ; ( ceftazidime , amoxy-clavulanic acid , co-trimoxazole and doxycycline ) for six months except for one who died due to fulminant septicemia .","paragraph":"<h3><u>Burkholderia pseudomallei musculoskeletal infections (melioidosis) in India.</u></h3>Melioidosis, an infection due to gram negative Burkholderia pseudomallei, is an important cause of sepsis in east Asia especially Thailand and northern Australia. It usually causes abscesses in lung, liver, spleen, skeletal muscle and parotids especially in patients with diabetes, chronic renal failure and thalassemia. Musculoskeletal melioidosis is not common in India even though sporadic cases have been reported mostly involving soft tissues. During a two-year-period, we had five patients with musculoskeletal melioidosis. All patients presented with multifocal osteomyelitis, recurrent osteomyelitis or septic arthritis. One patient died early because of septicemia and multi-organ failure. All patients were diagnosed on the basis of positive pus culture. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>surgical</i></b> <b style='color:DodgerBlue;'><i>debridement</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>antibiotics</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>ceftazidime</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>amoxy-clavulanic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>co-trimoxazole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxycycline</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>except</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>died</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>fulminant</i></b> <b style='color:DodgerBlue;'><i>septicemia</i></b> <b style='color:DodgerBlue;'><i>.</i></b> All other patients recovered completely with no recurrences. With increasing awareness and better diagnostic facilities, probably musculoskeletal melioidosis will be increasingly diagnosed in future.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"patients","start":4,"end":12,"id":1,"ws":true},{"text":"were","start":13,"end":17,"id":2,"ws":true},{"text":"treated","start":18,"end":25,"id":3,"ws":true},{"text":"by","start":26,"end":28,"id":4,"ws":true},{"text":"surgical","start":29,"end":37,"id":5,"ws":true},{"text":"debridement","start":38,"end":49,"id":6,"ws":true},{"text":"followed","start":50,"end":58,"id":7,"ws":true},{"text":"by","start":59,"end":61,"id":8,"ws":true},{"text":"a","start":62,"end":63,"id":9,"ws":true},{"text":"combination","start":64,"end":75,"id":10,"ws":true},{"text":"of","start":76,"end":78,"id":11,"ws":true},{"text":"antibiotics","start":79,"end":90,"id":12,"ws":true},{"text":";","start":91,"end":92,"id":13,"ws":true},{"text":"(","start":93,"end":94,"id":14,"ws":true},{"text":"ceftazidime","start":95,"end":106,"id":15,"ws":true},{"text":",","start":107,"end":108,"id":16,"ws":true},{"text":"amoxy-clavulanic","start":109,"end":125,"id":17,"ws":true},{"text":"acid","start":126,"end":130,"id":18,"ws":true},{"text":",","start":131,"end":132,"id":19,"ws":true},{"text":"co-trimoxazole","start":133,"end":147,"id":20,"ws":true},{"text":"and","start":148,"end":151,"id":21,"ws":true},{"text":"doxycycline","start":152,"end":163,"id":22,"ws":true},{"text":")","start":164,"end":165,"id":23,"ws":true},{"text":"for","start":166,"end":169,"id":24,"ws":true},{"text":"six","start":170,"end":173,"id":25,"ws":true},{"text":"months","start":174,"end":180,"id":26,"ws":true},{"text":"except","start":181,"end":187,"id":27,"ws":true},{"text":"for","start":188,"end":191,"id":28,"ws":true},{"text":"one","start":192,"end":195,"id":29,"ws":true},{"text":"who","start":196,"end":199,"id":30,"ws":true},{"text":"died","start":200,"end":204,"id":31,"ws":true},{"text":"due","start":205,"end":208,"id":32,"ws":true},{"text":"to","start":209,"end":211,"id":33,"ws":true},{"text":"fulminant","start":212,"end":221,"id":34,"ws":true},{"text":"septicemia","start":222,"end":232,"id":35,"ws":true},{"text":".","start":233,"end":234,"id":36,"ws":false}],"spans":[{"start":95,"end":106,"token_start":15,"token_end":15,"label":"DRUG"},{"start":109,"end":125,"token_start":17,"token_end":17,"label":"DRUG"},{"start":133,"end":147,"token_start":20,"token_end":20,"label":"DRUG"},{"start":152,"end":163,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20419012/","_input_hash":1130976532,"_task_hash":290964828,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":15,"child":17,"head_span":{"start":95,"end":106,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":109,"end":125,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":17,"child":20,"head_span":{"start":109,"end":125,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":133,"end":147,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":20,"child":22,"head_span":{"start":133,"end":147,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":152,"end":163,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"To evaluate the eradication of Helicobacter pylori by therapy with a combination of 60 mg lansoprazole and 800 mg clarithromycin .","paragraph":"<h3><u>Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori.</u></h3> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>eradication</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Helicobacter</i></b> <b style='color:DodgerBlue;'><i>pylori</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>lansoprazole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>800</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods In an open therapeutic trial, 30 H. pylori-positive patients with active ulcer disease took 30 mg <b style='color:Tomato;'><i>lansoprazole</i></b> twice a day and 400 mg <b style='color:Tomato;'><i>clarithromycin</i></b> twice a day for the first 2 weeks, followed by 30 mg <b style='color:Tomato;'><i>lansoprazole</i></b> once a day for 4-6 weeks. Endoscopy was performed both before and at the end of therapy, and 4 weeks after the end of the therapy. H. pylori was detected by using a combination of smear, culture and tissue sections. ### results Complete pain relief occurred within 3 days in all patients and all ulcers were healed by the end of the therapy. The H. pylori clearance rate was 83.3% and the eradication rate was 73.3%. A minor side effect (metallic taste) was reported by only one patient (3.3%). ### conclusions Therapy with a combination of 60 mg <b style='color:Tomato;'><i>lansoprazole</i></b> and 800 mg <b style='color:Tomato;'><i>clarithromycin</i></b> is efficacious in the eradication of H. pylori and has the advantage of a low incidence of side effects and quick pain relief for patients with active ulcers.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"evaluate","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"eradication","start":16,"end":27,"id":3,"ws":true},{"text":"of","start":28,"end":30,"id":4,"ws":true},{"text":"Helicobacter","start":31,"end":43,"id":5,"ws":true},{"text":"pylori","start":44,"end":50,"id":6,"ws":true},{"text":"by","start":51,"end":53,"id":7,"ws":true},{"text":"therapy","start":54,"end":61,"id":8,"ws":true},{"text":"with","start":62,"end":66,"id":9,"ws":true},{"text":"a","start":67,"end":68,"id":10,"ws":true},{"text":"combination","start":69,"end":80,"id":11,"ws":true},{"text":"of","start":81,"end":83,"id":12,"ws":true},{"text":"60","start":84,"end":86,"id":13,"ws":true},{"text":"mg","start":87,"end":89,"id":14,"ws":true},{"text":"lansoprazole","start":90,"end":102,"id":15,"ws":true},{"text":"and","start":103,"end":106,"id":16,"ws":true},{"text":"800","start":107,"end":110,"id":17,"ws":true},{"text":"mg","start":111,"end":113,"id":18,"ws":true},{"text":"clarithromycin","start":114,"end":128,"id":19,"ws":true},{"text":".","start":129,"end":130,"id":20,"ws":false}],"spans":[{"start":90,"end":102,"token_start":15,"token_end":15,"label":"DRUG"},{"start":114,"end":128,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8574739/","_input_hash":-1870005838,"_task_hash":2124968462,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":15,"child":19,"head_span":{"start":90,"end":102,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":114,"end":128,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"All patients were treated with vincristine , doxorubicin , cyclophosphamide and actinomycin-D , alternating with ifosfamide and etoposide every 3 weeks .","paragraph":"<h3><u>Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.</u></h3>The aim of this study was to evaluate prognostic factors, survival rate and the efficacy of the treatment modalities used in patients with extraskeletal Ewing's sarcoma. ### methods Data of patients with extraskeletal Ewing's sarcoma followed up at our center between 1997 and 2010 were retrospectively analyzed. ### results The median age of 27 patients was 24 years (range, 16-54 years). The median follow-up was 31.8 months (range, 6-144 months). Tumor size was between 1.5 and 14 cm (median: 8 cm). Eighty-five percent of patients had localized disease at presentation and 15% had metastatic disease. Local therapy was surgery alone in 16% of patients, surgery combined with radiotherapy in 42% and radiotherapy alone in 27%. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alternating</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In patients with localized disease at presentation, the 5-year event-free survival and overall survival were 59.7 and 64.5%, respectively. At univariate analysis, patients with tumor size \u2265 8 cm, high serum lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy and positive surgical margin had significantly worse event-free survival. The significant predictors of worse overall survival at univariate analysis were tumor size 8 \u2265 cm, high lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy, radiotherapy only as local treatment and positive surgical margin. ### conclusions Prognostic factors were similar to primary osseous Ewing's sarcomas. Adequate surgical resection, aggressive chemotherapy (<b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b> and actinomycin-D alternating with <b style='color:Tomato;'><i>ifosfamide</i></b> and <b style='color:Tomato;'><i>etoposide</i></b>) and radiotherapy if indicated are the recommended therapy for patients with extraskeletal Ewing's sarcoma.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"patients","start":4,"end":12,"id":1,"ws":true},{"text":"were","start":13,"end":17,"id":2,"ws":true},{"text":"treated","start":18,"end":25,"id":3,"ws":true},{"text":"with","start":26,"end":30,"id":4,"ws":true},{"text":"vincristine","start":31,"end":42,"id":5,"ws":true},{"text":",","start":43,"end":44,"id":6,"ws":true},{"text":"doxorubicin","start":45,"end":56,"id":7,"ws":true},{"text":",","start":57,"end":58,"id":8,"ws":true},{"text":"cyclophosphamide","start":59,"end":75,"id":9,"ws":true},{"text":"and","start":76,"end":79,"id":10,"ws":true},{"text":"actinomycin-D","start":80,"end":93,"id":11,"ws":true},{"text":",","start":94,"end":95,"id":12,"ws":true},{"text":"alternating","start":96,"end":107,"id":13,"ws":true},{"text":"with","start":108,"end":112,"id":14,"ws":true},{"text":"ifosfamide","start":113,"end":123,"id":15,"ws":true},{"text":"and","start":124,"end":127,"id":16,"ws":true},{"text":"etoposide","start":128,"end":137,"id":17,"ws":true},{"text":"every","start":138,"end":143,"id":18,"ws":true},{"text":"3","start":144,"end":145,"id":19,"ws":true},{"text":"weeks","start":146,"end":151,"id":20,"ws":true},{"text":".","start":152,"end":153,"id":21,"ws":false}],"spans":[{"start":31,"end":42,"token_start":5,"token_end":5,"label":"DRUG"},{"start":45,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},{"start":59,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},{"start":80,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},{"start":113,"end":123,"token_start":15,"token_end":15,"label":"DRUG"},{"start":128,"end":137,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22416252/","_input_hash":-1284586151,"_task_hash":-1817856654,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":5,"child":7,"head_span":{"start":31,"end":42,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":45,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":7,"child":9,"head_span":{"start":45,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":59,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":11,"head_span":{"start":59,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":11,"child":15,"head_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":113,"end":123,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":15,"child":17,"head_span":{"start":113,"end":123,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":128,"end":137,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"We identified 49 and 220 patients treated with sorafenib and sunitinib , respectively , as first-line therapy in the Asan Medical Centre from April 2005 to March 2011 .","paragraph":"<h3><u>Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.</u></h3>This study investigated the efficacy and toxicity of <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>sunitinib</i></b> as primary treatment for patients with metastatic renal cell carcinoma (mRCC). ### methods <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>identified</i></b> <b style='color:DodgerBlue;'><i>49</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>220</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Asan</i></b> <b style='color:DodgerBlue;'><i>Medical</i></b> <b style='color:DodgerBlue;'><i>Centre</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>April</i></b> <b style='color:DodgerBlue;'><i>2005</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>March</i></b> <b style='color:DodgerBlue;'><i>2011</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Disease control rates of 71 and 74% were achieved with <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>sunitinib</i></b>, respectively (p = 0.687). After a median follow-up of 27.6 months, progression-free survival (PFS) and overall survival (OS) were not significantly different between the <b style='color:Tomato;'><i>sorafenib</i></b> and the <b style='color:Tomato;'><i>sunitinib</i></b> group (PFS 8.6 vs. 9.9 months, respectively, p = 0.948, and OS 25.7 vs. 22.6 months, p = 0.774). Patients treated with <b style='color:Tomato;'><i>sorafenib</i></b> required dose reduction due to toxicities less frequently than those treated with <b style='color:Tomato;'><i>sunitinib</i></b> (37 vs. 54%, p = 0.034). Haematological toxicity of grade 3 or 4 was more common in the <b style='color:Tomato;'><i>sunitinib</i></b> group than in the <b style='color:Tomato;'><i>sorafenib</i></b> group (45 vs. 4%, p < 0.001). Multivariate analysis showed old age, Heng's risk group, and bone and liver metastases, but not the type of vascular endothelial growth factor tyrosine kinase inhibitor, were independent prognostic factors affecting OS. ### conclusion The results of this study indicate that <b style='color:Tomato;'><i>sorafenib</i></b> has comparable efficacy to <b style='color:Tomato;'><i>sunitinib</i></b> in the treatment of mRCC patients and fewer and less severe toxicities, but the number of patients included in the study was small.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"identified","start":3,"end":13,"id":1,"ws":true},{"text":"49","start":14,"end":16,"id":2,"ws":true},{"text":"and","start":17,"end":20,"id":3,"ws":true},{"text":"220","start":21,"end":24,"id":4,"ws":true},{"text":"patients","start":25,"end":33,"id":5,"ws":true},{"text":"treated","start":34,"end":41,"id":6,"ws":true},{"text":"with","start":42,"end":46,"id":7,"ws":true},{"text":"sorafenib","start":47,"end":56,"id":8,"ws":true},{"text":"and","start":57,"end":60,"id":9,"ws":true},{"text":"sunitinib","start":61,"end":70,"id":10,"ws":true},{"text":",","start":71,"end":72,"id":11,"ws":true},{"text":"respectively","start":73,"end":85,"id":12,"ws":true},{"text":",","start":86,"end":87,"id":13,"ws":true},{"text":"as","start":88,"end":90,"id":14,"ws":true},{"text":"first-line","start":91,"end":101,"id":15,"ws":true},{"text":"therapy","start":102,"end":109,"id":16,"ws":true},{"text":"in","start":110,"end":112,"id":17,"ws":true},{"text":"the","start":113,"end":116,"id":18,"ws":true},{"text":"Asan","start":117,"end":121,"id":19,"ws":true},{"text":"Medical","start":122,"end":129,"id":20,"ws":true},{"text":"Centre","start":130,"end":136,"id":21,"ws":true},{"text":"from","start":137,"end":141,"id":22,"ws":true},{"text":"April","start":142,"end":147,"id":23,"ws":true},{"text":"2005","start":148,"end":152,"id":24,"ws":true},{"text":"to","start":153,"end":155,"id":25,"ws":true},{"text":"March","start":156,"end":161,"id":26,"ws":true},{"text":"2011","start":162,"end":166,"id":27,"ws":true},{"text":".","start":167,"end":168,"id":28,"ws":false}],"spans":[{"start":47,"end":56,"token_start":8,"token_end":8,"label":"DRUG"},{"start":61,"end":70,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23548259/","_input_hash":923599862,"_task_hash":-319191677,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We studied the combination of pemetrexed , a multi-targeted antifolate , and cetuximab , an mAb against the epidermal growth factor receptor , with radiotherapy in poor prognosis head and neck cancer .","paragraph":"<h3><u>Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multi-targeted</i></b> <b style='color:DodgerBlue;'><i>antifolate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>mAb</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>epidermal</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>poor</i></b> <b style='color:DodgerBlue;'><i>prognosis</i></b> <b style='color:DodgerBlue;'><i>head</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>neck</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods Patients received <b style='color:Tomato;'><i>pemetrexed</i></b> on days 1, 22, and 43 on a dose-escalation scheme with starting level (0) 350 mg/m(2) (level -1, 200 mg/m(2); level +1, 500 mg/m(2)) with concurrent radiotherapy (2 Gy/day) and <b style='color:Tomato;'><i>cetuximab</i></b> in two separate cohorts, not previously irradiated (A) and previously irradiated (B), who received 70 and 60-66 Gy, respectively. Genetic polymorphisms of thymidylate synthase and methylenetetrahydrofolate reductase were evaluated. ### results Thirty-two patients were enrolled. The maximum tolerated dose of <b style='color:Tomato;'><i>pemetrexed</i></b> was 500 mg/m(2) in cohort A and 350 mg/m(2) in cohort B. Prophylactic antibiotics were required. In cohort A, two dose-limiting toxicities (DLTs) occurred (febrile neutropenia), one each at levels 0 and +1. In cohort B, two DLTs occurred at level +1 (febrile neutropenia; death from perforated duodenal ulcer and sepsis). Grade 3 mucositis was common. No association of gene polymorphisms with toxicity or efficacy was evident. ### conclusion The addition of <b style='color:Tomato;'><i>pemetrexed</i></b> 500 mg/m(2) to <b style='color:Tomato;'><i>cetuximab</i></b> and radiotherapy is recommended for further study in not previously irradiated patients.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"studied","start":3,"end":10,"id":1,"ws":true},{"text":"the","start":11,"end":14,"id":2,"ws":true},{"text":"combination","start":15,"end":26,"id":3,"ws":true},{"text":"of","start":27,"end":29,"id":4,"ws":true},{"text":"pemetrexed","start":30,"end":40,"id":5,"ws":true},{"text":",","start":41,"end":42,"id":6,"ws":true},{"text":"a","start":43,"end":44,"id":7,"ws":true},{"text":"multi-targeted","start":45,"end":59,"id":8,"ws":true},{"text":"antifolate","start":60,"end":70,"id":9,"ws":true},{"text":",","start":71,"end":72,"id":10,"ws":true},{"text":"and","start":73,"end":76,"id":11,"ws":true},{"text":"cetuximab","start":77,"end":86,"id":12,"ws":true},{"text":",","start":87,"end":88,"id":13,"ws":true},{"text":"an","start":89,"end":91,"id":14,"ws":true},{"text":"mAb","start":92,"end":95,"id":15,"ws":true},{"text":"against","start":96,"end":103,"id":16,"ws":true},{"text":"the","start":104,"end":107,"id":17,"ws":true},{"text":"epidermal","start":108,"end":117,"id":18,"ws":true},{"text":"growth","start":118,"end":124,"id":19,"ws":true},{"text":"factor","start":125,"end":131,"id":20,"ws":true},{"text":"receptor","start":132,"end":140,"id":21,"ws":true},{"text":",","start":141,"end":142,"id":22,"ws":true},{"text":"with","start":143,"end":147,"id":23,"ws":true},{"text":"radiotherapy","start":148,"end":160,"id":24,"ws":true},{"text":"in","start":161,"end":163,"id":25,"ws":true},{"text":"poor","start":164,"end":168,"id":26,"ws":true},{"text":"prognosis","start":169,"end":178,"id":27,"ws":true},{"text":"head","start":179,"end":183,"id":28,"ws":true},{"text":"and","start":184,"end":187,"id":29,"ws":true},{"text":"neck","start":188,"end":192,"id":30,"ws":true},{"text":"cancer","start":193,"end":199,"id":31,"ws":true},{"text":".","start":200,"end":201,"id":32,"ws":false}],"spans":[{"start":30,"end":40,"token_start":5,"token_end":5,"label":"DRUG"},{"start":77,"end":86,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21363880/","_input_hash":-1439597952,"_task_hash":-2062337790,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":5,"child":12,"head_span":{"start":30,"end":40,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":77,"end":86,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Boosting darunavir with ritonavir instead of with cobicistat may be preferred if darunavir is to be combined with etravirine in clinical practice .","paragraph":"<h3><u>Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.</u></h3>To determine the effect of <b style='color:Tomato;'><i>etravirine</i></b> on the pharmacokinetics of <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> and vice versa. Safety and tolerability of this combination were also evaluated. ### methods Open-label, fixed-sequence trial in two cohorts of HIV-infected patients on therapy with <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> 800/150\u2009mg once daily (DRV cohort; n\u2009=\u200915) or <b style='color:Tomato;'><i>etravirine</i></b> 400\u2009mg once daily (ETR cohort; n\u2009=\u200915). <b style='color:Tomato;'><i>etravirine</i></b> or <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> were added on days 1-14 and 1-7 in participants in the DRV or ETR cohort, respectively. Full pharmacokinetic profiles were obtained on days 0 and 14 in the DRV cohort, and on days 0 and 7 in the ETR cohort. <b style='color:Tomato;'><i>darunavir</i></b>, <b style='color:Tomato;'><i>cobicistat</i></b> and <b style='color:Tomato;'><i>etravirine</i></b> pharmacokinetic parameters [AUC0-24, Cmax and trough concentrations in plasma (C24)] were calculated for each individual by non-compartmental analysis and were compared using linear mixed-effects models. Adverse events and HIV-1 RNA in plasma were monitored. ### results <b style='color:Tomato;'><i>etravirine</i></b> co-administration decreased <b style='color:Tomato;'><i>cobicistat</i></b> AUC0-24, Cmax and C24 by 30%, 14% and 66%, respectively. Although <b style='color:Tomato;'><i>darunavir</i></b> AUC0-24 and Cmax were unchanged by <b style='color:Tomato;'><i>etravirine</i></b>, <b style='color:Tomato;'><i>darunavir</i></b> C24 was 56% lower for <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> co-administered with <b style='color:Tomato;'><i>etravirine</i></b> relative to <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> alone. <b style='color:Tomato;'><i>etravirine</i></b> pharmacokinetics were unchanged by <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b>. Treatments were well tolerated, and HIV-1 RNA remained undetectable in all participants. ### conclusions Although <b style='color:Tomato;'><i>etravirine</i></b> pharmacokinetics was unchanged by <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b>, there was a significant decrease in <b style='color:Tomato;'><i>cobicistat</i></b> exposure and in <b style='color:Tomato;'><i>darunavir</i></b> C24 when <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> was co-administered with <b style='color:Tomato;'><i>etravirine</i></b>. <b style='color:DodgerBlue;'><i>Boosting</i></b> <b style='color:MediumOrchid;'><i>darunavir</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ritonavir</i></b> <b style='color:DodgerBlue;'><i>instead</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cobicistat</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>if</i></b> <b style='color:MediumOrchid;'><i>darunavir</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>etravirine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>practice</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Boosting","start":0,"end":8,"id":0,"ws":true},{"text":"darunavir","start":9,"end":18,"id":1,"ws":true},{"text":"with","start":19,"end":23,"id":2,"ws":true},{"text":"ritonavir","start":24,"end":33,"id":3,"ws":true},{"text":"instead","start":34,"end":41,"id":4,"ws":true},{"text":"of","start":42,"end":44,"id":5,"ws":true},{"text":"with","start":45,"end":49,"id":6,"ws":true},{"text":"cobicistat","start":50,"end":60,"id":7,"ws":true},{"text":"may","start":61,"end":64,"id":8,"ws":true},{"text":"be","start":65,"end":67,"id":9,"ws":true},{"text":"preferred","start":68,"end":77,"id":10,"ws":true},{"text":"if","start":78,"end":80,"id":11,"ws":true},{"text":"darunavir","start":81,"end":90,"id":12,"ws":true},{"text":"is","start":91,"end":93,"id":13,"ws":true},{"text":"to","start":94,"end":96,"id":14,"ws":true},{"text":"be","start":97,"end":99,"id":15,"ws":true},{"text":"combined","start":100,"end":108,"id":16,"ws":true},{"text":"with","start":109,"end":113,"id":17,"ws":true},{"text":"etravirine","start":114,"end":124,"id":18,"ws":true},{"text":"in","start":125,"end":127,"id":19,"ws":true},{"text":"clinical","start":128,"end":136,"id":20,"ws":true},{"text":"practice","start":137,"end":145,"id":21,"ws":true},{"text":".","start":146,"end":147,"id":22,"ws":false}],"spans":[{"start":9,"end":18,"token_start":1,"token_end":1,"label":"DRUG"},{"start":24,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},{"start":50,"end":60,"token_start":7,"token_end":7,"label":"DRUG"},{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},{"start":114,"end":124,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29237008/","_input_hash":-1591603289,"_task_hash":-1954409406,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":1,"child":3,"head_span":{"start":9,"end":18,"token_start":1,"token_end":1,"label":"DRUG"},"child_span":{"start":24,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":3,"child":18,"head_span":{"start":24,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":114,"end":124,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Single-agent paclitaxel and vinorelbine are recommended treatments for advanced breast cancer ( ABC ) non-responsive to hormone therapy and without visceral crisis .","paragraph":"<h3><u>Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial).</u></h3> <b style='color:DodgerBlue;'><i>Single-agent</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>treatments</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ABC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>non-responsive</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>hormone</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>visceral</i></b> <b style='color:DodgerBlue;'><i>crisis</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This phase II trial compared first-line oral <b style='color:Tomato;'><i>vinorelbine</i></b> versus weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for ABC. ### methods Eligible female patients had measurable locally recurrent/metastatic estrogen receptor-positive HER2-negative breast cancer and had received prior endocrine therapy (any setting) but no chemotherapy for ABC. Patients were stratified by prior taxane and visceral metastases and randomized to either oral <b style='color:Tomato;'><i>vinorelbine</i></b> 80\u202fmg/m ### results The 131 randomized patients had received a median of 2 prior endocrine therapies; >70% had prior (neo)adjuvant chemotherapy and 79% visceral metastases. DCR was 75.8% (95% confidence interval: 63.6-85.5%) with <b style='color:Tomato;'><i>vinorelbine</i></b> and 75.4% (63.1-85.2%) with <b style='color:Tomato;'><i>paclitaxel</i></b>. The most common grade 3/4 adverse events were neutropenia (52%), fatigue (11%), and vomiting (5%) with <b style='color:Tomato;'><i>vinorelbine</i></b>, and neutropenia (17%), dyspnea (6%), hypertension (6%), and peripheral sensory neuropathy (5%) with <b style='color:Tomato;'><i>paclitaxel</i></b>. Grade 2 alopecia occurred in 2% of <b style='color:Tomato;'><i>vinorelbine</i></b>-treated and 34% of <b style='color:Tomato;'><i>paclitaxel</i></b>-treated patients. Neither arm showed relevant global health status changes. ### conclusion Oral <b style='color:Tomato;'><i>vinorelbine</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> demonstrated similar DCRs (\u223c75%). Safety profiles differed and, together with administration route and convenience, may influence treatment choice (EudraCT number, 2012-003530-16).","tokens":[{"text":"Single-agent","start":0,"end":12,"id":0,"ws":true},{"text":"paclitaxel","start":13,"end":23,"id":1,"ws":true},{"text":"and","start":24,"end":27,"id":2,"ws":true},{"text":"vinorelbine","start":28,"end":39,"id":3,"ws":true},{"text":"are","start":40,"end":43,"id":4,"ws":true},{"text":"recommended","start":44,"end":55,"id":5,"ws":true},{"text":"treatments","start":56,"end":66,"id":6,"ws":true},{"text":"for","start":67,"end":70,"id":7,"ws":true},{"text":"advanced","start":71,"end":79,"id":8,"ws":true},{"text":"breast","start":80,"end":86,"id":9,"ws":true},{"text":"cancer","start":87,"end":93,"id":10,"ws":true},{"text":"(","start":94,"end":95,"id":11,"ws":true},{"text":"ABC","start":96,"end":99,"id":12,"ws":true},{"text":")","start":100,"end":101,"id":13,"ws":true},{"text":"non-responsive","start":102,"end":116,"id":14,"ws":true},{"text":"to","start":117,"end":119,"id":15,"ws":true},{"text":"hormone","start":120,"end":127,"id":16,"ws":true},{"text":"therapy","start":128,"end":135,"id":17,"ws":true},{"text":"and","start":136,"end":139,"id":18,"ws":true},{"text":"without","start":140,"end":147,"id":19,"ws":true},{"text":"visceral","start":148,"end":156,"id":20,"ws":true},{"text":"crisis","start":157,"end":163,"id":21,"ws":true},{"text":".","start":164,"end":165,"id":22,"ws":false}],"spans":[{"start":13,"end":23,"token_start":1,"token_end":1,"label":"DRUG"},{"start":28,"end":39,"token_start":3,"token_end":3,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30802822/","_input_hash":824817462,"_task_hash":979881391,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Nal-IRI with 5-fluorouracil ( 5-FU ) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial ( AIO-YMO HEP-0315 )","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Nal-IRI</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>biliary</i></b> <b style='color:DodgerBlue;'><i>tract</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>NIFE</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AIO-YMO</i></b> <b style='color:DodgerBlue;'><i>HEP-0315</i></b> <b style='color:DodgerBlue;'><i>)</i></b></u></h3>Biliary tract cancer (BTC) has a high mortality. Primary diagnosis is frequently delayed due to mostly unspecific symptoms, resulting in a high number of advanced cases at the time of diagnosis. Advanced BTCs are in principle chemotherapy sensitive as determined by improved disease control, survival and quality of life (QoL). However, median OS does not exceed 11.7\u2009months with the current standard of care <b style='color:Tomato;'><i>gemcitabine</i></b> plus <b style='color:Tomato;'><i>cisplatin</i></b>. Thereby, novel drug formulations like nanoliposomal-<b style='color:Tomato;'><i>irinotecan</i></b> (nal-IRI) in combination with 5- <b style='color:Tomato;'><i>fluorouracil</i></b> (5-FU)/<b style='color:Tomato;'><i>leucovorin</i></b> may have the potential to improve therapeutic outcomes in this disease. ### methods NIFE is an interventional, prospective, randomized, controlled, open label, two-sided phase II study. Within the study, 2\u2009\u00d7\u200946 patients with locally advanced, non-resectable or metastatic BTC are to be enrolled by two stage design of Simon. Data analysis will be done unconnected for both arms. Patients are allocated in two arms: Arm A (experimental intervention) nal-IRI mg/m ### discussion The NIFE trial evaluates the potential of a nanoliposomal-<b style='color:Tomato;'><i>irinotecan</i></b>/5-FU/<b style='color:Tomato;'><i>leucovorin</i></b> combination in the first line therapy of advanced BTCs and additionally offers a unique chance for translational research. ### Trial Registration Clinicaltrials.gov NCT03044587. Registration Date February 7th 2017.","tokens":[{"text":"Nal-IRI","start":0,"end":7,"id":0,"ws":true},{"text":"with","start":8,"end":12,"id":1,"ws":true},{"text":"5-fluorouracil","start":13,"end":27,"id":2,"ws":true},{"text":"(","start":28,"end":29,"id":3,"ws":true},{"text":"5-FU","start":30,"end":34,"id":4,"ws":true},{"text":")","start":35,"end":36,"id":5,"ws":true},{"text":"and","start":37,"end":40,"id":6,"ws":true},{"text":"leucovorin","start":41,"end":51,"id":7,"ws":true},{"text":"or","start":52,"end":54,"id":8,"ws":true},{"text":"gemcitabine","start":55,"end":66,"id":9,"ws":true},{"text":"plus","start":67,"end":71,"id":10,"ws":true},{"text":"cisplatin","start":72,"end":81,"id":11,"ws":true},{"text":"in","start":82,"end":84,"id":12,"ws":true},{"text":"advanced","start":85,"end":93,"id":13,"ws":true},{"text":"biliary","start":94,"end":101,"id":14,"ws":true},{"text":"tract","start":102,"end":107,"id":15,"ws":true},{"text":"cancer","start":108,"end":114,"id":16,"ws":true},{"text":"-","start":115,"end":116,"id":17,"ws":true},{"text":"the","start":117,"end":120,"id":18,"ws":true},{"text":"NIFE","start":121,"end":125,"id":19,"ws":true},{"text":"trial","start":126,"end":131,"id":20,"ws":true},{"text":"(","start":132,"end":133,"id":21,"ws":true},{"text":"AIO-YMO","start":134,"end":141,"id":22,"ws":true},{"text":"HEP-0315","start":142,"end":150,"id":23,"ws":true},{"text":")","start":151,"end":152,"id":24,"ws":false}],"spans":[{"start":13,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},{"start":41,"end":51,"token_start":7,"token_end":7,"label":"DRUG"},{"start":55,"end":66,"token_start":9,"token_end":9,"label":"DRUG"},{"start":72,"end":81,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31646981/","_input_hash":-1862521886,"_task_hash":-1288207837,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":2,"child":7,"head_span":{"start":13,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":41,"end":51,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":9,"child":11,"head_span":{"start":55,"end":66,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":72,"end":81,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":[],"answer":"accept"}
{"text":"Ten patients were withdrawn from the terbutaline group because treatment was insufficiently effective , whereas only one dropped out of the budesonide group .","paragraph":"<h3><u>Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma.</u></h3>The presence of airway inflammation even in mild asthma points to the potential value of antiinflammatory therapy. We compared the effect of an inhaled corticosteroid, <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b>, with that of an inhaled beta 2-agonist, <b style='color:Tomato;'><i>terbutaline</i></b>, in the long-term treatment of newly detected asthma. ### methods We studied 103 patients (29 male and 74 female patients 15 to 64 years old) in whom asthma had appeared within the previous year. The patients were randomly assigned in blinded fashion to two treatment groups: one to receive 600 micrograms of inhaled <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> twice a day, and the other to receive 375 micrograms of inhaled <b style='color:Tomato;'><i>terbutaline</i></b> twice a day. The study period was two years. ### results After six weeks of treatment, the patients treated with <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> tolerated inhaled histamine better than the patients treated with <b style='color:Tomato;'><i>terbutaline</i></b> (a difference of one doubling dose step, P less than 0.001), and the difference was sustained. Patients' diaries kept during the first three months of the study and during the last month of the first and second years showed <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> to be more effective than <b style='color:Tomato;'><i>terbutaline</i></b> in improving peak expiratory flow in the morning (average increase from the pretreatment value, 32.8 liters per minute for <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> vs. 4.8 liters per minute for <b style='color:Tomato;'><i>terbutaline</i></b>; P less than 0.001) and in the evening (P less than 0.01). <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> was also more effective in reducing the symptoms of asthma (P less than 0.01) and the use of supplemental beta 2-agonist medication (P less than 0.01). <b style='color:DodgerBlue;'><i>Ten</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>withdrawn</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>terbutaline</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>insufficiently</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>whereas</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>dropped</i></b> <b style='color:DodgerBlue;'><i>out</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>budesonide</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The adverse reactions to both treatments were few and mild. ### conclusions Antiinflammatory therapy with inhaled <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> is an effective first-line treatment for patients with newly detected, mild asthma, and it is superior to the use of <b style='color:Tomato;'><i>terbutaline</i></b> in such patients.","tokens":[{"text":"Ten","start":0,"end":3,"id":0,"ws":true},{"text":"patients","start":4,"end":12,"id":1,"ws":true},{"text":"were","start":13,"end":17,"id":2,"ws":true},{"text":"withdrawn","start":18,"end":27,"id":3,"ws":true},{"text":"from","start":28,"end":32,"id":4,"ws":true},{"text":"the","start":33,"end":36,"id":5,"ws":true},{"text":"terbutaline","start":37,"end":48,"id":6,"ws":true},{"text":"group","start":49,"end":54,"id":7,"ws":true},{"text":"because","start":55,"end":62,"id":8,"ws":true},{"text":"treatment","start":63,"end":72,"id":9,"ws":true},{"text":"was","start":73,"end":76,"id":10,"ws":true},{"text":"insufficiently","start":77,"end":91,"id":11,"ws":true},{"text":"effective","start":92,"end":101,"id":12,"ws":true},{"text":",","start":102,"end":103,"id":13,"ws":true},{"text":"whereas","start":104,"end":111,"id":14,"ws":true},{"text":"only","start":112,"end":116,"id":15,"ws":true},{"text":"one","start":117,"end":120,"id":16,"ws":true},{"text":"dropped","start":121,"end":128,"id":17,"ws":true},{"text":"out","start":129,"end":132,"id":18,"ws":true},{"text":"of","start":133,"end":135,"id":19,"ws":true},{"text":"the","start":136,"end":139,"id":20,"ws":true},{"text":"budesonide","start":140,"end":150,"id":21,"ws":true},{"text":"group","start":151,"end":156,"id":22,"ws":true},{"text":".","start":157,"end":158,"id":23,"ws":false}],"spans":[{"start":37,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},{"start":140,"end":150,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2062329/","_input_hash":-1100714668,"_task_hash":1982259093,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We conducted a double-blind cross-over study in ten volunteers aged from 19 to 30 years , to compare the pain control effects of a single oral dose of two analgesic compounds ( drug A : propyphenazone mg 250 , ethylmorphine mg 5 , caffeine mg 5 ; drug B : dipyrone mg 500 , diphenhydramine mg 12.5 , adiphenine mg 5 , ethyl aminobenzoate mg 2.5 ) in an experimental pain model using stimulation of dental pulp .","paragraph":"<h3><u>[Electric stimulation of the dental pulp in the evaluation of the central effect of analgesics].</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>cross-over</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>ten</i></b> <b style='color:DodgerBlue;'><i>volunteers</i></b> <b style='color:DodgerBlue;'><i>aged</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>19</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>analgesic</i></b> <b style='color:DodgerBlue;'><i>compounds</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>propyphenazone</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>250</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ethylmorphine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>caffeine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>dipyrone</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>500</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>diphenhydramine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>12.5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>adiphenine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ethyl</i></b> <b style='color:DodgerBlue;'><i>aminobenzoate</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>2.5</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>stimulation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dental</i></b> <b style='color:DodgerBlue;'><i>pulp</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Constant voltage stimuli were delivered through silver chloride electrodes placed in contact with the vestibular surface of the upper medial incisor. At the beginning of the session, the pain input was graded by asking the subject to identify the weakest stimulus perceived (threshold level) and the strongest stimulus endurable (tolerance level). The range between threshold and tolerance level was divided in nine steps plus a subliminal step. The ten steps were delivered randomly, and each series of steps was repeated eight times. The subjects were instructed to rate the pain sensation in an arbitrary scale of 5 degrees. The procedure was repeated at 60 min and 180 min after drug administration. Each subject received two tablets of drug A or drug B in two different sessions at weekly intervals. Statistical analysis of the procedures showed that neither drug A nor drug B significantly affected the pain threshold. Drug A significantly reduced the total pain score (P less than 0.01) and its action peaked 60 min after administration.(ABSTRACT TRUNCATED AT 250 WORDS)","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"conducted","start":3,"end":12,"id":1,"ws":true},{"text":"a","start":13,"end":14,"id":2,"ws":true},{"text":"double-blind","start":15,"end":27,"id":3,"ws":true},{"text":"cross-over","start":28,"end":38,"id":4,"ws":true},{"text":"study","start":39,"end":44,"id":5,"ws":true},{"text":"in","start":45,"end":47,"id":6,"ws":true},{"text":"ten","start":48,"end":51,"id":7,"ws":true},{"text":"volunteers","start":52,"end":62,"id":8,"ws":true},{"text":"aged","start":63,"end":67,"id":9,"ws":true},{"text":"from","start":68,"end":72,"id":10,"ws":true},{"text":"19","start":73,"end":75,"id":11,"ws":true},{"text":"to","start":76,"end":78,"id":12,"ws":true},{"text":"30","start":79,"end":81,"id":13,"ws":true},{"text":"years","start":82,"end":87,"id":14,"ws":true},{"text":",","start":88,"end":89,"id":15,"ws":true},{"text":"to","start":90,"end":92,"id":16,"ws":true},{"text":"compare","start":93,"end":100,"id":17,"ws":true},{"text":"the","start":101,"end":104,"id":18,"ws":true},{"text":"pain","start":105,"end":109,"id":19,"ws":true},{"text":"control","start":110,"end":117,"id":20,"ws":true},{"text":"effects","start":118,"end":125,"id":21,"ws":true},{"text":"of","start":126,"end":128,"id":22,"ws":true},{"text":"a","start":129,"end":130,"id":23,"ws":true},{"text":"single","start":131,"end":137,"id":24,"ws":true},{"text":"oral","start":138,"end":142,"id":25,"ws":true},{"text":"dose","start":143,"end":147,"id":26,"ws":true},{"text":"of","start":148,"end":150,"id":27,"ws":true},{"text":"two","start":151,"end":154,"id":28,"ws":true},{"text":"analgesic","start":155,"end":164,"id":29,"ws":true},{"text":"compounds","start":165,"end":174,"id":30,"ws":true},{"text":"(","start":175,"end":176,"id":31,"ws":true},{"text":"drug","start":177,"end":181,"id":32,"ws":true},{"text":"A","start":182,"end":183,"id":33,"ws":true},{"text":":","start":184,"end":185,"id":34,"ws":true},{"text":"propyphenazone","start":186,"end":200,"id":35,"ws":true},{"text":"mg","start":201,"end":203,"id":36,"ws":true},{"text":"250","start":204,"end":207,"id":37,"ws":true},{"text":",","start":208,"end":209,"id":38,"ws":true},{"text":"ethylmorphine","start":210,"end":223,"id":39,"ws":true},{"text":"mg","start":224,"end":226,"id":40,"ws":true},{"text":"5","start":227,"end":228,"id":41,"ws":true},{"text":",","start":229,"end":230,"id":42,"ws":true},{"text":"caffeine","start":231,"end":239,"id":43,"ws":true},{"text":"mg","start":240,"end":242,"id":44,"ws":true},{"text":"5","start":243,"end":244,"id":45,"ws":true},{"text":";","start":245,"end":246,"id":46,"ws":true},{"text":"drug","start":247,"end":251,"id":47,"ws":true},{"text":"B","start":252,"end":253,"id":48,"ws":true},{"text":":","start":254,"end":255,"id":49,"ws":true},{"text":"dipyrone","start":256,"end":264,"id":50,"ws":true},{"text":"mg","start":265,"end":267,"id":51,"ws":true},{"text":"500","start":268,"end":271,"id":52,"ws":true},{"text":",","start":272,"end":273,"id":53,"ws":true},{"text":"diphenhydramine","start":274,"end":289,"id":54,"ws":true},{"text":"mg","start":290,"end":292,"id":55,"ws":true},{"text":"12.5","start":293,"end":297,"id":56,"ws":true},{"text":",","start":298,"end":299,"id":57,"ws":true},{"text":"adiphenine","start":300,"end":310,"id":58,"ws":true},{"text":"mg","start":311,"end":313,"id":59,"ws":true},{"text":"5","start":314,"end":315,"id":60,"ws":true},{"text":",","start":316,"end":317,"id":61,"ws":true},{"text":"ethyl","start":318,"end":323,"id":62,"ws":true},{"text":"aminobenzoate","start":324,"end":337,"id":63,"ws":true},{"text":"mg","start":338,"end":340,"id":64,"ws":true},{"text":"2.5","start":341,"end":344,"id":65,"ws":true},{"text":")","start":345,"end":346,"id":66,"ws":true},{"text":"in","start":347,"end":349,"id":67,"ws":true},{"text":"an","start":350,"end":352,"id":68,"ws":true},{"text":"experimental","start":353,"end":365,"id":69,"ws":true},{"text":"pain","start":366,"end":370,"id":70,"ws":true},{"text":"model","start":371,"end":376,"id":71,"ws":true},{"text":"using","start":377,"end":382,"id":72,"ws":true},{"text":"stimulation","start":383,"end":394,"id":73,"ws":true},{"text":"of","start":395,"end":397,"id":74,"ws":true},{"text":"dental","start":398,"end":404,"id":75,"ws":true},{"text":"pulp","start":405,"end":409,"id":76,"ws":true},{"text":".","start":410,"end":411,"id":77,"ws":false}],"spans":[{"start":186,"end":200,"token_start":35,"token_end":35,"label":"DRUG"},{"start":210,"end":223,"token_start":39,"token_end":39,"label":"DRUG"},{"start":231,"end":239,"token_start":43,"token_end":43,"label":"DRUG"},{"start":256,"end":264,"token_start":50,"token_end":50,"label":"DRUG"},{"start":274,"end":289,"token_start":54,"token_end":54,"label":"DRUG"},{"start":300,"end":310,"token_start":58,"token_end":58,"label":"DRUG"},{"start":324,"end":337,"token_start":63,"token_end":63,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/1979494/","_input_hash":52952750,"_task_hash":1148323975,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":35,"child":39,"head_span":{"start":186,"end":200,"token_start":35,"token_end":35,"label":"DRUG"},"child_span":{"start":210,"end":223,"token_start":39,"token_end":39,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":39,"child":43,"head_span":{"start":210,"end":223,"token_start":39,"token_end":39,"label":"DRUG"},"child_span":{"start":231,"end":239,"token_start":43,"token_end":43,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":50,"child":54,"head_span":{"start":256,"end":264,"token_start":50,"token_end":50,"label":"DRUG"},"child_span":{"start":274,"end":289,"token_start":54,"token_end":54,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":54,"child":58,"head_span":{"start":274,"end":289,"token_start":54,"token_end":54,"label":"DRUG"},"child_span":{"start":300,"end":310,"token_start":58,"token_end":58,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":58,"child":63,"head_span":{"start":300,"end":310,"token_start":58,"token_end":58,"label":"DRUG"},"child_span":{"start":324,"end":337,"token_start":63,"token_end":63,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Forty-three mCRC patients who received cetuximab or panitumumab between April 2012 and December 2015 were the subjects of the present study .","paragraph":"<h3><u>Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.</u></h3>Anti-EGFR monoclonal antibody is effective for KRAS wild-type metastatic colorectal cancer (mCRC), but frequently causes several adverse reactions, including hypomagnesemia and skin disorders. The present study was designed to investigate the relationship between the incidence of adverse reactions and therapeutic effects in mCRC patients receiving anti-EGFR monoclonal antibody in combination with first-line chemotherapy. ### methods <b style='color:DodgerBlue;'><i>Forty-three</i></b> <b style='color:DodgerBlue;'><i>mCRC</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>panitumumab</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>April</i></b> <b style='color:DodgerBlue;'><i>2012</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>December</i></b> <b style='color:DodgerBlue;'><i>2015</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>subjects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b> All patients were pretreated with oral <b style='color:Tomato;'><i>minocycline</i></b> in combination with skin treatment using moisturizer for prevention of skin rash. Hypomagnesemia and acneiform rash were graded according to the Common Terminology Criteria for Adverse Events, version 3.0. Overall response rate (ORR) and time to treatment failure (TTF) were compared between patients with and without these adverse events. ### results The incidence rates of hypomagnesemia and acneiform rash were 32.6\u00a0% (grade 1: 20.9\u00a0%, grade 2: 11.6\u00a0%) and 93.0\u00a0% (grade 1: 41.9\u00a0%, grade 2: 41.9\u00a0%, grade 3: 9.3\u00a0%), respectively. ORR was significantly higher in patients with hypomagnesemia than in those without it (71.4 vs 34.5\u00a0%, P\u00a0=\u00a00.048). Median TTF tended to be longer, though not significantly, in patients with hypomagnesemia than in those without it. However, no significant difference in both ORR and median TTF was observed between patients with and without acneiform rash. ### conclusion Hypomagnesemia may become a predicting factor for therapeutic effects of anti-EGFR monoclonal antibody in mCRC patients.","tokens":[{"text":"Forty-three","start":0,"end":11,"id":0,"ws":true},{"text":"mCRC","start":12,"end":16,"id":1,"ws":true},{"text":"patients","start":17,"end":25,"id":2,"ws":true},{"text":"who","start":26,"end":29,"id":3,"ws":true},{"text":"received","start":30,"end":38,"id":4,"ws":true},{"text":"cetuximab","start":39,"end":48,"id":5,"ws":true},{"text":"or","start":49,"end":51,"id":6,"ws":true},{"text":"panitumumab","start":52,"end":63,"id":7,"ws":true},{"text":"between","start":64,"end":71,"id":8,"ws":true},{"text":"April","start":72,"end":77,"id":9,"ws":true},{"text":"2012","start":78,"end":82,"id":10,"ws":true},{"text":"and","start":83,"end":86,"id":11,"ws":true},{"text":"December","start":87,"end":95,"id":12,"ws":true},{"text":"2015","start":96,"end":100,"id":13,"ws":true},{"text":"were","start":101,"end":105,"id":14,"ws":true},{"text":"the","start":106,"end":109,"id":15,"ws":true},{"text":"subjects","start":110,"end":118,"id":16,"ws":true},{"text":"of","start":119,"end":121,"id":17,"ws":true},{"text":"the","start":122,"end":125,"id":18,"ws":true},{"text":"present","start":126,"end":133,"id":19,"ws":true},{"text":"study","start":134,"end":139,"id":20,"ws":true},{"text":".","start":140,"end":141,"id":21,"ws":false}],"spans":[{"start":39,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},{"start":52,"end":63,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27106835/","_input_hash":-1825043399,"_task_hash":-1164830701,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Furthermore , 11 AML patients at primary diagnosis , including five AML patients with P-gp overexpression , who were treated with idarubicin , vepesid , and cytarabine V ( ara-C ) showed a complete remission .","paragraph":"<h3><u>Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversal.</u></h3>P-glycoprotein (P-gp) expression in mononuclear bone marrow cells was analyzed in 119 patients, including 60 with chronic myelogenous leukemia (CML), 48 with myelodysplastic syndromes (MDS), and 11 with acute myelogenous leukemia (AML). For P-gp measurement an immunocytological method using monoclonal antibodies C219, 4E3, and MRK 16 and the reverse transcription-polymerase chain reaction technique were applied. According to our results obtained in healthy volunteers using the immunocytological method, the limit for P-gp overexpression was set at > or = 10% P-gp-positive mononuclear bone marrow cells and at > or = 30% P-gp-positive mononuclear peripheral blood cells. All 42 CML patients in chronic phase had normal P-gp expression. P-gp overexpression was demonstrated in four of six patients in accelerated myelogenous blast cell phase and in four of 12 CML-BC patients. Of eight CML patients in blast crisis (BC) with normal P-gp expression, partial remission was achieved in three and minor response in five after <b style='color:Tomato;'><i>prednisone</i></b>/vindesine therapy. All four of the 12 CML-BC patients with P-gp overexpression did not respond to this therapy. Normal P-gp expression was seen in 41 (85.4%) of 48 untreated MDS patients. While P-gp overexpression did not develop during therapy in any of the myelodysplastic syndrome patients treated with low-dose ara-C alone, four of eight treated with low-dose ara-C plus GM-CSF and four of 11 treated with low-dose ara-C and IL-3 developed P-gp overexpression after therapy. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>11</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>diagnosis</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>five</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>P-gp</i></b> <b style='color:DodgerBlue;'><i>overexpression</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>idarubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>vepesid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>V</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ara-C</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>remission</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Additionally, one <b style='color:Tomato;'><i>daunorubicin</i></b>-<b style='color:Tomato;'><i>cytarabine</i></b>-pretreated refractory AML patient was treated with the oral form of the P-gp modulator drug dexniguldipine and achieved complete remission for a duration of 7 months. Our results suggest that in CML patients in BC, P-gp expression influences outcome after therapy. Further more, studies in a larger series of patients are necessary to prove the efficacy and toxicity of <b style='color:Tomato;'><i>idarubicin</i></b>/vepesid and cytardbine--or dexniguldipine-containing--therapy in relation to P-gp expression of AML patients.","tokens":[{"text":"Furthermore","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"11","start":14,"end":16,"id":2,"ws":true},{"text":"AML","start":17,"end":20,"id":3,"ws":true},{"text":"patients","start":21,"end":29,"id":4,"ws":true},{"text":"at","start":30,"end":32,"id":5,"ws":true},{"text":"primary","start":33,"end":40,"id":6,"ws":true},{"text":"diagnosis","start":41,"end":50,"id":7,"ws":true},{"text":",","start":51,"end":52,"id":8,"ws":true},{"text":"including","start":53,"end":62,"id":9,"ws":true},{"text":"five","start":63,"end":67,"id":10,"ws":true},{"text":"AML","start":68,"end":71,"id":11,"ws":true},{"text":"patients","start":72,"end":80,"id":12,"ws":true},{"text":"with","start":81,"end":85,"id":13,"ws":true},{"text":"P-gp","start":86,"end":90,"id":14,"ws":true},{"text":"overexpression","start":91,"end":105,"id":15,"ws":true},{"text":",","start":106,"end":107,"id":16,"ws":true},{"text":"who","start":108,"end":111,"id":17,"ws":true},{"text":"were","start":112,"end":116,"id":18,"ws":true},{"text":"treated","start":117,"end":124,"id":19,"ws":true},{"text":"with","start":125,"end":129,"id":20,"ws":true},{"text":"idarubicin","start":130,"end":140,"id":21,"ws":true},{"text":",","start":141,"end":142,"id":22,"ws":true},{"text":"vepesid","start":143,"end":150,"id":23,"ws":true},{"text":",","start":151,"end":152,"id":24,"ws":true},{"text":"and","start":153,"end":156,"id":25,"ws":true},{"text":"cytarabine","start":157,"end":167,"id":26,"ws":true},{"text":"V","start":168,"end":169,"id":27,"ws":true},{"text":"(","start":170,"end":171,"id":28,"ws":true},{"text":"ara-C","start":172,"end":177,"id":29,"ws":true},{"text":")","start":178,"end":179,"id":30,"ws":true},{"text":"showed","start":180,"end":186,"id":31,"ws":true},{"text":"a","start":187,"end":188,"id":32,"ws":true},{"text":"complete","start":189,"end":197,"id":33,"ws":true},{"text":"remission","start":198,"end":207,"id":34,"ws":true},{"text":".","start":208,"end":209,"id":35,"ws":false}],"spans":[{"start":130,"end":140,"token_start":21,"token_end":21,"label":"DRUG"},{"start":143,"end":150,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7914749/","_input_hash":-1874619752,"_task_hash":363322718,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":21,"child":23,"head_span":{"start":130,"end":140,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":143,"end":150,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":23,"child":26,"head_span":{"start":143,"end":150,"token_start":23,"token_end":23,"label":"DRUG"},"child_span":{"start":157,"end":167,"token_start":26,"token_end":26,"label":null},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>Ib</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Bavituximab</i></b> <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:MediumOrchid;'><i>Carboplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Pemetrexed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Chemotherapy-Naive</i></b> <b style='color:DodgerBlue;'><i>Advanced</i></b> <b style='color:DodgerBlue;'><i>Nonsquamous</i></b> <b style='color:DodgerBlue;'><i>Non-Small-Cell</i></b> <b style='color:DodgerBlue;'><i>Lung</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>bavituximab</i></b> is an immunomodulatory chimeric monoclonal antibody that inhibits phosphatidylserine signaling, which promotes innate and adaptive immune responses. In this phase Ib trial we evaluated the safety, tolerability, and preliminary antitumor activity of <b style='color:Tomato;'><i>pemetrexed</i></b>, <b style='color:Tomato;'><i>carboplatin</i></b>, <b style='color:Tomato;'><i>bavituximab</i></b> in advanced non-small-cell lung cancer (NSCLC). ### Patients And Methods Patients with advanced nonsquamous NSCLC and performance status 0 or 1 were treated with <b style='color:Tomato;'><i>pemetrexed</i></b> 500 mg/m ### results Between March 29, 2011 and December 30, 2013, 26 patients were enrolled. Three patients each were enrolled into dose escalation cohorts of <b style='color:Tomato;'><i>bavituximab</i></b> (0.3, 1, and 3 mg/kg). Therapy was well tolerated with no DLTs, and toxicities were consistent with those expected from <b style='color:Tomato;'><i>pemetrexed</i></b>/<b style='color:Tomato;'><i>carboplatin</i></b>. Overall response was 28%, with a median progression-free and overall survival of 4.8 months and 12.2 months, respectively. ### conclusion The combination of <b style='color:Tomato;'><i>pemetrexed</i></b>, <b style='color:Tomato;'><i>carboplatin</i></b>, <b style='color:Tomato;'><i>bavituximab</i></b> is well tolerated. However, with toxicities and preliminary efficacy signal similar to <b style='color:Tomato;'><i>pemetrexed</i></b>/<b style='color:Tomato;'><i>carboplatin</i></b> alone, further studies of <b style='color:Tomato;'><i>bavituximab</i></b> should focus on ways to enhance its immunomodulatory role.","tokens":[{"text":"Phase","start":0,"end":5,"id":0,"ws":true},{"text":"Ib","start":6,"end":8,"id":1,"ws":true},{"text":"Study","start":9,"end":14,"id":2,"ws":true},{"text":"of","start":15,"end":17,"id":3,"ws":true},{"text":"Bavituximab","start":18,"end":29,"id":4,"ws":true},{"text":"With","start":30,"end":34,"id":5,"ws":true},{"text":"Carboplatin","start":35,"end":46,"id":6,"ws":true},{"text":"and","start":47,"end":50,"id":7,"ws":true},{"text":"Pemetrexed","start":51,"end":61,"id":8,"ws":true},{"text":"in","start":62,"end":64,"id":9,"ws":true},{"text":"Chemotherapy-Naive","start":65,"end":83,"id":10,"ws":true},{"text":"Advanced","start":84,"end":92,"id":11,"ws":true},{"text":"Nonsquamous","start":93,"end":104,"id":12,"ws":true},{"text":"Non-Small-Cell","start":105,"end":119,"id":13,"ws":true},{"text":"Lung","start":120,"end":124,"id":14,"ws":true},{"text":"Cancer","start":125,"end":131,"id":15,"ws":true},{"text":".","start":132,"end":133,"id":16,"ws":false}],"spans":[{"start":18,"end":29,"token_start":4,"token_end":4,"label":"DRUG"},{"start":35,"end":46,"token_start":6,"token_end":6,"label":"DRUG"},{"start":51,"end":61,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29631965/","_input_hash":-910966445,"_task_hash":-558478627,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":18,"end":29,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":35,"end":46,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":6,"child":8,"head_span":{"start":35,"end":46,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":51,"end":61,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"In this multicenter study , the reliability of two nonradiometric , fully automated systems , the MB/BacT and BACTEC MGIT 960 systems , for testing the susceptibilities of 82 Mycobacterium tuberculosis strains to isoniazid , rifampin , ethambutol , and streptomycin was evaluated in comparison with the radiometric BACTEC 460 TB system .","paragraph":"<h3><u>Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis.</u></h3> <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>multicenter</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>reliability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>nonradiometric</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>fully</i></b> <b style='color:DodgerBlue;'><i>automated</i></b> <b style='color:DodgerBlue;'><i>systems</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>MB/BacT</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>BACTEC</i></b> <b style='color:DodgerBlue;'><i>MGIT</i></b> <b style='color:DodgerBlue;'><i>960</i></b> <b style='color:DodgerBlue;'><i>systems</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>testing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>susceptibilities</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>82</i></b> <b style='color:DodgerBlue;'><i>Mycobacterium</i></b> <b style='color:DodgerBlue;'><i>tuberculosis</i></b> <b style='color:DodgerBlue;'><i>strains</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>isoniazid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>rifampin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ethambutol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>streptomycin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>comparison</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>radiometric</i></b> <b style='color:DodgerBlue;'><i>BACTEC</i></b> <b style='color:DodgerBlue;'><i>460</i></b> <b style='color:DodgerBlue;'><i>TB</i></b> <b style='color:DodgerBlue;'><i>system</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The arbitration of discrepant results was done by the reanalysis of the strain, the determination of the MIC, and the molecular characterization of some resistance determinants. The overall level of agreement with BACTEC 460TB results was 96% with the MB/BacT test and 97.2% with the BACTEC MGIT 960 system. With both methods, the level of agreement with BACTEC 460TB results was 96.3% for <b style='color:Tomato;'><i>isoniazid</i></b>, 98.8% for <b style='color:Tomato;'><i>rifampin</i></b>, and 98.8% for <b style='color:Tomato;'><i>ethambutol</i></b>. The level of agreement for <b style='color:Tomato;'><i>streptomycin</i></b> was 90.2% with MB/BacT and 97.5% with BACTEC MGIT 960. Overall, there were 11 very major errors and 2 major errors with the MB/BacT method and 5 very major errors and 2 major errors with the BACTEC MGIT 960 system. In general, the MB/BacT and BACTEC MGIT 960 systems showed good performance for susceptibility testing with first-line antituberculosis drugs.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"this","start":3,"end":7,"id":1,"ws":true},{"text":"multicenter","start":8,"end":19,"id":2,"ws":true},{"text":"study","start":20,"end":25,"id":3,"ws":true},{"text":",","start":26,"end":27,"id":4,"ws":true},{"text":"the","start":28,"end":31,"id":5,"ws":true},{"text":"reliability","start":32,"end":43,"id":6,"ws":true},{"text":"of","start":44,"end":46,"id":7,"ws":true},{"text":"two","start":47,"end":50,"id":8,"ws":true},{"text":"nonradiometric","start":51,"end":65,"id":9,"ws":true},{"text":",","start":66,"end":67,"id":10,"ws":true},{"text":"fully","start":68,"end":73,"id":11,"ws":true},{"text":"automated","start":74,"end":83,"id":12,"ws":true},{"text":"systems","start":84,"end":91,"id":13,"ws":true},{"text":",","start":92,"end":93,"id":14,"ws":true},{"text":"the","start":94,"end":97,"id":15,"ws":true},{"text":"MB/BacT","start":98,"end":105,"id":16,"ws":true},{"text":"and","start":106,"end":109,"id":17,"ws":true},{"text":"BACTEC","start":110,"end":116,"id":18,"ws":true},{"text":"MGIT","start":117,"end":121,"id":19,"ws":true},{"text":"960","start":122,"end":125,"id":20,"ws":true},{"text":"systems","start":126,"end":133,"id":21,"ws":true},{"text":",","start":134,"end":135,"id":22,"ws":true},{"text":"for","start":136,"end":139,"id":23,"ws":true},{"text":"testing","start":140,"end":147,"id":24,"ws":true},{"text":"the","start":148,"end":151,"id":25,"ws":true},{"text":"susceptibilities","start":152,"end":168,"id":26,"ws":true},{"text":"of","start":169,"end":171,"id":27,"ws":true},{"text":"82","start":172,"end":174,"id":28,"ws":true},{"text":"Mycobacterium","start":175,"end":188,"id":29,"ws":true},{"text":"tuberculosis","start":189,"end":201,"id":30,"ws":true},{"text":"strains","start":202,"end":209,"id":31,"ws":true},{"text":"to","start":210,"end":212,"id":32,"ws":true},{"text":"isoniazid","start":213,"end":222,"id":33,"ws":true},{"text":",","start":223,"end":224,"id":34,"ws":true},{"text":"rifampin","start":225,"end":233,"id":35,"ws":true},{"text":",","start":234,"end":235,"id":36,"ws":true},{"text":"ethambutol","start":236,"end":246,"id":37,"ws":true},{"text":",","start":247,"end":248,"id":38,"ws":true},{"text":"and","start":249,"end":252,"id":39,"ws":true},{"text":"streptomycin","start":253,"end":265,"id":40,"ws":true},{"text":"was","start":266,"end":269,"id":41,"ws":true},{"text":"evaluated","start":270,"end":279,"id":42,"ws":true},{"text":"in","start":280,"end":282,"id":43,"ws":true},{"text":"comparison","start":283,"end":293,"id":44,"ws":true},{"text":"with","start":294,"end":298,"id":45,"ws":true},{"text":"the","start":299,"end":302,"id":46,"ws":true},{"text":"radiometric","start":303,"end":314,"id":47,"ws":true},{"text":"BACTEC","start":315,"end":321,"id":48,"ws":true},{"text":"460","start":322,"end":325,"id":49,"ws":true},{"text":"TB","start":326,"end":328,"id":50,"ws":true},{"text":"system","start":329,"end":335,"id":51,"ws":true},{"text":".","start":336,"end":337,"id":52,"ws":false}],"spans":[{"start":213,"end":222,"token_start":33,"token_end":33,"label":"DRUG"},{"start":225,"end":233,"token_start":35,"token_end":35,"label":"DRUG"},{"start":236,"end":246,"token_start":37,"token_end":37,"label":"DRUG"},{"start":253,"end":265,"token_start":40,"token_end":40,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17442793/","_input_hash":-1960772817,"_task_hash":153031742,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Most frequent first line therapy was Sunitinib ( 66 % ) , followed by Sorafenib ( 20 % ) and Pazopanib ( 10 % ) .","paragraph":"<h3><u>The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.</u></h3>Tyrosine kinase inhibitor therapy (TKI) has changed the treatment paradigm of metastatic renal cell carcinoma (mRCC). The recent CARMENA and SURTIME trials challenged the role of the cytoreductive nephrectomy (CN). ### objective To assess the impact of CN prior to TKI therapy in patients with mRCC in a real-world setting. ### methods Overall, 262 consecutive patients with mRCC were treated with CN plus TKI or TKI only at our institution between 2000 and 2016. Patients with prior immunotherapy or metastasectomy were excluded. Multiple imputation and inverse probability of treatment weighting (IPTW) were performed to account for missing values and imbalances between the treatment groups, respectively. Unadjusted and adjusted Kaplan-Meier estimates were used to determine differences in progression-free (PFS), overall (OS), and cancer-specific survival (CSS). ### results Overall, 104 (40%) patients received CN before TKI treatment. <b style='color:DodgerBlue;'><i>Most</i></b> <b style='color:DodgerBlue;'><i>frequent</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:MediumOrchid;'><i>Sunitinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>66</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>Sorafenib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Pazopanib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> After adjustment with IPTW, there was no difference in PFS, CSS, and OS (all P > 0.05) between the treatment groups. In subgroup analyses, CSS was improved when CN was performed in patients with sarcomatoid features and clear cell histology (P\u202f=\u202f0.04 and P\u202f=\u202f0.03) and PFS was improved in patients with clear cell histology when CN was performed [0.04]). CN did not improve OS in any subgroup analysis. ### conclusion The role of CN remains controversial. We found no difference in survival outcomes between patients treated with and without CN before TKI therapy. However, CN was associated with improved survival in specific patient subgroups. Tailored, individualized treatment is key to further improve oncological outcomes for mRCC.","tokens":[{"text":"Most","start":0,"end":4,"id":0,"ws":true},{"text":"frequent","start":5,"end":13,"id":1,"ws":true},{"text":"first","start":14,"end":19,"id":2,"ws":true},{"text":"line","start":20,"end":24,"id":3,"ws":true},{"text":"therapy","start":25,"end":32,"id":4,"ws":true},{"text":"was","start":33,"end":36,"id":5,"ws":true},{"text":"Sunitinib","start":37,"end":46,"id":6,"ws":true},{"text":"(","start":47,"end":48,"id":7,"ws":true},{"text":"66","start":49,"end":51,"id":8,"ws":true},{"text":"%","start":52,"end":53,"id":9,"ws":true},{"text":")","start":54,"end":55,"id":10,"ws":true},{"text":",","start":56,"end":57,"id":11,"ws":true},{"text":"followed","start":58,"end":66,"id":12,"ws":true},{"text":"by","start":67,"end":69,"id":13,"ws":true},{"text":"Sorafenib","start":70,"end":79,"id":14,"ws":true},{"text":"(","start":80,"end":81,"id":15,"ws":true},{"text":"20","start":82,"end":84,"id":16,"ws":true},{"text":"%","start":85,"end":86,"id":17,"ws":true},{"text":")","start":87,"end":88,"id":18,"ws":true},{"text":"and","start":89,"end":92,"id":19,"ws":true},{"text":"Pazopanib","start":93,"end":102,"id":20,"ws":true},{"text":"(","start":103,"end":104,"id":21,"ws":true},{"text":"10","start":105,"end":107,"id":22,"ws":true},{"text":"%","start":108,"end":109,"id":23,"ws":true},{"text":")","start":110,"end":111,"id":24,"ws":true},{"text":".","start":112,"end":113,"id":25,"ws":false}],"spans":[{"start":37,"end":46,"token_start":6,"token_end":6,"label":"DRUG"},{"start":70,"end":79,"token_start":14,"token_end":14,"label":"DRUG"},{"start":93,"end":102,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32576526/","_input_hash":-1193138832,"_task_hash":1267016825,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Treatment of unresectable GISTs involves systemic chemotherapy with tyrosine kinase inhibitors , imatinib and sunitinib being first-line and second-line drugs .","paragraph":"<h3><u>A gastrointestinal stromal tumour with pulmonary metastases mimicking unilateral gynaecomastia.</u></h3>Gastrointestinal stromal tumours (GISTs) represent 1% of primary gastrointestinal cancers. These neoplasms most frequently metastasise to the liver and peritoneum and rarely to the lungs and bones. <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>unresectable</i></b> <b style='color:DodgerBlue;'><i>GISTs</i></b> <b style='color:DodgerBlue;'><i>involves</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>tyrosine</i></b> <b style='color:DodgerBlue;'><i>kinase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>imatinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>being</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We report the case of a 52-year-old man with GIST who developed a right-sided subareolar breast swelling and subsequently discovered to be an invasive metastatic pulmonary GIST. Given that gynaecomastia is a known adverse effect of <b style='color:Tomato;'><i>imatinib</i></b> and <b style='color:Tomato;'><i>sunitinib</i></b>, this case report illustrates the importance of including metastatic disease in the differential diagnosis of patients with GIST and with the new onset of soft tissue masses.","tokens":[{"text":"Treatment","start":0,"end":9,"id":0,"ws":true},{"text":"of","start":10,"end":12,"id":1,"ws":true},{"text":"unresectable","start":13,"end":25,"id":2,"ws":true},{"text":"GISTs","start":26,"end":31,"id":3,"ws":true},{"text":"involves","start":32,"end":40,"id":4,"ws":true},{"text":"systemic","start":41,"end":49,"id":5,"ws":true},{"text":"chemotherapy","start":50,"end":62,"id":6,"ws":true},{"text":"with","start":63,"end":67,"id":7,"ws":true},{"text":"tyrosine","start":68,"end":76,"id":8,"ws":true},{"text":"kinase","start":77,"end":83,"id":9,"ws":true},{"text":"inhibitors","start":84,"end":94,"id":10,"ws":true},{"text":",","start":95,"end":96,"id":11,"ws":true},{"text":"imatinib","start":97,"end":105,"id":12,"ws":true},{"text":"and","start":106,"end":109,"id":13,"ws":true},{"text":"sunitinib","start":110,"end":119,"id":14,"ws":true},{"text":"being","start":120,"end":125,"id":15,"ws":true},{"text":"first-line","start":126,"end":136,"id":16,"ws":true},{"text":"and","start":137,"end":140,"id":17,"ws":true},{"text":"second-line","start":141,"end":152,"id":18,"ws":true},{"text":"drugs","start":153,"end":158,"id":19,"ws":true},{"text":".","start":159,"end":160,"id":20,"ws":false}],"spans":[{"start":97,"end":105,"token_start":12,"token_end":12,"label":"DRUG"},{"start":110,"end":119,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24343802/","_input_hash":-1360996283,"_task_hash":249055749,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":12,"child":14,"head_span":{"start":97,"end":105,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":110,"end":119,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Such therapy has included weekly paclitaxel in combination with carboplatin/cisplatin plus topotecan , and carboplatin plus doxorubicin .","paragraph":"<h3><u>Role of weekly paclitaxel in the treatment of advanced ovarian cancer.</u></h3>Dose-dense weekly administration of <b style='color:Tomato;'><i>paclitaxel</i></b> has the potential advantage of allowing a larger percentage of cancer cells to enter the vulnerable phase of their cell cycle when cytotoxic <b style='color:Tomato;'><i>paclitaxel</i></b> concentrations are present. The lower doses and shorter infusion times used with weekly dosing should also minimize bone marrow suppression and other toxicities associated with standard <b style='color:Tomato;'><i>paclitaxel</i></b> 3-weekly administration. Clinical studies have confirmed that <b style='color:Tomato;'><i>paclitaxel</i></b> can be safely delivered on a weekly schedule as a 1-h infusion to patients with advanced ovarian cancer. Weekly administration of <b style='color:Tomato;'><i>paclitaxel</i></b> also appears to be better tolerated than 3-weekly administration. Single-agent weekly <b style='color:Tomato;'><i>paclitaxel</i></b> is associated with response rates of 20-65%. Combination therapy with weekly <b style='color:Tomato;'><i>paclitaxel</i></b> has mainly involved <b style='color:Tomato;'><i>carboplatin</i></b> and response rates with such regimens range from 60-88%. Triple-drug combination therapy has produced response rates of 42-67.5%. <b style='color:DodgerBlue;'><i>Such</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>carboplatin/cisplatin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In an attempt to avoid problems with high corticosteroid doses, <b style='color:Tomato;'><i>dexamethasone</i></b> doses of 10 and 8 mg have been used successfully in premedication regimens for weekly <b style='color:Tomato;'><i>paclitaxel</i></b> in ovarian cancer.","tokens":[{"text":"Such","start":0,"end":4,"id":0,"ws":true},{"text":"therapy","start":5,"end":12,"id":1,"ws":true},{"text":"has","start":13,"end":16,"id":2,"ws":true},{"text":"included","start":17,"end":25,"id":3,"ws":true},{"text":"weekly","start":26,"end":32,"id":4,"ws":true},{"text":"paclitaxel","start":33,"end":43,"id":5,"ws":true},{"text":"in","start":44,"end":46,"id":6,"ws":true},{"text":"combination","start":47,"end":58,"id":7,"ws":true},{"text":"with","start":59,"end":63,"id":8,"ws":true},{"text":"carboplatin/cisplatin","start":64,"end":85,"id":9,"ws":true},{"text":"plus","start":86,"end":90,"id":10,"ws":true},{"text":"topotecan","start":91,"end":100,"id":11,"ws":true},{"text":",","start":101,"end":102,"id":12,"ws":true},{"text":"and","start":103,"end":106,"id":13,"ws":true},{"text":"carboplatin","start":107,"end":118,"id":14,"ws":true},{"text":"plus","start":119,"end":123,"id":15,"ws":true},{"text":"doxorubicin","start":124,"end":135,"id":16,"ws":true},{"text":".","start":136,"end":137,"id":17,"ws":false}],"spans":[{"start":33,"end":43,"token_start":5,"token_end":5,"label":"DRUG"},{"start":91,"end":100,"token_start":11,"token_end":11,"label":"DRUG"},{"start":107,"end":118,"token_start":14,"token_end":14,"label":"DRUG"},{"start":124,"end":135,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12505598/","_input_hash":1625402879,"_task_hash":-1892171795,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":5,"child":9,"head_span":{"start":33,"end":43,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":64,"end":85,"token_start":9,"token_end":9,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":9,"child":11,"head_span":{"start":64,"end":85,"token_start":9,"token_end":9,"label":null},"child_span":{"start":91,"end":100,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":14,"head_span":{"start":33,"end":43,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":107,"end":118,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":14,"child":16,"head_span":{"start":107,"end":118,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":124,"end":135,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS21"],"answer":"accept"}
{"text":"This phase II study was performed to assess the efficacy and safety of the combination regimen of temozolomide and docetaxel in patients with advanced metastatic melanoma .","paragraph":"<h3><u>Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.</u></h3><b style='color:Tomato;'><i>temozolomide</i></b> is a novel oral alkylating agent that is effective against melanoma. Moreover, <b style='color:Tomato;'><i>temozolomide</i></b> readily crosses the blood-brain barrier and may consequently be effective in patients with brain metastases. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>assess</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods Sixty-five patients with metastatic melanoma were enrolled. Treatment consisted of intravenous <b style='color:Tomato;'><i>docetaxel</i></b> (80 mg/m(2)) on day 1 and oral <b style='color:Tomato;'><i>temozolomide</i></b> (150 mg/m(2)) on days 1 to 5, every 4 weeks, for a maximum of six cycles. ### results Sixty-two patients were eligible for the efficacy and safety analysis. Seventeen patients (27%) achieved an objective response, including five complete (8%) and 12 partial responses (19%). Median response duration was 9.5 months. Among responders, median time to progression (TTP) was 11.2 months and median overall survival (OS) was 16 months. For all treated patients, the median TTP was 4 months and median OS was 11 months. Three (38%) of eight patients who presented with brain metastases had a partial response for 5, 6, and 12 months. Of 52 patients who did not have brain involvement at presentation, only four (8%) developed brain metastases at a median follow-up of 14 months. Myelosuppression was the primary toxicity. ### conclusion The combination of <b style='color:Tomato;'><i>temozolomide</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> was effective and well tolerated as first-line treatment for patients with advanced metastatic melanoma and demonstrated encouraging antitumor activity against brain metastases.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"phase","start":5,"end":10,"id":1,"ws":true},{"text":"II","start":11,"end":13,"id":2,"ws":true},{"text":"study","start":14,"end":19,"id":3,"ws":true},{"text":"was","start":20,"end":23,"id":4,"ws":true},{"text":"performed","start":24,"end":33,"id":5,"ws":true},{"text":"to","start":34,"end":36,"id":6,"ws":true},{"text":"assess","start":37,"end":43,"id":7,"ws":true},{"text":"the","start":44,"end":47,"id":8,"ws":true},{"text":"efficacy","start":48,"end":56,"id":9,"ws":true},{"text":"and","start":57,"end":60,"id":10,"ws":true},{"text":"safety","start":61,"end":67,"id":11,"ws":true},{"text":"of","start":68,"end":70,"id":12,"ws":true},{"text":"the","start":71,"end":74,"id":13,"ws":true},{"text":"combination","start":75,"end":86,"id":14,"ws":true},{"text":"regimen","start":87,"end":94,"id":15,"ws":true},{"text":"of","start":95,"end":97,"id":16,"ws":true},{"text":"temozolomide","start":98,"end":110,"id":17,"ws":true},{"text":"and","start":111,"end":114,"id":18,"ws":true},{"text":"docetaxel","start":115,"end":124,"id":19,"ws":true},{"text":"in","start":125,"end":127,"id":20,"ws":true},{"text":"patients","start":128,"end":136,"id":21,"ws":true},{"text":"with","start":137,"end":141,"id":22,"ws":true},{"text":"advanced","start":142,"end":150,"id":23,"ws":true},{"text":"metastatic","start":151,"end":161,"id":24,"ws":true},{"text":"melanoma","start":162,"end":170,"id":25,"ws":true},{"text":".","start":171,"end":172,"id":26,"ws":false}],"spans":[{"start":98,"end":110,"token_start":17,"token_end":17,"label":"DRUG"},{"start":115,"end":124,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11786569/","_input_hash":1159878705,"_task_hash":2116484808,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":17,"child":19,"head_span":{"start":98,"end":110,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":115,"end":124,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>verapamil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>initial</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Based on experimental observations that <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>tamoxifen</i></b> reverse multiple drug resistance, the authors investigated the feasibility of combining both agents with the initial chemotherapy of extensive small cell lung cancer. Overall, in a consecutive series of 58 patients the most important toxicity was myelosuppression, and there was a 24% rate of severe infections. Therapeutic results included 24% complete and 34% partial response rates, median time to disease progression of 32 weeks, and median survival of 46 weeks. In three consecutive cohorts of patients the dose of either <b style='color:Tomato;'><i>tamoxifen</i></b> or <b style='color:Tomato;'><i>verapamil</i></b> were escalated by 25% and 33%, respectively. The cohort of patients receiving <b style='color:Tomato;'><i>verapamil</i></b> 360 mg/day and <b style='color:Tomato;'><i>tamoxifen</i></b> 100 mg/day (level 2) had slightly more toxicity but also more responses than the other groups. Therefore, the authors recommend that these doses be used in controlled trials to confirm the promising results of their study.","tokens":[{"text":"Addition","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"verapamil","start":12,"end":21,"id":2,"ws":true},{"text":"and","start":22,"end":25,"id":3,"ws":true},{"text":"tamoxifen","start":26,"end":35,"id":4,"ws":true},{"text":"to","start":36,"end":38,"id":5,"ws":true},{"text":"the","start":39,"end":42,"id":6,"ws":true},{"text":"initial","start":43,"end":50,"id":7,"ws":true},{"text":"chemotherapy","start":51,"end":63,"id":8,"ws":true},{"text":"of","start":64,"end":66,"id":9,"ws":true},{"text":"small","start":67,"end":72,"id":10,"ws":true},{"text":"cell","start":73,"end":77,"id":11,"ws":true},{"text":"lung","start":78,"end":82,"id":12,"ws":true},{"text":"cancer","start":83,"end":89,"id":13,"ws":true},{"text":".","start":90,"end":91,"id":14,"ws":false}],"spans":[{"start":12,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":26,"end":35,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2164872/","_input_hash":-375551766,"_task_hash":-1507493145,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":12,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":26,"end":35,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"In a scenario analysis comparing pembrolizumab with ipilimumab , the estimated ICER was USD8,904 .","paragraph":"<h3><u>Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong.</u></h3><b style='color:Tomato;'><i>pembrolizumab</i></b> has been shown to improve overall survival (OS) and progression free survival (PFS) compared to <b style='color:Tomato;'><i>ipilimumab</i></b> in patients with <b style='color:Tomato;'><i>ipilimumab</i></b>-na\u00efve advanced melanoma; however, there are no published data on the cost-effectiveness for <b style='color:Tomato;'><i>pembrolizumab</i></b> compared to standard-of-care treatments currently used in Hong Kong for advanced melanoma. ### methods A partitioned-survival model based on data from a recent randomized phase 3 study (KEYNOTE-006) and meta-analysis was used to derive time in PFS, OS, and post-progression survival for <b style='color:Tomato;'><i>pembrolizumab</i></b> and chemotherapy, such as <b style='color:Tomato;'><i>dacarbazine</i></b> (DTIC), <b style='color:Tomato;'><i>temozolomide</i></b> (TMZ), and the <b style='color:Tomato;'><i>paclitaxel</i></b>-<b style='color:Tomato;'><i>carboplatin</i></b> combination (PC). A combination of clinical trial data, published data, results of meta-analysis, and melanoma registry data was used to extrapolate PFS and OS curves. The base-case time horizon for the model was 30\u00a0years with costs and health outcomes discounted at a rate of 5% per year. Individual patient level data on utilities and frequencies of adverse events were obtained from the final analysis of KEYNOTE-006 (cut-off date: 3-Dec-15) for <b style='color:Tomato;'><i>pembrolizumab</i></b>. Cost data included drug acquisition, treatment administration, adverse event management, and clinical management of advanced melanoma. The distribution of patient weight from the Hong Kong population was applied to calculate the drug costs. Analyses were performed from a payer's perspective. The incremental cost effectiveness ratio (ICER) expressed as cost in US Dollars (USD) per quality-adjusted life years (QALYs) was the main outcome. ### results In base-case scenario, the ICER for <b style='color:Tomato;'><i>pembrolizumab</i></b> as a first-line treatment for advanced melanoma was USD49,232 compared to DTIC, with the ICER values lower than cost-effectiveness threshold in Hong Kong. Results comparing <b style='color:Tomato;'><i>pembrolizumab</i></b> to TMZ and to PC were similar to that when compared to DTIC. Probability sensitivity analyses showed that 99% of the simulated ICERs were below three times the Gross Domestic Product (GDP) per capita for Hong Kong (currently at $119,274//QALY threshold). <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>scenario</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:MediumOrchid;'><i>pembrolizumab</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>estimated</i></b> <b style='color:DodgerBlue;'><i>ICER</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>USD8,904</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions <b style='color:Tomato;'><i>pembrolizumab</i></b> is cost-effective relative to chemotherapy (DTIC, TMZ and PC), and highly-cost-effective compared to <b style='color:Tomato;'><i>ipilimumab</i></b>, for the first-line treatment of advanced melanoma in Hong Kong.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"a","start":3,"end":4,"id":1,"ws":true},{"text":"scenario","start":5,"end":13,"id":2,"ws":true},{"text":"analysis","start":14,"end":22,"id":3,"ws":true},{"text":"comparing","start":23,"end":32,"id":4,"ws":true},{"text":"pembrolizumab","start":33,"end":46,"id":5,"ws":true},{"text":"with","start":47,"end":51,"id":6,"ws":true},{"text":"ipilimumab","start":52,"end":62,"id":7,"ws":true},{"text":",","start":63,"end":64,"id":8,"ws":true},{"text":"the","start":65,"end":68,"id":9,"ws":true},{"text":"estimated","start":69,"end":78,"id":10,"ws":true},{"text":"ICER","start":79,"end":83,"id":11,"ws":true},{"text":"was","start":84,"end":87,"id":12,"ws":true},{"text":"USD8,904","start":88,"end":96,"id":13,"ws":true},{"text":".","start":97,"end":98,"id":14,"ws":false}],"spans":[{"start":33,"end":46,"token_start":5,"token_end":5,"label":"DRUG"},{"start":52,"end":62,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31969794/","_input_hash":561908098,"_task_hash":-2137009120,"_session_id":"drug_drug_test_set_2-shaked","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Cardiac events occurred after posaconazole administration , incriminating posaconazole use , alone or in combination with voriconazole , as the culpable agent .","paragraph":"<h3><u>Long QT Syndrome Leading to Multiple Cardiac Arrests After Posaconazole Administration in an Immune-Compromised Patient with Sepsis: An Unusual Case Report.</u></h3>We present the case of a septic patient with severe immunodeficiency, who developed QT interval prolongation followed by episodes of lethal cardiac arrhythmia. <b style='color:DodgerBlue;'><i>Cardiac</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>occurred</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>posaconazole</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>incriminating</i></b> <b style='color:MediumOrchid;'><i>posaconazole</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>voriconazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>culpable</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Case Report A 26-year-old female patient underwent orthopedic surgery to remove ectopic calcifications in her left hip joint. On the first post-operative day she became septic due to a surgical wound infection. Despite being treated according to the therapeutic protocols for sepsis, no clinical improvement was noticed and further assessment revealed an underlying immunodeficiency. Considering the underlying immunodeficiency and to that point poor clinical response, an antifungal agent was added to the antibiotic regiment. Following discontinuation of multiple antifungal agents due to adverse effects, <b style='color:Tomato;'><i>posaconazole</i></b> was administered. <b style='color:Tomato;'><i>posaconazole</i></b> oral intake was followed by episodes of bradycardia and QT interval prolongation. The patient suffered continuous incidents of cardiac arrest due to polymorphic ventricular tachycardia (torsades des pointes) that degenerated to lethal ventricular fibrillation. <b style='color:Tomato;'><i>posaconazole</i></b> was immediately discontinued and a temporary pacemaker was installed. The patient finally recovered without any neurological deficit, and was discharged in a good clinical status. ### conclusions Close cardiac monitoring is recommended in cases where <b style='color:Tomato;'><i>posaconazole</i></b> administration is combined with coexisting risk factors, as they may lead to severe ECG abnormalities and cardiac arrhythmias such as long QT interval syndrome and torsades de pointes. <b style='color:Tomato;'><i>posaconazole</i></b> interactions with medications metabolized via the CYP3A4 pathway should be considered an additional risk factor for lethal cardiac incidents.","tokens":[{"text":"Cardiac","start":0,"end":7,"id":0,"ws":true},{"text":"events","start":8,"end":14,"id":1,"ws":true},{"text":"occurred","start":15,"end":23,"id":2,"ws":true},{"text":"after","start":24,"end":29,"id":3,"ws":true},{"text":"posaconazole","start":30,"end":42,"id":4,"ws":true},{"text":"administration","start":43,"end":57,"id":5,"ws":true},{"text":",","start":58,"end":59,"id":6,"ws":true},{"text":"incriminating","start":60,"end":73,"id":7,"ws":true},{"text":"posaconazole","start":74,"end":86,"id":8,"ws":true},{"text":"use","start":87,"end":90,"id":9,"ws":true},{"text":",","start":91,"end":92,"id":10,"ws":true},{"text":"alone","start":93,"end":98,"id":11,"ws":true},{"text":"or","start":99,"end":101,"id":12,"ws":true},{"text":"in","start":102,"end":104,"id":13,"ws":true},{"text":"combination","start":105,"end":116,"id":14,"ws":true},{"text":"with","start":117,"end":121,"id":15,"ws":true},{"text":"voriconazole","start":122,"end":134,"id":16,"ws":true},{"text":",","start":135,"end":136,"id":17,"ws":true},{"text":"as","start":137,"end":139,"id":18,"ws":true},{"text":"the","start":140,"end":143,"id":19,"ws":true},{"text":"culpable","start":144,"end":152,"id":20,"ws":true},{"text":"agent","start":153,"end":158,"id":21,"ws":true},{"text":".","start":159,"end":160,"id":22,"ws":false}],"spans":[{"start":30,"end":42,"token_start":4,"token_end":4,"label":"DRUG"},{"start":74,"end":86,"token_start":8,"token_end":8,"label":"DRUG"},{"start":122,"end":134,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27125217/","_input_hash":-9132301,"_task_hash":-1195455115,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":8,"child":16,"head_span":{"start":74,"end":86,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":122,"end":134,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"Prognostic value of expression of Kit67 , p53 , TopoIIa and GSTP1 for curatively resected advanced gastric cancer patients receiving adjuvant paclitaxel plus capecitabine chemotherapy .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Prognostic</i></b> <b style='color:DodgerBlue;'><i>value</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Kit67</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>p53</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>TopoIIa</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>GSTP1</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>curatively</i></b> <b style='color:DodgerBlue;'><i>resected</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>gastric</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>To investigate the role of Kit67, p53, topoisomerase II (TopoII) and glutathione S-transferase P1 (GSTP1) in predicting clinical outcome of advanced gastric cancer patients receiving <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> chemotherapy. ### methodology The clinical data and tissue samples from 136 curatively resected advanced gastric cancer patients receiving <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> in the third affiliated hospital of Kunming medical university from January 2005 to December 2007 were retrospectively collected and analyzed for Kit67, p53, TopoIIa and GSTP1 expressions by immunohistochemistry. The relationships between expressions of the biomarkers and survival were analyzed. ### results p53 expression were associated with the significantly shorter disease-free survival (DFS) (p<0.001) and overall survival (OS) (p=0.012) in the curatively resected advanced gastric cancer patients receiving <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b>. Kit67, TopoIIa and GSTP1 expressions were not related to DFS and OS. ### conclusions p53 expression positive might predict prognosis in gastric cancer patients who underwent curative surgery followed by adjuvant <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> chemotherapy. A favorable effect of <b style='color:Tomato;'><i>capecitabine</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> might therefore be expected in patients that do not express p53.","tokens":[{"text":"Prognostic","start":0,"end":10,"id":0,"ws":true},{"text":"value","start":11,"end":16,"id":1,"ws":true},{"text":"of","start":17,"end":19,"id":2,"ws":true},{"text":"expression","start":20,"end":30,"id":3,"ws":true},{"text":"of","start":31,"end":33,"id":4,"ws":true},{"text":"Kit67","start":34,"end":39,"id":5,"ws":true},{"text":",","start":40,"end":41,"id":6,"ws":true},{"text":"p53","start":42,"end":45,"id":7,"ws":true},{"text":",","start":46,"end":47,"id":8,"ws":true},{"text":"TopoIIa","start":48,"end":55,"id":9,"ws":true},{"text":"and","start":56,"end":59,"id":10,"ws":true},{"text":"GSTP1","start":60,"end":65,"id":11,"ws":true},{"text":"for","start":66,"end":69,"id":12,"ws":true},{"text":"curatively","start":70,"end":80,"id":13,"ws":true},{"text":"resected","start":81,"end":89,"id":14,"ws":true},{"text":"advanced","start":90,"end":98,"id":15,"ws":true},{"text":"gastric","start":99,"end":106,"id":16,"ws":true},{"text":"cancer","start":107,"end":113,"id":17,"ws":true},{"text":"patients","start":114,"end":122,"id":18,"ws":true},{"text":"receiving","start":123,"end":132,"id":19,"ws":true},{"text":"adjuvant","start":133,"end":141,"id":20,"ws":true},{"text":"paclitaxel","start":142,"end":152,"id":21,"ws":true},{"text":"plus","start":153,"end":157,"id":22,"ws":true},{"text":"capecitabine","start":158,"end":170,"id":23,"ws":true},{"text":"chemotherapy","start":171,"end":183,"id":24,"ws":true},{"text":".","start":184,"end":185,"id":25,"ws":false}],"spans":[{"start":142,"end":152,"token_start":21,"token_end":21,"label":"DRUG"},{"start":158,"end":170,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22534478/","_input_hash":-1836483379,"_task_hash":-417698877,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":21,"child":23,"head_span":{"start":142,"end":152,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":158,"end":170,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The standard adjuvant treatment of colon cancer is fluorouracil plus leucovorin ( FL ) .","paragraph":"<h3><u>Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>colon</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:MediumOrchid;'><i>fluorouracil</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FL</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>oxaliplatin</i></b> improves the efficacy of this combination in patients with metastatic colorectal cancer. We evaluated the efficacy of treatment with FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b> in the postoperative adjuvant setting. ### methods We randomly assigned 2246 patients who had undergone curative resection for stage II or III colon cancer to receive FL alone or with <b style='color:Tomato;'><i>oxaliplatin</i></b> for six months. The primary end point was disease-free survival. ### results A total of 1123 patients were randomly assigned to each group. After a median follow-up of 37.9 months, 237 patients in the group given FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b> had had a cancer-related event, as compared with 293 patients in the FL group (21.1 percent vs. 26.1 percent; hazard ratio for recurrence, 0.77; P=0.002). The rate of disease-free survival at three years was 78.2 percent (95 percent confidence interval, 75.6 to 80.7) in the group given FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b> and 72.9 percent (95 percent confidence interval, 70.2 to 75.7) in the FL group (P=0.002 by the stratified log-rank test). In the group given FL plus <b style='color:Tomato;'><i>oxaliplatin</i></b>, the incidence of febrile neutropenia was 1.8 percent, the incidence of gastrointestinal adverse effects was low, and the incidence of grade 3 sensory neuropathy was 12.4 percent during treatment, decreasing to 1.1 percent at one year of follow-up. Six patients in each group died during treatment (death rate, 0.5 percent). ### conclusions Adding <b style='color:Tomato;'><i>oxaliplatin</i></b> to a regimen of <b style='color:Tomato;'><i>fluorouracil</i></b> and <b style='color:Tomato;'><i>leucovorin</i></b> improves the adjuvant treatment of colon cancer.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"standard","start":4,"end":12,"id":1,"ws":true},{"text":"adjuvant","start":13,"end":21,"id":2,"ws":true},{"text":"treatment","start":22,"end":31,"id":3,"ws":true},{"text":"of","start":32,"end":34,"id":4,"ws":true},{"text":"colon","start":35,"end":40,"id":5,"ws":true},{"text":"cancer","start":41,"end":47,"id":6,"ws":true},{"text":"is","start":48,"end":50,"id":7,"ws":true},{"text":"fluorouracil","start":51,"end":63,"id":8,"ws":true},{"text":"plus","start":64,"end":68,"id":9,"ws":true},{"text":"leucovorin","start":69,"end":79,"id":10,"ws":true},{"text":"(","start":80,"end":81,"id":11,"ws":true},{"text":"FL","start":82,"end":84,"id":12,"ws":true},{"text":")","start":85,"end":86,"id":13,"ws":true},{"text":".","start":87,"end":88,"id":14,"ws":false}],"spans":[{"start":51,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},{"start":69,"end":79,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15175436/","_input_hash":312360282,"_task_hash":409765963,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":51,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":69,"end":79,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Effects of ultrasound were similar at baseline and after propranolol but increased after phenylephrine .","paragraph":"<h3><u>Alteration of left ventricular endocardial function by intracavitary high-power ultrasound interacts with volume, inotropic state, and alpha 1-adrenergic stimulation.</u></h3>High-power intracavitary ultrasound abbreviates left ventricular (LV) ejection duration, thereby decreasing mechanical LV performance, presumably by selective impairment of endocardial endothelial function. ### Methods And Results Effects of ultrasound were evaluated in the ejecting LV of anesthetized, open-chest dogs under different conditions of LV volume and contractile state and after mild selective alpha 1-adrenergic stimulation. LV pressures, left atrial pressures, and regional segment lengths were measured in anterior and posterior midwall. A cylindrical ultrasound probe (0.9 MHz, 25 W) mounted on a catheter was inserted into the LV cavity through the apex and was activated for 4 minutes in each condition. In protocol A (n = 7), LV volume was altered with caval vein occlusion and intravenous dextran infusion. The ultrasound probe was activated at low (4.1 +/- 0.9 mm Hg), mid (10.6 +/- 1.5 mm Hg), and high (17.9 +/- 1.8 mm Hg) LV end-diastolic pressure (EDP). Effects of ultrasound were less pronounced at higher EDP. For example, the time interval from end-diastole to peak (-)dP/dt decreased by 7.5 +/- 2.3% at low, 4.4 +/- 2.2% at mid, and 1.9 +/- 1.6% at high LVEDP (p < 0.001). In protocol B (n = 7), LV inotropic state was altered by slow intravenous infusion of low-dose calcium. The ultrasound probe was activated before and after calcium. Effects of ultrasound were less pronounced after calcium. Time from end-diastole to peak (-)dP/dt decreased by 8.4 +/- 3.1% at baseline and by 3.5 +/- 2.1% after calcium (p < 0.001). In protocol C (n = 7), activation of the ultrasound probe was performed at baseline and after mild selective alpha 1-adrenergic stimulation (<b style='color:Tomato;'><i>propranolol</i></b> plus <b style='color:Tomato;'><i>phenylephrine</i></b>). <b style='color:DodgerBlue;'><i>Effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ultrasound</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>baseline</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>phenylephrine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Time from end-diastole to peak (-)dP/dt decreased by 5.2 +/- 2.4% at baseline, by 5.3 +/- 1.9% after <b style='color:Tomato;'><i>propranolol</i></b>, and by 8.9 +/- 3.2% after <b style='color:Tomato;'><i>phenylephrine</i></b> (p < 0.05). ### conclusions Effects of intracavitary ultrasound, which are presumably mediated through modulation of endocardial endothelial function, were more important at low volume, lower calcium, and under mild selective alpha 1-adrenergic stimulation.","tokens":[{"text":"Effects","start":0,"end":7,"id":0,"ws":true},{"text":"of","start":8,"end":10,"id":1,"ws":true},{"text":"ultrasound","start":11,"end":21,"id":2,"ws":true},{"text":"were","start":22,"end":26,"id":3,"ws":true},{"text":"similar","start":27,"end":34,"id":4,"ws":true},{"text":"at","start":35,"end":37,"id":5,"ws":true},{"text":"baseline","start":38,"end":46,"id":6,"ws":true},{"text":"and","start":47,"end":50,"id":7,"ws":true},{"text":"after","start":51,"end":56,"id":8,"ws":true},{"text":"propranolol","start":57,"end":68,"id":9,"ws":true},{"text":"but","start":69,"end":72,"id":10,"ws":true},{"text":"increased","start":73,"end":82,"id":11,"ws":true},{"text":"after","start":83,"end":88,"id":12,"ws":true},{"text":"phenylephrine","start":89,"end":102,"id":13,"ws":true},{"text":".","start":103,"end":104,"id":14,"ws":false}],"spans":[{"start":57,"end":68,"token_start":9,"token_end":9,"label":"DRUG"},{"start":89,"end":102,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7681734/","_input_hash":-1194206629,"_task_hash":325387940,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Thirty-four patients ( 4 patients with stage IIIb , 30 patients in stage IV ) , with median age 66 and performance status 0 - 1 , were administered paclitaxel , 175 mg/m(2 ) in a 3-h infusion rate on day 1 and vinorelbine , 25 mg/m(2 ) in a 10-min infusion rate on days 1 , and 8 with G-CSF and EPO support .","paragraph":"<h3><u>A phase II study of non-platinum based chemotherapy with paclitaxel and vinorelbine in non-small cell lung cancer.</u></h3><b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> combination in previous untreated patients with stage IIIb-IV non-small cell lung cancer (NSCLC) as a phase II study. ### Patients And Methods <b style='color:DodgerBlue;'><i>Thirty-four</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IIIb</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>age</i></b> <b style='color:DodgerBlue;'><i>66</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>performance</i></b> <b style='color:DodgerBlue;'><i>status</i></b> <b style='color:DodgerBlue;'><i>0</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>175</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>3-h</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>10-min</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>G-CSF</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>EPO</i></b> <b style='color:DodgerBlue;'><i>support</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Among our 33 evaluable patients for toxicity 16 patients (48.4%) presented leukopenia and 15 patients (45.4%) presented anemia despite G-CSF and EPO administration. Two patients (6%) presented Grade III-IV peripheral neuropathy. The overall response rate was 67.7%; 5 patients (16.1%) showed complete response (2 patients stage IIIb) and 16 patients (51.6%) showed partial response (1 patient stage IIIb). The overall median survival time was 10 months (range 3-18 months) and the median disease-free survival was 9 months (range 3-15 months) with an 1-year survival time of 45.1% (14 patients). ### conclusion The results of the combination as 1st line treatment for patients with non-operable NSCLC are promising and should be further investigated.","tokens":[{"text":"Thirty-four","start":0,"end":11,"id":0,"ws":true},{"text":"patients","start":12,"end":20,"id":1,"ws":true},{"text":"(","start":21,"end":22,"id":2,"ws":true},{"text":"4","start":23,"end":24,"id":3,"ws":true},{"text":"patients","start":25,"end":33,"id":4,"ws":true},{"text":"with","start":34,"end":38,"id":5,"ws":true},{"text":"stage","start":39,"end":44,"id":6,"ws":true},{"text":"IIIb","start":45,"end":49,"id":7,"ws":true},{"text":",","start":50,"end":51,"id":8,"ws":true},{"text":"30","start":52,"end":54,"id":9,"ws":true},{"text":"patients","start":55,"end":63,"id":10,"ws":true},{"text":"in","start":64,"end":66,"id":11,"ws":true},{"text":"stage","start":67,"end":72,"id":12,"ws":true},{"text":"IV","start":73,"end":75,"id":13,"ws":true},{"text":")","start":76,"end":77,"id":14,"ws":true},{"text":",","start":78,"end":79,"id":15,"ws":true},{"text":"with","start":80,"end":84,"id":16,"ws":true},{"text":"median","start":85,"end":91,"id":17,"ws":true},{"text":"age","start":92,"end":95,"id":18,"ws":true},{"text":"66","start":96,"end":98,"id":19,"ws":true},{"text":"and","start":99,"end":102,"id":20,"ws":true},{"text":"performance","start":103,"end":114,"id":21,"ws":true},{"text":"status","start":115,"end":121,"id":22,"ws":true},{"text":"0","start":122,"end":123,"id":23,"ws":true},{"text":"-","start":124,"end":125,"id":24,"ws":true},{"text":"1","start":126,"end":127,"id":25,"ws":true},{"text":",","start":128,"end":129,"id":26,"ws":true},{"text":"were","start":130,"end":134,"id":27,"ws":true},{"text":"administered","start":135,"end":147,"id":28,"ws":true},{"text":"paclitaxel","start":148,"end":158,"id":29,"ws":true},{"text":",","start":159,"end":160,"id":30,"ws":true},{"text":"175","start":161,"end":164,"id":31,"ws":true},{"text":"mg/m(2","start":165,"end":171,"id":32,"ws":true},{"text":")","start":172,"end":173,"id":33,"ws":true},{"text":"in","start":174,"end":176,"id":34,"ws":true},{"text":"a","start":177,"end":178,"id":35,"ws":true},{"text":"3-h","start":179,"end":182,"id":36,"ws":true},{"text":"infusion","start":183,"end":191,"id":37,"ws":true},{"text":"rate","start":192,"end":196,"id":38,"ws":true},{"text":"on","start":197,"end":199,"id":39,"ws":true},{"text":"day","start":200,"end":203,"id":40,"ws":true},{"text":"1","start":204,"end":205,"id":41,"ws":true},{"text":"and","start":206,"end":209,"id":42,"ws":true},{"text":"vinorelbine","start":210,"end":221,"id":43,"ws":true},{"text":",","start":222,"end":223,"id":44,"ws":true},{"text":"25","start":224,"end":226,"id":45,"ws":true},{"text":"mg/m(2","start":227,"end":233,"id":46,"ws":true},{"text":")","start":234,"end":235,"id":47,"ws":true},{"text":"in","start":236,"end":238,"id":48,"ws":true},{"text":"a","start":239,"end":240,"id":49,"ws":true},{"text":"10-min","start":241,"end":247,"id":50,"ws":true},{"text":"infusion","start":248,"end":256,"id":51,"ws":true},{"text":"rate","start":257,"end":261,"id":52,"ws":true},{"text":"on","start":262,"end":264,"id":53,"ws":true},{"text":"days","start":265,"end":269,"id":54,"ws":true},{"text":"1","start":270,"end":271,"id":55,"ws":true},{"text":",","start":272,"end":273,"id":56,"ws":true},{"text":"and","start":274,"end":277,"id":57,"ws":true},{"text":"8","start":278,"end":279,"id":58,"ws":true},{"text":"with","start":280,"end":284,"id":59,"ws":true},{"text":"G-CSF","start":285,"end":290,"id":60,"ws":true},{"text":"and","start":291,"end":294,"id":61,"ws":true},{"text":"EPO","start":295,"end":298,"id":62,"ws":true},{"text":"support","start":299,"end":306,"id":63,"ws":true},{"text":".","start":307,"end":308,"id":64,"ws":false}],"spans":[{"start":148,"end":158,"token_start":29,"token_end":29,"label":"DRUG"},{"start":210,"end":221,"token_start":43,"token_end":43,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12399133/","_input_hash":1446922198,"_task_hash":1350048234,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":29,"child":43,"head_span":{"start":148,"end":158,"token_start":29,"token_end":29,"label":"DRUG"},"child_span":{"start":210,"end":221,"token_start":43,"token_end":43,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>I</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>decitabine</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>valproic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>myeloid</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>To determine an optimal biologic dose (OBD) of <b style='color:Tomato;'><i>decitabine</i></b> as a single agent and then the maximum-tolerated dose (MTD) of <b style='color:Tomato;'><i>valproic</i></b> acid (VA) combined with <b style='color:Tomato;'><i>decitabine</i></b> in acute myeloid leukemia (AML). ### Patients And Methods Twenty-five patients (median age, 70 years) were enrolled; 12 were untreated and 13 had relapsed AML. To determine an OBD (based on a gene re-expression end point), 14 patients received <b style='color:Tomato;'><i>decitabine</i></b> alone for 10 days. To determine the MTD, 11 patients received <b style='color:Tomato;'><i>decitabine</i></b> (at OBD, days 1 through 10) plus dose-escalating VA (days 5 through 21). ### results The OBD of <b style='color:Tomato;'><i>decitabine</i></b> was 20 mg/m(2)/d intravenously, with limited nonhematologic toxicity. In patients treated with <b style='color:Tomato;'><i>decitabine</i></b> plus VA, dose-limiting encephalopathy occurred in two of two patients at VA 25 mg/kg/d and one of six patients at VA 20 mg/kg/d. Drug-induced re-expression of estrogen receptor (ER) was associated with clinical response (P < or = .05). ER promoter demethylation, global DNA hypomethylation, depletion of DNA methyltransferase enzyme, and histone hyperacetylation were also observed. In an intent-to-treat analysis, the response rate was 44% (11 of 25). Of 21 assessable patients, 11 (52%) responded: four with morphologic and cytogenetic complete remission (CR; each had complex karyotype), four with incomplete CR, and three with partial remission. In untreated AML, four of nine assessable patients achieved CR. Clinical responses appeared similar for <b style='color:Tomato;'><i>decitabine</i></b> alone or with VA. ### conclusion Low-dose <b style='color:Tomato;'><i>decitabine</i></b> was safe and showed encouraging clinical and biologic activity in AML, but the addition of VA led to encephalopathy at relatively low doses. On the basis of these results, additional studies of <b style='color:Tomato;'><i>decitabine</i></b> (20 mg/m(2)/d for 10 days) alone or with an alternative deacetylating agent are warranted.","tokens":[{"text":"Phase","start":0,"end":5,"id":0,"ws":true},{"text":"I","start":6,"end":7,"id":1,"ws":true},{"text":"study","start":8,"end":13,"id":2,"ws":true},{"text":"of","start":14,"end":16,"id":3,"ws":true},{"text":"decitabine","start":17,"end":27,"id":4,"ws":true},{"text":"alone","start":28,"end":33,"id":5,"ws":true},{"text":"or","start":34,"end":36,"id":6,"ws":true},{"text":"in","start":37,"end":39,"id":7,"ws":true},{"text":"combination","start":40,"end":51,"id":8,"ws":true},{"text":"with","start":52,"end":56,"id":9,"ws":true},{"text":"valproic","start":57,"end":65,"id":10,"ws":true},{"text":"acid","start":66,"end":70,"id":11,"ws":true},{"text":"in","start":71,"end":73,"id":12,"ws":true},{"text":"acute","start":74,"end":79,"id":13,"ws":true},{"text":"myeloid","start":80,"end":87,"id":14,"ws":true},{"text":"leukemia","start":88,"end":96,"id":15,"ws":true},{"text":".","start":97,"end":98,"id":16,"ws":false}],"spans":[{"start":17,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},{"start":57,"end":65,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17679729/","_input_hash":741112160,"_task_hash":-528000752,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":10,"child":4,"head_span":{"start":57,"end":65,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":17,"end":27,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Early discontinuation of clopidogrel results in a transient rebound increase in risk of recurrence in acute coronary syndromes , but there are no published data on any similar rebound effect in patients with TIA or stroke that might inform the design of clinical trials of aspirin and clopidogrel in the acute phase .","paragraph":"<h3><u>Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke.</u></h3>The combination of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke. <b style='color:DodgerBlue;'><i>Early</i></b> <b style='color:DodgerBlue;'><i>discontinuation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>transient</i></b> <b style='color:DodgerBlue;'><i>rebound</i></b> <b style='color:DodgerBlue;'><i>increase</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>recurrence</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>coronary</i></b> <b style='color:DodgerBlue;'><i>syndromes</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>there</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>published</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>any</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>rebound</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>TIA</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>stroke</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>might</i></b> <b style='color:DodgerBlue;'><i>inform</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>design</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A 30-day course of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> (both 75 mg daily) was given to high-risk patients with TIA or minor ischemic stroke seen acutely in the EXPRESS study clinic from April 1, 2002, to March 31, 2009. <b style='color:Tomato;'><i>clopidogrel</i></b> was stopped after 30 days and <b style='color:Tomato;'><i>aspirin</i></b> continued. Recurrent events were ascertained at face-to-face follow-up. ### results A total of 320 patients were prescribed a 30-day course of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> acutely after TIA or minor stroke. There were 5 recurrent ischemic strokes and 7 TIAs during the <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> treatment period, but no strokes and 4 TIAs during the 30 days after stopping <b style='color:Tomato;'><i>clopidogrel</i></b>. A similar temporal trend in stroke risk was seen in the 487 patients prescribed <b style='color:Tomato;'><i>aspirin</i></b> alone in the acute phase, with 12 and 5 strokes in the equivalent time periods. The upper 95% confidence intervals of the observed 0% risk of stroke during the 30 days after stopping <b style='color:Tomato;'><i>clopidogrel</i></b> was 1.15% overall. ### conclusion Although larger studies are required, our findings suggest there is unlikely to be a large rebound effect after discontinuation of a 30-day course of <b style='color:Tomato;'><i>clopidogrel</i></b> in acute TIA and minor ischemic stroke. However, planned trials of <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>clopidogrel</i></b> in the acute phase after TIA or stroke should still follow-up beyond the cessation of <b style='color:Tomato;'><i>clopidogrel</i></b> treatment.","tokens":[{"text":"Early","start":0,"end":5,"id":0,"ws":true},{"text":"discontinuation","start":6,"end":21,"id":1,"ws":true},{"text":"of","start":22,"end":24,"id":2,"ws":true},{"text":"clopidogrel","start":25,"end":36,"id":3,"ws":true},{"text":"results","start":37,"end":44,"id":4,"ws":true},{"text":"in","start":45,"end":47,"id":5,"ws":true},{"text":"a","start":48,"end":49,"id":6,"ws":true},{"text":"transient","start":50,"end":59,"id":7,"ws":true},{"text":"rebound","start":60,"end":67,"id":8,"ws":true},{"text":"increase","start":68,"end":76,"id":9,"ws":true},{"text":"in","start":77,"end":79,"id":10,"ws":true},{"text":"risk","start":80,"end":84,"id":11,"ws":true},{"text":"of","start":85,"end":87,"id":12,"ws":true},{"text":"recurrence","start":88,"end":98,"id":13,"ws":true},{"text":"in","start":99,"end":101,"id":14,"ws":true},{"text":"acute","start":102,"end":107,"id":15,"ws":true},{"text":"coronary","start":108,"end":116,"id":16,"ws":true},{"text":"syndromes","start":117,"end":126,"id":17,"ws":true},{"text":",","start":127,"end":128,"id":18,"ws":true},{"text":"but","start":129,"end":132,"id":19,"ws":true},{"text":"there","start":133,"end":138,"id":20,"ws":true},{"text":"are","start":139,"end":142,"id":21,"ws":true},{"text":"no","start":143,"end":145,"id":22,"ws":true},{"text":"published","start":146,"end":155,"id":23,"ws":true},{"text":"data","start":156,"end":160,"id":24,"ws":true},{"text":"on","start":161,"end":163,"id":25,"ws":true},{"text":"any","start":164,"end":167,"id":26,"ws":true},{"text":"similar","start":168,"end":175,"id":27,"ws":true},{"text":"rebound","start":176,"end":183,"id":28,"ws":true},{"text":"effect","start":184,"end":190,"id":29,"ws":true},{"text":"in","start":191,"end":193,"id":30,"ws":true},{"text":"patients","start":194,"end":202,"id":31,"ws":true},{"text":"with","start":203,"end":207,"id":32,"ws":true},{"text":"TIA","start":208,"end":211,"id":33,"ws":true},{"text":"or","start":212,"end":214,"id":34,"ws":true},{"text":"stroke","start":215,"end":221,"id":35,"ws":true},{"text":"that","start":222,"end":226,"id":36,"ws":true},{"text":"might","start":227,"end":232,"id":37,"ws":true},{"text":"inform","start":233,"end":239,"id":38,"ws":true},{"text":"the","start":240,"end":243,"id":39,"ws":true},{"text":"design","start":244,"end":250,"id":40,"ws":true},{"text":"of","start":251,"end":253,"id":41,"ws":true},{"text":"clinical","start":254,"end":262,"id":42,"ws":true},{"text":"trials","start":263,"end":269,"id":43,"ws":true},{"text":"of","start":270,"end":272,"id":44,"ws":true},{"text":"aspirin","start":273,"end":280,"id":45,"ws":true},{"text":"and","start":281,"end":284,"id":46,"ws":true},{"text":"clopidogrel","start":285,"end":296,"id":47,"ws":true},{"text":"in","start":297,"end":299,"id":48,"ws":true},{"text":"the","start":300,"end":303,"id":49,"ws":true},{"text":"acute","start":304,"end":309,"id":50,"ws":true},{"text":"phase","start":310,"end":315,"id":51,"ws":true},{"text":".","start":316,"end":317,"id":52,"ws":false}],"spans":[{"start":25,"end":36,"token_start":3,"token_end":3,"label":"DRUG"},{"start":273,"end":280,"token_start":45,"token_end":45,"label":"DRUG"},{"start":285,"end":296,"token_start":47,"token_end":47,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20530325/","_input_hash":779656601,"_task_hash":1542041114,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":45,"child":47,"head_span":{"start":273,"end":280,"token_start":45,"token_end":45,"label":"DRUG"},"child_span":{"start":285,"end":296,"token_start":47,"token_end":47,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Patients received docetaxel 35 mg/m(2 ) and irinotecan 60 mg/m(2 ) , intravenously , on Days 1 and 8 , every 21 days , until disease progression .","paragraph":"<h3><u>Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.</u></h3><b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b> have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). The authors sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN. ### methods Eligibility criteria included recurrent or metastatic SCCHN with measurable disease, good performance status, and adequate laboratory parameters. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>intravenously</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>Days</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>21</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>until</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The authors assessed UGT1A1 genotype, vascular endothelial growth factor (VEGF) in serum, and cyclooxygenase-2 and VEGF in baseline tumor tissue. ### results Fifty-two patients were analyzable: 20 chemotherapy naive (Group A) and 32 previously treated with 1 chemotherapy regimen (Group B); 73% of patients had distant metastasis, and 60% were <b style='color:Tomato;'><i>paclitaxel</i></b>-exposed. In Group A, 3 (15%) patients achieved a partial response; in Group B, 1 (3%) patient achieved a partial response. Median progression-free survival (PFS) and overall survival were 3.3 and 8.2 months in Group A and 1.9 and 5.0 months in Group B, respectively. Common serious toxicities were diarrhea, fatigue, and anorexia. Patients with high serum VEGF had a median PFS of 2.8 months versus 1.7 months for patients with low VEGF (P = .085). ### conclusions <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b> had acceptable toxicities, but efficacy results in unselected patients with recurrent or metastatic SCCHN did not suggest an advantage over <b style='color:Tomato;'><i>docetaxel</i></b> alone or platinum-based regimens.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"received","start":9,"end":17,"id":1,"ws":true},{"text":"docetaxel","start":18,"end":27,"id":2,"ws":true},{"text":"35","start":28,"end":30,"id":3,"ws":true},{"text":"mg/m(2","start":31,"end":37,"id":4,"ws":true},{"text":")","start":38,"end":39,"id":5,"ws":true},{"text":"and","start":40,"end":43,"id":6,"ws":true},{"text":"irinotecan","start":44,"end":54,"id":7,"ws":true},{"text":"60","start":55,"end":57,"id":8,"ws":true},{"text":"mg/m(2","start":58,"end":64,"id":9,"ws":true},{"text":")","start":65,"end":66,"id":10,"ws":true},{"text":",","start":67,"end":68,"id":11,"ws":true},{"text":"intravenously","start":69,"end":82,"id":12,"ws":true},{"text":",","start":83,"end":84,"id":13,"ws":true},{"text":"on","start":85,"end":87,"id":14,"ws":true},{"text":"Days","start":88,"end":92,"id":15,"ws":true},{"text":"1","start":93,"end":94,"id":16,"ws":true},{"text":"and","start":95,"end":98,"id":17,"ws":true},{"text":"8","start":99,"end":100,"id":18,"ws":true},{"text":",","start":101,"end":102,"id":19,"ws":true},{"text":"every","start":103,"end":108,"id":20,"ws":true},{"text":"21","start":109,"end":111,"id":21,"ws":true},{"text":"days","start":112,"end":116,"id":22,"ws":true},{"text":",","start":117,"end":118,"id":23,"ws":true},{"text":"until","start":119,"end":124,"id":24,"ws":true},{"text":"disease","start":125,"end":132,"id":25,"ws":true},{"text":"progression","start":133,"end":144,"id":26,"ws":true},{"text":".","start":145,"end":146,"id":27,"ws":false}],"spans":[{"start":18,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},{"start":44,"end":54,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19634157/","_input_hash":-1994564215,"_task_hash":-1898193515,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":2,"child":7,"head_span":{"start":18,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":44,"end":54,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Most patients with advanced ovarian cancer achieve a clinical complete remission following cytoreductive surgery and chemotherapy with paclitaxel plus carboplatin .","paragraph":"<h3><u>Gemcitabine and carboplatin in second-line ovarian cancer.</u></h3> <b style='color:DodgerBlue;'><i>Most</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>remission</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>cytoreductive</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, a majority of these patients will ultimately recur, and second-line treatment for this group of patients is an important aspect of management of this disease as well as an area of active clinical investigation. Until recently, for patients with platinum-sensitive ovarian cancer (more than 6-month disease-free interval), chemotherapy with single-agent <b style='color:Tomato;'><i>carboplatin</i></b> was frequently recommended. However, two recent prospective randomized trials have shown that combination chemotherapy produces higher response rates and improvement in progression-free survival compared with treatment with single-agent <b style='color:Tomato;'><i>carboplatin</i></b>. One trial compared treatment with <b style='color:Tomato;'><i>paclitaxel</i></b> plus a platinum compound with re-treatment with platinum, and a second trial compared <b style='color:Tomato;'><i>carboplatin</i></b> plus <b style='color:Tomato;'><i>gemcitabine</i></b> re-treatment against <b style='color:Tomato;'><i>carboplatin</i></b> in patients with platinum-sensitive recurrent ovarian cancer. Both trials showed a 3-month improvement in progression-free survival in patients treated with the combination, as well as acceptable toxicity. In the absence of a prospective randomized trial comparing these two regimens in patients with platinum-sensitive recurrent ovarian cancer, the choice of which combination to use may depend on toxicity considerations.","tokens":[{"text":"Most","start":0,"end":4,"id":0,"ws":true},{"text":"patients","start":5,"end":13,"id":1,"ws":true},{"text":"with","start":14,"end":18,"id":2,"ws":true},{"text":"advanced","start":19,"end":27,"id":3,"ws":true},{"text":"ovarian","start":28,"end":35,"id":4,"ws":true},{"text":"cancer","start":36,"end":42,"id":5,"ws":true},{"text":"achieve","start":43,"end":50,"id":6,"ws":true},{"text":"a","start":51,"end":52,"id":7,"ws":true},{"text":"clinical","start":53,"end":61,"id":8,"ws":true},{"text":"complete","start":62,"end":70,"id":9,"ws":true},{"text":"remission","start":71,"end":80,"id":10,"ws":true},{"text":"following","start":81,"end":90,"id":11,"ws":true},{"text":"cytoreductive","start":91,"end":104,"id":12,"ws":true},{"text":"surgery","start":105,"end":112,"id":13,"ws":true},{"text":"and","start":113,"end":116,"id":14,"ws":true},{"text":"chemotherapy","start":117,"end":129,"id":15,"ws":true},{"text":"with","start":130,"end":134,"id":16,"ws":true},{"text":"paclitaxel","start":135,"end":145,"id":17,"ws":true},{"text":"plus","start":146,"end":150,"id":18,"ws":true},{"text":"carboplatin","start":151,"end":162,"id":19,"ws":true},{"text":".","start":163,"end":164,"id":20,"ws":false}],"spans":[{"start":135,"end":145,"token_start":17,"token_end":17,"label":"DRUG"},{"start":151,"end":162,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16143161/","_input_hash":-848463825,"_task_hash":1187260872,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":17,"child":19,"head_span":{"start":135,"end":145,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":151,"end":162,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Patients were assigned to receive either oxaliplatin ( 100 mg/m(2 ) ) in the SOX arm or docetaxel ( 40 mg/m(2 ) ) in the mDS arm on day 1 of every 3-week cycle .","paragraph":"<h3><u>Low-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma.</u></h3>Platinum-fluoropyrimidine combinations are the preferred first-line options for advanced gastric cancer (AGC) in East Asia. On the other hand, <b style='color:Tomato;'><i>docetaxel</i></b>-containing regimens without platinum have demonstrated promising activity in AGC. However, dose-related toxicity of <b style='color:Tomato;'><i>docetaxel</i></b> has limited its clinical adoption. This study compared the efficacy and safety of a modified low-dosed <b style='color:Tomato;'><i>docetaxel</i></b> plus S-1 (mDS) with <b style='color:Tomato;'><i>oxaliplatin</i></b> plus S-1 (SOX) in Chinese patients with AGC. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>SOX</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>40</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mDS</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3-week</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>.</i></b> S-1 80-120 mg/day was administered orally on days 1-14 in the 3-week cycle in both groups. One hundred and eighty-eight patients (mDS regimen 101; SOX 87) showed similar overall survival (OS; 13.1 vs 12.8 months, P = 0.878), progression-free survival (PFS; 5.8 vs 5.5 months, P = 0.924), and overall response rate (39.7 vs 44.2%, P = 0.569) in the mDS and SOX arms, respectively. mDS was associated with significantly less grade 3/4 toxicities in thrombocytopenia (5.9 vs 16.1%) and gastrointestinal disturbances (1.0 vs 8.0%). Furthermore, in patients who had ever received <b style='color:Tomato;'><i>oxaliplatin</i></b>-based adjuvant chemotherapy (N = 40), mDS resulted in significantly superior OS (17.8 vs 9.5 months, P = 0.015) and PFS (7.0 vs 4.2 months, P = 0.008) compared with SOX. In conclusion, mDS was as effective as SOX in Chinese patients with AGC, but it resulted in a significantly improved tolerability. In patients who received <b style='color:Tomato;'><i>oxaliplatin</i></b>-based adjuvant chemotherapy before, mDS was associated with improved efficacy in the first-line setting.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"were","start":9,"end":13,"id":1,"ws":true},{"text":"assigned","start":14,"end":22,"id":2,"ws":true},{"text":"to","start":23,"end":25,"id":3,"ws":true},{"text":"receive","start":26,"end":33,"id":4,"ws":true},{"text":"either","start":34,"end":40,"id":5,"ws":true},{"text":"oxaliplatin","start":41,"end":52,"id":6,"ws":true},{"text":"(","start":53,"end":54,"id":7,"ws":true},{"text":"100","start":55,"end":58,"id":8,"ws":true},{"text":"mg/m(2","start":59,"end":65,"id":9,"ws":true},{"text":")","start":66,"end":67,"id":10,"ws":true},{"text":")","start":68,"end":69,"id":11,"ws":true},{"text":"in","start":70,"end":72,"id":12,"ws":true},{"text":"the","start":73,"end":76,"id":13,"ws":true},{"text":"SOX","start":77,"end":80,"id":14,"ws":true},{"text":"arm","start":81,"end":84,"id":15,"ws":true},{"text":"or","start":85,"end":87,"id":16,"ws":true},{"text":"docetaxel","start":88,"end":97,"id":17,"ws":true},{"text":"(","start":98,"end":99,"id":18,"ws":true},{"text":"40","start":100,"end":102,"id":19,"ws":true},{"text":"mg/m(2","start":103,"end":109,"id":20,"ws":true},{"text":")","start":110,"end":111,"id":21,"ws":true},{"text":")","start":112,"end":113,"id":22,"ws":true},{"text":"in","start":114,"end":116,"id":23,"ws":true},{"text":"the","start":117,"end":120,"id":24,"ws":true},{"text":"mDS","start":121,"end":124,"id":25,"ws":true},{"text":"arm","start":125,"end":128,"id":26,"ws":true},{"text":"on","start":129,"end":131,"id":27,"ws":true},{"text":"day","start":132,"end":135,"id":28,"ws":true},{"text":"1","start":136,"end":137,"id":29,"ws":true},{"text":"of","start":138,"end":140,"id":30,"ws":true},{"text":"every","start":141,"end":146,"id":31,"ws":true},{"text":"3-week","start":147,"end":153,"id":32,"ws":true},{"text":"cycle","start":154,"end":159,"id":33,"ws":true},{"text":".","start":160,"end":161,"id":34,"ws":false}],"spans":[{"start":41,"end":52,"token_start":6,"token_end":6,"label":"DRUG"},{"start":88,"end":97,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26268397/","_input_hash":258919544,"_task_hash":389632687,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Agents in clinical trials for subsets of MDS include luspatercept , antibodies targeting CD33 , isocitrate dehydrogenase inhibitors , deacetylase inhibitors , venetoclax , and immunotherapies designed to overcome immune checkpoint inhibition .","paragraph":"<h3><u>Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches.</u></h3>It has been more than 10 years since any new disease-modifying therapies have received regulatory approval for indications related to myelodysplastic syndromes (MDS). Advances in our collective biological understanding of MDS in the last decade, however, have made it possible to hope that effective therapeutics can be designed to improve MDS-associated cytopenias and patients' quality of life, and perhaps even delay clonal progression and extend survival. Classes of MDS-associated mutations and disordered biological pathways targeted by developmental therapeutics include the following: aberrant messenger RNA splicing, neomorphic enzymes in the citric acid cycle with oncogenic activity, overactivated tyrosine and serine-threonine kinases, epigenetic and chromatin remodeling alterations, abnormal telomere dynamics, and failed protection of DNA integrity. At present, treatments for MDS are usually administered as sequential monotherapy, but there is a trend toward clinical trials of combination therapies-in which new agents are added to a DNA hypomethylating agent backbone-for both upfront treatment and the treatment of relapsed/refractory disease. <b style='color:DodgerBlue;'><i>Agents</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>subsets</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>MDS</i></b> <b style='color:DodgerBlue;'><i>include</i></b> <b style='color:MediumOrchid;'><i>luspatercept</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>antibodies</i></b> <b style='color:DodgerBlue;'><i>targeting</i></b> <b style='color:DodgerBlue;'><i>CD33</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>isocitrate</i></b> <b style='color:DodgerBlue;'><i>dehydrogenase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>deacetylase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>venetoclax</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>immunotherapies</i></b> <b style='color:DodgerBlue;'><i>designed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>overcome</i></b> <b style='color:DodgerBlue;'><i>immune</i></b> <b style='color:DodgerBlue;'><i>checkpoint</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These biologically based therapeutics, as well as the encouraging precedent of 7 new approvals by the US Food and Drug Administration in 2017 for the treatment of acute leukemia, offer the prospect that 10 more years will not elapse before another new therapy is approved for MDS.","tokens":[{"text":"Agents","start":0,"end":6,"id":0,"ws":true},{"text":"in","start":7,"end":9,"id":1,"ws":true},{"text":"clinical","start":10,"end":18,"id":2,"ws":true},{"text":"trials","start":19,"end":25,"id":3,"ws":true},{"text":"for","start":26,"end":29,"id":4,"ws":true},{"text":"subsets","start":30,"end":37,"id":5,"ws":true},{"text":"of","start":38,"end":40,"id":6,"ws":true},{"text":"MDS","start":41,"end":44,"id":7,"ws":true},{"text":"include","start":45,"end":52,"id":8,"ws":true},{"text":"luspatercept","start":53,"end":65,"id":9,"ws":true},{"text":",","start":66,"end":67,"id":10,"ws":true},{"text":"antibodies","start":68,"end":78,"id":11,"ws":true},{"text":"targeting","start":79,"end":88,"id":12,"ws":true},{"text":"CD33","start":89,"end":93,"id":13,"ws":true},{"text":",","start":94,"end":95,"id":14,"ws":true},{"text":"isocitrate","start":96,"end":106,"id":15,"ws":true},{"text":"dehydrogenase","start":107,"end":120,"id":16,"ws":true},{"text":"inhibitors","start":121,"end":131,"id":17,"ws":true},{"text":",","start":132,"end":133,"id":18,"ws":true},{"text":"deacetylase","start":134,"end":145,"id":19,"ws":true},{"text":"inhibitors","start":146,"end":156,"id":20,"ws":true},{"text":",","start":157,"end":158,"id":21,"ws":true},{"text":"venetoclax","start":159,"end":169,"id":22,"ws":true},{"text":",","start":170,"end":171,"id":23,"ws":true},{"text":"and","start":172,"end":175,"id":24,"ws":true},{"text":"immunotherapies","start":176,"end":191,"id":25,"ws":true},{"text":"designed","start":192,"end":200,"id":26,"ws":true},{"text":"to","start":201,"end":203,"id":27,"ws":true},{"text":"overcome","start":204,"end":212,"id":28,"ws":true},{"text":"immune","start":213,"end":219,"id":29,"ws":true},{"text":"checkpoint","start":220,"end":230,"id":30,"ws":true},{"text":"inhibition","start":231,"end":241,"id":31,"ws":true},{"text":".","start":242,"end":243,"id":32,"ws":false}],"spans":[{"start":53,"end":65,"token_start":9,"token_end":9,"label":"DRUG"},{"start":159,"end":169,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29741506/","_input_hash":85053744,"_task_hash":1768436942,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":9,"child":22,"head_span":{"start":53,"end":65,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":159,"end":169,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Possible differences between enalapril and captopril .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Possible</i></b> <b style='color:DodgerBlue;'><i>differences</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:MediumOrchid;'><i>enalapril</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>captopril</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Inhibitors of angiotensin converting enzyme block the conversion of angiotensin I to angiotensin II, the active hormone of the renin-angiotensin system. This inhibition leads to a reduction in angiotensin-mediated vasoconstriction and aldosterone production. Although converting enzyme inhibitors have other potential metabolic effects, their beneficial effects in hypertension and congestive heart failure appear to be, in large part, related to their ability to reduce angiotensin II. This causes an increase in plasma renin levels and a fall in plasma and urine aldosterone, which can be sustained for many years. As a consequence, converting enzyme inhibitors produce mild natriuresis and positive potassium balance. At conventionally used doses, <b style='color:Tomato;'><i>enalapril</i></b> more completely prevents posture-induced increases in aldosterone than does <b style='color:Tomato;'><i>captopril</i></b>, probably reflecting more complete inhibition of angiotensin II formation in vivo.","tokens":[{"text":"Possible","start":0,"end":8,"id":0,"ws":true},{"text":"differences","start":9,"end":20,"id":1,"ws":true},{"text":"between","start":21,"end":28,"id":2,"ws":true},{"text":"enalapril","start":29,"end":38,"id":3,"ws":true},{"text":"and","start":39,"end":42,"id":4,"ws":true},{"text":"captopril","start":43,"end":52,"id":5,"ws":true},{"text":".","start":53,"end":54,"id":6,"ws":false}],"spans":[{"start":29,"end":38,"token_start":3,"token_end":3,"label":"DRUG"},{"start":43,"end":52,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6089554/","_input_hash":-1441819874,"_task_hash":198220139,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Exposure of the saphenous veins to imipenem or imipenem combined with amphotericin B had no adverse effects on the viability of the endothelial cells with 12 h exposure .","paragraph":"<h3><u>Effects of antibiotics on the endothelium of fresh and cryopreserved canine saphenous veins.</u></h3>To determine if antibiotic solutions for potential use in antimicrobial treatment of tissues were detrimental to cell viability, canine saphenous veins were exposed to three different antibiotic solutions at 37 degrees C for 12 h. Viability was determined by tissue culture, utilizing a limiting dilution assay. The antibiotic series included two formulations currently used for the preservation of heart valves and a new formulation containing <b style='color:Tomato;'><i>imipenem</i></b>, a broad spectrum beta-lactam. Currently used antibiotic regimes and <b style='color:Tomato;'><i>imipenem</i></b> with <b style='color:Tomato;'><i>gentamicin</i></b> resulted in a decrease of 30 to 50% of the viable endothelial cells within 12 h. <b style='color:DodgerBlue;'><i>Exposure</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>saphenous</i></b> <b style='color:DodgerBlue;'><i>veins</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>imipenem</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>imipenem</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>adverse</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>viability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>endothelial</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>exposure</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, veins exposed to <b style='color:Tomato;'><i>amphotericin</i></b> B were more susceptible to subsequent damage during freezing and thawing than veins frozen after incubation with either <b style='color:Tomato;'><i>imipenem</i></b> alone or <b style='color:Tomato;'><i>imipenem</i></b> combined with <b style='color:Tomato;'><i>flucytosine</i></b>. These studies indicate that <b style='color:Tomato;'><i>imipenem</i></b> combined with <b style='color:Tomato;'><i>flucytosine</i></b> is suitable for use with vein grafts.","tokens":[{"text":"Exposure","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"saphenous","start":16,"end":25,"id":3,"ws":true},{"text":"veins","start":26,"end":31,"id":4,"ws":true},{"text":"to","start":32,"end":34,"id":5,"ws":true},{"text":"imipenem","start":35,"end":43,"id":6,"ws":true},{"text":"or","start":44,"end":46,"id":7,"ws":true},{"text":"imipenem","start":47,"end":55,"id":8,"ws":true},{"text":"combined","start":56,"end":64,"id":9,"ws":true},{"text":"with","start":65,"end":69,"id":10,"ws":true},{"text":"amphotericin","start":70,"end":82,"id":11,"ws":true},{"text":"B","start":83,"end":84,"id":12,"ws":true},{"text":"had","start":85,"end":88,"id":13,"ws":true},{"text":"no","start":89,"end":91,"id":14,"ws":true},{"text":"adverse","start":92,"end":99,"id":15,"ws":true},{"text":"effects","start":100,"end":107,"id":16,"ws":true},{"text":"on","start":108,"end":110,"id":17,"ws":true},{"text":"the","start":111,"end":114,"id":18,"ws":true},{"text":"viability","start":115,"end":124,"id":19,"ws":true},{"text":"of","start":125,"end":127,"id":20,"ws":true},{"text":"the","start":128,"end":131,"id":21,"ws":true},{"text":"endothelial","start":132,"end":143,"id":22,"ws":true},{"text":"cells","start":144,"end":149,"id":23,"ws":true},{"text":"with","start":150,"end":154,"id":24,"ws":true},{"text":"12","start":155,"end":157,"id":25,"ws":true},{"text":"h","start":158,"end":159,"id":26,"ws":true},{"text":"exposure","start":160,"end":168,"id":27,"ws":true},{"text":".","start":169,"end":170,"id":28,"ws":false}],"spans":[{"start":35,"end":43,"token_start":6,"token_end":6,"label":"DRUG"},{"start":47,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},{"start":70,"end":82,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8319486/","_input_hash":-1861796111,"_task_hash":1320881043,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":8,"child":11,"head_span":{"start":47,"end":55,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":70,"end":82,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"First-line chemotherapy was either R-CHOP ( rituximab , cyclophosphamide , doxorubicin , vincristine and prednisolone ) or CHOP-like-based regimen .","paragraph":"<h3><u>[Primary testicular non-Hodgkin's lymphoma: clinical analysis of 21 cases].</u></h3>To explore the clinical characteristics and prognosis of patients with primary testicular non-Hodgkin's lymphoma. ### methods The clinical profiles and prognostic factors of 21 cases newly diagnosed as primary testicular non-Hodgkin's lymphoma at Peking University Cancer Hospital from January 2005 to December 2012 were retrospectively analyzed. ### results Their median age was 59 (34-86) years. And they were classified as Ann Arbor stage I (n = 8), stage II (n = 2) and stage IV (n = 11). There were B symptoms (n = 4), extranodal involvement outside testis (n = 12) and elevated lactate dehydrogenase (LDH) at diagnosis (n = 6). The scores of international prognostic index (IPI) were 0-1 point (n = 10), 3 points (n = 10) and 4 points (n = 1). The regimens included orchidectomy as the initial treatment (n = 15), chemotherapy followed by radiotherapy (n = 7) and CNS prophylaxis during treatment (n = 15). All patients were pathologically diagnosed as diffuse large B-cell lymphoma. And 11 cases belonged to the non-germinal center B cell-like subgroup. <b style='color:DodgerBlue;'><i>First-line</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>R-CHOP</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisolone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>CHOP-like-based</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Complete response was achieved in 85.7% of patients. The median follow-up period was 18 (6-58) months. The 1, 2 and 3-year survival rates were 100%, 80% and 60% respectively. Statistical analysis showed that the first-line chemotherapy with <b style='color:Tomato;'><i>rituximab</i></b> was a prognostic factor (P = 0.038).Other factors included stage (P = 0.275), LDH level (P = 0.179) , \u03b22-microglobulin level (P = 0.229) and IPI (P = 0.275) . ### conclusions The prognosis of primary testicular non-Hodgkin's lymphoma is usually poor. The first-line chemotherapy with <b style='color:Tomato;'><i>rituximab</i></b> is a prognostic factor.","tokens":[{"text":"First-line","start":0,"end":10,"id":0,"ws":true},{"text":"chemotherapy","start":11,"end":23,"id":1,"ws":true},{"text":"was","start":24,"end":27,"id":2,"ws":true},{"text":"either","start":28,"end":34,"id":3,"ws":true},{"text":"R-CHOP","start":35,"end":41,"id":4,"ws":true},{"text":"(","start":42,"end":43,"id":5,"ws":true},{"text":"rituximab","start":44,"end":53,"id":6,"ws":true},{"text":",","start":54,"end":55,"id":7,"ws":true},{"text":"cyclophosphamide","start":56,"end":72,"id":8,"ws":true},{"text":",","start":73,"end":74,"id":9,"ws":true},{"text":"doxorubicin","start":75,"end":86,"id":10,"ws":true},{"text":",","start":87,"end":88,"id":11,"ws":true},{"text":"vincristine","start":89,"end":100,"id":12,"ws":true},{"text":"and","start":101,"end":104,"id":13,"ws":true},{"text":"prednisolone","start":105,"end":117,"id":14,"ws":true},{"text":")","start":118,"end":119,"id":15,"ws":true},{"text":"or","start":120,"end":122,"id":16,"ws":true},{"text":"CHOP-like-based","start":123,"end":138,"id":17,"ws":true},{"text":"regimen","start":139,"end":146,"id":18,"ws":true},{"text":".","start":147,"end":148,"id":19,"ws":false}],"spans":[{"start":44,"end":53,"token_start":6,"token_end":6,"label":"DRUG"},{"start":56,"end":72,"token_start":8,"token_end":8,"label":"DRUG"},{"start":75,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},{"start":89,"end":100,"token_start":12,"token_end":12,"label":"DRUG"},{"start":105,"end":117,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24169330/","_input_hash":1227589076,"_task_hash":-754511544,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":44,"end":53,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":56,"end":72,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":10,"child":8,"head_span":{"start":75,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":56,"end":72,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":6,"child":12,"head_span":{"start":44,"end":53,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":89,"end":100,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":6,"child":14,"head_span":{"start":44,"end":53,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":105,"end":117,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The combination of rituximab with vincristine and 5-day cyclophosphamide is able to produce CR in patients with advanced follicular lymphoma , even in patients resistant to third-generation regimens .","paragraph":"<h3><u>Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma.</u></h3>Therapeutic options for relapsed or refractory follicular lymphoma include combination chemotherapy, immunotherapy and, for selected patients, autotransplant. Because of the different mechanisms of action and non-overlapping toxicities, combination of <b style='color:Tomato;'><i>rituximab</i></b> with chemotherapy is a rational approach. ### methods 30 patients with follicular non-Hodgkin's lymphoma with advanced-stage disease were treated with four cycles of immunochemotherapy with <b style='color:Tomato;'><i>rituximab</i></b> 375 mg/m2 on day 1, <b style='color:Tomato;'><i>vincristine</i></b> 2 mg i.v. on day 2 and <b style='color:Tomato;'><i>cyclophosphamide</i></b> 400 mg/m2 i.v. from days 2 to 6, repeated at 3-week intervals. All patients had received multiple lines of therapy (median 3); 9 (30%) had relapses (2 after high-dose therapy with autologous transplant), and 21 (70%) were in relapse and refractory to salvage treatment (with an anthracycline-containing regimen in 19). ### results Of 29 patients evaluable for response, 16 (55 %) obtained a complete response (CR) and 3 (10%) a partial response (PR), with an overall response rate of 65% (19/29); 10 patients (35%) achieved less than PR. The median event-free survival was 16.1 months for all patients, being 22.8 months for responders. After a median follow-up of 2 years from the start of therapy (range 6 months to 3.8 years), of 16 patients who achieved CR, 10 remain free of disease. ### conclusion <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>5-day</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>able</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>CR</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>follicular</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>even</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>third-generation</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The regimen designed on the basis of pharmacokinetics of the chimeric antibody seemed important for the clinical efficacy of the combination.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"combination","start":4,"end":15,"id":1,"ws":true},{"text":"of","start":16,"end":18,"id":2,"ws":true},{"text":"rituximab","start":19,"end":28,"id":3,"ws":true},{"text":"with","start":29,"end":33,"id":4,"ws":true},{"text":"vincristine","start":34,"end":45,"id":5,"ws":true},{"text":"and","start":46,"end":49,"id":6,"ws":true},{"text":"5-day","start":50,"end":55,"id":7,"ws":true},{"text":"cyclophosphamide","start":56,"end":72,"id":8,"ws":true},{"text":"is","start":73,"end":75,"id":9,"ws":true},{"text":"able","start":76,"end":80,"id":10,"ws":true},{"text":"to","start":81,"end":83,"id":11,"ws":true},{"text":"produce","start":84,"end":91,"id":12,"ws":true},{"text":"CR","start":92,"end":94,"id":13,"ws":true},{"text":"in","start":95,"end":97,"id":14,"ws":true},{"text":"patients","start":98,"end":106,"id":15,"ws":true},{"text":"with","start":107,"end":111,"id":16,"ws":true},{"text":"advanced","start":112,"end":120,"id":17,"ws":true},{"text":"follicular","start":121,"end":131,"id":18,"ws":true},{"text":"lymphoma","start":132,"end":140,"id":19,"ws":true},{"text":",","start":141,"end":142,"id":20,"ws":true},{"text":"even","start":143,"end":147,"id":21,"ws":true},{"text":"in","start":148,"end":150,"id":22,"ws":true},{"text":"patients","start":151,"end":159,"id":23,"ws":true},{"text":"resistant","start":160,"end":169,"id":24,"ws":true},{"text":"to","start":170,"end":172,"id":25,"ws":true},{"text":"third-generation","start":173,"end":189,"id":26,"ws":true},{"text":"regimens","start":190,"end":198,"id":27,"ws":true},{"text":".","start":199,"end":200,"id":28,"ws":false}],"spans":[{"start":19,"end":28,"token_start":3,"token_end":3,"label":"DRUG"},{"start":34,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},{"start":56,"end":72,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16006752/","_input_hash":-1125996466,"_task_hash":-1111940363,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":19,"end":28,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":34,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":8,"head_span":{"start":34,"end":45,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":56,"end":72,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The results showed that lamotrigine did not produce any change in cognitive function , while carbamazepine produced cognitive dysfunction .","paragraph":"<h3><u>Effect of carbamazepine and lamotrigine on cognitive function and oxidative stress in brain during chemical epileptogenesis in rats.</u></h3>The present study assessed the effect of <b style='color:Tomato;'><i>carbamazepine</i></b> and <b style='color:Tomato;'><i>lamotrigine</i></b> on cognitive function and oxidative stress in brain during chemically induced epileptogenesis in rats. Epileptogenesis was induced by administration of pentylenetetrazole (30 mg/kg, s.c.) on alternate days (three times/week) for 9-11 weeks or until stage 4 of seizure score was achieved. The neurobehavioural parameters used for cognitive assessment were step-down latency in continuous avoidance apparatus and transfer latency in elevated plus maze test paradigm. <b style='color:Tomato;'><i>carbamazepine</i></b> and <b style='color:Tomato;'><i>lamotrigine</i></b> were administered intraperitoneally in doses of 60 mg/kg and 25 mg/kg, respectively, according to the groups, once a day for 11 weeks. Oxidative stress was assessed in isolated homogenized whole brain samples and estimated for the levels of malondialdehyde, reduced glutathione, catalase and superoxide dismutase. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>lamotrigine</i></b> <b style='color:DodgerBlue;'><i>did</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>any</i></b> <b style='color:DodgerBlue;'><i>change</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cognitive</i></b> <b style='color:DodgerBlue;'><i>function</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>while</i></b> <b style='color:MediumOrchid;'><i>carbamazepine</i></b> <b style='color:DodgerBlue;'><i>produced</i></b> <b style='color:DodgerBlue;'><i>cognitive</i></b> <b style='color:DodgerBlue;'><i>dysfunction</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Cognitive decline seen in the <b style='color:Tomato;'><i>carbamazepine</i></b>-treated pentylenetetrazole-kindled group was also associated with increased oxidative stress. <b style='color:Tomato;'><i>lamotrigine</i></b> treatment had no effect on oxidative stress parameters alone, while it significantly decreased oxidative stress in the pentylenetetrazole-kindled group as compared to the pentylenetetrazole-kindled <b style='color:Tomato;'><i>carbamazepine</i></b>-treated group.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"results","start":4,"end":11,"id":1,"ws":true},{"text":"showed","start":12,"end":18,"id":2,"ws":true},{"text":"that","start":19,"end":23,"id":3,"ws":true},{"text":"lamotrigine","start":24,"end":35,"id":4,"ws":true},{"text":"did","start":36,"end":39,"id":5,"ws":true},{"text":"not","start":40,"end":43,"id":6,"ws":true},{"text":"produce","start":44,"end":51,"id":7,"ws":true},{"text":"any","start":52,"end":55,"id":8,"ws":true},{"text":"change","start":56,"end":62,"id":9,"ws":true},{"text":"in","start":63,"end":65,"id":10,"ws":true},{"text":"cognitive","start":66,"end":75,"id":11,"ws":true},{"text":"function","start":76,"end":84,"id":12,"ws":true},{"text":",","start":85,"end":86,"id":13,"ws":true},{"text":"while","start":87,"end":92,"id":14,"ws":true},{"text":"carbamazepine","start":93,"end":106,"id":15,"ws":true},{"text":"produced","start":107,"end":115,"id":16,"ws":true},{"text":"cognitive","start":116,"end":125,"id":17,"ws":true},{"text":"dysfunction","start":126,"end":137,"id":18,"ws":true},{"text":".","start":138,"end":139,"id":19,"ws":false}],"spans":[{"start":24,"end":35,"token_start":4,"token_end":4,"label":"DRUG"},{"start":93,"end":106,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20002063/","_input_hash":1266528498,"_task_hash":-276814944,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"These results confirm that sequential decitabine and carboplatin requires further investigation as a combination treatment for melanoma .","paragraph":"<h3><u>Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.</u></h3>Melanoma has two key features, an over-representation of UV-induced mutations and resistance to DNA damaging chemotherapy agents. Both of these features may result from dysfunction of the nucleotide excision repair pathway, in particular the DNA damage detection branch, global genome repair (GGR). The key GGR component XPC does not respond to DNA damage in melanoma, the cause of this lack of response has not been investigated. In this study, we investigated the role of methylation in reduced XPC in melanoma. ### methods To reduce methylation and induce DNA-damage, melanoma cell lines were treated with <b style='color:Tomato;'><i>decitabine</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b>, individually and sequentially. Global DNA methylation levels, XPC mRNA and protein expression and methylation of the XPC promoter were examined. Apoptosis, cell proliferation and senescence were also quantified. XPC siRNA was used to determine that the responses seen were reliant on XPC induction. ### results Treatment with high-dose <b style='color:Tomato;'><i>decitabine</i></b> resulted in global demethylation, including the the shores of the XPC CpG island and significantly increased XPC mRNA expression. Lower, clinically relevant dose of <b style='color:Tomato;'><i>decitabine</i></b> also resulted in global demethylation including the CpG island shores and induced XPC in 50% of cell lines. <b style='color:Tomato;'><i>decitabine</i></b> followed by DNA-damaging <b style='color:Tomato;'><i>carboplatin</i></b> treatment led to significantly higher XPC expression in 75% of melanoma cell lines tested. Combined sequential treatment also resulted in a greater apoptotic response in 75% of cell lines compared to <b style='color:Tomato;'><i>carboplatin</i></b> alone, and significantly slowed cell proliferation, with some melanoma cell lines going into senescence. Inhibiting the increased XPC using siRNA had a small but significant negative effect, indicating that XPC plays a partial role in the response to sequential <b style='color:Tomato;'><i>decitabine</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b>. ### conclusions Demethylation using <b style='color:Tomato;'><i>decitabine</i></b> increased XPC and apoptosis after sequential <b style='color:Tomato;'><i>carboplatin</i></b>. <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>confirm</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:MediumOrchid;'><i>decitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>requires</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>investigation</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"results","start":6,"end":13,"id":1,"ws":true},{"text":"confirm","start":14,"end":21,"id":2,"ws":true},{"text":"that","start":22,"end":26,"id":3,"ws":true},{"text":"sequential","start":27,"end":37,"id":4,"ws":true},{"text":"decitabine","start":38,"end":48,"id":5,"ws":true},{"text":"and","start":49,"end":52,"id":6,"ws":true},{"text":"carboplatin","start":53,"end":64,"id":7,"ws":true},{"text":"requires","start":65,"end":73,"id":8,"ws":true},{"text":"further","start":74,"end":81,"id":9,"ws":true},{"text":"investigation","start":82,"end":95,"id":10,"ws":true},{"text":"as","start":96,"end":98,"id":11,"ws":true},{"text":"a","start":99,"end":100,"id":12,"ws":true},{"text":"combination","start":101,"end":112,"id":13,"ws":true},{"text":"treatment","start":113,"end":122,"id":14,"ws":true},{"text":"for","start":123,"end":126,"id":15,"ws":true},{"text":"melanoma","start":127,"end":135,"id":16,"ws":true},{"text":".","start":136,"end":137,"id":17,"ws":false}],"spans":[{"start":38,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},{"start":53,"end":64,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29373959/","_input_hash":329451074,"_task_hash":947957786,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":5,"child":7,"head_span":{"start":38,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":53,"end":64,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"[ Rhabdomyosarcoma of the urinary bladder : complete remission induced by vinblastine , cis-platinum , and bleomycin ] .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>Rhabdomyosarcoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>urinary</i></b> <b style='color:DodgerBlue;'><i>bladder</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>remission</i></b> <b style='color:DodgerBlue;'><i>induced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>cis-platinum</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bleomycin</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Combination therapy consisting of <b style='color:Tomato;'><i>vincristine</i></b>, actinomycin-D, and <b style='color:Tomato;'><i>cyclophosphamide</i></b> with or without adriamycin is the most common chemotherapy for rhabdomyosarcoma in childhood. But the effective chemotherapy for rhabdomyosarcoma resistant to these four drugs has not been established. We report a case with rhabdomyosarcoma, which was resistant to these four drugs but responded completely to three drug combination chemotherapy consisting of <b style='color:Tomato;'><i>vinblastine</i></b>, cis-platinum, and <b style='color:Tomato;'><i>bleomycin</i></b> (VPB therapy). A 11-months-old boy was referred to us because of giant abdominal tumor. Postoperative diagnosis was Group III embryonal rhabdomyosarcoma of the urinary bladder. Partial resection was followed by <b style='color:Tomato;'><i>vincristine</i></b>, actinomycin-D, <b style='color:Tomato;'><i>cyclophosphamide</i></b>, and adriamycin, but his residual tumor was growing. Then VPB therapy was administered and the first course of the chemotherapy reduced the size of tumor. After three courses of VPB therapy the second-look operation was performed. At operation no residual tumor was found and a complete remission was confirmed. During the course of VPB therapy no severe adverse effect was detectable.","tokens":[{"text":"[","start":0,"end":1,"id":0,"ws":true},{"text":"Rhabdomyosarcoma","start":2,"end":18,"id":1,"ws":true},{"text":"of","start":19,"end":21,"id":2,"ws":true},{"text":"the","start":22,"end":25,"id":3,"ws":true},{"text":"urinary","start":26,"end":33,"id":4,"ws":true},{"text":"bladder","start":34,"end":41,"id":5,"ws":true},{"text":":","start":42,"end":43,"id":6,"ws":true},{"text":"complete","start":44,"end":52,"id":7,"ws":true},{"text":"remission","start":53,"end":62,"id":8,"ws":true},{"text":"induced","start":63,"end":70,"id":9,"ws":true},{"text":"by","start":71,"end":73,"id":10,"ws":true},{"text":"vinblastine","start":74,"end":85,"id":11,"ws":true},{"text":",","start":86,"end":87,"id":12,"ws":true},{"text":"cis-platinum","start":88,"end":100,"id":13,"ws":true},{"text":",","start":101,"end":102,"id":14,"ws":true},{"text":"and","start":103,"end":106,"id":15,"ws":true},{"text":"bleomycin","start":107,"end":116,"id":16,"ws":true},{"text":"]","start":117,"end":118,"id":17,"ws":true},{"text":".","start":119,"end":120,"id":18,"ws":false}],"spans":[{"start":74,"end":85,"token_start":11,"token_end":11,"label":"DRUG"},{"start":88,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},{"start":107,"end":116,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6191695/","_input_hash":1763146291,"_task_hash":228955403,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":11,"child":13,"head_span":{"start":74,"end":85,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":88,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":16,"child":13,"head_span":{"start":107,"end":116,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":88,"end":100,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Recent comparative studies suggest that atenolol ( 200 mg daily ) , metoprolol ( 200 mg daily ) ; acebutolol ( 400 mg daily ) , oxprenolol ( 160 mg daily ) , nadolol ( 80 mg daily ) and timolol ( 20 mg daily ) produce a beneficial clinical response equal to that seen with propranolol ( 160 mg daily ) .","paragraph":"<h3><u>Use of beta-adrenoceptor blocking drugs in hyperthyroidism.</u></h3>There is an increasing use and variety of beta-adrenoceptor blocking agents (beta-blockers) available for the treatment of hyperthyroidism. <b style='color:DodgerBlue;'><i>Recent</i></b> <b style='color:DodgerBlue;'><i>comparative</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:MediumOrchid;'><i>atenolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>metoprolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>200</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:MediumOrchid;'><i>acebutolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>400</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>oxprenolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>160</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>nadolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>80</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>timolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>produce</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>beneficial</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>equal</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>seen</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>propranolol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>160</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>daily</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Most beta-blockers reduce resting heart rate by approximately 25 to 30 beats/min, although a lesser reduction is seen with those possessing intrinsic sympathomimetic activity such as <b style='color:Tomato;'><i>oxprenolol</i></b> and <b style='color:Tomato;'><i>pindolol</i></b>. While earlier studies employing large doses of intravenous <b style='color:Tomato;'><i>propranolol</i></b> concluded that beta-blockade reduced myocardial contractility, more recent non-invasive studies suggest that the predominant cardiac effect is on heart rate. In patients with cardiac failure, beta-blockers may, however, produce a profound fall in cardiac output. Nevertheless, in combination with <b style='color:Tomato;'><i>digoxin</i></b> they may be useful in controlling the atrial fibrillation of thyrocardiac disease. beta-Blockers improve nervousness and tremor (although to a lesser extent with cardioselective agents) and severe myopathy, and they also reduce the frequency of paralysis in patients with thyrotoxic periodic paralysis. There is often subjective improvement in sweating but usually no major effect on eye signs. Recent studies show a 10% reduction in oxygen consumption/basal metabolic rate with long term oral use of selective or nonselective beta-blockers. In addition, many agents (<b style='color:Tomato;'><i>propranolol</i></b>, <b style='color:Tomato;'><i>metoprolol</i></b>, <b style='color:Tomato;'><i>nadolol</i></b> and <b style='color:Tomato;'><i>sotalol</i></b> but not <b style='color:Tomato;'><i>acebutolol</i></b>, <b style='color:Tomato;'><i>atenolol</i></b> or <b style='color:Tomato;'><i>oxprenolol</i></b>) reduce circulating tri-iodothyronine (T3) concentration by between 10 and 40%, although the clinical significance of this effect (if any) is not established. beta-Blockers may also have endocrinological effects on gastrin, cyclic AMP, catecholamines and other hormone levels. Given in adequate dosage, <b style='color:Tomato;'><i>propranolol</i></b> has been shown to control thyrotoxic hypercalcaemia. Minor side effects (nausea, headaches, tiredness, etc.) are quite common but overall beta-blockers are well tolerated by the thyrotoxic patient. The major use of these drugs is in symptomatic control while awaiting definitive diagnosis or treatment. As an adjunct to antithyroid drugs or radioactive iodine, beta-blockers will produce a satisfactory clinical response in the weeks to months before these forms of therapy produce a euthyroid state. beta-Blockers are more convenient than antithyroid drugs in the control of patients receiving therapeutic radioiodine, in that continuous therapy and assessment of biochemical response is possible.(ABSTRACT TRUNCATED AT 400 WORDS)","tokens":[{"text":"Recent","start":0,"end":6,"id":0,"ws":true},{"text":"comparative","start":7,"end":18,"id":1,"ws":true},{"text":"studies","start":19,"end":26,"id":2,"ws":true},{"text":"suggest","start":27,"end":34,"id":3,"ws":true},{"text":"that","start":35,"end":39,"id":4,"ws":true},{"text":"atenolol","start":40,"end":48,"id":5,"ws":true},{"text":"(","start":49,"end":50,"id":6,"ws":true},{"text":"200","start":51,"end":54,"id":7,"ws":true},{"text":"mg","start":55,"end":57,"id":8,"ws":true},{"text":"daily","start":58,"end":63,"id":9,"ws":true},{"text":")","start":64,"end":65,"id":10,"ws":true},{"text":",","start":66,"end":67,"id":11,"ws":true},{"text":"metoprolol","start":68,"end":78,"id":12,"ws":true},{"text":"(","start":79,"end":80,"id":13,"ws":true},{"text":"200","start":81,"end":84,"id":14,"ws":true},{"text":"mg","start":85,"end":87,"id":15,"ws":true},{"text":"daily","start":88,"end":93,"id":16,"ws":true},{"text":")","start":94,"end":95,"id":17,"ws":true},{"text":";","start":96,"end":97,"id":18,"ws":true},{"text":"acebutolol","start":98,"end":108,"id":19,"ws":true},{"text":"(","start":109,"end":110,"id":20,"ws":true},{"text":"400","start":111,"end":114,"id":21,"ws":true},{"text":"mg","start":115,"end":117,"id":22,"ws":true},{"text":"daily","start":118,"end":123,"id":23,"ws":true},{"text":")","start":124,"end":125,"id":24,"ws":true},{"text":",","start":126,"end":127,"id":25,"ws":true},{"text":"oxprenolol","start":128,"end":138,"id":26,"ws":true},{"text":"(","start":139,"end":140,"id":27,"ws":true},{"text":"160","start":141,"end":144,"id":28,"ws":true},{"text":"mg","start":145,"end":147,"id":29,"ws":true},{"text":"daily","start":148,"end":153,"id":30,"ws":true},{"text":")","start":154,"end":155,"id":31,"ws":true},{"text":",","start":156,"end":157,"id":32,"ws":true},{"text":"nadolol","start":158,"end":165,"id":33,"ws":true},{"text":"(","start":166,"end":167,"id":34,"ws":true},{"text":"80","start":168,"end":170,"id":35,"ws":true},{"text":"mg","start":171,"end":173,"id":36,"ws":true},{"text":"daily","start":174,"end":179,"id":37,"ws":true},{"text":")","start":180,"end":181,"id":38,"ws":true},{"text":"and","start":182,"end":185,"id":39,"ws":true},{"text":"timolol","start":186,"end":193,"id":40,"ws":true},{"text":"(","start":194,"end":195,"id":41,"ws":true},{"text":"20","start":196,"end":198,"id":42,"ws":true},{"text":"mg","start":199,"end":201,"id":43,"ws":true},{"text":"daily","start":202,"end":207,"id":44,"ws":true},{"text":")","start":208,"end":209,"id":45,"ws":true},{"text":"produce","start":210,"end":217,"id":46,"ws":true},{"text":"a","start":218,"end":219,"id":47,"ws":true},{"text":"beneficial","start":220,"end":230,"id":48,"ws":true},{"text":"clinical","start":231,"end":239,"id":49,"ws":true},{"text":"response","start":240,"end":248,"id":50,"ws":true},{"text":"equal","start":249,"end":254,"id":51,"ws":true},{"text":"to","start":255,"end":257,"id":52,"ws":true},{"text":"that","start":258,"end":262,"id":53,"ws":true},{"text":"seen","start":263,"end":267,"id":54,"ws":true},{"text":"with","start":268,"end":272,"id":55,"ws":true},{"text":"propranolol","start":273,"end":284,"id":56,"ws":true},{"text":"(","start":285,"end":286,"id":57,"ws":true},{"text":"160","start":287,"end":290,"id":58,"ws":true},{"text":"mg","start":291,"end":293,"id":59,"ws":true},{"text":"daily","start":294,"end":299,"id":60,"ws":true},{"text":")","start":300,"end":301,"id":61,"ws":true},{"text":".","start":302,"end":303,"id":62,"ws":false}],"spans":[{"start":40,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},{"start":68,"end":78,"token_start":12,"token_end":12,"label":"DRUG"},{"start":98,"end":108,"token_start":19,"token_end":19,"label":"DRUG"},{"start":128,"end":138,"token_start":26,"token_end":26,"label":"DRUG"},{"start":158,"end":165,"token_start":33,"token_end":33,"label":"DRUG"},{"start":186,"end":193,"token_start":40,"token_end":40,"label":"DRUG"},{"start":273,"end":284,"token_start":56,"token_end":56,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6144501/","_input_hash":990193972,"_task_hash":-9132630,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":5,"child":12,"head_span":{"start":40,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":68,"end":78,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":19,"child":12,"head_span":{"start":98,"end":108,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":68,"end":78,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":26,"child":19,"head_span":{"start":128,"end":138,"token_start":26,"token_end":26,"label":"DRUG"},"child_span":{"start":98,"end":108,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":33,"child":40,"head_span":{"start":158,"end":165,"token_start":33,"token_end":33,"label":"DRUG"},"child_span":{"start":186,"end":193,"token_start":40,"token_end":40,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":19,"child":33,"head_span":{"start":98,"end":108,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":158,"end":165,"token_start":33,"token_end":33,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"All the animals in the placebo group had tumors in each lobe compared with only 43 % each in the dorsolateral ( DLP ) and anterior prostate ( AP ) of the animals treated with raloxifene ( 10 mg/kg/day ) plus nimesulide .","paragraph":"<h3><u>Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.</u></h3>The chemopreventive efficacies of <b style='color:Tomato;'><i>raloxifene</i></b> and <b style='color:Tomato;'><i>nimesulide</i></b>, an anti-estrogen but with anti-androgen action and a cyclooxygenase-2 (COX-2) selective inhibitor, respectively, were evaluated in probasin/SV40 T antigen (Tag) transgenic (TG) rats. The treatment groups were placebo, <b style='color:Tomato;'><i>nimesulide</i></b> (400 p.p.m. in basal diet p.o.), <b style='color:Tomato;'><i>raloxifene</i></b> (slow-release pellets implanted s.c., 5 mg/kg/day), <b style='color:Tomato;'><i>raloxifene</i></b> (5 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> (400 p.p.m.), and <b style='color:Tomato;'><i>raloxifene</i></b> (10 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> (400 p.p.m.). Animals were killed at 17 weeks of age, and prostate tissues were harvested and weighed by lobes. Tissues were evaluated by histology, immunohistochemistry, and western blot analyses and blood was collected to measure the testosterone levels. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>animals</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>lobe</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>43</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>dorsolateral</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>DLP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>anterior</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>animals</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>raloxifene</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg/kg/day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>nimesulide</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The total prostate weights and adenocarcinoma portions were significantly reduced in the three <b style='color:Tomato;'><i>raloxifene</i></b>-treated groups, whereas atrophic glands were increased. There were no significant differences between the <b style='color:Tomato;'><i>nimesulide</i></b> alone and placebo groups or between the <b style='color:Tomato;'><i>raloxifene</i></b> (5 mg/kg/day) alone and <b style='color:Tomato;'><i>raloxifene</i></b> (5 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> group, suggesting a lack of cancer preventive effects of the COX-2 inhibitor in this animal model. PCNA positive rates in ventral prostate (VP) and DLP, and androgen receptor (AR) levels in VP were significantly reduced in the three <b style='color:Tomato;'><i>raloxifene</i></b>-treated groups. Furthermore, circulating testosterone was decreased after <b style='color:Tomato;'><i>raloxifene</i></b> (10 mg/kg/day) plus <b style='color:Tomato;'><i>nimesulide</i></b> treatment. These results demonstrate that <b style='color:Tomato;'><i>raloxifene</i></b>, but not <b style='color:Tomato;'><i>nimesulide</i></b>, inhibits prostate carcinogenesis in SV40 Tag TG rats associated with a decline in circulating testosterone levels and a loss of AR expression, as well as an inhibition of cell proliferation.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"the","start":4,"end":7,"id":1,"ws":true},{"text":"animals","start":8,"end":15,"id":2,"ws":true},{"text":"in","start":16,"end":18,"id":3,"ws":true},{"text":"the","start":19,"end":22,"id":4,"ws":true},{"text":"placebo","start":23,"end":30,"id":5,"ws":true},{"text":"group","start":31,"end":36,"id":6,"ws":true},{"text":"had","start":37,"end":40,"id":7,"ws":true},{"text":"tumors","start":41,"end":47,"id":8,"ws":true},{"text":"in","start":48,"end":50,"id":9,"ws":true},{"text":"each","start":51,"end":55,"id":10,"ws":true},{"text":"lobe","start":56,"end":60,"id":11,"ws":true},{"text":"compared","start":61,"end":69,"id":12,"ws":true},{"text":"with","start":70,"end":74,"id":13,"ws":true},{"text":"only","start":75,"end":79,"id":14,"ws":true},{"text":"43","start":80,"end":82,"id":15,"ws":true},{"text":"%","start":83,"end":84,"id":16,"ws":true},{"text":"each","start":85,"end":89,"id":17,"ws":true},{"text":"in","start":90,"end":92,"id":18,"ws":true},{"text":"the","start":93,"end":96,"id":19,"ws":true},{"text":"dorsolateral","start":97,"end":109,"id":20,"ws":true},{"text":"(","start":110,"end":111,"id":21,"ws":true},{"text":"DLP","start":112,"end":115,"id":22,"ws":true},{"text":")","start":116,"end":117,"id":23,"ws":true},{"text":"and","start":118,"end":121,"id":24,"ws":true},{"text":"anterior","start":122,"end":130,"id":25,"ws":true},{"text":"prostate","start":131,"end":139,"id":26,"ws":true},{"text":"(","start":140,"end":141,"id":27,"ws":true},{"text":"AP","start":142,"end":144,"id":28,"ws":true},{"text":")","start":145,"end":146,"id":29,"ws":true},{"text":"of","start":147,"end":149,"id":30,"ws":true},{"text":"the","start":150,"end":153,"id":31,"ws":true},{"text":"animals","start":154,"end":161,"id":32,"ws":true},{"text":"treated","start":162,"end":169,"id":33,"ws":true},{"text":"with","start":170,"end":174,"id":34,"ws":true},{"text":"raloxifene","start":175,"end":185,"id":35,"ws":true},{"text":"(","start":186,"end":187,"id":36,"ws":true},{"text":"10","start":188,"end":190,"id":37,"ws":true},{"text":"mg/kg/day","start":191,"end":200,"id":38,"ws":true},{"text":")","start":201,"end":202,"id":39,"ws":true},{"text":"plus","start":203,"end":207,"id":40,"ws":true},{"text":"nimesulide","start":208,"end":218,"id":41,"ws":true},{"text":".","start":219,"end":220,"id":42,"ws":false}],"spans":[{"start":175,"end":185,"token_start":35,"token_end":35,"label":"DRUG"},{"start":208,"end":218,"token_start":41,"token_end":41,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15731164/","_input_hash":-1074706345,"_task_hash":911107500,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":35,"child":41,"head_span":{"start":175,"end":185,"token_start":35,"token_end":35,"label":"DRUG"},"child_span":{"start":208,"end":218,"token_start":41,"token_end":41,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Overdose of dolutegravir in combination with tenofovir disaproxil fumarate/emtricitabine in suicide attempt in a 21-year old patient .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Overdose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>dolutegravir</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tenofovir</i></b> <b style='color:DodgerBlue;'><i>disaproxil</i></b> <b style='color:DodgerBlue;'><i>fumarate/emtricitabine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>suicide</i></b> <b style='color:DodgerBlue;'><i>attempt</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>21-year</i></b> <b style='color:DodgerBlue;'><i>old</i></b> <b style='color:DodgerBlue;'><i>patient</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>A 21\u00a0year old MSM patient with newly diagnosed HIV infection was hospitalized in our department after ingestion of an overdose of his antiretroviral therapy (ART) comprising <b style='color:Tomato;'><i>dolutegravir</i></b> (DTG - Tivicay\u00ae) and <b style='color:Tomato;'><i>tenofovir</i></b> disaproxil fumarate/<b style='color:Tomato;'><i>emtricitabine</i></b> (Truvada\u00ae) in suicidal intention. On admission, the patient did not show any clinical signs of intoxication and laboratory findings were unremarkable. After 6\u00a0hours of intensive care monitoring, the patient was referred to a psychiatric clinic. 5\u00a0days after the day of intoxication, serum creatinine levels increased to high normal values (1.2\u00a0mg/dl). However, levels never exceeded the upper threshold. 8 and 12\u00a0weeks later, serum creatinine normalized to levels measured prior to the intoxication. No other adverse events occurred, and the patient does not suffer from permanent impairments.","tokens":[{"text":"Overdose","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"dolutegravir","start":12,"end":24,"id":2,"ws":true},{"text":"in","start":25,"end":27,"id":3,"ws":true},{"text":"combination","start":28,"end":39,"id":4,"ws":true},{"text":"with","start":40,"end":44,"id":5,"ws":true},{"text":"tenofovir","start":45,"end":54,"id":6,"ws":true},{"text":"disaproxil","start":55,"end":65,"id":7,"ws":true},{"text":"fumarate/emtricitabine","start":66,"end":88,"id":8,"ws":true},{"text":"in","start":89,"end":91,"id":9,"ws":true},{"text":"suicide","start":92,"end":99,"id":10,"ws":true},{"text":"attempt","start":100,"end":107,"id":11,"ws":true},{"text":"in","start":108,"end":110,"id":12,"ws":true},{"text":"a","start":111,"end":112,"id":13,"ws":true},{"text":"21-year","start":113,"end":120,"id":14,"ws":true},{"text":"old","start":121,"end":124,"id":15,"ws":true},{"text":"patient","start":125,"end":132,"id":16,"ws":true},{"text":".","start":133,"end":134,"id":17,"ws":false}],"spans":[{"start":12,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},{"start":45,"end":54,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26045712/","_input_hash":-247737991,"_task_hash":-854886939,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":6,"child":2,"head_span":{"start":45,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":12,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer : a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes .","paragraph":"<h3><u><b style='color:MediumOrchid;'><i>Abiraterone</i></b> <b style='color:DodgerBlue;'><i>acetate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pre-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>post-docetaxel</i></b> <b style='color:DodgerBlue;'><i>setting</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>mono-institutional</i></b> <b style='color:DodgerBlue;'><i>experience</i></b> <b style='color:DodgerBlue;'><i>focused</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>cardiovascular</i></b> <b style='color:DodgerBlue;'><i>events</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>their</i></b> <b style='color:DodgerBlue;'><i>impact</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>outcomes</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The aim of this work was to to evaluate the incidence and risk factors of adverse events (AEs), focusing on cardiovascular events (CVEs) and hypokalemia, in patients treated with <b style='color:Tomato;'><i>abiraterone</i></b> acetate (AA) and <b style='color:Tomato;'><i>prednisone</i></b> (PDN) outside clinical trials, and their association with survival outcomes. ### methods This was a retrospective cohort study of 105 patients treated from 2011 to 2016. Incidence of AEs was descriptively summarized in the whole cohort and by subgroup (pre- ### results Overall, median PFS and OS were 14.9 and 24.6 months, respectively. Prostate-specific antigen (PSA) \u2a7e 10 ng/ml ( ### conclusions Median PFS and OS estimates and incidence of CVEs and hypokalemia in our series are consistent with those of pivotal trials of AA plus PDN, confirming the efficacy and safety of this regimen also in the real-world setting. Elderly patients have higher odds of developing/worsening CVEs. However, regardless of age, CVEs were not associated with worse outcomes. Treatment-related hypokalemia seemed to be associated with longer OS, albeit this finding needs confirmation within larger, prospective series.","tokens":[{"text":"Abiraterone","start":0,"end":11,"id":0,"ws":true},{"text":"acetate","start":12,"end":19,"id":1,"ws":true},{"text":"and","start":20,"end":23,"id":2,"ws":true},{"text":"prednisone","start":24,"end":34,"id":3,"ws":true},{"text":"in","start":35,"end":37,"id":4,"ws":true},{"text":"the","start":38,"end":41,"id":5,"ws":true},{"text":"pre-","start":42,"end":46,"id":6,"ws":true},{"text":"and","start":47,"end":50,"id":7,"ws":true},{"text":"post-docetaxel","start":51,"end":65,"id":8,"ws":true},{"text":"setting","start":66,"end":73,"id":9,"ws":true},{"text":"for","start":74,"end":77,"id":10,"ws":true},{"text":"metastatic","start":78,"end":88,"id":11,"ws":true},{"text":"castration-resistant","start":89,"end":109,"id":12,"ws":true},{"text":"prostate","start":110,"end":118,"id":13,"ws":true},{"text":"cancer","start":119,"end":125,"id":14,"ws":true},{"text":":","start":126,"end":127,"id":15,"ws":true},{"text":"a","start":128,"end":129,"id":16,"ws":true},{"text":"mono-institutional","start":130,"end":148,"id":17,"ws":true},{"text":"experience","start":149,"end":159,"id":18,"ws":true},{"text":"focused","start":160,"end":167,"id":19,"ws":true},{"text":"on","start":168,"end":170,"id":20,"ws":true},{"text":"cardiovascular","start":171,"end":185,"id":21,"ws":true},{"text":"events","start":186,"end":192,"id":22,"ws":true},{"text":"and","start":193,"end":196,"id":23,"ws":true},{"text":"their","start":197,"end":202,"id":24,"ws":true},{"text":"impact","start":203,"end":209,"id":25,"ws":true},{"text":"on","start":210,"end":212,"id":26,"ws":true},{"text":"clinical","start":213,"end":221,"id":27,"ws":true},{"text":"outcomes","start":222,"end":230,"id":28,"ws":true},{"text":".","start":231,"end":232,"id":29,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":24,"end":34,"token_start":3,"token_end":3,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29383035/","_input_hash":-1606804744,"_task_hash":761335342,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":0,"child":3,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":24,"end":34,"token_start":3,"token_end":3,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Nivolumab plus ipilimumab combined therapy is among the most effective therapies for advanced melanoma .","paragraph":"<h3><u>Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma.</u></h3> <b style='color:MediumOrchid;'><i>Nivolumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>among</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, this therapy is also associated with a high frequency of immune-related adverse events (irAEs). To avoid such severe irAEs caused by additional administration of anti-CTLA4 antibodies, biomarkers to distinguish responders from non-responders among patients treated with anti-PD1 antibodies are important. The purpose of this study is to evaluate the increased serum levels of CCL11, CCL24, and CCL26 as a predictive biomarker for the efficacy of anti-PD1 antibodies in advanced cutaneous melanoma patients. This study analyzed increased serum levels of CCL11, CCL24, and CCL26 in 46 cases of advanced cutaneous melanoma treated with anti-PD1 antibodies. Serum levels on day 42 were compared to baseline (day 0) and analyzed statistically. Receiver operating characteristic curves were established to evaluate the correlation between serum levels of CCL11, CCL24, and CCL26 and efficacy of anti-PD1 antibodies. Increased serum levels of CCL26 correlated significantly with the efficacy of anti-PD1 antibodies. In contrast, no significant correlations were seen between increased serum levels of CCL11 and CCL24 and efficacy of anti-PD1 antibodies. Increased serum levels of CCL26 may be a useful biomarker for identifying those patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.","tokens":[{"text":"Nivolumab","start":0,"end":9,"id":0,"ws":true},{"text":"plus","start":10,"end":14,"id":1,"ws":true},{"text":"ipilimumab","start":15,"end":25,"id":2,"ws":true},{"text":"combined","start":26,"end":34,"id":3,"ws":true},{"text":"therapy","start":35,"end":42,"id":4,"ws":true},{"text":"is","start":43,"end":45,"id":5,"ws":true},{"text":"among","start":46,"end":51,"id":6,"ws":true},{"text":"the","start":52,"end":55,"id":7,"ws":true},{"text":"most","start":56,"end":60,"id":8,"ws":true},{"text":"effective","start":61,"end":70,"id":9,"ws":true},{"text":"therapies","start":71,"end":80,"id":10,"ws":true},{"text":"for","start":81,"end":84,"id":11,"ws":true},{"text":"advanced","start":85,"end":93,"id":12,"ws":true},{"text":"melanoma","start":94,"end":102,"id":13,"ws":true},{"text":".","start":103,"end":104,"id":14,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":15,"end":25,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32658051/","_input_hash":238886149,"_task_hash":2049657732,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":15,"end":25,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Cells that were sequentially exposed to rapamycin and topotecan had significantly higher levels of cleaved caspase-8 , -3 , and PARP compared to those treated with topotecan alone .","paragraph":"<h3><u>Rapamycin-topotecan combination exhibited enhanced antitumor efficacy compared to topotecan used alone in cisplatin-resistant ovarian cancer cells.</u></h3>The present study aimed to investigate the antitumor efficacy of combination of <b style='color:Tomato;'><i>topotecan</i></b> with <b style='color:Tomato;'><i>rapamycin</i></b>, a\u00a0mTOR inhibitor, in cisplatin-resistant ovarian cancer cells A2780cis and COC1/DDP. Expressions of mTOR and its target molecules p70S6K and 4E-BP1 were determined in A2780cis and COC1/DDP and the parental cells A2780 and COC1 that are sensitive to cisplatin using Western blotting. Cell proliferation was examined using MTT assay in vitro and a\u00a0nude mouse model in vivo, respectively. Cell apoptosis and the relevant proteins were determined by flow cytometry and Western blotting. We found that the levels of phosphorylated mTOR, p70S6K, and 4E-BP1 were obviously higher in A2780cis and COC1/DDP cells than that in A2780 and COC1 cells. Pretreatment with <b style='color:Tomato;'><i>rapamycin</i></b> significantly enhanced the effects of <b style='color:Tomato;'><i>topotecan</i></b> in suppressing cell proliferation and soliciting cell apoptosis in A2780cis and COC1/DDP cells. <b style='color:DodgerBlue;'><i>Cells</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>sequentially</i></b> <b style='color:DodgerBlue;'><i>exposed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>higher</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cleaved</i></b> <b style='color:DodgerBlue;'><i>caspase-8</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>-3</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>PARP</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Mice co-administered <b style='color:Tomato;'><i>rapamycin</i></b> and <b style='color:Tomato;'><i>topotecan</i></b> had significantly decreased terminal tumor burden without additional loss of bodyweight compared to the mice received <b style='color:Tomato;'><i>topotecan</i></b> alone. The results suggested that <b style='color:Tomato;'><i>rapamycin</i></b> sensitized A2780cis and COC1/DDP cells to <b style='color:Tomato;'><i>topotecan</i></b>-induced apoptosis and <b style='color:Tomato;'><i>rapamycin</i></b>-<b style='color:Tomato;'><i>topotecan</i></b> combination might have a\u00a0value in treatment of cisplatin-resistant ovarian cancer.","tokens":[{"text":"Cells","start":0,"end":5,"id":0,"ws":true},{"text":"that","start":6,"end":10,"id":1,"ws":true},{"text":"were","start":11,"end":15,"id":2,"ws":true},{"text":"sequentially","start":16,"end":28,"id":3,"ws":true},{"text":"exposed","start":29,"end":36,"id":4,"ws":true},{"text":"to","start":37,"end":39,"id":5,"ws":true},{"text":"rapamycin","start":40,"end":49,"id":6,"ws":true},{"text":"and","start":50,"end":53,"id":7,"ws":true},{"text":"topotecan","start":54,"end":63,"id":8,"ws":true},{"text":"had","start":64,"end":67,"id":9,"ws":true},{"text":"significantly","start":68,"end":81,"id":10,"ws":true},{"text":"higher","start":82,"end":88,"id":11,"ws":true},{"text":"levels","start":89,"end":95,"id":12,"ws":true},{"text":"of","start":96,"end":98,"id":13,"ws":true},{"text":"cleaved","start":99,"end":106,"id":14,"ws":true},{"text":"caspase-8","start":107,"end":116,"id":15,"ws":true},{"text":",","start":117,"end":118,"id":16,"ws":true},{"text":"-3","start":119,"end":121,"id":17,"ws":true},{"text":",","start":122,"end":123,"id":18,"ws":true},{"text":"and","start":124,"end":127,"id":19,"ws":true},{"text":"PARP","start":128,"end":132,"id":20,"ws":true},{"text":"compared","start":133,"end":141,"id":21,"ws":true},{"text":"to","start":142,"end":144,"id":22,"ws":true},{"text":"those","start":145,"end":150,"id":23,"ws":true},{"text":"treated","start":151,"end":158,"id":24,"ws":true},{"text":"with","start":159,"end":163,"id":25,"ws":true},{"text":"topotecan","start":164,"end":173,"id":26,"ws":true},{"text":"alone","start":174,"end":179,"id":27,"ws":true},{"text":".","start":180,"end":181,"id":28,"ws":false}],"spans":[{"start":40,"end":49,"token_start":6,"token_end":6,"label":"DRUG"},{"start":54,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},{"start":164,"end":173,"token_start":26,"token_end":26,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26278147/","_input_hash":1375843614,"_task_hash":-289441407,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":40,"end":49,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":54,"end":63,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"No cross-resistance was found with conventional drugs , being PNU-159548 active also in cells resistant to doxorubicin and with a multidrug resistance phenotype ( associated with MDR1 gene/P-glycoprotein overexpression ) , as well as in cells resistant to methotrexate or to cisplatin .","paragraph":"<h3><u>4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients.</u></h3>The effectiveness of the alkycycline 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-<b style='color:Tomato;'><i>daunorubicin</i></b> (PNU-159548, ladirubicin), a new drug with high antitumour activity against a broad range of neoplasms, was evaluated by using a panel of 32 human osteosarcoma cell lines, including cell lines resistant to <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, or cisplatin. PNU-159548 resulted to be highly active in all cell lines. <b style='color:DodgerBlue;'><i>No</i></b> <b style='color:DodgerBlue;'><i>cross-resistance</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>conventional</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>being</i></b> <b style='color:DodgerBlue;'><i>PNU-159548</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multidrug</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>phenotype</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>MDR1</i></b> <b style='color:DodgerBlue;'><i>gene/P-glycoprotein</i></b> <b style='color:DodgerBlue;'><i>overexpression</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Analysis of drug-drug interactions showed that PNU-159548 could be successfully used in combination with all the most important drugs currently used in OS chemotherapy. In fact, the simultaneous administration of PNU-159548 and <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, or cisplatin produced mostly additive or synergistic effects. Sequential exposure to PNU-159548 followed immediately by <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, or cisplatin was the most effective sequence of administration, invariably resulting in additive or synergistic effects in both drug-sensitive and drug-resistant osteosarcoma cell lines. In conclusion, the high in vitro effectiveness, the absence of cross-resistance with <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, or cisplatin and the possibility to be successfully used in combination with these drugs indicate PNU-159548 as a promising candidate to be considered for planning new therapeutic regimens for osteosarcoma patients, who show a decreased response to conventional chemotherapy.","tokens":[{"text":"No","start":0,"end":2,"id":0,"ws":true},{"text":"cross-resistance","start":3,"end":19,"id":1,"ws":true},{"text":"was","start":20,"end":23,"id":2,"ws":true},{"text":"found","start":24,"end":29,"id":3,"ws":true},{"text":"with","start":30,"end":34,"id":4,"ws":true},{"text":"conventional","start":35,"end":47,"id":5,"ws":true},{"text":"drugs","start":48,"end":53,"id":6,"ws":true},{"text":",","start":54,"end":55,"id":7,"ws":true},{"text":"being","start":56,"end":61,"id":8,"ws":true},{"text":"PNU-159548","start":62,"end":72,"id":9,"ws":true},{"text":"active","start":73,"end":79,"id":10,"ws":true},{"text":"also","start":80,"end":84,"id":11,"ws":true},{"text":"in","start":85,"end":87,"id":12,"ws":true},{"text":"cells","start":88,"end":93,"id":13,"ws":true},{"text":"resistant","start":94,"end":103,"id":14,"ws":true},{"text":"to","start":104,"end":106,"id":15,"ws":true},{"text":"doxorubicin","start":107,"end":118,"id":16,"ws":true},{"text":"and","start":119,"end":122,"id":17,"ws":true},{"text":"with","start":123,"end":127,"id":18,"ws":true},{"text":"a","start":128,"end":129,"id":19,"ws":true},{"text":"multidrug","start":130,"end":139,"id":20,"ws":true},{"text":"resistance","start":140,"end":150,"id":21,"ws":true},{"text":"phenotype","start":151,"end":160,"id":22,"ws":true},{"text":"(","start":161,"end":162,"id":23,"ws":true},{"text":"associated","start":163,"end":173,"id":24,"ws":true},{"text":"with","start":174,"end":178,"id":25,"ws":true},{"text":"MDR1","start":179,"end":183,"id":26,"ws":true},{"text":"gene/P-glycoprotein","start":184,"end":203,"id":27,"ws":true},{"text":"overexpression","start":204,"end":218,"id":28,"ws":true},{"text":")","start":219,"end":220,"id":29,"ws":true},{"text":",","start":221,"end":222,"id":30,"ws":true},{"text":"as","start":223,"end":225,"id":31,"ws":true},{"text":"well","start":226,"end":230,"id":32,"ws":true},{"text":"as","start":231,"end":233,"id":33,"ws":true},{"text":"in","start":234,"end":236,"id":34,"ws":true},{"text":"cells","start":237,"end":242,"id":35,"ws":true},{"text":"resistant","start":243,"end":252,"id":36,"ws":true},{"text":"to","start":253,"end":255,"id":37,"ws":true},{"text":"methotrexate","start":256,"end":268,"id":38,"ws":true},{"text":"or","start":269,"end":271,"id":39,"ws":true},{"text":"to","start":272,"end":274,"id":40,"ws":true},{"text":"cisplatin","start":275,"end":284,"id":41,"ws":true},{"text":".","start":285,"end":286,"id":42,"ws":false}],"spans":[{"start":62,"end":72,"token_start":9,"token_end":9,"label":"DRUG"},{"start":107,"end":118,"token_start":16,"token_end":16,"label":"DRUG"},{"start":256,"end":268,"token_start":38,"token_end":38,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16140527/","_input_hash":-1391381095,"_task_hash":938422382,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The focus of this study is to investigate , whether altered expression levels of potentially relevant microRNAs ( miRs ) in serum are associated with response to trastuzumab or lapatinib .","paragraph":"<h3><u>Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.</u></h3><b style='color:Tomato;'><i>trastuzumab</i></b> and <b style='color:Tomato;'><i>lapatinib</i></b> are established treatments for patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer with different mechanisms of action. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>focus</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>investigate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>whether</i></b> <b style='color:DodgerBlue;'><i>altered</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>levels</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>potentially</i></b> <b style='color:DodgerBlue;'><i>relevant</i></b> <b style='color:DodgerBlue;'><i>microRNAs</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>miRs</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>lapatinib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Circulating miR-21, miR-210, and miR-373 were quantified with TaqMan MicroRNA assays in serum of 127 HER2-postive breast cancer patients before and after neoadjuvant therapy and in 19 healthy controls. Patients received chemotherapy combined with either <b style='color:Tomato;'><i>trastuzumab</i></b> or <b style='color:Tomato;'><i>lapatinib</i></b> within the prospectively randomized Geparquinto trial. The association between miR levels and pathological response (pCR) to therapy and type of therapy was examined. Serum levels of miR-21 (p\u00a0=\u00a05.04e-08, p\u00a0=\u00a01.43e-10), miR-210 (p\u00a0=\u00a00.00151, p\u00a0=\u00a01.6e-05), and miR-373 (p\u00a0=\u00a07.87e-06, p\u00a0=\u00a01.75e-07) were significantly higher in patients before and after chemotherapy than in healthy women. Concentrations of miR-21 (p\u00a0=\u00a05.73e-08), miR-210 (p\u00a0=\u00a00.000724), and miR-373 (p\u00a0=\u00a00.00209) increased further after chemotherapy. A significant association of higher serum levels of miR-373 with advanced clinical tumor stage could be detected (p\u00a0<\u00a00.002). An association of miR-21 levels before (p\u00a0=\u00a00.0091) and after (p\u00a0=\u00a00.037) chemotherapy with overall survival of the patients could be detected, independent of type of anti-HER2 therapy. No association of circulating miRs with pCR was found. Our findings demonstrate a specific influence of neoadjuvant therapy on the serum levels of miR-21, miR-210, and miR-373 in breast cancer patients together with a prognostic value of miR-21.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"focus","start":4,"end":9,"id":1,"ws":true},{"text":"of","start":10,"end":12,"id":2,"ws":true},{"text":"this","start":13,"end":17,"id":3,"ws":true},{"text":"study","start":18,"end":23,"id":4,"ws":true},{"text":"is","start":24,"end":26,"id":5,"ws":true},{"text":"to","start":27,"end":29,"id":6,"ws":true},{"text":"investigate","start":30,"end":41,"id":7,"ws":true},{"text":",","start":42,"end":43,"id":8,"ws":true},{"text":"whether","start":44,"end":51,"id":9,"ws":true},{"text":"altered","start":52,"end":59,"id":10,"ws":true},{"text":"expression","start":60,"end":70,"id":11,"ws":true},{"text":"levels","start":71,"end":77,"id":12,"ws":true},{"text":"of","start":78,"end":80,"id":13,"ws":true},{"text":"potentially","start":81,"end":92,"id":14,"ws":true},{"text":"relevant","start":93,"end":101,"id":15,"ws":true},{"text":"microRNAs","start":102,"end":111,"id":16,"ws":true},{"text":"(","start":112,"end":113,"id":17,"ws":true},{"text":"miRs","start":114,"end":118,"id":18,"ws":true},{"text":")","start":119,"end":120,"id":19,"ws":true},{"text":"in","start":121,"end":123,"id":20,"ws":true},{"text":"serum","start":124,"end":129,"id":21,"ws":true},{"text":"are","start":130,"end":133,"id":22,"ws":true},{"text":"associated","start":134,"end":144,"id":23,"ws":true},{"text":"with","start":145,"end":149,"id":24,"ws":true},{"text":"response","start":150,"end":158,"id":25,"ws":true},{"text":"to","start":159,"end":161,"id":26,"ws":true},{"text":"trastuzumab","start":162,"end":173,"id":27,"ws":true},{"text":"or","start":174,"end":176,"id":28,"ws":true},{"text":"lapatinib","start":177,"end":186,"id":29,"ws":true},{"text":".","start":187,"end":188,"id":30,"ws":false}],"spans":[{"start":162,"end":173,"token_start":27,"token_end":27,"label":"DRUG"},{"start":177,"end":186,"token_start":29,"token_end":29,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25086636/","_input_hash":1312052038,"_task_hash":391736444,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"These results suggest that the addition of intravenous ceftriaxone during the first 3 days of hospitalization does not improve the cost-efficacy of oral norfloxacin in the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding and high risk of infection .","paragraph":"<h3><u>Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding.</u></h3>Selective intestinal decontamination with <b style='color:Tomato;'><i>norfloxacin</i></b> is useful in the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding. However, bleeding cirrhotic patients with ascites, encephalopathy, or shock are at high risk to develop bacterial infections in spite of prophylactic <b style='color:Tomato;'><i>norfloxacin</i></b>. The aim of this study was to assess whether the addition of intravenous <b style='color:Tomato;'><i>ceftriaxone</i></b> could improve the efficacy of prophylaxis with <b style='color:Tomato;'><i>norfloxacin</i></b> in these patients. ### methods Fifty-six cirrhotic patients with gastrointestinal hemorrhage and ascites, encephalopathy, or shock were randomized into two groups: Group 1 (n = 28) received oral <b style='color:Tomato;'><i>norfloxacin</i></b> 400 mg/12 h for 7 days, and group 2 (n = 28) received <b style='color:Tomato;'><i>norfloxacin</i></b> plus intravenous <b style='color:Tomato;'><i>ceftriaxone</i></b> 2 g daily during the first 3 days of admission. ### results Ten patients were excluded because of community-acquired infection, surgery, or death within the first 24 h. The incidence of bacterial infections during hospitalization was 18.1% in group 1 and 12.5% in group 2 (p = NS). The incidence of severe infections (spontaneous bacterial peritonitis, bacteremia, or pneumonia) was also similar in both groups: 9% in group 1 versus 8.3% in group 2 (p = NS). There were no statistical differences between the two groups with respect to duration of hospitalization or mortality. The cost of antibiotic therapy (including prophylaxis and treatment of infections) was significantly higher in group 2. ### conclusion <b style='color:DodgerBlue;'><i>These</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>ceftriaxone</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>hospitalization</i></b> <b style='color:DodgerBlue;'><i>does</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>improve</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>cost-efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>norfloxacin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>prevention</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>bacterial</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cirrhotic</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>gastrointestinal</i></b> <b style='color:DodgerBlue;'><i>bleeding</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>high</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"These","start":0,"end":5,"id":0,"ws":true},{"text":"results","start":6,"end":13,"id":1,"ws":true},{"text":"suggest","start":14,"end":21,"id":2,"ws":true},{"text":"that","start":22,"end":26,"id":3,"ws":true},{"text":"the","start":27,"end":30,"id":4,"ws":true},{"text":"addition","start":31,"end":39,"id":5,"ws":true},{"text":"of","start":40,"end":42,"id":6,"ws":true},{"text":"intravenous","start":43,"end":54,"id":7,"ws":true},{"text":"ceftriaxone","start":55,"end":66,"id":8,"ws":true},{"text":"during","start":67,"end":73,"id":9,"ws":true},{"text":"the","start":74,"end":77,"id":10,"ws":true},{"text":"first","start":78,"end":83,"id":11,"ws":true},{"text":"3","start":84,"end":85,"id":12,"ws":true},{"text":"days","start":86,"end":90,"id":13,"ws":true},{"text":"of","start":91,"end":93,"id":14,"ws":true},{"text":"hospitalization","start":94,"end":109,"id":15,"ws":true},{"text":"does","start":110,"end":114,"id":16,"ws":true},{"text":"not","start":115,"end":118,"id":17,"ws":true},{"text":"improve","start":119,"end":126,"id":18,"ws":true},{"text":"the","start":127,"end":130,"id":19,"ws":true},{"text":"cost-efficacy","start":131,"end":144,"id":20,"ws":true},{"text":"of","start":145,"end":147,"id":21,"ws":true},{"text":"oral","start":148,"end":152,"id":22,"ws":true},{"text":"norfloxacin","start":153,"end":164,"id":23,"ws":true},{"text":"in","start":165,"end":167,"id":24,"ws":true},{"text":"the","start":168,"end":171,"id":25,"ws":true},{"text":"prevention","start":172,"end":182,"id":26,"ws":true},{"text":"of","start":183,"end":185,"id":27,"ws":true},{"text":"bacterial","start":186,"end":195,"id":28,"ws":true},{"text":"infections","start":196,"end":206,"id":29,"ws":true},{"text":"in","start":207,"end":209,"id":30,"ws":true},{"text":"cirrhotic","start":210,"end":219,"id":31,"ws":true},{"text":"patients","start":220,"end":228,"id":32,"ws":true},{"text":"with","start":229,"end":233,"id":33,"ws":true},{"text":"gastrointestinal","start":234,"end":250,"id":34,"ws":true},{"text":"bleeding","start":251,"end":259,"id":35,"ws":true},{"text":"and","start":260,"end":263,"id":36,"ws":true},{"text":"high","start":264,"end":268,"id":37,"ws":true},{"text":"risk","start":269,"end":273,"id":38,"ws":true},{"text":"of","start":274,"end":276,"id":39,"ws":true},{"text":"infection","start":277,"end":286,"id":40,"ws":true},{"text":".","start":287,"end":288,"id":41,"ws":false}],"spans":[{"start":55,"end":66,"token_start":8,"token_end":8,"label":"DRUG"},{"start":153,"end":164,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9860409/","_input_hash":-1538837134,"_task_hash":-782081798,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":23,"child":8,"head_span":{"start":153,"end":164,"token_start":23,"token_end":23,"label":"DRUG"},"child_span":{"start":55,"end":66,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
{"text":"However , clindamycin possesses only one of the two mechanisms of lincomycin action , which is bacteriostatic , against Escherichia coli .","paragraph":"<h3><u>Microbial kinetics of drug action against gram-positive and gram-negative organisms. III: Effect of lincomycin and clindamycin combinations on Staphylococcus aureus and Escherichia coli.</u></h3>The functional dependencies of apparent first-order generation rate constants kapp, of drug-affected cultures on drug concentrations indicate that <b style='color:Tomato;'><i>lincomycin</i></b> and <b style='color:Tomato;'><i>clindamycin</i></b> possess the same mechanism of action, which is bacteriostatic, against Staphylococcus aureus. <b style='color:Tomato;'><i>clindamycin</i></b> also possesses another mechanism of action, which is bactericidal, at high concentration levels. <b style='color:DodgerBlue;'><i>However</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clindamycin</i></b> <b style='color:DodgerBlue;'><i>possesses</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>mechanisms</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>lincomycin</i></b> <b style='color:DodgerBlue;'><i>action</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>which</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>bacteriostatic</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>Escherichia</i></b> <b style='color:DodgerBlue;'><i>coli</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The relative potency of action of a <b style='color:Tomato;'><i>clindamycin</i></b>-<b style='color:Tomato;'><i>lincomycin</i></b> combination against Staph. aureus is variable, and the effective ratio ranges between 5:1 and 9:1; the effective ratio against E. coli is fixed at 6:1 over a wide concentration range. This difference is attributed to differences in bioavailability and/or binding characteristics of the drugs for bioreceptors, as a consequence of structural modifications in the drug molecules, and to differences in modes of action in the respective organisms. Mixtures containing equipotent fractions of <b style='color:Tomato;'><i>clindamycin</i></b> and <b style='color:Tomato;'><i>lincomycin</i></b> show \"equivalence\" or \"indifference\" of effects on Staph. aureus. The combined action of the mixtures can be quantitatively predicted from the separate dose-response curves of either component drug alone. Therefore, it is concluded that <b style='color:Tomato;'><i>clindamycin</i></b> and <b style='color:Tomato;'><i>lincomycin</i></b> may bind to the same receptor site that is engaged in microbial protein synthesis to inhibit the generation of Staph. aureus. However, combinations of <b style='color:Tomato;'><i>clindamycin</i></b> and <b style='color:Tomato;'><i>lincomycin</i></b> are less active than the a priori equipotent concentration of either drug alone in their action against E. coli, demonstrating unequivocally an antagonism of effects. Furthermore, the degree of antagonism is dependent on the order of addition of the drugs, which is attributed to the possibility that <b style='color:Tomato;'><i>clindamycin</i></b> and <b style='color:Tomato;'><i>lincomycin</i></b> bind differently on active and allosteric loci of the same receptor site functionally engaged in protein synthesis in E. coli. A rational approach to the quantification and prediction of combined antibiotic action must, therefore, be based not only on the kinetics and mechanisms of action as well as on the dose-response relationship over a wide concentration range for the separate antibiotics but also on the strain and species of the test organism.","tokens":[{"text":"However","start":0,"end":7,"id":0,"ws":true},{"text":",","start":8,"end":9,"id":1,"ws":true},{"text":"clindamycin","start":10,"end":21,"id":2,"ws":true},{"text":"possesses","start":22,"end":31,"id":3,"ws":true},{"text":"only","start":32,"end":36,"id":4,"ws":true},{"text":"one","start":37,"end":40,"id":5,"ws":true},{"text":"of","start":41,"end":43,"id":6,"ws":true},{"text":"the","start":44,"end":47,"id":7,"ws":true},{"text":"two","start":48,"end":51,"id":8,"ws":true},{"text":"mechanisms","start":52,"end":62,"id":9,"ws":true},{"text":"of","start":63,"end":65,"id":10,"ws":true},{"text":"lincomycin","start":66,"end":76,"id":11,"ws":true},{"text":"action","start":77,"end":83,"id":12,"ws":true},{"text":",","start":84,"end":85,"id":13,"ws":true},{"text":"which","start":86,"end":91,"id":14,"ws":true},{"text":"is","start":92,"end":94,"id":15,"ws":true},{"text":"bacteriostatic","start":95,"end":109,"id":16,"ws":true},{"text":",","start":110,"end":111,"id":17,"ws":true},{"text":"against","start":112,"end":119,"id":18,"ws":true},{"text":"Escherichia","start":120,"end":131,"id":19,"ws":true},{"text":"coli","start":132,"end":136,"id":20,"ws":true},{"text":".","start":137,"end":138,"id":21,"ws":false}],"spans":[{"start":10,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":66,"end":76,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/1102659/","_input_hash":1108803543,"_task_hash":557502043,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We conducted a multicenter , retrospective study to evaluate the efficacy and safety of combination nivolumab plus ipilimumab ( NIVO+IPI ) in 35 patients with advanced or metastatic renal cell carcinoma ( mRCC ) .","paragraph":"<h3><u>Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multicenter</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>retrospective</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NIVO+IPI</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mRCC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In this study, we focused on patients who received NIVO+IPI and were stratified into intermediate- or poor-risk disease according to the International Metastatic Renal Cell Carcinoma Database Consortium model at five institutions in Japan. The primary endpoint was overall survival (OS). Secondary endpoints were disease control rate (DCR), best overall response (BOR), objective response rate (ORR), and progression-free survival (PFS). In addition, we evaluated the role of inflammatory cell ratios, namely neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), as predictive biomarkers in patients with mRCC. The median follow-up period was 1 year, and the 1-year OS rate was 95.8%. The ORR and DCR were 34.3% and 80.0%, respectively. According to BOR, four patients (11.4%) achieved complete response. According to NLR stratification, the 1-year PFS rates were 82.6% and 23.7% when the NLR was \u22644.6 and >4.6, respectively (","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"conducted","start":3,"end":12,"id":1,"ws":true},{"text":"a","start":13,"end":14,"id":2,"ws":true},{"text":"multicenter","start":15,"end":26,"id":3,"ws":true},{"text":",","start":27,"end":28,"id":4,"ws":true},{"text":"retrospective","start":29,"end":42,"id":5,"ws":true},{"text":"study","start":43,"end":48,"id":6,"ws":true},{"text":"to","start":49,"end":51,"id":7,"ws":true},{"text":"evaluate","start":52,"end":60,"id":8,"ws":true},{"text":"the","start":61,"end":64,"id":9,"ws":true},{"text":"efficacy","start":65,"end":73,"id":10,"ws":true},{"text":"and","start":74,"end":77,"id":11,"ws":true},{"text":"safety","start":78,"end":84,"id":12,"ws":true},{"text":"of","start":85,"end":87,"id":13,"ws":true},{"text":"combination","start":88,"end":99,"id":14,"ws":true},{"text":"nivolumab","start":100,"end":109,"id":15,"ws":true},{"text":"plus","start":110,"end":114,"id":16,"ws":true},{"text":"ipilimumab","start":115,"end":125,"id":17,"ws":true},{"text":"(","start":126,"end":127,"id":18,"ws":true},{"text":"NIVO+IPI","start":128,"end":136,"id":19,"ws":true},{"text":")","start":137,"end":138,"id":20,"ws":true},{"text":"in","start":139,"end":141,"id":21,"ws":true},{"text":"35","start":142,"end":144,"id":22,"ws":true},{"text":"patients","start":145,"end":153,"id":23,"ws":true},{"text":"with","start":154,"end":158,"id":24,"ws":true},{"text":"advanced","start":159,"end":167,"id":25,"ws":true},{"text":"or","start":168,"end":170,"id":26,"ws":true},{"text":"metastatic","start":171,"end":181,"id":27,"ws":true},{"text":"renal","start":182,"end":187,"id":28,"ws":true},{"text":"cell","start":188,"end":192,"id":29,"ws":true},{"text":"carcinoma","start":193,"end":202,"id":30,"ws":true},{"text":"(","start":203,"end":204,"id":31,"ws":true},{"text":"mRCC","start":205,"end":209,"id":32,"ws":true},{"text":")","start":210,"end":211,"id":33,"ws":true},{"text":".","start":212,"end":213,"id":34,"ws":false}],"spans":[{"start":100,"end":109,"token_start":15,"token_end":15,"label":"DRUG"},{"start":115,"end":125,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33916792/","_input_hash":-66354120,"_task_hash":-648982159,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":15,"child":17,"head_span":{"start":100,"end":109,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":115,"end":125,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"This study evaluated the response rate of the combination therapy of aprinocarsen , gemcitabine , and carboplatin in previously untreated patients with advanced non-small cell lung cancer ( NSCLC ) .","paragraph":"<h3><u>Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.</u></h3>The antisense oligonucleotide aprinocarsen specifically inhibits the transcription of protein kinase C-alpha. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rate</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>aprinocarsen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>non-small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Secondary objectives included the measurement of time-to-event efficacy parameters and toxicity. Patients with stage IV or stage IIIB disease (N(3) and/or pleural/pericardial effusion) were treated with <b style='color:Tomato;'><i>gemcitabine</i></b> 1,250 mg/m(2) on days 1 and 8 and <b style='color:Tomato;'><i>carboplatin</i></b> AUC 5 on day 1 every 21 days. Aprinocarsen was administered as 2mg/kg/day continuous iv infusion on the first 14 days of each cycle, following the <b style='color:Tomato;'><i>carboplatin</i></b> treatment. A total of 36 patients received a median of 3 treatment cycles, with 10 patients completing 6 cycles. No complete response was observed, while partial response was seen in 25% of patients. Stable disease and progressive disease was observed in 36.1% and 22.2% of patients. The median overall survival was 8.3 months, and the median duration of progression-free survival was 5.7 months (95% CI, 3.2-7.1 months). Thrombocytopenia (78%) and neutropenia (50%) were the major grade 3/4 toxicities. Enrollment for this study was stopped and the study was terminated in March 2003 due to the results of a large phase III study, which suggested that aprinocarsen did not improve response or add survival benefit to chemotherapy in advanced NSCLC. The addition of aprinocarsen to <b style='color:Tomato;'><i>gemcitabine</i></b>+<b style='color:Tomato;'><i>carboplatin</i></b> therapy in patients with NSCLC showed moderate activity. However, this combination resulted in severe thrombocytopenia in the majority of patients.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"study","start":5,"end":10,"id":1,"ws":true},{"text":"evaluated","start":11,"end":20,"id":2,"ws":true},{"text":"the","start":21,"end":24,"id":3,"ws":true},{"text":"response","start":25,"end":33,"id":4,"ws":true},{"text":"rate","start":34,"end":38,"id":5,"ws":true},{"text":"of","start":39,"end":41,"id":6,"ws":true},{"text":"the","start":42,"end":45,"id":7,"ws":true},{"text":"combination","start":46,"end":57,"id":8,"ws":true},{"text":"therapy","start":58,"end":65,"id":9,"ws":true},{"text":"of","start":66,"end":68,"id":10,"ws":true},{"text":"aprinocarsen","start":69,"end":81,"id":11,"ws":true},{"text":",","start":82,"end":83,"id":12,"ws":true},{"text":"gemcitabine","start":84,"end":95,"id":13,"ws":true},{"text":",","start":96,"end":97,"id":14,"ws":true},{"text":"and","start":98,"end":101,"id":15,"ws":true},{"text":"carboplatin","start":102,"end":113,"id":16,"ws":true},{"text":"in","start":114,"end":116,"id":17,"ws":true},{"text":"previously","start":117,"end":127,"id":18,"ws":true},{"text":"untreated","start":128,"end":137,"id":19,"ws":true},{"text":"patients","start":138,"end":146,"id":20,"ws":true},{"text":"with","start":147,"end":151,"id":21,"ws":true},{"text":"advanced","start":152,"end":160,"id":22,"ws":true},{"text":"non-small","start":161,"end":170,"id":23,"ws":true},{"text":"cell","start":171,"end":175,"id":24,"ws":true},{"text":"lung","start":176,"end":180,"id":25,"ws":true},{"text":"cancer","start":181,"end":187,"id":26,"ws":true},{"text":"(","start":188,"end":189,"id":27,"ws":true},{"text":"NSCLC","start":190,"end":195,"id":28,"ws":true},{"text":")","start":196,"end":197,"id":29,"ws":true},{"text":".","start":198,"end":199,"id":30,"ws":false}],"spans":[{"start":69,"end":81,"token_start":11,"token_end":11,"label":"DRUG"},{"start":84,"end":95,"token_start":13,"token_end":13,"label":"DRUG"},{"start":102,"end":113,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16507327/","_input_hash":-1769105221,"_task_hash":-1161201303,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":11,"child":13,"head_span":{"start":69,"end":81,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":84,"end":95,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":13,"child":16,"head_span":{"start":84,"end":95,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":102,"end":113,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"All patients were treated by surgical debridement followed by a combination of antibiotics ; ( ceftazidime , amoxy-clavulanic acid , co-trimoxazole and doxycycline ) for six months except for one who died due to fulminant septicemia .","paragraph":"<h3><u>Burkholderia pseudomallei musculoskeletal infections (melioidosis) in India.</u></h3>Melioidosis, an infection due to gram negative Burkholderia pseudomallei, is an important cause of sepsis in east Asia especially Thailand and northern Australia. It usually causes abscesses in lung, liver, spleen, skeletal muscle and parotids especially in patients with diabetes, chronic renal failure and thalassemia. Musculoskeletal melioidosis is not common in India even though sporadic cases have been reported mostly involving soft tissues. During a two-year-period, we had five patients with musculoskeletal melioidosis. All patients presented with multifocal osteomyelitis, recurrent osteomyelitis or septic arthritis. One patient died early because of septicemia and multi-organ failure. All patients were diagnosed on the basis of positive pus culture. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>surgical</i></b> <b style='color:DodgerBlue;'><i>debridement</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>antibiotics</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>ceftazidime</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>amoxy-clavulanic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>co-trimoxazole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>doxycycline</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>except</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>died</i></b> <b style='color:DodgerBlue;'><i>due</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>fulminant</i></b> <b style='color:DodgerBlue;'><i>septicemia</i></b> <b style='color:DodgerBlue;'><i>.</i></b> All other patients recovered completely with no recurrences. With increasing awareness and better diagnostic facilities, probably musculoskeletal melioidosis will be increasingly diagnosed in future.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"patients","start":4,"end":12,"id":1,"ws":true},{"text":"were","start":13,"end":17,"id":2,"ws":true},{"text":"treated","start":18,"end":25,"id":3,"ws":true},{"text":"by","start":26,"end":28,"id":4,"ws":true},{"text":"surgical","start":29,"end":37,"id":5,"ws":true},{"text":"debridement","start":38,"end":49,"id":6,"ws":true},{"text":"followed","start":50,"end":58,"id":7,"ws":true},{"text":"by","start":59,"end":61,"id":8,"ws":true},{"text":"a","start":62,"end":63,"id":9,"ws":true},{"text":"combination","start":64,"end":75,"id":10,"ws":true},{"text":"of","start":76,"end":78,"id":11,"ws":true},{"text":"antibiotics","start":79,"end":90,"id":12,"ws":true},{"text":";","start":91,"end":92,"id":13,"ws":true},{"text":"(","start":93,"end":94,"id":14,"ws":true},{"text":"ceftazidime","start":95,"end":106,"id":15,"ws":true},{"text":",","start":107,"end":108,"id":16,"ws":true},{"text":"amoxy-clavulanic","start":109,"end":125,"id":17,"ws":true},{"text":"acid","start":126,"end":130,"id":18,"ws":true},{"text":",","start":131,"end":132,"id":19,"ws":true},{"text":"co-trimoxazole","start":133,"end":147,"id":20,"ws":true},{"text":"and","start":148,"end":151,"id":21,"ws":true},{"text":"doxycycline","start":152,"end":163,"id":22,"ws":true},{"text":")","start":164,"end":165,"id":23,"ws":true},{"text":"for","start":166,"end":169,"id":24,"ws":true},{"text":"six","start":170,"end":173,"id":25,"ws":true},{"text":"months","start":174,"end":180,"id":26,"ws":true},{"text":"except","start":181,"end":187,"id":27,"ws":true},{"text":"for","start":188,"end":191,"id":28,"ws":true},{"text":"one","start":192,"end":195,"id":29,"ws":true},{"text":"who","start":196,"end":199,"id":30,"ws":true},{"text":"died","start":200,"end":204,"id":31,"ws":true},{"text":"due","start":205,"end":208,"id":32,"ws":true},{"text":"to","start":209,"end":211,"id":33,"ws":true},{"text":"fulminant","start":212,"end":221,"id":34,"ws":true},{"text":"septicemia","start":222,"end":232,"id":35,"ws":true},{"text":".","start":233,"end":234,"id":36,"ws":false}],"spans":[{"start":95,"end":106,"token_start":15,"token_end":15,"label":"DRUG"},{"start":109,"end":125,"token_start":17,"token_end":17,"label":"DRUG"},{"start":133,"end":147,"token_start":20,"token_end":20,"label":"DRUG"},{"start":152,"end":163,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20419012/","_input_hash":1130976532,"_task_hash":290964828,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":15,"child":17,"head_span":{"start":95,"end":106,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":109,"end":125,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":20,"child":22,"head_span":{"start":133,"end":147,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":152,"end":163,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":17,"child":20,"head_span":{"start":109,"end":125,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":133,"end":147,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"To evaluate the eradication of Helicobacter pylori by therapy with a combination of 60 mg lansoprazole and 800 mg clarithromycin .","paragraph":"<h3><u>Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori.</u></h3> <b style='color:DodgerBlue;'><i>To</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>eradication</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Helicobacter</i></b> <b style='color:DodgerBlue;'><i>pylori</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>60</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>lansoprazole</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>800</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods In an open therapeutic trial, 30 H. pylori-positive patients with active ulcer disease took 30 mg <b style='color:Tomato;'><i>lansoprazole</i></b> twice a day and 400 mg <b style='color:Tomato;'><i>clarithromycin</i></b> twice a day for the first 2 weeks, followed by 30 mg <b style='color:Tomato;'><i>lansoprazole</i></b> once a day for 4-6 weeks. Endoscopy was performed both before and at the end of therapy, and 4 weeks after the end of the therapy. H. pylori was detected by using a combination of smear, culture and tissue sections. ### results Complete pain relief occurred within 3 days in all patients and all ulcers were healed by the end of the therapy. The H. pylori clearance rate was 83.3% and the eradication rate was 73.3%. A minor side effect (metallic taste) was reported by only one patient (3.3%). ### conclusions Therapy with a combination of 60 mg <b style='color:Tomato;'><i>lansoprazole</i></b> and 800 mg <b style='color:Tomato;'><i>clarithromycin</i></b> is efficacious in the eradication of H. pylori and has the advantage of a low incidence of side effects and quick pain relief for patients with active ulcers.","tokens":[{"text":"To","start":0,"end":2,"id":0,"ws":true},{"text":"evaluate","start":3,"end":11,"id":1,"ws":true},{"text":"the","start":12,"end":15,"id":2,"ws":true},{"text":"eradication","start":16,"end":27,"id":3,"ws":true},{"text":"of","start":28,"end":30,"id":4,"ws":true},{"text":"Helicobacter","start":31,"end":43,"id":5,"ws":true},{"text":"pylori","start":44,"end":50,"id":6,"ws":true},{"text":"by","start":51,"end":53,"id":7,"ws":true},{"text":"therapy","start":54,"end":61,"id":8,"ws":true},{"text":"with","start":62,"end":66,"id":9,"ws":true},{"text":"a","start":67,"end":68,"id":10,"ws":true},{"text":"combination","start":69,"end":80,"id":11,"ws":true},{"text":"of","start":81,"end":83,"id":12,"ws":true},{"text":"60","start":84,"end":86,"id":13,"ws":true},{"text":"mg","start":87,"end":89,"id":14,"ws":true},{"text":"lansoprazole","start":90,"end":102,"id":15,"ws":true},{"text":"and","start":103,"end":106,"id":16,"ws":true},{"text":"800","start":107,"end":110,"id":17,"ws":true},{"text":"mg","start":111,"end":113,"id":18,"ws":true},{"text":"clarithromycin","start":114,"end":128,"id":19,"ws":true},{"text":".","start":129,"end":130,"id":20,"ws":false}],"spans":[{"start":90,"end":102,"token_start":15,"token_end":15,"label":"DRUG"},{"start":114,"end":128,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8574739/","_input_hash":-1870005838,"_task_hash":2124968462,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":15,"child":19,"head_span":{"start":90,"end":102,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":114,"end":128,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"All patients were treated with vincristine , doxorubicin , cyclophosphamide and actinomycin-D , alternating with ifosfamide and etoposide every 3 weeks .","paragraph":"<h3><u>Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.</u></h3>The aim of this study was to evaluate prognostic factors, survival rate and the efficacy of the treatment modalities used in patients with extraskeletal Ewing's sarcoma. ### methods Data of patients with extraskeletal Ewing's sarcoma followed up at our center between 1997 and 2010 were retrospectively analyzed. ### results The median age of 27 patients was 24 years (range, 16-54 years). The median follow-up was 31.8 months (range, 6-144 months). Tumor size was between 1.5 and 14 cm (median: 8 cm). Eighty-five percent of patients had localized disease at presentation and 15% had metastatic disease. Local therapy was surgery alone in 16% of patients, surgery combined with radiotherapy in 42% and radiotherapy alone in 27%. <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>actinomycin-D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>alternating</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In patients with localized disease at presentation, the 5-year event-free survival and overall survival were 59.7 and 64.5%, respectively. At univariate analysis, patients with tumor size \u2265 8 cm, high serum lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy and positive surgical margin had significantly worse event-free survival. The significant predictors of worse overall survival at univariate analysis were tumor size 8 \u2265 cm, high lactate dehydrogenase, metastasis at presentation, poor histological response to chemotherapy, radiotherapy only as local treatment and positive surgical margin. ### conclusions Prognostic factors were similar to primary osseous Ewing's sarcomas. Adequate surgical resection, aggressive chemotherapy (<b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b> and actinomycin-D alternating with <b style='color:Tomato;'><i>ifosfamide</i></b> and <b style='color:Tomato;'><i>etoposide</i></b>) and radiotherapy if indicated are the recommended therapy for patients with extraskeletal Ewing's sarcoma.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"patients","start":4,"end":12,"id":1,"ws":true},{"text":"were","start":13,"end":17,"id":2,"ws":true},{"text":"treated","start":18,"end":25,"id":3,"ws":true},{"text":"with","start":26,"end":30,"id":4,"ws":true},{"text":"vincristine","start":31,"end":42,"id":5,"ws":true},{"text":",","start":43,"end":44,"id":6,"ws":true},{"text":"doxorubicin","start":45,"end":56,"id":7,"ws":true},{"text":",","start":57,"end":58,"id":8,"ws":true},{"text":"cyclophosphamide","start":59,"end":75,"id":9,"ws":true},{"text":"and","start":76,"end":79,"id":10,"ws":true},{"text":"actinomycin-D","start":80,"end":93,"id":11,"ws":true},{"text":",","start":94,"end":95,"id":12,"ws":true},{"text":"alternating","start":96,"end":107,"id":13,"ws":true},{"text":"with","start":108,"end":112,"id":14,"ws":true},{"text":"ifosfamide","start":113,"end":123,"id":15,"ws":true},{"text":"and","start":124,"end":127,"id":16,"ws":true},{"text":"etoposide","start":128,"end":137,"id":17,"ws":true},{"text":"every","start":138,"end":143,"id":18,"ws":true},{"text":"3","start":144,"end":145,"id":19,"ws":true},{"text":"weeks","start":146,"end":151,"id":20,"ws":true},{"text":".","start":152,"end":153,"id":21,"ws":false}],"spans":[{"start":31,"end":42,"token_start":5,"token_end":5,"label":"DRUG"},{"start":45,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},{"start":59,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},{"start":80,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},{"start":113,"end":123,"token_start":15,"token_end":15,"label":"DRUG"},{"start":128,"end":137,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22416252/","_input_hash":-1284586151,"_task_hash":-1817856654,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":5,"child":7,"head_span":{"start":31,"end":42,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":45,"end":56,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":9,"child":11,"head_span":{"start":59,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":80,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":15,"child":17,"head_span":{"start":113,"end":123,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":128,"end":137,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"We identified 49 and 220 patients treated with sorafenib and sunitinib , respectively , as first-line therapy in the Asan Medical Centre from April 2005 to March 2011 .","paragraph":"<h3><u>Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.</u></h3>This study investigated the efficacy and toxicity of <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>sunitinib</i></b> as primary treatment for patients with metastatic renal cell carcinoma (mRCC). ### methods <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>identified</i></b> <b style='color:DodgerBlue;'><i>49</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>220</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Asan</i></b> <b style='color:DodgerBlue;'><i>Medical</i></b> <b style='color:DodgerBlue;'><i>Centre</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>April</i></b> <b style='color:DodgerBlue;'><i>2005</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>March</i></b> <b style='color:DodgerBlue;'><i>2011</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Disease control rates of 71 and 74% were achieved with <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>sunitinib</i></b>, respectively (p = 0.687). After a median follow-up of 27.6 months, progression-free survival (PFS) and overall survival (OS) were not significantly different between the <b style='color:Tomato;'><i>sorafenib</i></b> and the <b style='color:Tomato;'><i>sunitinib</i></b> group (PFS 8.6 vs. 9.9 months, respectively, p = 0.948, and OS 25.7 vs. 22.6 months, p = 0.774). Patients treated with <b style='color:Tomato;'><i>sorafenib</i></b> required dose reduction due to toxicities less frequently than those treated with <b style='color:Tomato;'><i>sunitinib</i></b> (37 vs. 54%, p = 0.034). Haematological toxicity of grade 3 or 4 was more common in the <b style='color:Tomato;'><i>sunitinib</i></b> group than in the <b style='color:Tomato;'><i>sorafenib</i></b> group (45 vs. 4%, p < 0.001). Multivariate analysis showed old age, Heng's risk group, and bone and liver metastases, but not the type of vascular endothelial growth factor tyrosine kinase inhibitor, were independent prognostic factors affecting OS. ### conclusion The results of this study indicate that <b style='color:Tomato;'><i>sorafenib</i></b> has comparable efficacy to <b style='color:Tomato;'><i>sunitinib</i></b> in the treatment of mRCC patients and fewer and less severe toxicities, but the number of patients included in the study was small.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"identified","start":3,"end":13,"id":1,"ws":true},{"text":"49","start":14,"end":16,"id":2,"ws":true},{"text":"and","start":17,"end":20,"id":3,"ws":true},{"text":"220","start":21,"end":24,"id":4,"ws":true},{"text":"patients","start":25,"end":33,"id":5,"ws":true},{"text":"treated","start":34,"end":41,"id":6,"ws":true},{"text":"with","start":42,"end":46,"id":7,"ws":true},{"text":"sorafenib","start":47,"end":56,"id":8,"ws":true},{"text":"and","start":57,"end":60,"id":9,"ws":true},{"text":"sunitinib","start":61,"end":70,"id":10,"ws":true},{"text":",","start":71,"end":72,"id":11,"ws":true},{"text":"respectively","start":73,"end":85,"id":12,"ws":true},{"text":",","start":86,"end":87,"id":13,"ws":true},{"text":"as","start":88,"end":90,"id":14,"ws":true},{"text":"first-line","start":91,"end":101,"id":15,"ws":true},{"text":"therapy","start":102,"end":109,"id":16,"ws":true},{"text":"in","start":110,"end":112,"id":17,"ws":true},{"text":"the","start":113,"end":116,"id":18,"ws":true},{"text":"Asan","start":117,"end":121,"id":19,"ws":true},{"text":"Medical","start":122,"end":129,"id":20,"ws":true},{"text":"Centre","start":130,"end":136,"id":21,"ws":true},{"text":"from","start":137,"end":141,"id":22,"ws":true},{"text":"April","start":142,"end":147,"id":23,"ws":true},{"text":"2005","start":148,"end":152,"id":24,"ws":true},{"text":"to","start":153,"end":155,"id":25,"ws":true},{"text":"March","start":156,"end":161,"id":26,"ws":true},{"text":"2011","start":162,"end":166,"id":27,"ws":true},{"text":".","start":167,"end":168,"id":28,"ws":false}],"spans":[{"start":47,"end":56,"token_start":8,"token_end":8,"label":"DRUG"},{"start":61,"end":70,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23548259/","_input_hash":923599862,"_task_hash":-319191677,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We studied the combination of pemetrexed , a multi-targeted antifolate , and cetuximab , an mAb against the epidermal growth factor receptor , with radiotherapy in poor prognosis head and neck cancer .","paragraph":"<h3><u>Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multi-targeted</i></b> <b style='color:DodgerBlue;'><i>antifolate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>mAb</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>epidermal</i></b> <b style='color:DodgerBlue;'><i>growth</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>poor</i></b> <b style='color:DodgerBlue;'><i>prognosis</i></b> <b style='color:DodgerBlue;'><i>head</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>neck</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods Patients received <b style='color:Tomato;'><i>pemetrexed</i></b> on days 1, 22, and 43 on a dose-escalation scheme with starting level (0) 350 mg/m(2) (level -1, 200 mg/m(2); level +1, 500 mg/m(2)) with concurrent radiotherapy (2 Gy/day) and <b style='color:Tomato;'><i>cetuximab</i></b> in two separate cohorts, not previously irradiated (A) and previously irradiated (B), who received 70 and 60-66 Gy, respectively. Genetic polymorphisms of thymidylate synthase and methylenetetrahydrofolate reductase were evaluated. ### results Thirty-two patients were enrolled. The maximum tolerated dose of <b style='color:Tomato;'><i>pemetrexed</i></b> was 500 mg/m(2) in cohort A and 350 mg/m(2) in cohort B. Prophylactic antibiotics were required. In cohort A, two dose-limiting toxicities (DLTs) occurred (febrile neutropenia), one each at levels 0 and +1. In cohort B, two DLTs occurred at level +1 (febrile neutropenia; death from perforated duodenal ulcer and sepsis). Grade 3 mucositis was common. No association of gene polymorphisms with toxicity or efficacy was evident. ### conclusion The addition of <b style='color:Tomato;'><i>pemetrexed</i></b> 500 mg/m(2) to <b style='color:Tomato;'><i>cetuximab</i></b> and radiotherapy is recommended for further study in not previously irradiated patients.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"studied","start":3,"end":10,"id":1,"ws":true},{"text":"the","start":11,"end":14,"id":2,"ws":true},{"text":"combination","start":15,"end":26,"id":3,"ws":true},{"text":"of","start":27,"end":29,"id":4,"ws":true},{"text":"pemetrexed","start":30,"end":40,"id":5,"ws":true},{"text":",","start":41,"end":42,"id":6,"ws":true},{"text":"a","start":43,"end":44,"id":7,"ws":true},{"text":"multi-targeted","start":45,"end":59,"id":8,"ws":true},{"text":"antifolate","start":60,"end":70,"id":9,"ws":true},{"text":",","start":71,"end":72,"id":10,"ws":true},{"text":"and","start":73,"end":76,"id":11,"ws":true},{"text":"cetuximab","start":77,"end":86,"id":12,"ws":true},{"text":",","start":87,"end":88,"id":13,"ws":true},{"text":"an","start":89,"end":91,"id":14,"ws":true},{"text":"mAb","start":92,"end":95,"id":15,"ws":true},{"text":"against","start":96,"end":103,"id":16,"ws":true},{"text":"the","start":104,"end":107,"id":17,"ws":true},{"text":"epidermal","start":108,"end":117,"id":18,"ws":true},{"text":"growth","start":118,"end":124,"id":19,"ws":true},{"text":"factor","start":125,"end":131,"id":20,"ws":true},{"text":"receptor","start":132,"end":140,"id":21,"ws":true},{"text":",","start":141,"end":142,"id":22,"ws":true},{"text":"with","start":143,"end":147,"id":23,"ws":true},{"text":"radiotherapy","start":148,"end":160,"id":24,"ws":true},{"text":"in","start":161,"end":163,"id":25,"ws":true},{"text":"poor","start":164,"end":168,"id":26,"ws":true},{"text":"prognosis","start":169,"end":178,"id":27,"ws":true},{"text":"head","start":179,"end":183,"id":28,"ws":true},{"text":"and","start":184,"end":187,"id":29,"ws":true},{"text":"neck","start":188,"end":192,"id":30,"ws":true},{"text":"cancer","start":193,"end":199,"id":31,"ws":true},{"text":".","start":200,"end":201,"id":32,"ws":false}],"spans":[{"start":30,"end":40,"token_start":5,"token_end":5,"label":"DRUG"},{"start":77,"end":86,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21363880/","_input_hash":-1439597952,"_task_hash":-2062337790,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":5,"child":12,"head_span":{"start":30,"end":40,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":77,"end":86,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Boosting darunavir with ritonavir instead of with cobicistat may be preferred if darunavir is to be combined with etravirine in clinical practice .","paragraph":"<h3><u>Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.</u></h3>To determine the effect of <b style='color:Tomato;'><i>etravirine</i></b> on the pharmacokinetics of <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> and vice versa. Safety and tolerability of this combination were also evaluated. ### methods Open-label, fixed-sequence trial in two cohorts of HIV-infected patients on therapy with <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> 800/150\u2009mg once daily (DRV cohort; n\u2009=\u200915) or <b style='color:Tomato;'><i>etravirine</i></b> 400\u2009mg once daily (ETR cohort; n\u2009=\u200915). <b style='color:Tomato;'><i>etravirine</i></b> or <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> were added on days 1-14 and 1-7 in participants in the DRV or ETR cohort, respectively. Full pharmacokinetic profiles were obtained on days 0 and 14 in the DRV cohort, and on days 0 and 7 in the ETR cohort. <b style='color:Tomato;'><i>darunavir</i></b>, <b style='color:Tomato;'><i>cobicistat</i></b> and <b style='color:Tomato;'><i>etravirine</i></b> pharmacokinetic parameters [AUC0-24, Cmax and trough concentrations in plasma (C24)] were calculated for each individual by non-compartmental analysis and were compared using linear mixed-effects models. Adverse events and HIV-1 RNA in plasma were monitored. ### results <b style='color:Tomato;'><i>etravirine</i></b> co-administration decreased <b style='color:Tomato;'><i>cobicistat</i></b> AUC0-24, Cmax and C24 by 30%, 14% and 66%, respectively. Although <b style='color:Tomato;'><i>darunavir</i></b> AUC0-24 and Cmax were unchanged by <b style='color:Tomato;'><i>etravirine</i></b>, <b style='color:Tomato;'><i>darunavir</i></b> C24 was 56% lower for <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> co-administered with <b style='color:Tomato;'><i>etravirine</i></b> relative to <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> alone. <b style='color:Tomato;'><i>etravirine</i></b> pharmacokinetics were unchanged by <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b>. Treatments were well tolerated, and HIV-1 RNA remained undetectable in all participants. ### conclusions Although <b style='color:Tomato;'><i>etravirine</i></b> pharmacokinetics was unchanged by <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b>, there was a significant decrease in <b style='color:Tomato;'><i>cobicistat</i></b> exposure and in <b style='color:Tomato;'><i>darunavir</i></b> C24 when <b style='color:Tomato;'><i>darunavir</i></b>/<b style='color:Tomato;'><i>cobicistat</i></b> was co-administered with <b style='color:Tomato;'><i>etravirine</i></b>. <b style='color:DodgerBlue;'><i>Boosting</i></b> <b style='color:MediumOrchid;'><i>darunavir</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ritonavir</i></b> <b style='color:DodgerBlue;'><i>instead</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>cobicistat</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>if</i></b> <b style='color:MediumOrchid;'><i>darunavir</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>etravirine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>practice</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Boosting","start":0,"end":8,"id":0,"ws":true},{"text":"darunavir","start":9,"end":18,"id":1,"ws":true},{"text":"with","start":19,"end":23,"id":2,"ws":true},{"text":"ritonavir","start":24,"end":33,"id":3,"ws":true},{"text":"instead","start":34,"end":41,"id":4,"ws":true},{"text":"of","start":42,"end":44,"id":5,"ws":true},{"text":"with","start":45,"end":49,"id":6,"ws":true},{"text":"cobicistat","start":50,"end":60,"id":7,"ws":true},{"text":"may","start":61,"end":64,"id":8,"ws":true},{"text":"be","start":65,"end":67,"id":9,"ws":true},{"text":"preferred","start":68,"end":77,"id":10,"ws":true},{"text":"if","start":78,"end":80,"id":11,"ws":true},{"text":"darunavir","start":81,"end":90,"id":12,"ws":true},{"text":"is","start":91,"end":93,"id":13,"ws":true},{"text":"to","start":94,"end":96,"id":14,"ws":true},{"text":"be","start":97,"end":99,"id":15,"ws":true},{"text":"combined","start":100,"end":108,"id":16,"ws":true},{"text":"with","start":109,"end":113,"id":17,"ws":true},{"text":"etravirine","start":114,"end":124,"id":18,"ws":true},{"text":"in","start":125,"end":127,"id":19,"ws":true},{"text":"clinical","start":128,"end":136,"id":20,"ws":true},{"text":"practice","start":137,"end":145,"id":21,"ws":true},{"text":".","start":146,"end":147,"id":22,"ws":false}],"spans":[{"start":9,"end":18,"token_start":1,"token_end":1,"label":"DRUG"},{"start":24,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},{"start":50,"end":60,"token_start":7,"token_end":7,"label":"DRUG"},{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},{"start":114,"end":124,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29237008/","_input_hash":-1591603289,"_task_hash":-1954409406,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":1,"child":3,"head_span":{"start":9,"end":18,"token_start":1,"token_end":1,"label":"DRUG"},"child_span":{"start":24,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":12,"child":18,"head_span":{"start":81,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":114,"end":124,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"Single-agent paclitaxel and vinorelbine are recommended treatments for advanced breast cancer ( ABC ) non-responsive to hormone therapy and without visceral crisis .","paragraph":"<h3><u>Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial).</u></h3> <b style='color:DodgerBlue;'><i>Single-agent</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>treatments</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ABC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>non-responsive</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>hormone</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>visceral</i></b> <b style='color:DodgerBlue;'><i>crisis</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This phase II trial compared first-line oral <b style='color:Tomato;'><i>vinorelbine</i></b> versus weekly <b style='color:Tomato;'><i>paclitaxel</i></b> for ABC. ### methods Eligible female patients had measurable locally recurrent/metastatic estrogen receptor-positive HER2-negative breast cancer and had received prior endocrine therapy (any setting) but no chemotherapy for ABC. Patients were stratified by prior taxane and visceral metastases and randomized to either oral <b style='color:Tomato;'><i>vinorelbine</i></b> 80\u202fmg/m ### results The 131 randomized patients had received a median of 2 prior endocrine therapies; >70% had prior (neo)adjuvant chemotherapy and 79% visceral metastases. DCR was 75.8% (95% confidence interval: 63.6-85.5%) with <b style='color:Tomato;'><i>vinorelbine</i></b> and 75.4% (63.1-85.2%) with <b style='color:Tomato;'><i>paclitaxel</i></b>. The most common grade 3/4 adverse events were neutropenia (52%), fatigue (11%), and vomiting (5%) with <b style='color:Tomato;'><i>vinorelbine</i></b>, and neutropenia (17%), dyspnea (6%), hypertension (6%), and peripheral sensory neuropathy (5%) with <b style='color:Tomato;'><i>paclitaxel</i></b>. Grade 2 alopecia occurred in 2% of <b style='color:Tomato;'><i>vinorelbine</i></b>-treated and 34% of <b style='color:Tomato;'><i>paclitaxel</i></b>-treated patients. Neither arm showed relevant global health status changes. ### conclusion Oral <b style='color:Tomato;'><i>vinorelbine</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> demonstrated similar DCRs (\u223c75%). Safety profiles differed and, together with administration route and convenience, may influence treatment choice (EudraCT number, 2012-003530-16).","tokens":[{"text":"Single-agent","start":0,"end":12,"id":0,"ws":true},{"text":"paclitaxel","start":13,"end":23,"id":1,"ws":true},{"text":"and","start":24,"end":27,"id":2,"ws":true},{"text":"vinorelbine","start":28,"end":39,"id":3,"ws":true},{"text":"are","start":40,"end":43,"id":4,"ws":true},{"text":"recommended","start":44,"end":55,"id":5,"ws":true},{"text":"treatments","start":56,"end":66,"id":6,"ws":true},{"text":"for","start":67,"end":70,"id":7,"ws":true},{"text":"advanced","start":71,"end":79,"id":8,"ws":true},{"text":"breast","start":80,"end":86,"id":9,"ws":true},{"text":"cancer","start":87,"end":93,"id":10,"ws":true},{"text":"(","start":94,"end":95,"id":11,"ws":true},{"text":"ABC","start":96,"end":99,"id":12,"ws":true},{"text":")","start":100,"end":101,"id":13,"ws":true},{"text":"non-responsive","start":102,"end":116,"id":14,"ws":true},{"text":"to","start":117,"end":119,"id":15,"ws":true},{"text":"hormone","start":120,"end":127,"id":16,"ws":true},{"text":"therapy","start":128,"end":135,"id":17,"ws":true},{"text":"and","start":136,"end":139,"id":18,"ws":true},{"text":"without","start":140,"end":147,"id":19,"ws":true},{"text":"visceral","start":148,"end":156,"id":20,"ws":true},{"text":"crisis","start":157,"end":163,"id":21,"ws":true},{"text":".","start":164,"end":165,"id":22,"ws":false}],"spans":[{"start":13,"end":23,"token_start":1,"token_end":1,"label":"DRUG"},{"start":28,"end":39,"token_start":3,"token_end":3,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30802822/","_input_hash":824817462,"_task_hash":979881391,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Nal-IRI with 5-fluorouracil ( 5-FU ) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial ( AIO-YMO HEP-0315 )","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Nal-IRI</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>biliary</i></b> <b style='color:DodgerBlue;'><i>tract</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>NIFE</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AIO-YMO</i></b> <b style='color:DodgerBlue;'><i>HEP-0315</i></b> <b style='color:DodgerBlue;'><i>)</i></b></u></h3>Biliary tract cancer (BTC) has a high mortality. Primary diagnosis is frequently delayed due to mostly unspecific symptoms, resulting in a high number of advanced cases at the time of diagnosis. Advanced BTCs are in principle chemotherapy sensitive as determined by improved disease control, survival and quality of life (QoL). However, median OS does not exceed 11.7\u2009months with the current standard of care <b style='color:Tomato;'><i>gemcitabine</i></b> plus cisplatin. Thereby, novel drug formulations like nanoliposomal-<b style='color:Tomato;'><i>irinotecan</i></b> (nal-IRI) in combination with 5- <b style='color:Tomato;'><i>fluorouracil</i></b> (5-FU)/<b style='color:Tomato;'><i>leucovorin</i></b> may have the potential to improve therapeutic outcomes in this disease. ### methods NIFE is an interventional, prospective, randomized, controlled, open label, two-sided phase II study. Within the study, 2\u2009\u00d7\u200946 patients with locally advanced, non-resectable or metastatic BTC are to be enrolled by two stage design of Simon. Data analysis will be done unconnected for both arms. Patients are allocated in two arms: Arm A (experimental intervention) nal-IRI mg/m ### discussion The NIFE trial evaluates the potential of a nanoliposomal-<b style='color:Tomato;'><i>irinotecan</i></b>/5-FU/<b style='color:Tomato;'><i>leucovorin</i></b> combination in the first line therapy of advanced BTCs and additionally offers a unique chance for translational research. ### Trial Registration Clinicaltrials.gov NCT03044587. Registration Date February 7th 2017.","tokens":[{"text":"Nal-IRI","start":0,"end":7,"id":0,"ws":true},{"text":"with","start":8,"end":12,"id":1,"ws":true},{"text":"5-fluorouracil","start":13,"end":27,"id":2,"ws":true},{"text":"(","start":28,"end":29,"id":3,"ws":true},{"text":"5-FU","start":30,"end":34,"id":4,"ws":true},{"text":")","start":35,"end":36,"id":5,"ws":true},{"text":"and","start":37,"end":40,"id":6,"ws":true},{"text":"leucovorin","start":41,"end":51,"id":7,"ws":true},{"text":"or","start":52,"end":54,"id":8,"ws":true},{"text":"gemcitabine","start":55,"end":66,"id":9,"ws":true},{"text":"plus","start":67,"end":71,"id":10,"ws":true},{"text":"cisplatin","start":72,"end":81,"id":11,"ws":true},{"text":"in","start":82,"end":84,"id":12,"ws":true},{"text":"advanced","start":85,"end":93,"id":13,"ws":true},{"text":"biliary","start":94,"end":101,"id":14,"ws":true},{"text":"tract","start":102,"end":107,"id":15,"ws":true},{"text":"cancer","start":108,"end":114,"id":16,"ws":true},{"text":"-","start":115,"end":116,"id":17,"ws":true},{"text":"the","start":117,"end":120,"id":18,"ws":true},{"text":"NIFE","start":121,"end":125,"id":19,"ws":true},{"text":"trial","start":126,"end":131,"id":20,"ws":true},{"text":"(","start":132,"end":133,"id":21,"ws":true},{"text":"AIO-YMO","start":134,"end":141,"id":22,"ws":true},{"text":"HEP-0315","start":142,"end":150,"id":23,"ws":true},{"text":")","start":151,"end":152,"id":24,"ws":false}],"spans":[{"start":0,"end":7,"token_start":0,"token_end":0,"label":"DRUG"},{"start":13,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},{"start":41,"end":51,"token_start":7,"token_end":7,"label":"DRUG"},{"start":55,"end":66,"token_start":9,"token_end":9,"label":"DRUG"},{"start":72,"end":81,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31646981/","_input_hash":-1862521886,"_task_hash":-1209946568,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":7,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":13,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":2,"child":7,"head_span":{"start":13,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":41,"end":51,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":9,"child":11,"head_span":{"start":55,"end":66,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":72,"end":81,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":[],"answer":"accept"}
{"text":"Ten patients were withdrawn from the terbutaline group because treatment was insufficiently effective , whereas only one dropped out of the budesonide group .","paragraph":"<h3><u>Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma.</u></h3>The presence of airway inflammation even in mild asthma points to the potential value of antiinflammatory therapy. We compared the effect of an inhaled corticosteroid, <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b>, with that of an inhaled beta 2-agonist, <b style='color:Tomato;'><i>terbutaline</i></b>, in the long-term treatment of newly detected asthma. ### methods We studied 103 patients (29 male and 74 female patients 15 to 64 years old) in whom asthma had appeared within the previous year. The patients were randomly assigned in blinded fashion to two treatment groups: one to receive 600 micrograms of inhaled <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> twice a day, and the other to receive 375 micrograms of inhaled <b style='color:Tomato;'><i>terbutaline</i></b> twice a day. The study period was two years. ### results After six weeks of treatment, the patients treated with <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> tolerated inhaled histamine better than the patients treated with <b style='color:Tomato;'><i>terbutaline</i></b> (a difference of one doubling dose step, P less than 0.001), and the difference was sustained. Patients' diaries kept during the first three months of the study and during the last month of the first and second years showed <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> to be more effective than <b style='color:Tomato;'><i>terbutaline</i></b> in improving peak expiratory flow in the morning (average increase from the pretreatment value, 32.8 liters per minute for <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> vs. 4.8 liters per minute for <b style='color:Tomato;'><i>terbutaline</i></b>; P less than 0.001) and in the evening (P less than 0.01). <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> was also more effective in reducing the symptoms of asthma (P less than 0.01) and the use of supplemental beta 2-agonist medication (P less than 0.01). <b style='color:DodgerBlue;'><i>Ten</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>withdrawn</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>terbutaline</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>insufficiently</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>whereas</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>dropped</i></b> <b style='color:DodgerBlue;'><i>out</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>budesonide</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The adverse reactions to both treatments were few and mild. ### conclusions Antiinflammatory therapy with inhaled <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b> is an effective first-line treatment for patients with newly detected, mild asthma, and it is superior to the use of <b style='color:Tomato;'><i>terbutaline</i></b> in such patients.","tokens":[{"text":"Ten","start":0,"end":3,"id":0,"ws":true},{"text":"patients","start":4,"end":12,"id":1,"ws":true},{"text":"were","start":13,"end":17,"id":2,"ws":true},{"text":"withdrawn","start":18,"end":27,"id":3,"ws":true},{"text":"from","start":28,"end":32,"id":4,"ws":true},{"text":"the","start":33,"end":36,"id":5,"ws":true},{"text":"terbutaline","start":37,"end":48,"id":6,"ws":true},{"text":"group","start":49,"end":54,"id":7,"ws":true},{"text":"because","start":55,"end":62,"id":8,"ws":true},{"text":"treatment","start":63,"end":72,"id":9,"ws":true},{"text":"was","start":73,"end":76,"id":10,"ws":true},{"text":"insufficiently","start":77,"end":91,"id":11,"ws":true},{"text":"effective","start":92,"end":101,"id":12,"ws":true},{"text":",","start":102,"end":103,"id":13,"ws":true},{"text":"whereas","start":104,"end":111,"id":14,"ws":true},{"text":"only","start":112,"end":116,"id":15,"ws":true},{"text":"one","start":117,"end":120,"id":16,"ws":true},{"text":"dropped","start":121,"end":128,"id":17,"ws":true},{"text":"out","start":129,"end":132,"id":18,"ws":true},{"text":"of","start":133,"end":135,"id":19,"ws":true},{"text":"the","start":136,"end":139,"id":20,"ws":true},{"text":"budesonide","start":140,"end":150,"id":21,"ws":true},{"text":"group","start":151,"end":156,"id":22,"ws":true},{"text":".","start":157,"end":158,"id":23,"ws":false}],"spans":[{"start":37,"end":48,"token_start":6,"token_end":6,"label":"DRUG"},{"start":140,"end":150,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2062329/","_input_hash":-1100714668,"_task_hash":1982259093,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We conducted a double-blind cross-over study in ten volunteers aged from 19 to 30 years , to compare the pain control effects of a single oral dose of two analgesic compounds ( drug A : propyphenazone mg 250 , ethylmorphine mg 5 , caffeine mg 5 ; drug B : dipyrone mg 500 , diphenhydramine mg 12.5 , adiphenine mg 5 , ethyl aminobenzoate mg 2.5 ) in an experimental pain model using stimulation of dental pulp .","paragraph":"<h3><u>[Electric stimulation of the dental pulp in the evaluation of the central effect of analgesics].</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>cross-over</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>ten</i></b> <b style='color:DodgerBlue;'><i>volunteers</i></b> <b style='color:DodgerBlue;'><i>aged</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>19</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>control</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>analgesic</i></b> <b style='color:DodgerBlue;'><i>compounds</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>propyphenazone</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>250</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ethylmorphine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>caffeine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>dipyrone</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>500</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>diphenhydramine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>12.5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>adiphenine</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ethyl</i></b> <b style='color:DodgerBlue;'><i>aminobenzoate</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>2.5</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>stimulation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>dental</i></b> <b style='color:DodgerBlue;'><i>pulp</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Constant voltage stimuli were delivered through silver chloride electrodes placed in contact with the vestibular surface of the upper medial incisor. At the beginning of the session, the pain input was graded by asking the subject to identify the weakest stimulus perceived (threshold level) and the strongest stimulus endurable (tolerance level). The range between threshold and tolerance level was divided in nine steps plus a subliminal step. The ten steps were delivered randomly, and each series of steps was repeated eight times. The subjects were instructed to rate the pain sensation in an arbitrary scale of 5 degrees. The procedure was repeated at 60 min and 180 min after drug administration. Each subject received two tablets of drug A or drug B in two different sessions at weekly intervals. Statistical analysis of the procedures showed that neither drug A nor drug B significantly affected the pain threshold. Drug A significantly reduced the total pain score (P less than 0.01) and its action peaked 60 min after administration.(ABSTRACT TRUNCATED AT 250 WORDS)","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"conducted","start":3,"end":12,"id":1,"ws":true},{"text":"a","start":13,"end":14,"id":2,"ws":true},{"text":"double-blind","start":15,"end":27,"id":3,"ws":true},{"text":"cross-over","start":28,"end":38,"id":4,"ws":true},{"text":"study","start":39,"end":44,"id":5,"ws":true},{"text":"in","start":45,"end":47,"id":6,"ws":true},{"text":"ten","start":48,"end":51,"id":7,"ws":true},{"text":"volunteers","start":52,"end":62,"id":8,"ws":true},{"text":"aged","start":63,"end":67,"id":9,"ws":true},{"text":"from","start":68,"end":72,"id":10,"ws":true},{"text":"19","start":73,"end":75,"id":11,"ws":true},{"text":"to","start":76,"end":78,"id":12,"ws":true},{"text":"30","start":79,"end":81,"id":13,"ws":true},{"text":"years","start":82,"end":87,"id":14,"ws":true},{"text":",","start":88,"end":89,"id":15,"ws":true},{"text":"to","start":90,"end":92,"id":16,"ws":true},{"text":"compare","start":93,"end":100,"id":17,"ws":true},{"text":"the","start":101,"end":104,"id":18,"ws":true},{"text":"pain","start":105,"end":109,"id":19,"ws":true},{"text":"control","start":110,"end":117,"id":20,"ws":true},{"text":"effects","start":118,"end":125,"id":21,"ws":true},{"text":"of","start":126,"end":128,"id":22,"ws":true},{"text":"a","start":129,"end":130,"id":23,"ws":true},{"text":"single","start":131,"end":137,"id":24,"ws":true},{"text":"oral","start":138,"end":142,"id":25,"ws":true},{"text":"dose","start":143,"end":147,"id":26,"ws":true},{"text":"of","start":148,"end":150,"id":27,"ws":true},{"text":"two","start":151,"end":154,"id":28,"ws":true},{"text":"analgesic","start":155,"end":164,"id":29,"ws":true},{"text":"compounds","start":165,"end":174,"id":30,"ws":true},{"text":"(","start":175,"end":176,"id":31,"ws":true},{"text":"drug","start":177,"end":181,"id":32,"ws":true},{"text":"A","start":182,"end":183,"id":33,"ws":true},{"text":":","start":184,"end":185,"id":34,"ws":true},{"text":"propyphenazone","start":186,"end":200,"id":35,"ws":true},{"text":"mg","start":201,"end":203,"id":36,"ws":true},{"text":"250","start":204,"end":207,"id":37,"ws":true},{"text":",","start":208,"end":209,"id":38,"ws":true},{"text":"ethylmorphine","start":210,"end":223,"id":39,"ws":true},{"text":"mg","start":224,"end":226,"id":40,"ws":true},{"text":"5","start":227,"end":228,"id":41,"ws":true},{"text":",","start":229,"end":230,"id":42,"ws":true},{"text":"caffeine","start":231,"end":239,"id":43,"ws":true},{"text":"mg","start":240,"end":242,"id":44,"ws":true},{"text":"5","start":243,"end":244,"id":45,"ws":true},{"text":";","start":245,"end":246,"id":46,"ws":true},{"text":"drug","start":247,"end":251,"id":47,"ws":true},{"text":"B","start":252,"end":253,"id":48,"ws":true},{"text":":","start":254,"end":255,"id":49,"ws":true},{"text":"dipyrone","start":256,"end":264,"id":50,"ws":true},{"text":"mg","start":265,"end":267,"id":51,"ws":true},{"text":"500","start":268,"end":271,"id":52,"ws":true},{"text":",","start":272,"end":273,"id":53,"ws":true},{"text":"diphenhydramine","start":274,"end":289,"id":54,"ws":true},{"text":"mg","start":290,"end":292,"id":55,"ws":true},{"text":"12.5","start":293,"end":297,"id":56,"ws":true},{"text":",","start":298,"end":299,"id":57,"ws":true},{"text":"adiphenine","start":300,"end":310,"id":58,"ws":true},{"text":"mg","start":311,"end":313,"id":59,"ws":true},{"text":"5","start":314,"end":315,"id":60,"ws":true},{"text":",","start":316,"end":317,"id":61,"ws":true},{"text":"ethyl","start":318,"end":323,"id":62,"ws":true},{"text":"aminobenzoate","start":324,"end":337,"id":63,"ws":true},{"text":"mg","start":338,"end":340,"id":64,"ws":true},{"text":"2.5","start":341,"end":344,"id":65,"ws":true},{"text":")","start":345,"end":346,"id":66,"ws":true},{"text":"in","start":347,"end":349,"id":67,"ws":true},{"text":"an","start":350,"end":352,"id":68,"ws":true},{"text":"experimental","start":353,"end":365,"id":69,"ws":true},{"text":"pain","start":366,"end":370,"id":70,"ws":true},{"text":"model","start":371,"end":376,"id":71,"ws":true},{"text":"using","start":377,"end":382,"id":72,"ws":true},{"text":"stimulation","start":383,"end":394,"id":73,"ws":true},{"text":"of","start":395,"end":397,"id":74,"ws":true},{"text":"dental","start":398,"end":404,"id":75,"ws":true},{"text":"pulp","start":405,"end":409,"id":76,"ws":true},{"text":".","start":410,"end":411,"id":77,"ws":false}],"spans":[{"start":186,"end":200,"token_start":35,"token_end":35,"label":"DRUG"},{"start":274,"end":289,"token_start":54,"token_end":54,"label":"DRUG"},{"start":300,"end":310,"token_start":58,"token_end":58,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/1979494/","_input_hash":52952750,"_task_hash":1148323975,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":35,"child":39,"head_span":{"start":186,"end":200,"token_start":35,"token_end":35,"label":"DRUG"},"child_span":{"start":210,"end":223,"token_start":39,"token_end":39,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":39,"child":43,"head_span":{"start":210,"end":223,"token_start":39,"token_end":39,"label":null},"child_span":{"start":231,"end":239,"token_start":43,"token_end":43,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":50,"child":54,"head_span":{"start":256,"end":264,"token_start":50,"token_end":50,"label":null},"child_span":{"start":274,"end":289,"token_start":54,"token_end":54,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":54,"child":58,"head_span":{"start":274,"end":289,"token_start":54,"token_end":54,"label":"DRUG"},"child_span":{"start":300,"end":310,"token_start":58,"token_end":58,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":58,"child":63,"head_span":{"start":300,"end":310,"token_start":58,"token_end":58,"label":"DRUG"},"child_span":{"start":324,"end":337,"token_start":63,"token_end":63,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Forty-three mCRC patients who received cetuximab or panitumumab between April 2012 and December 2015 were the subjects of the present study .","paragraph":"<h3><u>Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.</u></h3>Anti-EGFR monoclonal antibody is effective for KRAS wild-type metastatic colorectal cancer (mCRC), but frequently causes several adverse reactions, including hypomagnesemia and skin disorders. The present study was designed to investigate the relationship between the incidence of adverse reactions and therapeutic effects in mCRC patients receiving anti-EGFR monoclonal antibody in combination with first-line chemotherapy. ### methods <b style='color:DodgerBlue;'><i>Forty-three</i></b> <b style='color:DodgerBlue;'><i>mCRC</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:MediumOrchid;'><i>cetuximab</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>panitumumab</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>April</i></b> <b style='color:DodgerBlue;'><i>2012</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>December</i></b> <b style='color:DodgerBlue;'><i>2015</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>subjects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b> All patients were pretreated with oral <b style='color:Tomato;'><i>minocycline</i></b> in combination with skin treatment using moisturizer for prevention of skin rash. Hypomagnesemia and acneiform rash were graded according to the Common Terminology Criteria for Adverse Events, version 3.0. Overall response rate (ORR) and time to treatment failure (TTF) were compared between patients with and without these adverse events. ### results The incidence rates of hypomagnesemia and acneiform rash were 32.6\u00a0% (grade 1: 20.9\u00a0%, grade 2: 11.6\u00a0%) and 93.0\u00a0% (grade 1: 41.9\u00a0%, grade 2: 41.9\u00a0%, grade 3: 9.3\u00a0%), respectively. ORR was significantly higher in patients with hypomagnesemia than in those without it (71.4 vs 34.5\u00a0%, P\u00a0=\u00a00.048). Median TTF tended to be longer, though not significantly, in patients with hypomagnesemia than in those without it. However, no significant difference in both ORR and median TTF was observed between patients with and without acneiform rash. ### conclusion Hypomagnesemia may become a predicting factor for therapeutic effects of anti-EGFR monoclonal antibody in mCRC patients.","tokens":[{"text":"Forty-three","start":0,"end":11,"id":0,"ws":true},{"text":"mCRC","start":12,"end":16,"id":1,"ws":true},{"text":"patients","start":17,"end":25,"id":2,"ws":true},{"text":"who","start":26,"end":29,"id":3,"ws":true},{"text":"received","start":30,"end":38,"id":4,"ws":true},{"text":"cetuximab","start":39,"end":48,"id":5,"ws":true},{"text":"or","start":49,"end":51,"id":6,"ws":true},{"text":"panitumumab","start":52,"end":63,"id":7,"ws":true},{"text":"between","start":64,"end":71,"id":8,"ws":true},{"text":"April","start":72,"end":77,"id":9,"ws":true},{"text":"2012","start":78,"end":82,"id":10,"ws":true},{"text":"and","start":83,"end":86,"id":11,"ws":true},{"text":"December","start":87,"end":95,"id":12,"ws":true},{"text":"2015","start":96,"end":100,"id":13,"ws":true},{"text":"were","start":101,"end":105,"id":14,"ws":true},{"text":"the","start":106,"end":109,"id":15,"ws":true},{"text":"subjects","start":110,"end":118,"id":16,"ws":true},{"text":"of","start":119,"end":121,"id":17,"ws":true},{"text":"the","start":122,"end":125,"id":18,"ws":true},{"text":"present","start":126,"end":133,"id":19,"ws":true},{"text":"study","start":134,"end":139,"id":20,"ws":true},{"text":".","start":140,"end":141,"id":21,"ws":false}],"spans":[{"start":39,"end":48,"token_start":5,"token_end":5,"label":"DRUG"},{"start":52,"end":63,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27106835/","_input_hash":-1825043399,"_task_hash":-1164830701,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Furthermore , 11 AML patients at primary diagnosis , including five AML patients with P-gp overexpression , who were treated with idarubicin , vepesid , and cytarabine V ( ara-C ) showed a complete remission .","paragraph":"<h3><u>Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes--first experience with their reversal.</u></h3>P-glycoprotein (P-gp) expression in mononuclear bone marrow cells was analyzed in 119 patients, including 60 with chronic myelogenous leukemia (CML), 48 with myelodysplastic syndromes (MDS), and 11 with acute myelogenous leukemia (AML). For P-gp measurement an immunocytological method using monoclonal antibodies C219, 4E3, and MRK 16 and the reverse transcription-polymerase chain reaction technique were applied. According to our results obtained in healthy volunteers using the immunocytological method, the limit for P-gp overexpression was set at > or = 10% P-gp-positive mononuclear bone marrow cells and at > or = 30% P-gp-positive mononuclear peripheral blood cells. All 42 CML patients in chronic phase had normal P-gp expression. P-gp overexpression was demonstrated in four of six patients in accelerated myelogenous blast cell phase and in four of 12 CML-BC patients. Of eight CML patients in blast crisis (BC) with normal P-gp expression, partial remission was achieved in three and minor response in five after <b style='color:Tomato;'><i>prednisone</i></b>/vindesine therapy. All four of the 12 CML-BC patients with P-gp overexpression did not respond to this therapy. Normal P-gp expression was seen in 41 (85.4%) of 48 untreated MDS patients. While P-gp overexpression did not develop during therapy in any of the myelodysplastic syndrome patients treated with low-dose ara-C alone, four of eight treated with low-dose ara-C plus GM-CSF and four of 11 treated with low-dose ara-C and IL-3 developed P-gp overexpression after therapy. <b style='color:DodgerBlue;'><i>Furthermore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>11</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>diagnosis</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:DodgerBlue;'><i>five</i></b> <b style='color:DodgerBlue;'><i>AML</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>P-gp</i></b> <b style='color:DodgerBlue;'><i>overexpression</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>idarubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>vepesid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cytarabine</i></b> <b style='color:DodgerBlue;'><i>V</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ara-C</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>complete</i></b> <b style='color:DodgerBlue;'><i>remission</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Additionally, one <b style='color:Tomato;'><i>daunorubicin</i></b>-<b style='color:Tomato;'><i>cytarabine</i></b>-pretreated refractory AML patient was treated with the oral form of the P-gp modulator drug dexniguldipine and achieved complete remission for a duration of 7 months. Our results suggest that in CML patients in BC, P-gp expression influences outcome after therapy. Further more, studies in a larger series of patients are necessary to prove the efficacy and toxicity of <b style='color:Tomato;'><i>idarubicin</i></b>/vepesid and cytardbine--or dexniguldipine-containing--therapy in relation to P-gp expression of AML patients.","tokens":[{"text":"Furthermore","start":0,"end":11,"id":0,"ws":true},{"text":",","start":12,"end":13,"id":1,"ws":true},{"text":"11","start":14,"end":16,"id":2,"ws":true},{"text":"AML","start":17,"end":20,"id":3,"ws":true},{"text":"patients","start":21,"end":29,"id":4,"ws":true},{"text":"at","start":30,"end":32,"id":5,"ws":true},{"text":"primary","start":33,"end":40,"id":6,"ws":true},{"text":"diagnosis","start":41,"end":50,"id":7,"ws":true},{"text":",","start":51,"end":52,"id":8,"ws":true},{"text":"including","start":53,"end":62,"id":9,"ws":true},{"text":"five","start":63,"end":67,"id":10,"ws":true},{"text":"AML","start":68,"end":71,"id":11,"ws":true},{"text":"patients","start":72,"end":80,"id":12,"ws":true},{"text":"with","start":81,"end":85,"id":13,"ws":true},{"text":"P-gp","start":86,"end":90,"id":14,"ws":true},{"text":"overexpression","start":91,"end":105,"id":15,"ws":true},{"text":",","start":106,"end":107,"id":16,"ws":true},{"text":"who","start":108,"end":111,"id":17,"ws":true},{"text":"were","start":112,"end":116,"id":18,"ws":true},{"text":"treated","start":117,"end":124,"id":19,"ws":true},{"text":"with","start":125,"end":129,"id":20,"ws":true},{"text":"idarubicin","start":130,"end":140,"id":21,"ws":true},{"text":",","start":141,"end":142,"id":22,"ws":true},{"text":"vepesid","start":143,"end":150,"id":23,"ws":true},{"text":",","start":151,"end":152,"id":24,"ws":true},{"text":"and","start":153,"end":156,"id":25,"ws":true},{"text":"cytarabine","start":157,"end":167,"id":26,"ws":true},{"text":"V","start":168,"end":169,"id":27,"ws":true},{"text":"(","start":170,"end":171,"id":28,"ws":true},{"text":"ara-C","start":172,"end":177,"id":29,"ws":true},{"text":")","start":178,"end":179,"id":30,"ws":true},{"text":"showed","start":180,"end":186,"id":31,"ws":true},{"text":"a","start":187,"end":188,"id":32,"ws":true},{"text":"complete","start":189,"end":197,"id":33,"ws":true},{"text":"remission","start":198,"end":207,"id":34,"ws":true},{"text":".","start":208,"end":209,"id":35,"ws":false}],"spans":[{"start":130,"end":140,"token_start":21,"token_end":21,"label":"DRUG"},{"start":143,"end":150,"token_start":23,"token_end":23,"label":"DRUG"},{"start":157,"end":167,"token_start":26,"token_end":26,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7914749/","_input_hash":-1874619752,"_task_hash":363322718,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":21,"child":23,"head_span":{"start":130,"end":140,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":143,"end":150,"token_start":23,"token_end":23,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":23,"child":26,"head_span":{"start":143,"end":150,"token_start":23,"token_end":23,"label":"DRUG"},"child_span":{"start":157,"end":167,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>Ib</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>Bavituximab</i></b> <b style='color:DodgerBlue;'><i>With</i></b> <b style='color:MediumOrchid;'><i>Carboplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Pemetrexed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Chemotherapy-Naive</i></b> <b style='color:DodgerBlue;'><i>Advanced</i></b> <b style='color:DodgerBlue;'><i>Nonsquamous</i></b> <b style='color:DodgerBlue;'><i>Non-Small-Cell</i></b> <b style='color:DodgerBlue;'><i>Lung</i></b> <b style='color:DodgerBlue;'><i>Cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>bavituximab</i></b> is an immunomodulatory chimeric monoclonal antibody that inhibits phosphatidylserine signaling, which promotes innate and adaptive immune responses. In this phase Ib trial we evaluated the safety, tolerability, and preliminary antitumor activity of <b style='color:Tomato;'><i>pemetrexed</i></b>, <b style='color:Tomato;'><i>carboplatin</i></b>, <b style='color:Tomato;'><i>bavituximab</i></b> in advanced non-small-cell lung cancer (NSCLC). ### Patients And Methods Patients with advanced nonsquamous NSCLC and performance status 0 or 1 were treated with <b style='color:Tomato;'><i>pemetrexed</i></b> 500 mg/m ### results Between March 29, 2011 and December 30, 2013, 26 patients were enrolled. Three patients each were enrolled into dose escalation cohorts of <b style='color:Tomato;'><i>bavituximab</i></b> (0.3, 1, and 3 mg/kg). Therapy was well tolerated with no DLTs, and toxicities were consistent with those expected from <b style='color:Tomato;'><i>pemetrexed</i></b>/<b style='color:Tomato;'><i>carboplatin</i></b>. Overall response was 28%, with a median progression-free and overall survival of 4.8 months and 12.2 months, respectively. ### conclusion The combination of <b style='color:Tomato;'><i>pemetrexed</i></b>, <b style='color:Tomato;'><i>carboplatin</i></b>, <b style='color:Tomato;'><i>bavituximab</i></b> is well tolerated. However, with toxicities and preliminary efficacy signal similar to <b style='color:Tomato;'><i>pemetrexed</i></b>/<b style='color:Tomato;'><i>carboplatin</i></b> alone, further studies of <b style='color:Tomato;'><i>bavituximab</i></b> should focus on ways to enhance its immunomodulatory role.","tokens":[{"text":"Phase","start":0,"end":5,"id":0,"ws":true},{"text":"Ib","start":6,"end":8,"id":1,"ws":true},{"text":"Study","start":9,"end":14,"id":2,"ws":true},{"text":"of","start":15,"end":17,"id":3,"ws":true},{"text":"Bavituximab","start":18,"end":29,"id":4,"ws":true},{"text":"With","start":30,"end":34,"id":5,"ws":true},{"text":"Carboplatin","start":35,"end":46,"id":6,"ws":true},{"text":"and","start":47,"end":50,"id":7,"ws":true},{"text":"Pemetrexed","start":51,"end":61,"id":8,"ws":true},{"text":"in","start":62,"end":64,"id":9,"ws":true},{"text":"Chemotherapy-Naive","start":65,"end":83,"id":10,"ws":true},{"text":"Advanced","start":84,"end":92,"id":11,"ws":true},{"text":"Nonsquamous","start":93,"end":104,"id":12,"ws":true},{"text":"Non-Small-Cell","start":105,"end":119,"id":13,"ws":true},{"text":"Lung","start":120,"end":124,"id":14,"ws":true},{"text":"Cancer","start":125,"end":131,"id":15,"ws":true},{"text":".","start":132,"end":133,"id":16,"ws":false}],"spans":[{"start":18,"end":29,"token_start":4,"token_end":4,"label":"DRUG"},{"start":35,"end":46,"token_start":6,"token_end":6,"label":"DRUG"},{"start":51,"end":61,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29631965/","_input_hash":-910966445,"_task_hash":-558478627,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In this multicenter study , the reliability of two nonradiometric , fully automated systems , the MB/BacT and BACTEC MGIT 960 systems , for testing the susceptibilities of 82 Mycobacterium tuberculosis strains to isoniazid , rifampin , ethambutol , and streptomycin was evaluated in comparison with the radiometric BACTEC 460 TB system .","paragraph":"<h3><u>Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis.</u></h3> <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>multicenter</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>reliability</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>nonradiometric</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>fully</i></b> <b style='color:DodgerBlue;'><i>automated</i></b> <b style='color:DodgerBlue;'><i>systems</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>MB/BacT</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>BACTEC</i></b> <b style='color:DodgerBlue;'><i>MGIT</i></b> <b style='color:DodgerBlue;'><i>960</i></b> <b style='color:DodgerBlue;'><i>systems</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>testing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>susceptibilities</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>82</i></b> <b style='color:DodgerBlue;'><i>Mycobacterium</i></b> <b style='color:DodgerBlue;'><i>tuberculosis</i></b> <b style='color:DodgerBlue;'><i>strains</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>isoniazid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>rifampin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ethambutol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>streptomycin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>comparison</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>radiometric</i></b> <b style='color:DodgerBlue;'><i>BACTEC</i></b> <b style='color:DodgerBlue;'><i>460</i></b> <b style='color:DodgerBlue;'><i>TB</i></b> <b style='color:DodgerBlue;'><i>system</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The arbitration of discrepant results was done by the reanalysis of the strain, the determination of the MIC, and the molecular characterization of some resistance determinants. The overall level of agreement with BACTEC 460TB results was 96% with the MB/BacT test and 97.2% with the BACTEC MGIT 960 system. With both methods, the level of agreement with BACTEC 460TB results was 96.3% for <b style='color:Tomato;'><i>isoniazid</i></b>, 98.8% for <b style='color:Tomato;'><i>rifampin</i></b>, and 98.8% for <b style='color:Tomato;'><i>ethambutol</i></b>. The level of agreement for <b style='color:Tomato;'><i>streptomycin</i></b> was 90.2% with MB/BacT and 97.5% with BACTEC MGIT 960. Overall, there were 11 very major errors and 2 major errors with the MB/BacT method and 5 very major errors and 2 major errors with the BACTEC MGIT 960 system. In general, the MB/BacT and BACTEC MGIT 960 systems showed good performance for susceptibility testing with first-line antituberculosis drugs.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"this","start":3,"end":7,"id":1,"ws":true},{"text":"multicenter","start":8,"end":19,"id":2,"ws":true},{"text":"study","start":20,"end":25,"id":3,"ws":true},{"text":",","start":26,"end":27,"id":4,"ws":true},{"text":"the","start":28,"end":31,"id":5,"ws":true},{"text":"reliability","start":32,"end":43,"id":6,"ws":true},{"text":"of","start":44,"end":46,"id":7,"ws":true},{"text":"two","start":47,"end":50,"id":8,"ws":true},{"text":"nonradiometric","start":51,"end":65,"id":9,"ws":true},{"text":",","start":66,"end":67,"id":10,"ws":true},{"text":"fully","start":68,"end":73,"id":11,"ws":true},{"text":"automated","start":74,"end":83,"id":12,"ws":true},{"text":"systems","start":84,"end":91,"id":13,"ws":true},{"text":",","start":92,"end":93,"id":14,"ws":true},{"text":"the","start":94,"end":97,"id":15,"ws":true},{"text":"MB/BacT","start":98,"end":105,"id":16,"ws":true},{"text":"and","start":106,"end":109,"id":17,"ws":true},{"text":"BACTEC","start":110,"end":116,"id":18,"ws":true},{"text":"MGIT","start":117,"end":121,"id":19,"ws":true},{"text":"960","start":122,"end":125,"id":20,"ws":true},{"text":"systems","start":126,"end":133,"id":21,"ws":true},{"text":",","start":134,"end":135,"id":22,"ws":true},{"text":"for","start":136,"end":139,"id":23,"ws":true},{"text":"testing","start":140,"end":147,"id":24,"ws":true},{"text":"the","start":148,"end":151,"id":25,"ws":true},{"text":"susceptibilities","start":152,"end":168,"id":26,"ws":true},{"text":"of","start":169,"end":171,"id":27,"ws":true},{"text":"82","start":172,"end":174,"id":28,"ws":true},{"text":"Mycobacterium","start":175,"end":188,"id":29,"ws":true},{"text":"tuberculosis","start":189,"end":201,"id":30,"ws":true},{"text":"strains","start":202,"end":209,"id":31,"ws":true},{"text":"to","start":210,"end":212,"id":32,"ws":true},{"text":"isoniazid","start":213,"end":222,"id":33,"ws":true},{"text":",","start":223,"end":224,"id":34,"ws":true},{"text":"rifampin","start":225,"end":233,"id":35,"ws":true},{"text":",","start":234,"end":235,"id":36,"ws":true},{"text":"ethambutol","start":236,"end":246,"id":37,"ws":true},{"text":",","start":247,"end":248,"id":38,"ws":true},{"text":"and","start":249,"end":252,"id":39,"ws":true},{"text":"streptomycin","start":253,"end":265,"id":40,"ws":true},{"text":"was","start":266,"end":269,"id":41,"ws":true},{"text":"evaluated","start":270,"end":279,"id":42,"ws":true},{"text":"in","start":280,"end":282,"id":43,"ws":true},{"text":"comparison","start":283,"end":293,"id":44,"ws":true},{"text":"with","start":294,"end":298,"id":45,"ws":true},{"text":"the","start":299,"end":302,"id":46,"ws":true},{"text":"radiometric","start":303,"end":314,"id":47,"ws":true},{"text":"BACTEC","start":315,"end":321,"id":48,"ws":true},{"text":"460","start":322,"end":325,"id":49,"ws":true},{"text":"TB","start":326,"end":328,"id":50,"ws":true},{"text":"system","start":329,"end":335,"id":51,"ws":true},{"text":".","start":336,"end":337,"id":52,"ws":false}],"spans":[{"start":213,"end":222,"token_start":33,"token_end":33,"label":"DRUG"},{"start":225,"end":233,"token_start":35,"token_end":35,"label":"DRUG"},{"start":236,"end":246,"token_start":37,"token_end":37,"label":"DRUG"},{"start":253,"end":265,"token_start":40,"token_end":40,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17442793/","_input_hash":-1960772817,"_task_hash":153031742,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Most frequent first line therapy was Sunitinib ( 66 % ) , followed by Sorafenib ( 20 % ) and Pazopanib ( 10 % ) .","paragraph":"<h3><u>The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.</u></h3>Tyrosine kinase inhibitor therapy (TKI) has changed the treatment paradigm of metastatic renal cell carcinoma (mRCC). The recent CARMENA and SURTIME trials challenged the role of the cytoreductive nephrectomy (CN). ### objective To assess the impact of CN prior to TKI therapy in patients with mRCC in a real-world setting. ### methods Overall, 262 consecutive patients with mRCC were treated with CN plus TKI or TKI only at our institution between 2000 and 2016. Patients with prior immunotherapy or metastasectomy were excluded. Multiple imputation and inverse probability of treatment weighting (IPTW) were performed to account for missing values and imbalances between the treatment groups, respectively. Unadjusted and adjusted Kaplan-Meier estimates were used to determine differences in progression-free (PFS), overall (OS), and cancer-specific survival (CSS). ### results Overall, 104 (40%) patients received CN before TKI treatment. <b style='color:DodgerBlue;'><i>Most</i></b> <b style='color:DodgerBlue;'><i>frequent</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:MediumOrchid;'><i>Sunitinib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>66</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>Sorafenib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Pazopanib</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> After adjustment with IPTW, there was no difference in PFS, CSS, and OS (all P > 0.05) between the treatment groups. In subgroup analyses, CSS was improved when CN was performed in patients with sarcomatoid features and clear cell histology (P\u202f=\u202f0.04 and P\u202f=\u202f0.03) and PFS was improved in patients with clear cell histology when CN was performed [0.04]). CN did not improve OS in any subgroup analysis. ### conclusion The role of CN remains controversial. We found no difference in survival outcomes between patients treated with and without CN before TKI therapy. However, CN was associated with improved survival in specific patient subgroups. Tailored, individualized treatment is key to further improve oncological outcomes for mRCC.","tokens":[{"text":"Most","start":0,"end":4,"id":0,"ws":true},{"text":"frequent","start":5,"end":13,"id":1,"ws":true},{"text":"first","start":14,"end":19,"id":2,"ws":true},{"text":"line","start":20,"end":24,"id":3,"ws":true},{"text":"therapy","start":25,"end":32,"id":4,"ws":true},{"text":"was","start":33,"end":36,"id":5,"ws":true},{"text":"Sunitinib","start":37,"end":46,"id":6,"ws":true},{"text":"(","start":47,"end":48,"id":7,"ws":true},{"text":"66","start":49,"end":51,"id":8,"ws":true},{"text":"%","start":52,"end":53,"id":9,"ws":true},{"text":")","start":54,"end":55,"id":10,"ws":true},{"text":",","start":56,"end":57,"id":11,"ws":true},{"text":"followed","start":58,"end":66,"id":12,"ws":true},{"text":"by","start":67,"end":69,"id":13,"ws":true},{"text":"Sorafenib","start":70,"end":79,"id":14,"ws":true},{"text":"(","start":80,"end":81,"id":15,"ws":true},{"text":"20","start":82,"end":84,"id":16,"ws":true},{"text":"%","start":85,"end":86,"id":17,"ws":true},{"text":")","start":87,"end":88,"id":18,"ws":true},{"text":"and","start":89,"end":92,"id":19,"ws":true},{"text":"Pazopanib","start":93,"end":102,"id":20,"ws":true},{"text":"(","start":103,"end":104,"id":21,"ws":true},{"text":"10","start":105,"end":107,"id":22,"ws":true},{"text":"%","start":108,"end":109,"id":23,"ws":true},{"text":")","start":110,"end":111,"id":24,"ws":true},{"text":".","start":112,"end":113,"id":25,"ws":false}],"spans":[{"start":37,"end":46,"token_start":6,"token_end":6,"label":"DRUG"},{"start":70,"end":79,"token_start":14,"token_end":14,"label":"DRUG"},{"start":93,"end":102,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32576526/","_input_hash":-1193138832,"_task_hash":1267016825,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Treatment of unresectable GISTs involves systemic chemotherapy with tyrosine kinase inhibitors , imatinib and sunitinib being first-line and second-line drugs .","paragraph":"<h3><u>A gastrointestinal stromal tumour with pulmonary metastases mimicking unilateral gynaecomastia.</u></h3>Gastrointestinal stromal tumours (GISTs) represent 1% of primary gastrointestinal cancers. These neoplasms most frequently metastasise to the liver and peritoneum and rarely to the lungs and bones. <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>unresectable</i></b> <b style='color:DodgerBlue;'><i>GISTs</i></b> <b style='color:DodgerBlue;'><i>involves</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>tyrosine</i></b> <b style='color:DodgerBlue;'><i>kinase</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>imatinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>sunitinib</i></b> <b style='color:DodgerBlue;'><i>being</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>second-line</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We report the case of a 52-year-old man with GIST who developed a right-sided subareolar breast swelling and subsequently discovered to be an invasive metastatic pulmonary GIST. Given that gynaecomastia is a known adverse effect of <b style='color:Tomato;'><i>imatinib</i></b> and <b style='color:Tomato;'><i>sunitinib</i></b>, this case report illustrates the importance of including metastatic disease in the differential diagnosis of patients with GIST and with the new onset of soft tissue masses.","tokens":[{"text":"Treatment","start":0,"end":9,"id":0,"ws":true},{"text":"of","start":10,"end":12,"id":1,"ws":true},{"text":"unresectable","start":13,"end":25,"id":2,"ws":true},{"text":"GISTs","start":26,"end":31,"id":3,"ws":true},{"text":"involves","start":32,"end":40,"id":4,"ws":true},{"text":"systemic","start":41,"end":49,"id":5,"ws":true},{"text":"chemotherapy","start":50,"end":62,"id":6,"ws":true},{"text":"with","start":63,"end":67,"id":7,"ws":true},{"text":"tyrosine","start":68,"end":76,"id":8,"ws":true},{"text":"kinase","start":77,"end":83,"id":9,"ws":true},{"text":"inhibitors","start":84,"end":94,"id":10,"ws":true},{"text":",","start":95,"end":96,"id":11,"ws":true},{"text":"imatinib","start":97,"end":105,"id":12,"ws":true},{"text":"and","start":106,"end":109,"id":13,"ws":true},{"text":"sunitinib","start":110,"end":119,"id":14,"ws":true},{"text":"being","start":120,"end":125,"id":15,"ws":true},{"text":"first-line","start":126,"end":136,"id":16,"ws":true},{"text":"and","start":137,"end":140,"id":17,"ws":true},{"text":"second-line","start":141,"end":152,"id":18,"ws":true},{"text":"drugs","start":153,"end":158,"id":19,"ws":true},{"text":".","start":159,"end":160,"id":20,"ws":false}],"spans":[{"start":97,"end":105,"token_start":12,"token_end":12,"label":"DRUG"},{"start":110,"end":119,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24343802/","_input_hash":-1360996283,"_task_hash":249055749,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Such therapy has included weekly paclitaxel in combination with carboplatin/cisplatin plus topotecan , and carboplatin plus doxorubicin .","paragraph":"<h3><u>Role of weekly paclitaxel in the treatment of advanced ovarian cancer.</u></h3>Dose-dense weekly administration of <b style='color:Tomato;'><i>paclitaxel</i></b> has the potential advantage of allowing a larger percentage of cancer cells to enter the vulnerable phase of their cell cycle when cytotoxic <b style='color:Tomato;'><i>paclitaxel</i></b> concentrations are present. The lower doses and shorter infusion times used with weekly dosing should also minimize bone marrow suppression and other toxicities associated with standard <b style='color:Tomato;'><i>paclitaxel</i></b> 3-weekly administration. Clinical studies have confirmed that <b style='color:Tomato;'><i>paclitaxel</i></b> can be safely delivered on a weekly schedule as a 1-h infusion to patients with advanced ovarian cancer. Weekly administration of <b style='color:Tomato;'><i>paclitaxel</i></b> also appears to be better tolerated than 3-weekly administration. Single-agent weekly <b style='color:Tomato;'><i>paclitaxel</i></b> is associated with response rates of 20-65%. Combination therapy with weekly <b style='color:Tomato;'><i>paclitaxel</i></b> has mainly involved <b style='color:Tomato;'><i>carboplatin</i></b> and response rates with such regimens range from 60-88%. Triple-drug combination therapy has produced response rates of 42-67.5%. <b style='color:DodgerBlue;'><i>Such</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>included</i></b> <b style='color:DodgerBlue;'><i>weekly</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>carboplatin/cisplatin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In an attempt to avoid problems with high corticosteroid doses, <b style='color:Tomato;'><i>dexamethasone</i></b> doses of 10 and 8 mg have been used successfully in premedication regimens for weekly <b style='color:Tomato;'><i>paclitaxel</i></b> in ovarian cancer.","tokens":[{"text":"Such","start":0,"end":4,"id":0,"ws":true},{"text":"therapy","start":5,"end":12,"id":1,"ws":true},{"text":"has","start":13,"end":16,"id":2,"ws":true},{"text":"included","start":17,"end":25,"id":3,"ws":true},{"text":"weekly","start":26,"end":32,"id":4,"ws":true},{"text":"paclitaxel","start":33,"end":43,"id":5,"ws":true},{"text":"in","start":44,"end":46,"id":6,"ws":true},{"text":"combination","start":47,"end":58,"id":7,"ws":true},{"text":"with","start":59,"end":63,"id":8,"ws":true},{"text":"carboplatin/cisplatin","start":64,"end":85,"id":9,"ws":true},{"text":"plus","start":86,"end":90,"id":10,"ws":true},{"text":"topotecan","start":91,"end":100,"id":11,"ws":true},{"text":",","start":101,"end":102,"id":12,"ws":true},{"text":"and","start":103,"end":106,"id":13,"ws":true},{"text":"carboplatin","start":107,"end":118,"id":14,"ws":true},{"text":"plus","start":119,"end":123,"id":15,"ws":true},{"text":"doxorubicin","start":124,"end":135,"id":16,"ws":true},{"text":".","start":136,"end":137,"id":17,"ws":false}],"spans":[{"start":33,"end":43,"token_start":5,"token_end":5,"label":"DRUG"},{"start":64,"end":85,"token_start":9,"token_end":9,"label":"DRUG"},{"start":91,"end":100,"token_start":11,"token_end":11,"label":"DRUG"},{"start":107,"end":118,"token_start":14,"token_end":14,"label":"DRUG"},{"start":124,"end":135,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12505598/","_input_hash":1625402879,"_task_hash":-1892171795,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":5,"child":9,"head_span":{"start":33,"end":43,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":64,"end":85,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":9,"child":11,"head_span":{"start":64,"end":85,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":91,"end":100,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":14,"child":16,"head_span":{"start":107,"end":118,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":124,"end":135,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":[],"answer":"accept"}
{"text":"This phase II study was performed to assess the efficacy and safety of the combination regimen of temozolomide and docetaxel in patients with advanced metastatic melanoma .","paragraph":"<h3><u>Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.</u></h3><b style='color:Tomato;'><i>temozolomide</i></b> is a novel oral alkylating agent that is effective against melanoma. Moreover, <b style='color:Tomato;'><i>temozolomide</i></b> readily crosses the blood-brain barrier and may consequently be effective in patients with brain metastases. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>assess</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>safety</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>melanoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods Sixty-five patients with metastatic melanoma were enrolled. Treatment consisted of intravenous <b style='color:Tomato;'><i>docetaxel</i></b> (80 mg/m(2)) on day 1 and oral <b style='color:Tomato;'><i>temozolomide</i></b> (150 mg/m(2)) on days 1 to 5, every 4 weeks, for a maximum of six cycles. ### results Sixty-two patients were eligible for the efficacy and safety analysis. Seventeen patients (27%) achieved an objective response, including five complete (8%) and 12 partial responses (19%). Median response duration was 9.5 months. Among responders, median time to progression (TTP) was 11.2 months and median overall survival (OS) was 16 months. For all treated patients, the median TTP was 4 months and median OS was 11 months. Three (38%) of eight patients who presented with brain metastases had a partial response for 5, 6, and 12 months. Of 52 patients who did not have brain involvement at presentation, only four (8%) developed brain metastases at a median follow-up of 14 months. Myelosuppression was the primary toxicity. ### conclusion The combination of <b style='color:Tomato;'><i>temozolomide</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> was effective and well tolerated as first-line treatment for patients with advanced metastatic melanoma and demonstrated encouraging antitumor activity against brain metastases.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"phase","start":5,"end":10,"id":1,"ws":true},{"text":"II","start":11,"end":13,"id":2,"ws":true},{"text":"study","start":14,"end":19,"id":3,"ws":true},{"text":"was","start":20,"end":23,"id":4,"ws":true},{"text":"performed","start":24,"end":33,"id":5,"ws":true},{"text":"to","start":34,"end":36,"id":6,"ws":true},{"text":"assess","start":37,"end":43,"id":7,"ws":true},{"text":"the","start":44,"end":47,"id":8,"ws":true},{"text":"efficacy","start":48,"end":56,"id":9,"ws":true},{"text":"and","start":57,"end":60,"id":10,"ws":true},{"text":"safety","start":61,"end":67,"id":11,"ws":true},{"text":"of","start":68,"end":70,"id":12,"ws":true},{"text":"the","start":71,"end":74,"id":13,"ws":true},{"text":"combination","start":75,"end":86,"id":14,"ws":true},{"text":"regimen","start":87,"end":94,"id":15,"ws":true},{"text":"of","start":95,"end":97,"id":16,"ws":true},{"text":"temozolomide","start":98,"end":110,"id":17,"ws":true},{"text":"and","start":111,"end":114,"id":18,"ws":true},{"text":"docetaxel","start":115,"end":124,"id":19,"ws":true},{"text":"in","start":125,"end":127,"id":20,"ws":true},{"text":"patients","start":128,"end":136,"id":21,"ws":true},{"text":"with","start":137,"end":141,"id":22,"ws":true},{"text":"advanced","start":142,"end":150,"id":23,"ws":true},{"text":"metastatic","start":151,"end":161,"id":24,"ws":true},{"text":"melanoma","start":162,"end":170,"id":25,"ws":true},{"text":".","start":171,"end":172,"id":26,"ws":false}],"spans":[{"start":98,"end":110,"token_start":17,"token_end":17,"label":"DRUG"},{"start":115,"end":124,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11786569/","_input_hash":1159878705,"_task_hash":2116484808,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>verapamil</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>initial</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>small</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Based on experimental observations that <b style='color:Tomato;'><i>verapamil</i></b> and <b style='color:Tomato;'><i>tamoxifen</i></b> reverse multiple drug resistance, the authors investigated the feasibility of combining both agents with the initial chemotherapy of extensive small cell lung cancer. Overall, in a consecutive series of 58 patients the most important toxicity was myelosuppression, and there was a 24% rate of severe infections. Therapeutic results included 24% complete and 34% partial response rates, median time to disease progression of 32 weeks, and median survival of 46 weeks. In three consecutive cohorts of patients the dose of either <b style='color:Tomato;'><i>tamoxifen</i></b> or <b style='color:Tomato;'><i>verapamil</i></b> were escalated by 25% and 33%, respectively. The cohort of patients receiving <b style='color:Tomato;'><i>verapamil</i></b> 360 mg/day and <b style='color:Tomato;'><i>tamoxifen</i></b> 100 mg/day (level 2) had slightly more toxicity but also more responses than the other groups. Therefore, the authors recommend that these doses be used in controlled trials to confirm the promising results of their study.","tokens":[{"text":"Addition","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"verapamil","start":12,"end":21,"id":2,"ws":true},{"text":"and","start":22,"end":25,"id":3,"ws":true},{"text":"tamoxifen","start":26,"end":35,"id":4,"ws":true},{"text":"to","start":36,"end":38,"id":5,"ws":true},{"text":"the","start":39,"end":42,"id":6,"ws":true},{"text":"initial","start":43,"end":50,"id":7,"ws":true},{"text":"chemotherapy","start":51,"end":63,"id":8,"ws":true},{"text":"of","start":64,"end":66,"id":9,"ws":true},{"text":"small","start":67,"end":72,"id":10,"ws":true},{"text":"cell","start":73,"end":77,"id":11,"ws":true},{"text":"lung","start":78,"end":82,"id":12,"ws":true},{"text":"cancer","start":83,"end":89,"id":13,"ws":true},{"text":".","start":90,"end":91,"id":14,"ws":false}],"spans":[{"start":12,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":26,"end":35,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2164872/","_input_hash":-375551766,"_task_hash":-1507493145,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":12,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":26,"end":35,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In a scenario analysis comparing pembrolizumab with ipilimumab , the estimated ICER was USD8,904 .","paragraph":"<h3><u>Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong.</u></h3><b style='color:Tomato;'><i>pembrolizumab</i></b> has been shown to improve overall survival (OS) and progression free survival (PFS) compared to <b style='color:Tomato;'><i>ipilimumab</i></b> in patients with <b style='color:Tomato;'><i>ipilimumab</i></b>-na\u00efve advanced melanoma; however, there are no published data on the cost-effectiveness for <b style='color:Tomato;'><i>pembrolizumab</i></b> compared to standard-of-care treatments currently used in Hong Kong for advanced melanoma. ### methods A partitioned-survival model based on data from a recent randomized phase 3 study (KEYNOTE-006) and meta-analysis was used to derive time in PFS, OS, and post-progression survival for <b style='color:Tomato;'><i>pembrolizumab</i></b> and chemotherapy, such as <b style='color:Tomato;'><i>dacarbazine</i></b> (DTIC), <b style='color:Tomato;'><i>temozolomide</i></b> (TMZ), and the <b style='color:Tomato;'><i>paclitaxel</i></b>-<b style='color:Tomato;'><i>carboplatin</i></b> combination (PC). A combination of clinical trial data, published data, results of meta-analysis, and melanoma registry data was used to extrapolate PFS and OS curves. The base-case time horizon for the model was 30\u00a0years with costs and health outcomes discounted at a rate of 5% per year. Individual patient level data on utilities and frequencies of adverse events were obtained from the final analysis of KEYNOTE-006 (cut-off date: 3-Dec-15) for <b style='color:Tomato;'><i>pembrolizumab</i></b>. Cost data included drug acquisition, treatment administration, adverse event management, and clinical management of advanced melanoma. The distribution of patient weight from the Hong Kong population was applied to calculate the drug costs. Analyses were performed from a payer's perspective. The incremental cost effectiveness ratio (ICER) expressed as cost in US Dollars (USD) per quality-adjusted life years (QALYs) was the main outcome. ### results In base-case scenario, the ICER for <b style='color:Tomato;'><i>pembrolizumab</i></b> as a first-line treatment for advanced melanoma was USD49,232 compared to DTIC, with the ICER values lower than cost-effectiveness threshold in Hong Kong. Results comparing <b style='color:Tomato;'><i>pembrolizumab</i></b> to TMZ and to PC were similar to that when compared to DTIC. Probability sensitivity analyses showed that 99% of the simulated ICERs were below three times the Gross Domestic Product (GDP) per capita for Hong Kong (currently at $119,274//QALY threshold). <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>scenario</i></b> <b style='color:DodgerBlue;'><i>analysis</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:MediumOrchid;'><i>pembrolizumab</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>ipilimumab</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>estimated</i></b> <b style='color:DodgerBlue;'><i>ICER</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>USD8,904</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions <b style='color:Tomato;'><i>pembrolizumab</i></b> is cost-effective relative to chemotherapy (DTIC, TMZ and PC), and highly-cost-effective compared to <b style='color:Tomato;'><i>ipilimumab</i></b>, for the first-line treatment of advanced melanoma in Hong Kong.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"a","start":3,"end":4,"id":1,"ws":true},{"text":"scenario","start":5,"end":13,"id":2,"ws":true},{"text":"analysis","start":14,"end":22,"id":3,"ws":true},{"text":"comparing","start":23,"end":32,"id":4,"ws":true},{"text":"pembrolizumab","start":33,"end":46,"id":5,"ws":true},{"text":"with","start":47,"end":51,"id":6,"ws":true},{"text":"ipilimumab","start":52,"end":62,"id":7,"ws":true},{"text":",","start":63,"end":64,"id":8,"ws":true},{"text":"the","start":65,"end":68,"id":9,"ws":true},{"text":"estimated","start":69,"end":78,"id":10,"ws":true},{"text":"ICER","start":79,"end":83,"id":11,"ws":true},{"text":"was","start":84,"end":87,"id":12,"ws":true},{"text":"USD8,904","start":88,"end":96,"id":13,"ws":true},{"text":".","start":97,"end":98,"id":14,"ws":false}],"spans":[{"start":33,"end":46,"token_start":5,"token_end":5,"label":"DRUG"},{"start":52,"end":62,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/31969794/","_input_hash":561908098,"_task_hash":-2137009120,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Synergistic cytotoxic effects of recombinant human tumor necrosis factor and Etoposide ( VP16 ) or Doxorubicin on A2774 human epithelial ovarian cancer cell line .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Synergistic</i></b> <b style='color:DodgerBlue;'><i>cytotoxic</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>recombinant</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>necrosis</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VP16</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>Doxorubicin</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>A2774</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>epithelial</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>line</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Recombinant human tumor necrosis factor (rHuTNF) is a cytokine, with some antitumor activity, released by stimulated monocytes-macrophages. In vivo and in vitro cytotoxicity studies testing the effectiveness of rHuTNF alone or in combination with chemotherapeutic agents have been carried out. We have evaluated the direct cytotoxic effect of rHuTNF on a human epithelial ovarian cancer cell line in vitro (A2774), alone or in combination with <b style='color:Tomato;'><i>etoposide</i></b> (VP16) or <b style='color:Tomato;'><i>doxorubicin</i></b> (Doxo), some topoisomerase II (Topo II) targeted drugs, or in combination with Cisplatin (CDDP), a not Topo II interactive drug. Our results suggest that rHuTNF is directly cytotoxic and that it is also able to induce a potentiation of VP16- or Doxo-cytotoxicity, but it is unable to potentiate CDDP-cytotoxicity. These data represent a reasonable basis for combining rHuTNF with Topo II inhibitors within phase I studies. The combination regimen could be tested in ovarian cancer patients.","tokens":[{"text":"Synergistic","start":0,"end":11,"id":0,"ws":true},{"text":"cytotoxic","start":12,"end":21,"id":1,"ws":true},{"text":"effects","start":22,"end":29,"id":2,"ws":true},{"text":"of","start":30,"end":32,"id":3,"ws":true},{"text":"recombinant","start":33,"end":44,"id":4,"ws":true},{"text":"human","start":45,"end":50,"id":5,"ws":true},{"text":"tumor","start":51,"end":56,"id":6,"ws":true},{"text":"necrosis","start":57,"end":65,"id":7,"ws":true},{"text":"factor","start":66,"end":72,"id":8,"ws":true},{"text":"and","start":73,"end":76,"id":9,"ws":true},{"text":"Etoposide","start":77,"end":86,"id":10,"ws":true},{"text":"(","start":87,"end":88,"id":11,"ws":true},{"text":"VP16","start":89,"end":93,"id":12,"ws":true},{"text":")","start":94,"end":95,"id":13,"ws":true},{"text":"or","start":96,"end":98,"id":14,"ws":true},{"text":"Doxorubicin","start":99,"end":110,"id":15,"ws":true},{"text":"on","start":111,"end":113,"id":16,"ws":true},{"text":"A2774","start":114,"end":119,"id":17,"ws":true},{"text":"human","start":120,"end":125,"id":18,"ws":true},{"text":"epithelial","start":126,"end":136,"id":19,"ws":true},{"text":"ovarian","start":137,"end":144,"id":20,"ws":true},{"text":"cancer","start":145,"end":151,"id":21,"ws":true},{"text":"cell","start":152,"end":156,"id":22,"ws":true},{"text":"line","start":157,"end":161,"id":23,"ws":true},{"text":".","start":162,"end":163,"id":24,"ws":false}],"spans":[{"start":77,"end":86,"token_start":10,"token_end":10,"label":"DRUG"},{"start":99,"end":110,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11576250/","_input_hash":464556084,"_task_hash":-284315972,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Many ESBL-producing E. coli had significantly lower susceptibility to gentamicin ( p \uff1c 0.0001 ) and the quinolones nalidixic acid ( p\uff1d0.004 ) and ciprofloxacin ( p \uff1c 0.0001 ) than non-producers .","paragraph":"<h3><u>Antibiotic Susceptibilities and Genetic Characteristics of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates from Stools of Pediatric Diarrhea Patients in Surabaya, Indonesia.</u></h3>The purpose of this study was to investigate extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolates from pediatric (aged 0 to 3 years) diarrhea patients in Surabaya, Indonesia, where this kind of survey is rare; our study included assessment of their antibiotic susceptibilities, as well as ESBL typing, multilocus sequence typing (MLST), and diarrheagenic E. coli (DEC)-typing. ESBL-producing E. coli were detected in 18.8% of all the samples. <b style='color:DodgerBlue;'><i>Many</i></b> <b style='color:DodgerBlue;'><i>ESBL-producing</i></b> <b style='color:DodgerBlue;'><i>E.</i></b> <b style='color:DodgerBlue;'><i>coli</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>lower</i></b> <b style='color:DodgerBlue;'><i>susceptibility</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>\uff1c</i></b> <b style='color:DodgerBlue;'><i>0.0001</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>quinolones</i></b> <b style='color:MediumOrchid;'><i>nalidixic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p\uff1d0.004</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ciprofloxacin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>\uff1c</i></b> <b style='color:DodgerBlue;'><i>0.0001</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>non-producers</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In ESBL-producing E. coli, 84.0% of strains expressed CTX-M-15 alone or in combination with other ESBL types. MLST revealed that 24.0% of ESBL-producers had sequence type 617, all of which expressed the CTX-M-15 gene; we also detected expression of 3 DEC-related genes: 2 enteroaggregative E. coli genes and 1 enteropathogenic E. coli gene. In conclusion, CTX-M-15-type ESBL-producing E. coli ST617 appear to have spread to Indonesia.","tokens":[{"text":"Many","start":0,"end":4,"id":0,"ws":true},{"text":"ESBL-producing","start":5,"end":19,"id":1,"ws":true},{"text":"E.","start":20,"end":22,"id":2,"ws":true},{"text":"coli","start":23,"end":27,"id":3,"ws":true},{"text":"had","start":28,"end":31,"id":4,"ws":true},{"text":"significantly","start":32,"end":45,"id":5,"ws":true},{"text":"lower","start":46,"end":51,"id":6,"ws":true},{"text":"susceptibility","start":52,"end":66,"id":7,"ws":true},{"text":"to","start":67,"end":69,"id":8,"ws":true},{"text":"gentamicin","start":70,"end":80,"id":9,"ws":true},{"text":"(","start":81,"end":82,"id":10,"ws":true},{"text":"p","start":83,"end":84,"id":11,"ws":true},{"text":"\uff1c","start":85,"end":86,"id":12,"ws":true},{"text":"0.0001","start":87,"end":93,"id":13,"ws":true},{"text":")","start":94,"end":95,"id":14,"ws":true},{"text":"and","start":96,"end":99,"id":15,"ws":true},{"text":"the","start":100,"end":103,"id":16,"ws":true},{"text":"quinolones","start":104,"end":114,"id":17,"ws":true},{"text":"nalidixic","start":115,"end":124,"id":18,"ws":true},{"text":"acid","start":125,"end":129,"id":19,"ws":true},{"text":"(","start":130,"end":131,"id":20,"ws":true},{"text":"p\uff1d0.004","start":132,"end":139,"id":21,"ws":true},{"text":")","start":140,"end":141,"id":22,"ws":true},{"text":"and","start":142,"end":145,"id":23,"ws":true},{"text":"ciprofloxacin","start":146,"end":159,"id":24,"ws":true},{"text":"(","start":160,"end":161,"id":25,"ws":true},{"text":"p","start":162,"end":163,"id":26,"ws":true},{"text":"\uff1c","start":164,"end":165,"id":27,"ws":true},{"text":"0.0001","start":166,"end":172,"id":28,"ws":true},{"text":")","start":173,"end":174,"id":29,"ws":true},{"text":"than","start":175,"end":179,"id":30,"ws":true},{"text":"non-producers","start":180,"end":193,"id":31,"ws":true},{"text":".","start":194,"end":195,"id":32,"ws":false}],"spans":[{"start":70,"end":80,"token_start":9,"token_end":9,"label":"DRUG"},{"start":115,"end":124,"token_start":18,"token_end":18,"label":"DRUG"},{"start":146,"end":159,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/28003592/","_input_hash":-959830506,"_task_hash":1562370820,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The resistance of topotecan in MDR HL-60 cells was potently reversed by the addition of amlodipine .","paragraph":"<h3><u>Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.</u></h3>Multidrug resistance (MDR) is a major obstacle to successful cancer chemotherapy as the over-expressed MDR protein acts as an efflux pump, which leads to a reduction in the uptake of the anticancer agent by tumour cells. We combined <b style='color:Tomato;'><i>topotecan</i></b> and <b style='color:Tomato;'><i>amlodipine</i></b> together into the stealthy liposomes, in which <b style='color:Tomato;'><i>amlodipine</i></b> was applied as a MDR reversing agent to overcome the resistance. ### Materials And Methods Cytotoxicity, apoptosis and the signalling pathway assays were performed on human chronic myelogenous leukaemia K562, promyelocytic leukaemia HL-60 and MDR HL-60 cells, respectively. Pharmacokinetics and antitumour activity studies were performed on normal Kunming mice and female BALB/c nude mice with MDR HL-60 xenografts, respectively. ### results <b style='color:Tomato;'><i>topotecan</i></b> alone was effective in inhibiting the growth of non-resistant leukaemia cells, K562 and HL-60 cells but not the growth of MDR HL-60 cells. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>topotecan</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>MDR</i></b> <b style='color:DodgerBlue;'><i>HL-60</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>potently</i></b> <b style='color:DodgerBlue;'><i>reversed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amlodipine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Moreover, <b style='color:Tomato;'><i>amlodipine</i></b> enhanced the apoptosis-inducing effect of <b style='color:Tomato;'><i>topotecan</i></b> synergistically. Apoptosis was through activating caspases in a cascade: first, the initiator caspase 8 and then effectors caspase 3/7 (total activity of caspases 3 and 7) were activated. Being encapsulated into the stealthy liposomes with an acidic internal medium, <b style='color:Tomato;'><i>topotecan</i></b> existed dominantly in an active lactone species, which was reversibly changed from an inactive carboxylate form via a pH-dependent reaction. After administration of stealthy liposomes to mice, the blood exposure of the lactone form was evidently increased and extended. The antitumour effects in the MDR HL-60 xenografted tumour were stealthy liposomal <b style='color:Tomato;'><i>topotecan</i></b> (SLT) plus <b style='color:Tomato;'><i>amlodipine</i></b> > SLT > un-encapsulated <b style='color:Tomato;'><i>topotecan</i></b> > blank control. ### conclusions The enhanced antitumour activity in the MDR HL-60 cells by the SLT plus <b style='color:Tomato;'><i>amlodipine</i></b> could be owing to multiple reasons: (a) synergistic apoptosis inducing effect, (b) reversing MDR by <b style='color:Tomato;'><i>amlodipine</i></b> and (c) increasing the availability of active lactone of <b style='color:Tomato;'><i>topotecan</i></b> by the stealthy liposomes. The apoptosis induced by <b style='color:Tomato;'><i>amlodipine</i></b> is through caspase 8 and then the 3/7 signalling pathway.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"resistance","start":4,"end":14,"id":1,"ws":true},{"text":"of","start":15,"end":17,"id":2,"ws":true},{"text":"topotecan","start":18,"end":27,"id":3,"ws":true},{"text":"in","start":28,"end":30,"id":4,"ws":true},{"text":"MDR","start":31,"end":34,"id":5,"ws":true},{"text":"HL-60","start":35,"end":40,"id":6,"ws":true},{"text":"cells","start":41,"end":46,"id":7,"ws":true},{"text":"was","start":47,"end":50,"id":8,"ws":true},{"text":"potently","start":51,"end":59,"id":9,"ws":true},{"text":"reversed","start":60,"end":68,"id":10,"ws":true},{"text":"by","start":69,"end":71,"id":11,"ws":true},{"text":"the","start":72,"end":75,"id":12,"ws":true},{"text":"addition","start":76,"end":84,"id":13,"ws":true},{"text":"of","start":85,"end":87,"id":14,"ws":true},{"text":"amlodipine","start":88,"end":98,"id":15,"ws":true},{"text":".","start":99,"end":100,"id":16,"ws":false}],"spans":[{"start":18,"end":27,"token_start":3,"token_end":3,"label":"DRUG"},{"start":88,"end":98,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16684125/","_input_hash":920981054,"_task_hash":947211331,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":3,"child":15,"head_span":{"start":18,"end":27,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":88,"end":98,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"In separate studies , the electrocardiogram ( ECG ) and cardiovascular effects of loratadine ( 30 and 100 mg/kg , i.v . ) , terfenadine ( 10 mg/kg , i.v . ) , promethazine ( 5 mg/kg , i.v . ) and diphenhydramine ( 20 mg/kg , i.v . ) were evaluated .","paragraph":"<h3><u>Antihistamine activity, central nervous system and cardiovascular profiles of histamine H1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea-pigs.</u></h3>Sedation limits the clinical utility of classical H1 antihistamines, while newer antihistamines such as <b style='color:Tomato;'><i>loratadine</i></b> and <b style='color:Tomato;'><i>terfenadine</i></b> are non-sedating. However, clinical use of the <b style='color:Tomato;'><i>terfenadine</i></b> has been associated with rare but severe cardiac arrhythmias, in particular torsades de pointes. ### objective To establish a quantitative experimental model for assessing the sedating and cardiotoxicity potential of non-sedating and sedating antihistamines. ### methods Drugs were administered intravenously and the integrated amplitude of the cortical electroencephalogram (EEG) signal was recorded. The threshold dose that depressed EEG activity was compared with the dose required to inhibit by 50% the peripheral bronchospasm elicited by 10 micrograms/kg i.v., of histamine. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>separate</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>electrocardiogram</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ECG</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cardiovascular</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>loratadine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>terfenadine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>promethazine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>diphenhydramine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg/kg</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>i.v</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>evaluated</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results The sedating antihistamines, <b style='color:Tomato;'><i>diphenhydramine</i></b> and <b style='color:Tomato;'><i>promethazine</i></b>, depressed the integrated EEG at doses between 0.6 and 2.0 times their peripheral antihistamine doses. <b style='color:Tomato;'><i>loratadine</i></b> had no EEG depressant activity at 100 mg/kg, i.v., a dose more than 170 times its ED50 (0.58 mg/kg, i.v.) against histamine bronchospasm. We were unable to evaluate the EEG effects of <b style='color:Tomato;'><i>terfenadine</i></b>, because it produced cardiovascular collapse at 10 mg/kg, i.v. <b style='color:Tomato;'><i>loratadine</i></b> and <b style='color:Tomato;'><i>promethazine</i></b> did not produce adverse cardiovascular effects, nor did they alter normal ECG activity. <b style='color:Tomato;'><i>diphenhydramine</i></b> produced bradycardia followed by a transient hypertensive phase without affecting the QTc interval. In contrast, <b style='color:Tomato;'><i>terfenadine</i></b> elicited hypotension, bradycardia and significant arrhythmogenic activity, causing a prolongation of the QTc interval and a torsades de pointes--like ventricular arrhythmia. Pharmacokinetic studies after i.v. administration of <b style='color:Tomato;'><i>loratadine</i></b> (30 and 100 mg/kg) demonstrated plasma levels of <b style='color:Tomato;'><i>loratadine</i></b> and its major metabolite descarboethoxy<b style='color:Tomato;'><i>loratadine</i></b> to be several orders of magnitude greater than levels found in humans at the clinical dose of 10 mg. ### conclusion The CNS depressant effects of H1 antihistamines are <b style='color:Tomato;'><i>promethazine</i></b> approximately <b style='color:Tomato;'><i>diphenhydramine</i></b> >> <b style='color:Tomato;'><i>loratadine</i></b> = placebo. Of the non-sedating antihistamines, <b style='color:Tomato;'><i>loratadine</i></b> was devoid of adverse cardiovascular effects whereas <b style='color:Tomato;'><i>terfenadine</i></b> caused a pronounced disruption of the normal ECG, characterized by a torsades de pointes-like effect.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"separate","start":3,"end":11,"id":1,"ws":true},{"text":"studies","start":12,"end":19,"id":2,"ws":true},{"text":",","start":20,"end":21,"id":3,"ws":true},{"text":"the","start":22,"end":25,"id":4,"ws":true},{"text":"electrocardiogram","start":26,"end":43,"id":5,"ws":true},{"text":"(","start":44,"end":45,"id":6,"ws":true},{"text":"ECG","start":46,"end":49,"id":7,"ws":true},{"text":")","start":50,"end":51,"id":8,"ws":true},{"text":"and","start":52,"end":55,"id":9,"ws":true},{"text":"cardiovascular","start":56,"end":70,"id":10,"ws":true},{"text":"effects","start":71,"end":78,"id":11,"ws":true},{"text":"of","start":79,"end":81,"id":12,"ws":true},{"text":"loratadine","start":82,"end":92,"id":13,"ws":true},{"text":"(","start":93,"end":94,"id":14,"ws":true},{"text":"30","start":95,"end":97,"id":15,"ws":true},{"text":"and","start":98,"end":101,"id":16,"ws":true},{"text":"100","start":102,"end":105,"id":17,"ws":true},{"text":"mg/kg","start":106,"end":111,"id":18,"ws":true},{"text":",","start":112,"end":113,"id":19,"ws":true},{"text":"i.v","start":114,"end":117,"id":20,"ws":true},{"text":".","start":118,"end":119,"id":21,"ws":true},{"text":")","start":120,"end":121,"id":22,"ws":true},{"text":",","start":122,"end":123,"id":23,"ws":true},{"text":"terfenadine","start":124,"end":135,"id":24,"ws":true},{"text":"(","start":136,"end":137,"id":25,"ws":true},{"text":"10","start":138,"end":140,"id":26,"ws":true},{"text":"mg/kg","start":141,"end":146,"id":27,"ws":true},{"text":",","start":147,"end":148,"id":28,"ws":true},{"text":"i.v","start":149,"end":152,"id":29,"ws":true},{"text":".","start":153,"end":154,"id":30,"ws":true},{"text":")","start":155,"end":156,"id":31,"ws":true},{"text":",","start":157,"end":158,"id":32,"ws":true},{"text":"promethazine","start":159,"end":171,"id":33,"ws":true},{"text":"(","start":172,"end":173,"id":34,"ws":true},{"text":"5","start":174,"end":175,"id":35,"ws":true},{"text":"mg/kg","start":176,"end":181,"id":36,"ws":true},{"text":",","start":182,"end":183,"id":37,"ws":true},{"text":"i.v","start":184,"end":187,"id":38,"ws":true},{"text":".","start":188,"end":189,"id":39,"ws":true},{"text":")","start":190,"end":191,"id":40,"ws":true},{"text":"and","start":192,"end":195,"id":41,"ws":true},{"text":"diphenhydramine","start":196,"end":211,"id":42,"ws":true},{"text":"(","start":212,"end":213,"id":43,"ws":true},{"text":"20","start":214,"end":216,"id":44,"ws":true},{"text":"mg/kg","start":217,"end":222,"id":45,"ws":true},{"text":",","start":223,"end":224,"id":46,"ws":true},{"text":"i.v","start":225,"end":228,"id":47,"ws":true},{"text":".","start":229,"end":230,"id":48,"ws":true},{"text":")","start":231,"end":232,"id":49,"ws":true},{"text":"were","start":233,"end":237,"id":50,"ws":true},{"text":"evaluated","start":238,"end":247,"id":51,"ws":true},{"text":".","start":248,"end":249,"id":52,"ws":false}],"spans":[{"start":82,"end":92,"token_start":13,"token_end":13,"label":"DRUG"},{"start":124,"end":135,"token_start":24,"token_end":24,"label":"DRUG"},{"start":159,"end":171,"token_start":33,"token_end":33,"label":"DRUG"},{"start":196,"end":211,"token_start":42,"token_end":42,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8556569/","_input_hash":1378418684,"_task_hash":-1885246676,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"[ Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer -- comparative study of treatment with 2 and 4 cycles ] .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>Clinical</i></b> <b style='color:DodgerBlue;'><i>evaluation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>neoadjuvant</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cases</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>locally</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>--</i></b> <b style='color:DodgerBlue;'><i>comparative</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>4</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Neoadjuvant chemotherapy of <b style='color:Tomato;'><i>epirubicin</i></b> plus <b style='color:Tomato;'><i>paclitaxel</i></b> was administered to 75 patients (including a 2-cycle group of 39 patients and a 4-cycle group of 36 patients) with locally advanced breast cancer (35 cases of stage IIb, 28 of stage IIIa, 12 of stage IIIb) to compare efficacy and toxicity of 2 cycle and 4 cycle regimens. All patients were female. They were treated with <b style='color:Tomato;'><i>epirubicin</i></b> 60 mg/m2, on day 1, by i.v., followed by <b style='color:Tomato;'><i>paclitaxel</i></b> 150 mg/m2, by 3 hour continuous infusion on day 2 repeated every 3 weeks. Premedication with <b style='color:Tomato;'><i>dexamethasone</i></b>, <b style='color:Tomato;'><i>ondansetron</i></b>, <b style='color:Tomato;'><i>diphenhydramine</i></b> and <b style='color:Tomato;'><i>cimetidine</i></b> were administered to prevent gastroenteritic and allergic reactions before chemotherapy. Thirty-nine patients were given 2 cycles and thirty-six were given 4 cycles of this regimen. One of 39 patients had complete response, 28 had partial response and 10 had no change in the 2-cycle group. In addition, 21 of 36 patients had complete response (including 9 who had pathologic complete response), 13 had partial response and 2 had no change. The response rates were 74% (29/39) in the 2-cycle group and 94% (34/36) in the 4-cycle group. There were no progressive disease in these 2 groups. However a higher proportion of PR was observed in stage II patients than in stage III patients. Twelve of 36 patients underwent breast conserving surgery, as tumor size had become smaller and down-staging was realized after neoadjuvant chemotherapy. In addition, axillary lymph nodes were palpable in all 75 patients before neoadjuvant chemotherapy with the ET regimen. But 46% (18/39) in the 2-cycle group and 75% (27/36) in the 4-cycle group became impalpable. Conversely, major toxicities (including leukopenia and gastroenteric reactions) were similar in both groups, but myalgia, arthralgia, neurotoxicity and alopecia were more severe in the 4-cycle group than in the 2-cycle group. In the present study, neoadjuvant chemotherapy with a 4-cycle ET regimen was more effective than with a 2-cycle regimen in down staging locally advanced breast cancer. Although major toxicities were more severe in the 4-cycle group than in the 2-cycle group, the regimen was tolerable and safe.","tokens":[{"text":"[","start":0,"end":1,"id":0,"ws":true},{"text":"Clinical","start":2,"end":10,"id":1,"ws":true},{"text":"evaluation","start":11,"end":21,"id":2,"ws":true},{"text":"of","start":22,"end":24,"id":3,"ws":true},{"text":"effects","start":25,"end":32,"id":4,"ws":true},{"text":"from","start":33,"end":37,"id":5,"ws":true},{"text":"neoadjuvant","start":38,"end":49,"id":6,"ws":true},{"text":"chemotherapy","start":50,"end":62,"id":7,"ws":true},{"text":"with","start":63,"end":67,"id":8,"ws":true},{"text":"epirubicin","start":68,"end":78,"id":9,"ws":true},{"text":"plus","start":79,"end":83,"id":10,"ws":true},{"text":"paclitaxel","start":84,"end":94,"id":11,"ws":true},{"text":"in","start":95,"end":97,"id":12,"ws":true},{"text":"cases","start":98,"end":103,"id":13,"ws":true},{"text":"of","start":104,"end":106,"id":14,"ws":true},{"text":"locally","start":107,"end":114,"id":15,"ws":true},{"text":"advanced","start":115,"end":123,"id":16,"ws":true},{"text":"breast","start":124,"end":130,"id":17,"ws":true},{"text":"cancer","start":131,"end":137,"id":18,"ws":true},{"text":"--","start":138,"end":140,"id":19,"ws":true},{"text":"comparative","start":141,"end":152,"id":20,"ws":true},{"text":"study","start":153,"end":158,"id":21,"ws":true},{"text":"of","start":159,"end":161,"id":22,"ws":true},{"text":"treatment","start":162,"end":171,"id":23,"ws":true},{"text":"with","start":172,"end":176,"id":24,"ws":true},{"text":"2","start":177,"end":178,"id":25,"ws":true},{"text":"and","start":179,"end":182,"id":26,"ws":true},{"text":"4","start":183,"end":184,"id":27,"ws":true},{"text":"cycles","start":185,"end":191,"id":28,"ws":true},{"text":"]","start":192,"end":193,"id":29,"ws":true},{"text":".","start":194,"end":195,"id":30,"ws":false}],"spans":[{"start":68,"end":78,"token_start":9,"token_end":9,"label":"DRUG"},{"start":84,"end":94,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/14997752/","_input_hash":-2122849102,"_task_hash":1304982906,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":11,"child":9,"head_span":{"start":84,"end":94,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":68,"end":78,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"When systemically active chemotherapy doses were reached , further dose escalation was discontinued , and a phase II dose-range was established ( pemetrexed 500 mg/m(2 ) and carboplatin AUC = 5 - 6 ) .","paragraph":"<h3><u>A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.</u></h3>The primary objective of this phase I study was to determine the maximum tolerated dose for <b style='color:Tomato;'><i>pemetrexed</i></b>, alone and in combination with <b style='color:Tomato;'><i>carboplatin</i></b>, with concurrent radiotherapy. ### Experimental Design Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) or esophageal cancer were treated every 21 days for two cycles. Regimen 1 was <b style='color:Tomato;'><i>pemetrexed</i></b> (200-600 mg/m(2)); regimen 2 was <b style='color:Tomato;'><i>pemetrexed</i></b> (500 mg/m(2)) with escalating <b style='color:Tomato;'><i>carboplatin</i></b> doses (AUC = 4-6). Both regimens included concurrent radiation (40-66 Gy; palliative-intent doses were lower). ### results Thirty patients (18 locally advanced and 12 metastatic with dominant local symptoms) were enrolled, with an Eastern Cooperative Oncology Group performance status of 0/1/2 (n = 8/21/1). All dose levels were tolerable for regimen 1 (n = 18: 15 NSCLC and 3 esophageal cancers) and regimen 2 (n = 12: all NSCLC). In regimen 1, one dose-limiting toxicity (grade 4 esophagitis/anorexia) occurred (500 mg/m(2)). Grade 3 neutropenia (3 of 18 patients) was the main hematologic toxicity. In regimen 2, one dose-limiting toxicity (grade 3 esophagitis) occurred (500 mg/m(2); AUC = 6); grade 3/4 leukopenia (4 of 12 patients) was the main hematologic toxicity. Four complete responses (2 pathology proven) and eight partial responses were observed. <b style='color:DodgerBlue;'><i>When</i></b> <b style='color:DodgerBlue;'><i>systemically</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>reached</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>escalation</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>discontinued</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>dose-range</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>established</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>500</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>carboplatin</i></b> <b style='color:DodgerBlue;'><i>AUC</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusions The combination of <b style='color:Tomato;'><i>pemetrexed</i></b> (500 mg/m(2)) and <b style='color:Tomato;'><i>carboplatin</i></b> (AUC = 5 or 6) with concurrent radiation is well tolerated, allows for the administration of systemically active chemotherapy doses, and shows signs of activity. To further determine efficacy, safety profile, and optimal dosing, the Cancer and Leukemia Group B study 30407 is currently evaluating this regimen in patients with unresectable stage III NSCLC.","tokens":[{"text":"When","start":0,"end":4,"id":0,"ws":true},{"text":"systemically","start":5,"end":17,"id":1,"ws":true},{"text":"active","start":18,"end":24,"id":2,"ws":true},{"text":"chemotherapy","start":25,"end":37,"id":3,"ws":true},{"text":"doses","start":38,"end":43,"id":4,"ws":true},{"text":"were","start":44,"end":48,"id":5,"ws":true},{"text":"reached","start":49,"end":56,"id":6,"ws":true},{"text":",","start":57,"end":58,"id":7,"ws":true},{"text":"further","start":59,"end":66,"id":8,"ws":true},{"text":"dose","start":67,"end":71,"id":9,"ws":true},{"text":"escalation","start":72,"end":82,"id":10,"ws":true},{"text":"was","start":83,"end":86,"id":11,"ws":true},{"text":"discontinued","start":87,"end":99,"id":12,"ws":true},{"text":",","start":100,"end":101,"id":13,"ws":true},{"text":"and","start":102,"end":105,"id":14,"ws":true},{"text":"a","start":106,"end":107,"id":15,"ws":true},{"text":"phase","start":108,"end":113,"id":16,"ws":true},{"text":"II","start":114,"end":116,"id":17,"ws":true},{"text":"dose-range","start":117,"end":127,"id":18,"ws":true},{"text":"was","start":128,"end":131,"id":19,"ws":true},{"text":"established","start":132,"end":143,"id":20,"ws":true},{"text":"(","start":144,"end":145,"id":21,"ws":true},{"text":"pemetrexed","start":146,"end":156,"id":22,"ws":true},{"text":"500","start":157,"end":160,"id":23,"ws":true},{"text":"mg/m(2","start":161,"end":167,"id":24,"ws":true},{"text":")","start":168,"end":169,"id":25,"ws":true},{"text":"and","start":170,"end":173,"id":26,"ws":true},{"text":"carboplatin","start":174,"end":185,"id":27,"ws":true},{"text":"AUC","start":186,"end":189,"id":28,"ws":true},{"text":"=","start":190,"end":191,"id":29,"ws":true},{"text":"5","start":192,"end":193,"id":30,"ws":true},{"text":"-","start":194,"end":195,"id":31,"ws":true},{"text":"6","start":196,"end":197,"id":32,"ws":true},{"text":")","start":198,"end":199,"id":33,"ws":true},{"text":".","start":200,"end":201,"id":34,"ws":false}],"spans":[{"start":146,"end":156,"token_start":22,"token_end":22,"label":"DRUG"},{"start":174,"end":185,"token_start":27,"token_end":27,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17255273/","_input_hash":1071410750,"_task_hash":1537762818,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":27,"child":22,"head_span":{"start":174,"end":185,"token_start":27,"token_end":27,"label":"DRUG"},"child_span":{"start":146,"end":156,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Increased dose density is feasible : a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel , at 10- or 11-day intervals with filgrastim support in women with breast cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Increased</i></b> <b style='color:DodgerBlue;'><i>dose</i></b> <b style='color:DodgerBlue;'><i>density</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>feasible</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>pilot</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:MediumOrchid;'><i>epirubicin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>10-</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>11-day</i></b> <b style='color:DodgerBlue;'><i>intervals</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>filgrastim</i></b> <b style='color:DodgerBlue;'><i>support</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Because Cancer and Leukemia Group B 9741 trial showed a benefit for every 14-day administration of chemotherapy compared with every 21-day treatment, we hypothesized that even greater dose density would be more effective. We conducted a pilot trial to assess the feasibility of dose-dense chemotherapy consisting of a standard regime at 10- to 11-day intervals in the adjuvant/neoadjuvant setting. A 2-day window was allowed for scheduling logistics. ### Experimental Design Thirty-nine women with early-stage breast carcinoma were accrued from April 2004 to October 2004. Median age was 47 years (range, 26-67 years). Patients received therapy with 100 mg/m(2) <b style='color:Tomato;'><i>epirubicin</i></b> and 600 mg/m(2) <b style='color:Tomato;'><i>cyclophosphamide</i></b> (EC) q 10 to 11 days for four cycles followed by 175 mg/m(2) <b style='color:Tomato;'><i>paclitaxel</i></b> q 10 to 11 days for four cycles, all with <b style='color:Tomato;'><i>filgrastim</i></b> support (300 microg s.c. daily) from day 2 to 24 h before the next treatment. ### results Thirty-five (90%) patients completed all planned therapy. The median intertreatment interval was 10 days (range, 8-28 days). Cycles (80.7%) were delivered at no more than 10- to 11-day intervals. There were five dose reductions of 25% for grade 3 nonhematologic toxicity in five patients. Six (16%) patients developed febrile neutropenia defined as temperature >38 degrees C with absolute neutrophil count <1,000/microL. All febrile neutropenia was during therapy with EC. Other grade 3 toxicities included bone pain, hand and foot syndrome, neuropathy, mucositis, nausea, and vomiting. ### conclusions Therapy with EC for four cycles followed by <b style='color:Tomato;'><i>paclitaxel</i></b> for four cycles at 10- to 11-day intervals is feasible. The approximately 30% reduction in intertreatment interval compared with every 14-day treatment could increase the efficacy of adjuvant chemotherapy.","tokens":[{"text":"Increased","start":0,"end":9,"id":0,"ws":true},{"text":"dose","start":10,"end":14,"id":1,"ws":true},{"text":"density","start":15,"end":22,"id":2,"ws":true},{"text":"is","start":23,"end":25,"id":3,"ws":true},{"text":"feasible","start":26,"end":34,"id":4,"ws":true},{"text":":","start":35,"end":36,"id":5,"ws":true},{"text":"a","start":37,"end":38,"id":6,"ws":true},{"text":"pilot","start":39,"end":44,"id":7,"ws":true},{"text":"study","start":45,"end":50,"id":8,"ws":true},{"text":"of","start":51,"end":53,"id":9,"ws":true},{"text":"adjuvant","start":54,"end":62,"id":10,"ws":true},{"text":"epirubicin","start":63,"end":73,"id":11,"ws":true},{"text":"and","start":74,"end":77,"id":12,"ws":true},{"text":"cyclophosphamide","start":78,"end":94,"id":13,"ws":true},{"text":"followed","start":95,"end":103,"id":14,"ws":true},{"text":"by","start":104,"end":106,"id":15,"ws":true},{"text":"paclitaxel","start":107,"end":117,"id":16,"ws":true},{"text":",","start":118,"end":119,"id":17,"ws":true},{"text":"at","start":120,"end":122,"id":18,"ws":true},{"text":"10-","start":123,"end":126,"id":19,"ws":true},{"text":"or","start":127,"end":129,"id":20,"ws":true},{"text":"11-day","start":130,"end":136,"id":21,"ws":true},{"text":"intervals","start":137,"end":146,"id":22,"ws":true},{"text":"with","start":147,"end":151,"id":23,"ws":true},{"text":"filgrastim","start":152,"end":162,"id":24,"ws":true},{"text":"support","start":163,"end":170,"id":25,"ws":true},{"text":"in","start":171,"end":173,"id":26,"ws":true},{"text":"women","start":174,"end":179,"id":27,"ws":true},{"text":"with","start":180,"end":184,"id":28,"ws":true},{"text":"breast","start":185,"end":191,"id":29,"ws":true},{"text":"cancer","start":192,"end":198,"id":30,"ws":true},{"text":".","start":199,"end":200,"id":31,"ws":false}],"spans":[{"start":63,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},{"start":78,"end":94,"token_start":13,"token_end":13,"label":"DRUG"},{"start":107,"end":117,"token_start":16,"token_end":16,"label":"DRUG"},{"start":152,"end":162,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17200358/","_input_hash":939881528,"_task_hash":2125935323,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":13,"child":11,"head_span":{"start":78,"end":94,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":63,"end":73,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":13,"child":16,"head_span":{"start":78,"end":94,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":107,"end":117,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":16,"child":24,"head_span":{"start":107,"end":117,"token_start":16,"token_end":16,"label":"DRUG"},"child_span":{"start":152,"end":162,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Those who test positive are treated with combinations of the following agents : omeprazole , clarithromycin , amoxicillin , tetracycline , and metronidazole .","paragraph":"<h3><u>Pharmacist-managed Helicobacter pylori clinic.</u></h3>A pharmacist-managed Helicobacter pylori assessment clinic for ambulatory patients is described. The pharmacy service at a 400-bed Veterans Affairs Medical Center established a pharmacist-managed clinic to assess patients who were receiving long-term acid-suppressive medications (histamine H2-receptor antagonists, <b style='color:Tomato;'><i>sucralfate</i></b>, or <b style='color:Tomato;'><i>omeprazole</i></b>). Patients with active ulcer disease and those receiving ulcer prophylaxis are screened for the presence of H. pylori. <b style='color:DodgerBlue;'><i>Those</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>test</i></b> <b style='color:DodgerBlue;'><i>positive</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>tetracycline</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>metronidazole</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The pharmacist also may adjust or discontinue acid-suppressive drug regimens. The pharmacist is responsible for ordering all appropriate laboratory tests, monitoring patients for adverse effects, collecting data on patient outcomes, and providing patient education. The clinic provides opportunities for pharmacists to study the clinical effectiveness and pharmacoeconomics of various regimens for treating H. pylori-associated disease and for pharmacy students and residents to interact with patients. As of fall 1994, 20 patients had been evaluated at the clinic: 12 tested positive for H. pylori and were treated with antimicrobials and all were pain-free without medication at the end of treatment. An H. pylori assessment clinic enabled pharmacists to assume a primary care role, document improvement in patient outcomes, and study the effectiveness of various antimicrobial regimens.","tokens":[{"text":"Those","start":0,"end":5,"id":0,"ws":true},{"text":"who","start":6,"end":9,"id":1,"ws":true},{"text":"test","start":10,"end":14,"id":2,"ws":true},{"text":"positive","start":15,"end":23,"id":3,"ws":true},{"text":"are","start":24,"end":27,"id":4,"ws":true},{"text":"treated","start":28,"end":35,"id":5,"ws":true},{"text":"with","start":36,"end":40,"id":6,"ws":true},{"text":"combinations","start":41,"end":53,"id":7,"ws":true},{"text":"of","start":54,"end":56,"id":8,"ws":true},{"text":"the","start":57,"end":60,"id":9,"ws":true},{"text":"following","start":61,"end":70,"id":10,"ws":true},{"text":"agents","start":71,"end":77,"id":11,"ws":true},{"text":":","start":78,"end":79,"id":12,"ws":true},{"text":"omeprazole","start":80,"end":90,"id":13,"ws":true},{"text":",","start":91,"end":92,"id":14,"ws":true},{"text":"clarithromycin","start":93,"end":107,"id":15,"ws":true},{"text":",","start":108,"end":109,"id":16,"ws":true},{"text":"amoxicillin","start":110,"end":121,"id":17,"ws":true},{"text":",","start":122,"end":123,"id":18,"ws":true},{"text":"tetracycline","start":124,"end":136,"id":19,"ws":true},{"text":",","start":137,"end":138,"id":20,"ws":true},{"text":"and","start":139,"end":142,"id":21,"ws":true},{"text":"metronidazole","start":143,"end":156,"id":22,"ws":true},{"text":".","start":157,"end":158,"id":23,"ws":false}],"spans":[{"start":80,"end":90,"token_start":13,"token_end":13,"label":"DRUG"},{"start":93,"end":107,"token_start":15,"token_end":15,"label":"DRUG"},{"start":110,"end":121,"token_start":17,"token_end":17,"label":"DRUG"},{"start":124,"end":136,"token_start":19,"token_end":19,"label":"DRUG"},{"start":143,"end":156,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12879545/","_input_hash":-1629384935,"_task_hash":-792898755,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":80,"end":90,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":93,"end":107,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":15,"child":17,"head_span":{"start":93,"end":107,"token_start":15,"token_end":15,"label":"DRUG"},"child_span":{"start":110,"end":121,"token_start":17,"token_end":17,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":17,"child":19,"head_span":{"start":110,"end":121,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":124,"end":136,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":19,"child":22,"head_span":{"start":124,"end":136,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":143,"end":156,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Patients can be treatment-na\u00efve for mCRPC or on first-line androgen receptor-targeted therapy for mCRPC ( ie , abiraterone or enzalutamide ) without evidence of progression at enrolment , and with no prior chemotherapy for mCRPC .","paragraph":"<h3><u>Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.</u></h3>Preliminary evidence supports the beneficial role of physical activity on prostate cancer outcomes. This phase III randomised controlled trial (RCT) is designed to determine if supervised high-intensity aerobic and resistance exercise increases overall survival (OS) in patients with metastatic castrate-resistant prostate cancer (mCRPC). ### Methods And Analysis Participants (n=866) must have histologically documented metastatic prostate cancer with evidence of progressive disease on androgen deprivation therapy (defined as mCRPC). <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>treatment-na\u00efve</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>mCRPC</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>androgen</i></b> <b style='color:DodgerBlue;'><i>receptor-targeted</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>mCRPC</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ie</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>abiraterone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>evidence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>enrolment</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>prior</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>mCRPC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Patients will receive psychosocial support and will be randomly assigned (1:1) to either supervised exercise (high-intensity aerobic and resistance training) or self-directed exercise (provision of guidelines), stratified by treatment status and site. Exercise prescriptions will be tailored to each participant's fitness and morbidities. The primary endpoint is OS. Secondary endpoints include time to disease progression, occurrence of a skeletal-related event or progression of pain, and degree of pain, opiate use, physical and emotional quality of life, and changes in metabolic biomarkers. An assessment of whether immune function, inflammation, dysregulation of insulin and energy metabolism, and androgen biomarkers are associated with OS will be performed, and whether they mediate the primary association between exercise and OS will also be investigated. This study will also establish a biobank for future biomarker discovery or validation. ### Ethics And Dissemination Validation of exercise as medicine and its mechanisms of action will create evidence to change clinical practice. Accordingly, outcomes of this RCT will be published in international, peer-reviewed journals, and presented at national and international conferences. Ethics approval was first obtained at Edith Cowan University (ID: 13236 NEWTON), with a further 10 investigator sites since receiving ethics approval, prior to activation. ### Trial Registration Number NCT02730338.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"can","start":9,"end":12,"id":1,"ws":true},{"text":"be","start":13,"end":15,"id":2,"ws":true},{"text":"treatment-na\u00efve","start":16,"end":31,"id":3,"ws":true},{"text":"for","start":32,"end":35,"id":4,"ws":true},{"text":"mCRPC","start":36,"end":41,"id":5,"ws":true},{"text":"or","start":42,"end":44,"id":6,"ws":true},{"text":"on","start":45,"end":47,"id":7,"ws":true},{"text":"first-line","start":48,"end":58,"id":8,"ws":true},{"text":"androgen","start":59,"end":67,"id":9,"ws":true},{"text":"receptor-targeted","start":68,"end":85,"id":10,"ws":true},{"text":"therapy","start":86,"end":93,"id":11,"ws":true},{"text":"for","start":94,"end":97,"id":12,"ws":true},{"text":"mCRPC","start":98,"end":103,"id":13,"ws":true},{"text":"(","start":104,"end":105,"id":14,"ws":true},{"text":"ie","start":106,"end":108,"id":15,"ws":true},{"text":",","start":109,"end":110,"id":16,"ws":true},{"text":"abiraterone","start":111,"end":122,"id":17,"ws":true},{"text":"or","start":123,"end":125,"id":18,"ws":true},{"text":"enzalutamide","start":126,"end":138,"id":19,"ws":true},{"text":")","start":139,"end":140,"id":20,"ws":true},{"text":"without","start":141,"end":148,"id":21,"ws":true},{"text":"evidence","start":149,"end":157,"id":22,"ws":true},{"text":"of","start":158,"end":160,"id":23,"ws":true},{"text":"progression","start":161,"end":172,"id":24,"ws":true},{"text":"at","start":173,"end":175,"id":25,"ws":true},{"text":"enrolment","start":176,"end":185,"id":26,"ws":true},{"text":",","start":186,"end":187,"id":27,"ws":true},{"text":"and","start":188,"end":191,"id":28,"ws":true},{"text":"with","start":192,"end":196,"id":29,"ws":true},{"text":"no","start":197,"end":199,"id":30,"ws":true},{"text":"prior","start":200,"end":205,"id":31,"ws":true},{"text":"chemotherapy","start":206,"end":218,"id":32,"ws":true},{"text":"for","start":219,"end":222,"id":33,"ws":true},{"text":"mCRPC","start":223,"end":228,"id":34,"ws":true},{"text":".","start":229,"end":230,"id":35,"ws":false}],"spans":[{"start":111,"end":122,"token_start":17,"token_end":17,"label":"DRUG"},{"start":126,"end":138,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29764892/","_input_hash":-196170261,"_task_hash":1174955668,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"CYP2D6 metabolizes other opioid analgesics , including tramadol , dihydrocodeine , oxycodone and hydrocodone , although they have been less systematically studied .","paragraph":"<h3><u>Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.</u></h3><b style='color:Tomato;'><i>codeine</i></b> is metabolized by the cytochrome P450 2D6 (CYP2D6) to morphine. <b style='color:Tomato;'><i>codeine</i></b> is a much weaker agonist at mu opioid receptors than morphine. Therefore, <b style='color:Tomato;'><i>codeine</i></b> analgesia is highly dependent on CYP2D6 activity. Large prospective studies in the clinical environment do not exist, but it appears reasonable to avoid <b style='color:Tomato;'><i>codeine</i></b> use in CYP2D6 poor metabolizers (PMs). <b style='color:DodgerBlue;'><i>CYP2D6</i></b> <b style='color:DodgerBlue;'><i>metabolizes</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>opioid</i></b> <b style='color:DodgerBlue;'><i>analgesics</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>tramadol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>dihydrocodeine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>oxycodone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>hydrocodone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>although</i></b> <b style='color:DodgerBlue;'><i>they</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>less</i></b> <b style='color:DodgerBlue;'><i>systematically</i></b> <b style='color:DodgerBlue;'><i>studied</i></b> <b style='color:DodgerBlue;'><i>.</i></b> It is unclear whether these other pro-drugs may be as completely dependent on CYP2D6 for their analgesia as <b style='color:Tomato;'><i>codeine</i></b>. We describe a patient identified as a CYP2D6 PM with a history of problems with opioid analgesics. The patient was an 85-year-old female Caucasian who had hip surgery. The patient had a long-standing intolerance to <b style='color:Tomato;'><i>codeine</i></b>. In her first admission, she couldn't tolerate the regimen of oxycodone combined with <b style='color:Tomato;'><i>tramadol</i></b> prns (as needed). She was genotyped as a CYP2D6 PM and after the information was provided to the treating physician in her second admission, she seemed to have a better response to <b style='color:Tomato;'><i>hydrocodone</i></b>. Large case-control naturalistic studies followed by randomized trials in patients taking opioid analgesics may be needed to definitively establish that CYP2D6 genotyping has clinical relevance in the use of several opioid analgesics.","tokens":[{"text":"CYP2D6","start":0,"end":6,"id":0,"ws":true},{"text":"metabolizes","start":7,"end":18,"id":1,"ws":true},{"text":"other","start":19,"end":24,"id":2,"ws":true},{"text":"opioid","start":25,"end":31,"id":3,"ws":true},{"text":"analgesics","start":32,"end":42,"id":4,"ws":true},{"text":",","start":43,"end":44,"id":5,"ws":true},{"text":"including","start":45,"end":54,"id":6,"ws":true},{"text":"tramadol","start":55,"end":63,"id":7,"ws":true},{"text":",","start":64,"end":65,"id":8,"ws":true},{"text":"dihydrocodeine","start":66,"end":80,"id":9,"ws":true},{"text":",","start":81,"end":82,"id":10,"ws":true},{"text":"oxycodone","start":83,"end":92,"id":11,"ws":true},{"text":"and","start":93,"end":96,"id":12,"ws":true},{"text":"hydrocodone","start":97,"end":108,"id":13,"ws":true},{"text":",","start":109,"end":110,"id":14,"ws":true},{"text":"although","start":111,"end":119,"id":15,"ws":true},{"text":"they","start":120,"end":124,"id":16,"ws":true},{"text":"have","start":125,"end":129,"id":17,"ws":true},{"text":"been","start":130,"end":134,"id":18,"ws":true},{"text":"less","start":135,"end":139,"id":19,"ws":true},{"text":"systematically","start":140,"end":154,"id":20,"ws":true},{"text":"studied","start":155,"end":162,"id":21,"ws":true},{"text":".","start":163,"end":164,"id":22,"ws":false}],"spans":[{"start":55,"end":63,"token_start":7,"token_end":7,"label":"DRUG"},{"start":97,"end":108,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16631290/","_input_hash":180518504,"_task_hash":386885726,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Atracurium or vecuronium was given for intubation .","paragraph":"<h3><u>Prediction of oculocardiac reflex in strabismus surgery using neural networks.</u></h3>Successfully predicting an oculocardiac reflex (OCR) is difficult to achieve despite various proposed maneuvers. The aim of this study was to test the models built up by neural networks to predict the occurrence of OCR during strabismus surgery in children. Premedication was not given. <b style='color:Tomato;'><i>atropine</i></b> 0.01 mg/kg was medicated just before induction. Induction was performed with fentanyl or <b style='color:Tomato;'><i>ketorolac</i></b>, followed by <b style='color:Tomato;'><i>propofol</i></b>. <b style='color:MediumOrchid;'><i>Atracurium</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>vecuronium</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>intubation</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Anesthesia was maintained with O2-N2O with continuous <b style='color:Tomato;'><i>propofol</i></b> infusion. Chi-square test was performed for induction agents, gender, weight, muscle blockade, repaired muscle, number of repaired muscles, duration of operation to detect any association between the occurrence of OCR and to develop the model of neural networks. The multi-layer perceptron, radial basis function and Bayesian backpropagation network were tested. The occurrence of OCR was significantly associated with gender and repaired muscle (p < 0.05). Gender, repaired muscle and age were considered as input for the multi-layer perceptron, radial basis function and Bayesian backpropagation network. Three neural networks had predicted the same correction rate in the occurrence of OCR as being 87.5% overall among 16 patients' records tested. These models are conceptually different in predicting compared to conventional maneuvers, and have the advantage of testing individually and foretelling the propensity. By comparison neural networks use grouped experiential data and predict OCR by the learning rule. Neural networks require a relatively abundant number of experienced and homogenous patients' records to establish an accurate model. The multi-layer perceptron, radial basis function and Bayesian backpropagation modeling network may be an alternative way, and preferable to vagal tone maneuvers if the associated relationships to the occurrence of OCR are more clearly defined.","tokens":[{"text":"Atracurium","start":0,"end":10,"id":0,"ws":true},{"text":"or","start":11,"end":13,"id":1,"ws":true},{"text":"vecuronium","start":14,"end":24,"id":2,"ws":true},{"text":"was","start":25,"end":28,"id":3,"ws":true},{"text":"given","start":29,"end":34,"id":4,"ws":true},{"text":"for","start":35,"end":38,"id":5,"ws":true},{"text":"intubation","start":39,"end":49,"id":6,"ws":true},{"text":".","start":50,"end":51,"id":7,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":14,"end":24,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10412336/","_input_hash":1481785694,"_task_hash":868944343,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The data show that knockdown of Rad51 or BRCA2 greatly sensitizes cells to DSBs and the induction of cell death following temozolomide and nimustine ( ACNU ) .","paragraph":"<h3><u>Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs.</u></h3>First line chemotherapeutics for brain tumors (malignant gliomas) are alkylating agents such as <b style='color:Tomato;'><i>temozolomide</i></b> and <b style='color:Tomato;'><i>nimustine</i></b>. Despite growing knowledge of how these agents work, patients suffering from this malignancy still face a dismal prognosis. Alkylating agents target DNA, forming the killing lesion O(6)-alkylguanine, which is converted into DNA double-strand breaks (DSBs) that trigger apoptosis. Here we assessed whether inhibiting repair of DSBs by homologous recombination (HR) or non-homologous end joining (NHEJ) is a reasonable strategy for sensitizing glioma cells to alkylating agents. For down-regulation of HR in glioma cells, we used an interference RNA (iRNA) approach targeting Rad51 and BRCA2, and for NHEJ we employed the DNA-PK inhibitor NU7026. We also assessed whether inhibition of poly(ADP)ribosyltransferase (PARP) by <b style='color:Tomato;'><i>olaparib</i></b> would enhance the killing effect. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>show</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>knockdown</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Rad51</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>BRCA2</i></b> <b style='color:DodgerBlue;'><i>greatly</i></b> <b style='color:DodgerBlue;'><i>sensitizes</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>DSBs</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>death</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>nimustine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ACNU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> It did not sensitize to ionizing radiation (IR). The expression of O(6)-methylguanine-DNA methyltransferase (MGMT) abolished all these effects, indicating that O(6)-alkylguanine induced by these drugs is the primary lesion responsible for the formation of DSBs and increased sensitivity of glioma cells following knockdown of Rad51 and BRCA2. Inhibition of DNA-PK only slightly sensitized to <b style='color:Tomato;'><i>temozolomide</i></b> whereas a significant effect was observed with IR. A triple strategy including siRNA and the PARP inhibitor <b style='color:Tomato;'><i>olaparib</i></b> further improved the killing effect of <b style='color:Tomato;'><i>temozolomide</i></b>. The data provides evidence that down-regulation of Rad51 or BRCA2 is a reasonable strategy for sensitizing glioma cells to killing by O(6)-alkylating anti-cancer drugs. The data also provide proof of principle that a triple strategy involving down-regulation of HR, PARP inhibition and MGMT depletion may greatly enhance the therapeutic effect of <b style='color:Tomato;'><i>temozolomide</i></b>.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"data","start":4,"end":8,"id":1,"ws":true},{"text":"show","start":9,"end":13,"id":2,"ws":true},{"text":"that","start":14,"end":18,"id":3,"ws":true},{"text":"knockdown","start":19,"end":28,"id":4,"ws":true},{"text":"of","start":29,"end":31,"id":5,"ws":true},{"text":"Rad51","start":32,"end":37,"id":6,"ws":true},{"text":"or","start":38,"end":40,"id":7,"ws":true},{"text":"BRCA2","start":41,"end":46,"id":8,"ws":true},{"text":"greatly","start":47,"end":54,"id":9,"ws":true},{"text":"sensitizes","start":55,"end":65,"id":10,"ws":true},{"text":"cells","start":66,"end":71,"id":11,"ws":true},{"text":"to","start":72,"end":74,"id":12,"ws":true},{"text":"DSBs","start":75,"end":79,"id":13,"ws":true},{"text":"and","start":80,"end":83,"id":14,"ws":true},{"text":"the","start":84,"end":87,"id":15,"ws":true},{"text":"induction","start":88,"end":97,"id":16,"ws":true},{"text":"of","start":98,"end":100,"id":17,"ws":true},{"text":"cell","start":101,"end":105,"id":18,"ws":true},{"text":"death","start":106,"end":111,"id":19,"ws":true},{"text":"following","start":112,"end":121,"id":20,"ws":true},{"text":"temozolomide","start":122,"end":134,"id":21,"ws":true},{"text":"and","start":135,"end":138,"id":22,"ws":true},{"text":"nimustine","start":139,"end":148,"id":23,"ws":true},{"text":"(","start":149,"end":150,"id":24,"ws":true},{"text":"ACNU","start":151,"end":155,"id":25,"ws":true},{"text":")","start":156,"end":157,"id":26,"ws":true},{"text":".","start":158,"end":159,"id":27,"ws":false}],"spans":[{"start":122,"end":134,"token_start":21,"token_end":21,"label":"DRUG"},{"start":139,"end":148,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22073281/","_input_hash":-1385267655,"_task_hash":1362201328,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The systemic treatment in both studies consisted of a four-drug-regimen ( VACA = vincristine , actinomycin D , cyclophosphamide , and adriamycin ; or VAIA = vincristine , actinomycin D , ifosfamide , and adriamycin ) and a total number of four courses , each lasting nine weeks , was recommended by the protocol .","paragraph":"<h3><u>Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.</u></h3>During recent years, more intensified systemic and local treatment regimens have increased the 5-year survival figures in localized Ewing's sarcoma to more than 60%. There is, however, concern about the risk of second malignancies (SM) in long-term survivors. We have analyzed the second malignancies in patients treated in the German Ewing's Sarcoma Studies CESS 81 and CESS 86. ### Materials And Methods From January 1981 through June 1991, 674 patients were registered in the two sequential multicentric Ewing's sarcoma trials CESS 81 (recruitment period 1981-1985) and CESS 86 (1986-1991). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>systemic</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>consisted</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>four-drug-regimen</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VACA</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin</i></b> <b style='color:DodgerBlue;'><i>D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>VAIA</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>actinomycin</i></b> <b style='color:DodgerBlue;'><i>D</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>adriamycin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>number</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>courses</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>each</i></b> <b style='color:DodgerBlue;'><i>lasting</i></b> <b style='color:DodgerBlue;'><i>nine</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>recommended</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Local therapy in curative patients was either complete surgery (n = 162), surgery plus postoperative radiotherapy with 36-46Gy (n = 274), or definitive radiotherapy with 46-60Gy (n = 212). The median follow-up at the time of this analysis was 5.1 years, the maximum follow-up 16.5 years. ### results The overall survival of all patients including metastatic patients was 55% after 5 years, 48% after 10 years, and 37% after 15 years. Eight out of 674 patients (1.2%) developed a SM. Five of these were acute myelogenic leukemias (n = 4) or MDS (n = 1), and three were sarcomas. The interval between diagnosis of Ewing's sarcoma and the diagnosis of the SM was 17-78 months for the four AMLs, 96 months for the MDS and 82-136 months for the three sarcomas. The cumulative risk of an SM was 0.7% after 5 years, 2.9% after 10 years, and 4.7% after 15 years. Out of five patients with AML/MDS, three died of rapid AML-progression, and two are living with disease. Local therapy (surgery vs. surgery plus postoperative irradiation vs. definitive radiotherapy) had no impact on the frequency of AML/MDS, but local therapy did influence the risk of secondary sarcomas. All three patients with secondary sarcomas had received radiotherapy; however, all three sarcomas were salvaged by subsequent treatment and are in clinical remission with a follow-up of 1 month, 4.3 years, and 7.5 years after the diagnosis of the secondary sarcoma. Thus far, SM contributed to less than 1 % (3/328) of all deaths in the CESS-studies. ### conclusions The risk of leukemia after treatment for Ewing's sarcoma is probably in the range of 2%. The risk of solid tumors also seems to be low within the first 10 years after treatment and remains in the range of 5 % after 15 years. In the CESS-studies, less than 1% of all deaths within the first 10 years after diagnosis were caused by SM. Effective salvage therapy for secondary sarcomas is feasible.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"systemic","start":4,"end":12,"id":1,"ws":true},{"text":"treatment","start":13,"end":22,"id":2,"ws":true},{"text":"in","start":23,"end":25,"id":3,"ws":true},{"text":"both","start":26,"end":30,"id":4,"ws":true},{"text":"studies","start":31,"end":38,"id":5,"ws":true},{"text":"consisted","start":39,"end":48,"id":6,"ws":true},{"text":"of","start":49,"end":51,"id":7,"ws":true},{"text":"a","start":52,"end":53,"id":8,"ws":true},{"text":"four-drug-regimen","start":54,"end":71,"id":9,"ws":true},{"text":"(","start":72,"end":73,"id":10,"ws":true},{"text":"VACA","start":74,"end":78,"id":11,"ws":true},{"text":"=","start":79,"end":80,"id":12,"ws":true},{"text":"vincristine","start":81,"end":92,"id":13,"ws":true},{"text":",","start":93,"end":94,"id":14,"ws":true},{"text":"actinomycin","start":95,"end":106,"id":15,"ws":true},{"text":"D","start":107,"end":108,"id":16,"ws":true},{"text":",","start":109,"end":110,"id":17,"ws":true},{"text":"cyclophosphamide","start":111,"end":127,"id":18,"ws":true},{"text":",","start":128,"end":129,"id":19,"ws":true},{"text":"and","start":130,"end":133,"id":20,"ws":true},{"text":"adriamycin","start":134,"end":144,"id":21,"ws":true},{"text":";","start":145,"end":146,"id":22,"ws":true},{"text":"or","start":147,"end":149,"id":23,"ws":true},{"text":"VAIA","start":150,"end":154,"id":24,"ws":true},{"text":"=","start":155,"end":156,"id":25,"ws":true},{"text":"vincristine","start":157,"end":168,"id":26,"ws":true},{"text":",","start":169,"end":170,"id":27,"ws":true},{"text":"actinomycin","start":171,"end":182,"id":28,"ws":true},{"text":"D","start":183,"end":184,"id":29,"ws":true},{"text":",","start":185,"end":186,"id":30,"ws":true},{"text":"ifosfamide","start":187,"end":197,"id":31,"ws":true},{"text":",","start":198,"end":199,"id":32,"ws":true},{"text":"and","start":200,"end":203,"id":33,"ws":true},{"text":"adriamycin","start":204,"end":214,"id":34,"ws":true},{"text":")","start":215,"end":216,"id":35,"ws":true},{"text":"and","start":217,"end":220,"id":36,"ws":true},{"text":"a","start":221,"end":222,"id":37,"ws":true},{"text":"total","start":223,"end":228,"id":38,"ws":true},{"text":"number","start":229,"end":235,"id":39,"ws":true},{"text":"of","start":236,"end":238,"id":40,"ws":true},{"text":"four","start":239,"end":243,"id":41,"ws":true},{"text":"courses","start":244,"end":251,"id":42,"ws":true},{"text":",","start":252,"end":253,"id":43,"ws":true},{"text":"each","start":254,"end":258,"id":44,"ws":true},{"text":"lasting","start":259,"end":266,"id":45,"ws":true},{"text":"nine","start":267,"end":271,"id":46,"ws":true},{"text":"weeks","start":272,"end":277,"id":47,"ws":true},{"text":",","start":278,"end":279,"id":48,"ws":true},{"text":"was","start":280,"end":283,"id":49,"ws":true},{"text":"recommended","start":284,"end":295,"id":50,"ws":true},{"text":"by","start":296,"end":298,"id":51,"ws":true},{"text":"the","start":299,"end":302,"id":52,"ws":true},{"text":"protocol","start":303,"end":311,"id":53,"ws":true},{"text":".","start":312,"end":313,"id":54,"ws":false}],"spans":[{"start":81,"end":92,"token_start":13,"token_end":13,"label":"DRUG"},{"start":111,"end":127,"token_start":18,"token_end":18,"label":"DRUG"},{"start":134,"end":144,"token_start":21,"token_end":21,"label":"DRUG"},{"start":157,"end":168,"token_start":26,"token_end":26,"label":"DRUG"},{"start":187,"end":197,"token_start":31,"token_end":31,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9788419/","_input_hash":261521970,"_task_hash":456606957,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":81,"end":92,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":95,"end":106,"token_start":15,"token_end":15,"label":null},"color":"#96e8ce","label":"COMB1"},{"head":15,"child":18,"head_span":{"start":95,"end":106,"token_start":15,"token_end":15,"label":null},"child_span":{"start":111,"end":127,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":18,"child":21,"head_span":{"start":111,"end":127,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":134,"end":144,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":26,"child":28,"head_span":{"start":157,"end":168,"token_start":26,"token_end":26,"label":"DRUG"},"child_span":{"start":171,"end":182,"token_start":28,"token_end":28,"label":null},"color":"#ffd1b2","label":"COMB2"},{"head":28,"child":31,"head_span":{"start":171,"end":182,"token_start":28,"token_end":28,"label":null},"child_span":{"start":187,"end":197,"token_start":31,"token_end":31,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"},{"head":31,"child":34,"head_span":{"start":187,"end":197,"token_start":31,"token_end":31,"label":"DRUG"},"child_span":{"start":204,"end":214,"token_start":34,"token_end":34,"label":null},"color":"#ffd1b2","label":"COMB2"}],"radio":[],"answer":"accept"}
{"text":"Rationale , design , and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive , nonhypercholesterolemic subjects with microalbuminuria ( the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [ PREVEND IT ] ) .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Rationale</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>design</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>baseline</i></b> <b style='color:DodgerBlue;'><i>characteristics</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>prevention</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>cardiovascular</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>fosinopril</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>pravastatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>nonhypertensive</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>nonhypercholesterolemic</i></b> <b style='color:DodgerBlue;'><i>subjects</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>microalbuminuria</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>Prevention</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>REnal</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Vascular</i></b> <b style='color:DodgerBlue;'><i>ENdstage</i></b> <b style='color:DodgerBlue;'><i>Disease</i></b> <b style='color:DodgerBlue;'><i>Intervention</i></b> <b style='color:DodgerBlue;'><i>Trial</i></b> <b style='color:DodgerBlue;'><i>[</i></b> <b style='color:DodgerBlue;'><i>PREVEND</i></b> <b style='color:DodgerBlue;'><i>IT</i></b> <b style='color:DodgerBlue;'><i>]</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>This study describes the rationale, design, and baseline characteristics of a trial to determine whether treatment with <b style='color:Tomato;'><i>fosinopril</i></b> 20 mg/day and/or <b style='color:Tomato;'><i>pravastatin</i></b> 40 mg/ day will prevent cardiovascular and renal disease in nonhypertensive (RR <160/100 mm Hg and not using antihypertensive medication) and nonhypercholesterolemic (total cholesterol <8.0 or <5.0 mmol/L in case of previous myocardial infarction and not using lipid lowering medication) men and women with persistent microalbuminuria (urinary albumin excretion >10 mg/L once in an early morning spot urine and 15 to 300 mg/24-hour at least once in two 24-hour urine collections). The Prevention of REnal and Vascular ENdstage Disease Intervention Trial is a single-center, double-blind, randomized, placebo-controlled trial with a 2 x 2 factorial design. The 864 randomized subjects will be monitored for a minimum of 4 years and a maximum of 5 years. The primary efficacy parameter is defined as the combined incidence of all-cause mortality or hospital admission for documented (1) nonfatal myocardial infarction, (2) myocardial ischemia, (3) heart failure, (4) peripheral vascular disease, (5) cerebrovascular accident and/or (6) end-stage renal disease.","tokens":[{"text":"Rationale","start":0,"end":9,"id":0,"ws":true},{"text":",","start":10,"end":11,"id":1,"ws":true},{"text":"design","start":12,"end":18,"id":2,"ws":true},{"text":",","start":19,"end":20,"id":3,"ws":true},{"text":"and","start":21,"end":24,"id":4,"ws":true},{"text":"baseline","start":25,"end":33,"id":5,"ws":true},{"text":"characteristics","start":34,"end":49,"id":6,"ws":true},{"text":"of","start":50,"end":52,"id":7,"ws":true},{"text":"a","start":53,"end":54,"id":8,"ws":true},{"text":"trial","start":55,"end":60,"id":9,"ws":true},{"text":"of","start":61,"end":63,"id":10,"ws":true},{"text":"prevention","start":64,"end":74,"id":11,"ws":true},{"text":"of","start":75,"end":77,"id":12,"ws":true},{"text":"cardiovascular","start":78,"end":92,"id":13,"ws":true},{"text":"and","start":93,"end":96,"id":14,"ws":true},{"text":"renal","start":97,"end":102,"id":15,"ws":true},{"text":"disease","start":103,"end":110,"id":16,"ws":true},{"text":"with","start":111,"end":115,"id":17,"ws":true},{"text":"fosinopril","start":116,"end":126,"id":18,"ws":true},{"text":"and","start":127,"end":130,"id":19,"ws":true},{"text":"pravastatin","start":131,"end":142,"id":20,"ws":true},{"text":"in","start":143,"end":145,"id":21,"ws":true},{"text":"nonhypertensive","start":146,"end":161,"id":22,"ws":true},{"text":",","start":162,"end":163,"id":23,"ws":true},{"text":"nonhypercholesterolemic","start":164,"end":187,"id":24,"ws":true},{"text":"subjects","start":188,"end":196,"id":25,"ws":true},{"text":"with","start":197,"end":201,"id":26,"ws":true},{"text":"microalbuminuria","start":202,"end":218,"id":27,"ws":true},{"text":"(","start":219,"end":220,"id":28,"ws":true},{"text":"the","start":221,"end":224,"id":29,"ws":true},{"text":"Prevention","start":225,"end":235,"id":30,"ws":true},{"text":"of","start":236,"end":238,"id":31,"ws":true},{"text":"REnal","start":239,"end":244,"id":32,"ws":true},{"text":"and","start":245,"end":248,"id":33,"ws":true},{"text":"Vascular","start":249,"end":257,"id":34,"ws":true},{"text":"ENdstage","start":258,"end":266,"id":35,"ws":true},{"text":"Disease","start":267,"end":274,"id":36,"ws":true},{"text":"Intervention","start":275,"end":287,"id":37,"ws":true},{"text":"Trial","start":288,"end":293,"id":38,"ws":true},{"text":"[","start":294,"end":295,"id":39,"ws":true},{"text":"PREVEND","start":296,"end":303,"id":40,"ws":true},{"text":"IT","start":304,"end":306,"id":41,"ws":true},{"text":"]","start":307,"end":308,"id":42,"ws":true},{"text":")","start":309,"end":310,"id":43,"ws":true},{"text":".","start":311,"end":312,"id":44,"ws":false}],"spans":[{"start":116,"end":126,"token_start":18,"token_end":18,"label":"DRUG"},{"start":131,"end":142,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10980214/","_input_hash":-1982290624,"_task_hash":1322187593,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":18,"child":20,"head_span":{"start":116,"end":126,"token_start":18,"token_end":18,"label":"DRUG"},"child_span":{"start":131,"end":142,"token_start":20,"token_end":20,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"In the present study , rabbits prepared with chronic vascular cannulae were used to study the effects of nicotine administration on plasma corticosterone , catecholamine ( epinephrine , norepinephrine and dopamine ) and glucose responses to physical restraint stress .","paragraph":"<h3><u>Neuroendocrine responses to nicotine and stress: enhancement of peripheral stress responses by the administration of nicotine.</u></h3>Habitual smokers frequently report that when they are stressed smoking helps them to relax. One potential explanation for the reported stress ameliorating effect of smoking is that cigarette consumption (<b style='color:Tomato;'><i>nicotine</i></b> self-administration) may decrease the sympathetic autonomic nervous system activity which is associated with the stress response. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>rabbits</i></b> <b style='color:DodgerBlue;'><i>prepared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>vascular</i></b> <b style='color:DodgerBlue;'><i>cannulae</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>nicotine</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>corticosterone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>catecholamine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>epinephrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>norepinephrine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>dopamine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>glucose</i></b> <b style='color:DodgerBlue;'><i>responses</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>physical</i></b> <b style='color:DodgerBlue;'><i>restraint</i></b> <b style='color:DodgerBlue;'><i>stress</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>nicotine</i></b> (0.025, 0.05 or 0.10 mg <b style='color:Tomato;'><i>nicotine</i></b> base/kg body weight) was administered for 10 days prior to the \"stress test\" to allow for the development of habituation/tolerance to its acute toxic effects. Independent administration of <b style='color:Tomato;'><i>nicotine</i></b>, or the application of the physical restraint stressor, resulted in increases in the plasma concentrations of corticosterone, <b style='color:Tomato;'><i>epinephrine</i></b>, nor<b style='color:Tomato;'><i>epinephrine</i></b>, and glucose. <b style='color:Tomato;'><i>nicotine</i></b> administration during restraint stress enhanced the increase in plasma corticosterone and <b style='color:Tomato;'><i>epinephrine</i></b>, as compared to the responses induced by either factor alone. The results suggest that the stress ameliorating effect of continued cigarette smoking, as reported by habitual smokers, is not due to a reduction in the activity of the peripheral sympathetic autonomic nervous system.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"present","start":7,"end":14,"id":2,"ws":true},{"text":"study","start":15,"end":20,"id":3,"ws":true},{"text":",","start":21,"end":22,"id":4,"ws":true},{"text":"rabbits","start":23,"end":30,"id":5,"ws":true},{"text":"prepared","start":31,"end":39,"id":6,"ws":true},{"text":"with","start":40,"end":44,"id":7,"ws":true},{"text":"chronic","start":45,"end":52,"id":8,"ws":true},{"text":"vascular","start":53,"end":61,"id":9,"ws":true},{"text":"cannulae","start":62,"end":70,"id":10,"ws":true},{"text":"were","start":71,"end":75,"id":11,"ws":true},{"text":"used","start":76,"end":80,"id":12,"ws":true},{"text":"to","start":81,"end":83,"id":13,"ws":true},{"text":"study","start":84,"end":89,"id":14,"ws":true},{"text":"the","start":90,"end":93,"id":15,"ws":true},{"text":"effects","start":94,"end":101,"id":16,"ws":true},{"text":"of","start":102,"end":104,"id":17,"ws":true},{"text":"nicotine","start":105,"end":113,"id":18,"ws":true},{"text":"administration","start":114,"end":128,"id":19,"ws":true},{"text":"on","start":129,"end":131,"id":20,"ws":true},{"text":"plasma","start":132,"end":138,"id":21,"ws":true},{"text":"corticosterone","start":139,"end":153,"id":22,"ws":true},{"text":",","start":154,"end":155,"id":23,"ws":true},{"text":"catecholamine","start":156,"end":169,"id":24,"ws":true},{"text":"(","start":170,"end":171,"id":25,"ws":true},{"text":"epinephrine","start":172,"end":183,"id":26,"ws":true},{"text":",","start":184,"end":185,"id":27,"ws":true},{"text":"norepinephrine","start":186,"end":200,"id":28,"ws":true},{"text":"and","start":201,"end":204,"id":29,"ws":true},{"text":"dopamine","start":205,"end":213,"id":30,"ws":true},{"text":")","start":214,"end":215,"id":31,"ws":true},{"text":"and","start":216,"end":219,"id":32,"ws":true},{"text":"glucose","start":220,"end":227,"id":33,"ws":true},{"text":"responses","start":228,"end":237,"id":34,"ws":true},{"text":"to","start":238,"end":240,"id":35,"ws":true},{"text":"physical","start":241,"end":249,"id":36,"ws":true},{"text":"restraint","start":250,"end":259,"id":37,"ws":true},{"text":"stress","start":260,"end":266,"id":38,"ws":true},{"text":".","start":267,"end":268,"id":39,"ws":false}],"spans":[{"start":105,"end":113,"token_start":18,"token_end":18,"label":"DRUG"},{"start":172,"end":183,"token_start":26,"token_end":26,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2505296/","_input_hash":-1406796643,"_task_hash":386005025,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Phase III , randomized , double-blind , multicenter trial comparing orteronel ( TAK-700 ) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy : ELM-PC 5 .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>double-blind</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>multicenter</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:DodgerBlue;'><i>orteronel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>TAK-700</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>progressed</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>docetaxel-based</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>ELM-PC</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Orteronel (<b style='color:Tomato;'><i>tak-700</i></b>) is an investigational, nonsteroidal, reversible, selective 17,20-lyase inhibitor. This study examined orteronel in patients with metastatic castration-resistant prostate cancer that progressed after <b style='color:Tomato;'><i>docetaxel</i></b> therapy. ### Patients And Methods In our study, 1,099 men were randomly assigned in a 2:1 schedule to receive orteronel 400 mg plus <b style='color:Tomato;'><i>prednisone</i></b> 5 mg twice daily or placebo plus <b style='color:Tomato;'><i>prednisone</i></b> 5 mg twice daily, stratified by region (Europe, North America [NA], and non-Europe/NA) and Brief Pain Inventory-Short Form worst pain score. Primary end point was overall survival (OS). Key secondary end points (radiographic progression-free survival [rPFS], \u2265 50% decrease of prostate-specific antigen [PSA50], and pain response at 12 weeks) were to undergo statistical testing only if the primary end point analysis was significant. ### results The study was unblinded after crossing a prespecified OS futility boundary. The median OS was 17.0 months versus 15.2 months with orteronel-<b style='color:Tomato;'><i>prednisone</i></b> versus placebo-<b style='color:Tomato;'><i>prednisone</i></b> (hazard ratio [HR], 0.886; 95% CI, 0.739 to 1.062; P = .190). Improved rPFS was observed with orteronel-<b style='color:Tomato;'><i>prednisone</i></b> (median, 8.3 v 5.7 months; HR, 0.760; 95% CI, 0.653 to 0.885; P < .001). Orteronel-<b style='color:Tomato;'><i>prednisone</i></b> showed advantages over placebo-<b style='color:Tomato;'><i>prednisone</i></b> in PSA50 rate (25% v 10%, P < .001) and time to PSA progression (median, 5.5 v 2.9 months, P < .001) but not pain response rate (12% v 9%; P = .128). Adverse events (all grades) were generally more frequent with orteronel-<b style='color:Tomato;'><i>prednisone</i></b>, including nausea (42% v 26%), vomiting (36% v 17%), fatigue (29% v 23%), and increased amylase (14% v 2%). ### conclusion Our study did not meet the primary end point of OS. Longer rPFS and a higher PSA50 rate with orteronel-<b style='color:Tomato;'><i>prednisone</i></b> indicate antitumor activity.","tokens":[{"text":"Phase","start":0,"end":5,"id":0,"ws":true},{"text":"III","start":6,"end":9,"id":1,"ws":true},{"text":",","start":10,"end":11,"id":2,"ws":true},{"text":"randomized","start":12,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"double-blind","start":25,"end":37,"id":5,"ws":true},{"text":",","start":38,"end":39,"id":6,"ws":true},{"text":"multicenter","start":40,"end":51,"id":7,"ws":true},{"text":"trial","start":52,"end":57,"id":8,"ws":true},{"text":"comparing","start":58,"end":67,"id":9,"ws":true},{"text":"orteronel","start":68,"end":77,"id":10,"ws":true},{"text":"(","start":78,"end":79,"id":11,"ws":true},{"text":"TAK-700","start":80,"end":87,"id":12,"ws":true},{"text":")","start":88,"end":89,"id":13,"ws":true},{"text":"plus","start":90,"end":94,"id":14,"ws":true},{"text":"prednisone","start":95,"end":105,"id":15,"ws":true},{"text":"with","start":106,"end":110,"id":16,"ws":true},{"text":"placebo","start":111,"end":118,"id":17,"ws":true},{"text":"plus","start":119,"end":123,"id":18,"ws":true},{"text":"prednisone","start":124,"end":134,"id":19,"ws":true},{"text":"in","start":135,"end":137,"id":20,"ws":true},{"text":"patients","start":138,"end":146,"id":21,"ws":true},{"text":"with","start":147,"end":151,"id":22,"ws":true},{"text":"metastatic","start":152,"end":162,"id":23,"ws":true},{"text":"castration-resistant","start":163,"end":183,"id":24,"ws":true},{"text":"prostate","start":184,"end":192,"id":25,"ws":true},{"text":"cancer","start":193,"end":199,"id":26,"ws":true},{"text":"that","start":200,"end":204,"id":27,"ws":true},{"text":"has","start":205,"end":208,"id":28,"ws":true},{"text":"progressed","start":209,"end":219,"id":29,"ws":true},{"text":"during","start":220,"end":226,"id":30,"ws":true},{"text":"or","start":227,"end":229,"id":31,"ws":true},{"text":"after","start":230,"end":235,"id":32,"ws":true},{"text":"docetaxel-based","start":236,"end":251,"id":33,"ws":true},{"text":"therapy","start":252,"end":259,"id":34,"ws":true},{"text":":","start":260,"end":261,"id":35,"ws":true},{"text":"ELM-PC","start":262,"end":268,"id":36,"ws":true},{"text":"5","start":269,"end":270,"id":37,"ws":true},{"text":".","start":271,"end":272,"id":38,"ws":false}],"spans":[{"start":80,"end":87,"token_start":12,"token_end":12,"label":"DRUG"},{"start":95,"end":105,"token_start":15,"token_end":15,"label":"DRUG"},{"start":124,"end":134,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25624429/","_input_hash":-1244978902,"_task_hash":632074452,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":12,"child":15,"head_span":{"start":80,"end":87,"token_start":12,"token_end":12,"label":"DRUG"},"child_span":{"start":95,"end":105,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Five clinical trials with temozolomide or dacarbazine have been performed in metastatic colorectal cancer ( mCRC ) with selection based on methyl-specific PCR ( MSP ) testing with modest results .","paragraph":"<h3><u>Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in\u00a0metastatic colorectal cancer patients.</u></h3>O(6)-methylguanine-DNA-methyltransferase (MGMT) is a repair protein, and its deficiency makes tumours more susceptible to the cytotoxic effect of alkylating agents. <b style='color:DodgerBlue;'><i>Five</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>temozolomide</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>performed</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>mCRC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>selection</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>methyl-specific</i></b> <b style='color:DodgerBlue;'><i>PCR</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>MSP</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>testing</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>modest</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We hypothesised that mitigated results are consequences of unspecific patient selection and that alternative methodologies for MGMT testing such as immunohistochemistry (IHC) and digital polymerase chain reaction (PCR) could enhance patient enrolment. ### Patients And Methods Formalin-fixed paraffin embedded archival tumour tissue samples from four phase II studies of <b style='color:Tomato;'><i>temozolomide</i></b> or <b style='color:Tomato;'><i>dacarbazine</i></b> in MGMT MSP-positive mCRCs were analysed by IHC for MGMT protein expression and by methyl-BEAMing (MB) for percentage of promoter methylation. Pooled data were then retrospectively analysed according to objective response rate, progression-free survival (PFS) and overall survival (OS). ### results One hundred and five patients were included in the study. Twelve had achieved partial response (PR) (11.4%), 24 stable disease (SD; 22.9%) and 69 progressive disease (PD; 65.7%). Patients with PR/SD had lower IHC scores and higher MB levels than those with PD. MGMT expression by IHC was negatively and MB levels positively associated with PFS (p\u00a0<\u00a00.001 and 0.004, respectively), but not with OS. By combining both assays, IHC low/MB high patients displayed an 87% reduction in the hazard of progression (p\u00a0<\u00a00.001) and a 77% in the hazard for death (p\u00a0=\u00a00.001). ### conclusion In mCRC selected for MGMT deficiency by MSP, IHC and MB testing improve clinical outcome to alkylating agents. Their combination could enhance patient selection in this setting.","tokens":[{"text":"Five","start":0,"end":4,"id":0,"ws":true},{"text":"clinical","start":5,"end":13,"id":1,"ws":true},{"text":"trials","start":14,"end":20,"id":2,"ws":true},{"text":"with","start":21,"end":25,"id":3,"ws":true},{"text":"temozolomide","start":26,"end":38,"id":4,"ws":true},{"text":"or","start":39,"end":41,"id":5,"ws":true},{"text":"dacarbazine","start":42,"end":53,"id":6,"ws":true},{"text":"have","start":54,"end":58,"id":7,"ws":true},{"text":"been","start":59,"end":63,"id":8,"ws":true},{"text":"performed","start":64,"end":73,"id":9,"ws":true},{"text":"in","start":74,"end":76,"id":10,"ws":true},{"text":"metastatic","start":77,"end":87,"id":11,"ws":true},{"text":"colorectal","start":88,"end":98,"id":12,"ws":true},{"text":"cancer","start":99,"end":105,"id":13,"ws":true},{"text":"(","start":106,"end":107,"id":14,"ws":true},{"text":"mCRC","start":108,"end":112,"id":15,"ws":true},{"text":")","start":113,"end":114,"id":16,"ws":true},{"text":"with","start":115,"end":119,"id":17,"ws":true},{"text":"selection","start":120,"end":129,"id":18,"ws":true},{"text":"based","start":130,"end":135,"id":19,"ws":true},{"text":"on","start":136,"end":138,"id":20,"ws":true},{"text":"methyl-specific","start":139,"end":154,"id":21,"ws":true},{"text":"PCR","start":155,"end":158,"id":22,"ws":true},{"text":"(","start":159,"end":160,"id":23,"ws":true},{"text":"MSP","start":161,"end":164,"id":24,"ws":true},{"text":")","start":165,"end":166,"id":25,"ws":true},{"text":"testing","start":167,"end":174,"id":26,"ws":true},{"text":"with","start":175,"end":179,"id":27,"ws":true},{"text":"modest","start":180,"end":186,"id":28,"ws":true},{"text":"results","start":187,"end":194,"id":29,"ws":true},{"text":".","start":195,"end":196,"id":30,"ws":false}],"spans":[{"start":26,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},{"start":42,"end":53,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27997874/","_input_hash":-261435108,"_task_hash":-743889492,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":4,"child":6,"head_span":{"start":26,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":42,"end":53,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Heparin infusion , followed by oral warfarin , is indicated for symptomatic thromboembolic disease as well as for asymptomatic patients with substantial proximal deep venous thrombosis or large pulmonary emboli .","paragraph":"<h3><u>Therapy for postoperative thromboembolic disease:  indications and treatment.</u></h3>Postarthroplasty patients develop venous thromboembolic disease because of venous stasis, hypercoaguability, and vessel wall injury.  However, most venous thrombi are nonocclusive or small and elicit few symptoms; pulmonary emboli also tend to be asymptomatic.  Noninvasive techniques to detect deep vein thrombosis do not appear to be reliable in this population, so venography may be required.  Postoperative perfusion lung scans, with comparison to preoperative perfusion scans, are the best screen for asymptomatic pulmonary emboli. <b style='color:MediumOrchid;'><i>Heparin</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>warfarin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>indicated</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>symptomatic</i></b> <b style='color:DodgerBlue;'><i>thromboembolic</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>asymptomatic</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>substantial</i></b> <b style='color:DodgerBlue;'><i>proximal</i></b> <b style='color:DodgerBlue;'><i>deep</i></b> <b style='color:DodgerBlue;'><i>venous</i></b> <b style='color:DodgerBlue;'><i>thrombosis</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>large</i></b> <b style='color:DodgerBlue;'><i>pulmonary</i></b> <b style='color:DodgerBlue;'><i>emboli</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Heparin","start":0,"end":7,"id":0,"ws":true},{"text":"infusion","start":8,"end":16,"id":1,"ws":true},{"text":",","start":17,"end":18,"id":2,"ws":true},{"text":"followed","start":19,"end":27,"id":3,"ws":true},{"text":"by","start":28,"end":30,"id":4,"ws":true},{"text":"oral","start":31,"end":35,"id":5,"ws":true},{"text":"warfarin","start":36,"end":44,"id":6,"ws":true},{"text":",","start":45,"end":46,"id":7,"ws":true},{"text":"is","start":47,"end":49,"id":8,"ws":true},{"text":"indicated","start":50,"end":59,"id":9,"ws":true},{"text":"for","start":60,"end":63,"id":10,"ws":true},{"text":"symptomatic","start":64,"end":75,"id":11,"ws":true},{"text":"thromboembolic","start":76,"end":90,"id":12,"ws":true},{"text":"disease","start":91,"end":98,"id":13,"ws":true},{"text":"as","start":99,"end":101,"id":14,"ws":true},{"text":"well","start":102,"end":106,"id":15,"ws":true},{"text":"as","start":107,"end":109,"id":16,"ws":true},{"text":"for","start":110,"end":113,"id":17,"ws":true},{"text":"asymptomatic","start":114,"end":126,"id":18,"ws":true},{"text":"patients","start":127,"end":135,"id":19,"ws":true},{"text":"with","start":136,"end":140,"id":20,"ws":true},{"text":"substantial","start":141,"end":152,"id":21,"ws":true},{"text":"proximal","start":153,"end":161,"id":22,"ws":true},{"text":"deep","start":162,"end":166,"id":23,"ws":true},{"text":"venous","start":167,"end":173,"id":24,"ws":true},{"text":"thrombosis","start":174,"end":184,"id":25,"ws":true},{"text":"or","start":185,"end":187,"id":26,"ws":true},{"text":"large","start":188,"end":193,"id":27,"ws":true},{"text":"pulmonary","start":194,"end":203,"id":28,"ws":true},{"text":"emboli","start":204,"end":210,"id":29,"ws":true},{"text":".","start":211,"end":212,"id":30,"ws":false}],"spans":[{"start":0,"end":7,"token_start":0,"token_end":0,"label":"DRUG"},{"start":36,"end":44,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10147578/","_input_hash":630344348,"_task_hash":-1639191693,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Fluoxetine and paroxetine are potent inhibitors of CYP2D6 and administration of these SSRIs reduces the clinical benefit of an anticancer drug , such as tamoxifen , by decreasing the formation of active metabolites of this drug .","paragraph":"<h3><u>Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract.</u></h3>Different antidepressant drugs are currently used for the treatment of depression in cancer patients, such as second-generation antidepressants and, recently, the extracts of Hypericum perforatum. These agents are susceptible to metabolically-based drug interactions with anticancer drugs. The aim of the present article is to provide an updated review of clinically relevant metabolic drug interactions between selected anticancer drugs and antidepressants, focusing on selective serotonin reuptake inhibitors (SSRIs) and Hypericum extract. SSRIs can cause pharmacokinetic interactions through their in vitro ability to inhibit one or more cytochrome P450 isoenzymes (CYPs). SSRIs differ in their potential for metabolic drug interactions with anticancer drugs. <b style='color:MediumOrchid;'><i>Fluoxetine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paroxetine</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>potent</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>CYP2D6</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>SSRIs</i></b> <b style='color:DodgerBlue;'><i>reduces</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>benefit</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anticancer</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>decreasing</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>formation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>active</i></b> <b style='color:DodgerBlue;'><i>metabolites</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Women with breast cancer who receive <b style='color:Tomato;'><i>paroxetine</i></b> in combination with <b style='color:Tomato;'><i>tamoxifen</i></b> are at increased risk for death. Other SSRIs, including <b style='color:Tomato;'><i>citalopram</i></b>, es<b style='color:Tomato;'><i>citalopram</i></b>, are weak or negligible inhibitors of CYP2D6 and are less likely to interact with anticancer drugs, while <b style='color:Tomato;'><i>sertraline</i></b> causes significant inhibition of this isoform only at high doses. Hypericum extract, by inducing both the CYP3A4 and the P-glycoprotein (P-gp), can reduce the plasma concentrations of different antineoplastic agents such as <b style='color:Tomato;'><i>imatinib</i></b>, <b style='color:Tomato;'><i>irinotecan</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b>, thus reducing the clinical efficacy of these drugs. Although these interactions are often predictable, the use of <b style='color:Tomato;'><i>fluoxetine</i></b>, <b style='color:Tomato;'><i>paroxetine</i></b> and Hypericum extract should be avoided in cancer patients.","tokens":[{"text":"Fluoxetine","start":0,"end":10,"id":0,"ws":true},{"text":"and","start":11,"end":14,"id":1,"ws":true},{"text":"paroxetine","start":15,"end":25,"id":2,"ws":true},{"text":"are","start":26,"end":29,"id":3,"ws":true},{"text":"potent","start":30,"end":36,"id":4,"ws":true},{"text":"inhibitors","start":37,"end":47,"id":5,"ws":true},{"text":"of","start":48,"end":50,"id":6,"ws":true},{"text":"CYP2D6","start":51,"end":57,"id":7,"ws":true},{"text":"and","start":58,"end":61,"id":8,"ws":true},{"text":"administration","start":62,"end":76,"id":9,"ws":true},{"text":"of","start":77,"end":79,"id":10,"ws":true},{"text":"these","start":80,"end":85,"id":11,"ws":true},{"text":"SSRIs","start":86,"end":91,"id":12,"ws":true},{"text":"reduces","start":92,"end":99,"id":13,"ws":true},{"text":"the","start":100,"end":103,"id":14,"ws":true},{"text":"clinical","start":104,"end":112,"id":15,"ws":true},{"text":"benefit","start":113,"end":120,"id":16,"ws":true},{"text":"of","start":121,"end":123,"id":17,"ws":true},{"text":"an","start":124,"end":126,"id":18,"ws":true},{"text":"anticancer","start":127,"end":137,"id":19,"ws":true},{"text":"drug","start":138,"end":142,"id":20,"ws":true},{"text":",","start":143,"end":144,"id":21,"ws":true},{"text":"such","start":145,"end":149,"id":22,"ws":true},{"text":"as","start":150,"end":152,"id":23,"ws":true},{"text":"tamoxifen","start":153,"end":162,"id":24,"ws":true},{"text":",","start":163,"end":164,"id":25,"ws":true},{"text":"by","start":165,"end":167,"id":26,"ws":true},{"text":"decreasing","start":168,"end":178,"id":27,"ws":true},{"text":"the","start":179,"end":182,"id":28,"ws":true},{"text":"formation","start":183,"end":192,"id":29,"ws":true},{"text":"of","start":193,"end":195,"id":30,"ws":true},{"text":"active","start":196,"end":202,"id":31,"ws":true},{"text":"metabolites","start":203,"end":214,"id":32,"ws":true},{"text":"of","start":215,"end":217,"id":33,"ws":true},{"text":"this","start":218,"end":222,"id":34,"ws":true},{"text":"drug","start":223,"end":227,"id":35,"ws":true},{"text":".","start":228,"end":229,"id":36,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":15,"end":25,"token_start":2,"token_end":2,"label":"DRUG"},{"start":153,"end":162,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21395523/","_input_hash":-1272081112,"_task_hash":-110484064,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":0,"child":24,"head_span":{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":153,"end":162,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":2,"child":24,"head_span":{"start":15,"end":25,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":153,"end":162,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#ffdaf9","label":"NEG2"}],"radio":["NEG10","NEG20"],"answer":"accept"}
{"text":"Epirubicin is an anthracyclin , analogous to doxorubicin , with a different toxicologic pattern .","paragraph":"<h3><u>A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.</u></h3>Few chemotherapeutic agents have demonstrated their efficacy in malignant mesothelioma. The cisplatin plus <b style='color:Tomato;'><i>doxorubicin</i></b> combination has one of the highest response rates. <b style='color:MediumOrchid;'><i>Epirubicin</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>anthracyclin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>analogous</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>different</i></b> <b style='color:DodgerBlue;'><i>toxicologic</i></b> <b style='color:DodgerBlue;'><i>pattern</i></b> <b style='color:DodgerBlue;'><i>.</i></b> As there are no data on the activity of the combination cisplatin plus <b style='color:Tomato;'><i>epirubicin</i></b> in malignant mesothelioma, the European Lung Cancer Working Party (ELCWP) designed a phase II study with response rate as primary objective. Sixty-nine eligible patients with malignant pleural mesothelioma were centrally registered. The majority of the patients were male (n=59), had a Karnofsky performance status of 80 or more (n=62) and presented with an epithelial histologic subtype (n=43). Median age was 62 years. In nine patients, metastases were documented at the initial work-up, mainly in bone, lung and skin. Three hundred and twenty-four cycles of chemotherapy were administered. The main toxicities were nausea and vomiting, neutropenia and alopecia. Among 63 assessable patients, response rate was 19.0% (95% confidence interval [CI] 9-29%). Median survival was 13.3 months. In multivariate analysis, poor prognostic factors for survival were neutrophil count and CALGB groups 4-6. In conclusion, cisplatin plus <b style='color:Tomato;'><i>epirubicin</i></b> appears as an effective regimen in malignant mesothelioma, with a favourable toxicity profile. However, it does not demonstrate superior activity to other active regimens in this disease.","tokens":[{"text":"Epirubicin","start":0,"end":10,"id":0,"ws":true},{"text":"is","start":11,"end":13,"id":1,"ws":true},{"text":"an","start":14,"end":16,"id":2,"ws":true},{"text":"anthracyclin","start":17,"end":29,"id":3,"ws":true},{"text":",","start":30,"end":31,"id":4,"ws":true},{"text":"analogous","start":32,"end":41,"id":5,"ws":true},{"text":"to","start":42,"end":44,"id":6,"ws":true},{"text":"doxorubicin","start":45,"end":56,"id":7,"ws":true},{"text":",","start":57,"end":58,"id":8,"ws":true},{"text":"with","start":59,"end":63,"id":9,"ws":true},{"text":"a","start":64,"end":65,"id":10,"ws":true},{"text":"different","start":66,"end":75,"id":11,"ws":true},{"text":"toxicologic","start":76,"end":87,"id":12,"ws":true},{"text":"pattern","start":88,"end":95,"id":13,"ws":true},{"text":".","start":96,"end":97,"id":14,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":45,"end":56,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16005104/","_input_hash":-1375944148,"_task_hash":-1600740243,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"A total of 460 patients were randomized into four 10-day therapeutic schemes ( 115 patients per group ): ( i ) standard OCA , omeprazole , clarithromycin and amoxicillin ; ( ii ) triple OLA , omeprazole , levofloxacin and amoxicillin ; ( iii ) sequential OACM , omeprazole plus amoxicillin for 5 days , followed by omeprazole plus clarithromycin plus metronidazole for 5 days ; and ( iv ) modified sequential OALM , using levofloxacin instead of clarithromycin .","paragraph":"<h3><u>Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.</u></h3>Helicobacter pylori eradication rates with standard triple therapy have declined to unacceptable levels. ### aim To compare <b style='color:Tomato;'><i>clarithromycin</i></b> and <b style='color:Tomato;'><i>levofloxacin</i></b> in triple and sequential first-line regimens. ### methods <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>total</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>460</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>into</i></b> <b style='color:DodgerBlue;'><i>four</i></b> <b style='color:DodgerBlue;'><i>10-day</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>schemes</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>115</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>):</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>i</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>OCA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>ii</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>triple</i></b> <b style='color:DodgerBlue;'><i>OLA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>iii</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>OACM</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>amoxicillin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>metronidazole</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>iv</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>modified</i></b> <b style='color:DodgerBlue;'><i>sequential</i></b> <b style='color:DodgerBlue;'><i>OALM</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:MediumOrchid;'><i>levofloxacin</i></b> <b style='color:DodgerBlue;'><i>instead</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>clarithromycin</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Eradication was confirmed by 13C-urea breath test. Adverse effects and compliance were assessed by a questionnaire. ### results Per protocol cure rates were: OCA (66%; 95% CI: 57-74%), OLA (82.6%; 75-89%), OACM (80.8%; 73-88%) and OALM (85.2%; 78-91%). Intention-to-treat cure rates were: OCA (64%; 55-73%), OLA (80.8%; 73-88%), OACM (76.5%; 69-85%) and OALM (82.5%; 75-89%). Eradication rates were lower with OCA than with all the other regimens (P < 0.05). No differences in compliance or adverse effects were demonstrated among treatments. ### conclusions <b style='color:Tomato;'><i>levofloxacin</i></b>-based and sequential therapy are superior to standard triple scheme as first-line regimens in a setting with high <b style='color:Tomato;'><i>clarithromycin</i></b> resistance. However, all of these therapies still have a 20% failure rate.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"total","start":2,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"460","start":11,"end":14,"id":3,"ws":true},{"text":"patients","start":15,"end":23,"id":4,"ws":true},{"text":"were","start":24,"end":28,"id":5,"ws":true},{"text":"randomized","start":29,"end":39,"id":6,"ws":true},{"text":"into","start":40,"end":44,"id":7,"ws":true},{"text":"four","start":45,"end":49,"id":8,"ws":true},{"text":"10-day","start":50,"end":56,"id":9,"ws":true},{"text":"therapeutic","start":57,"end":68,"id":10,"ws":true},{"text":"schemes","start":69,"end":76,"id":11,"ws":true},{"text":"(","start":77,"end":78,"id":12,"ws":true},{"text":"115","start":79,"end":82,"id":13,"ws":true},{"text":"patients","start":83,"end":91,"id":14,"ws":true},{"text":"per","start":92,"end":95,"id":15,"ws":true},{"text":"group","start":96,"end":101,"id":16,"ws":true},{"text":"):","start":102,"end":104,"id":17,"ws":true},{"text":"(","start":105,"end":106,"id":18,"ws":true},{"text":"i","start":107,"end":108,"id":19,"ws":true},{"text":")","start":109,"end":110,"id":20,"ws":true},{"text":"standard","start":111,"end":119,"id":21,"ws":true},{"text":"OCA","start":120,"end":123,"id":22,"ws":true},{"text":",","start":124,"end":125,"id":23,"ws":true},{"text":"omeprazole","start":126,"end":136,"id":24,"ws":true},{"text":",","start":137,"end":138,"id":25,"ws":true},{"text":"clarithromycin","start":139,"end":153,"id":26,"ws":true},{"text":"and","start":154,"end":157,"id":27,"ws":true},{"text":"amoxicillin","start":158,"end":169,"id":28,"ws":true},{"text":";","start":170,"end":171,"id":29,"ws":true},{"text":"(","start":172,"end":173,"id":30,"ws":true},{"text":"ii","start":174,"end":176,"id":31,"ws":true},{"text":")","start":177,"end":178,"id":32,"ws":true},{"text":"triple","start":179,"end":185,"id":33,"ws":true},{"text":"OLA","start":186,"end":189,"id":34,"ws":true},{"text":",","start":190,"end":191,"id":35,"ws":true},{"text":"omeprazole","start":192,"end":202,"id":36,"ws":true},{"text":",","start":203,"end":204,"id":37,"ws":true},{"text":"levofloxacin","start":205,"end":217,"id":38,"ws":true},{"text":"and","start":218,"end":221,"id":39,"ws":true},{"text":"amoxicillin","start":222,"end":233,"id":40,"ws":true},{"text":";","start":234,"end":235,"id":41,"ws":true},{"text":"(","start":236,"end":237,"id":42,"ws":true},{"text":"iii","start":238,"end":241,"id":43,"ws":true},{"text":")","start":242,"end":243,"id":44,"ws":true},{"text":"sequential","start":244,"end":254,"id":45,"ws":true},{"text":"OACM","start":255,"end":259,"id":46,"ws":true},{"text":",","start":260,"end":261,"id":47,"ws":true},{"text":"omeprazole","start":262,"end":272,"id":48,"ws":true},{"text":"plus","start":273,"end":277,"id":49,"ws":true},{"text":"amoxicillin","start":278,"end":289,"id":50,"ws":true},{"text":"for","start":290,"end":293,"id":51,"ws":true},{"text":"5","start":294,"end":295,"id":52,"ws":true},{"text":"days","start":296,"end":300,"id":53,"ws":true},{"text":",","start":301,"end":302,"id":54,"ws":true},{"text":"followed","start":303,"end":311,"id":55,"ws":true},{"text":"by","start":312,"end":314,"id":56,"ws":true},{"text":"omeprazole","start":315,"end":325,"id":57,"ws":true},{"text":"plus","start":326,"end":330,"id":58,"ws":true},{"text":"clarithromycin","start":331,"end":345,"id":59,"ws":true},{"text":"plus","start":346,"end":350,"id":60,"ws":true},{"text":"metronidazole","start":351,"end":364,"id":61,"ws":true},{"text":"for","start":365,"end":368,"id":62,"ws":true},{"text":"5","start":369,"end":370,"id":63,"ws":true},{"text":"days","start":371,"end":375,"id":64,"ws":true},{"text":";","start":376,"end":377,"id":65,"ws":true},{"text":"and","start":378,"end":381,"id":66,"ws":true},{"text":"(","start":382,"end":383,"id":67,"ws":true},{"text":"iv","start":384,"end":386,"id":68,"ws":true},{"text":")","start":387,"end":388,"id":69,"ws":true},{"text":"modified","start":389,"end":397,"id":70,"ws":true},{"text":"sequential","start":398,"end":408,"id":71,"ws":true},{"text":"OALM","start":409,"end":413,"id":72,"ws":true},{"text":",","start":414,"end":415,"id":73,"ws":true},{"text":"using","start":416,"end":421,"id":74,"ws":true},{"text":"levofloxacin","start":422,"end":434,"id":75,"ws":true},{"text":"instead","start":435,"end":442,"id":76,"ws":true},{"text":"of","start":443,"end":445,"id":77,"ws":true},{"text":"clarithromycin","start":446,"end":460,"id":78,"ws":true},{"text":".","start":461,"end":462,"id":79,"ws":false}],"spans":[{"start":126,"end":136,"token_start":24,"token_end":24,"label":"DRUG"},{"start":139,"end":153,"token_start":26,"token_end":26,"label":"DRUG"},{"start":158,"end":169,"token_start":28,"token_end":28,"label":"DRUG"},{"start":192,"end":202,"token_start":36,"token_end":36,"label":"DRUG"},{"start":205,"end":217,"token_start":38,"token_end":38,"label":"DRUG"},{"start":222,"end":233,"token_start":40,"token_end":40,"label":"DRUG"},{"start":262,"end":272,"token_start":48,"token_end":48,"label":"DRUG"},{"start":278,"end":289,"token_start":50,"token_end":50,"label":"DRUG"},{"start":315,"end":325,"token_start":57,"token_end":57,"label":"DRUG"},{"start":331,"end":345,"token_start":59,"token_end":59,"label":"DRUG"},{"start":351,"end":364,"token_start":61,"token_end":61,"label":"DRUG"},{"start":422,"end":434,"token_start":75,"token_end":75,"label":"DRUG"},{"start":446,"end":460,"token_start":78,"token_end":78,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20180787/","_input_hash":1528379475,"_task_hash":831950146,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":24,"child":26,"head_span":{"start":126,"end":136,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":139,"end":153,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":26,"child":28,"head_span":{"start":139,"end":153,"token_start":26,"token_end":26,"label":"DRUG"},"child_span":{"start":158,"end":169,"token_start":28,"token_end":28,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":36,"child":38,"head_span":{"start":192,"end":202,"token_start":36,"token_end":36,"label":"DRUG"},"child_span":{"start":205,"end":217,"token_start":38,"token_end":38,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":38,"child":40,"head_span":{"start":205,"end":217,"token_start":38,"token_end":38,"label":"DRUG"},"child_span":{"start":222,"end":233,"token_start":40,"token_end":40,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":48,"child":50,"head_span":{"start":262,"end":272,"token_start":48,"token_end":48,"label":"DRUG"},"child_span":{"start":278,"end":289,"token_start":50,"token_end":50,"label":"DRUG"},"color":"#d9fbad","label":"POS3"},{"head":50,"child":59,"head_span":{"start":278,"end":289,"token_start":50,"token_end":50,"label":"DRUG"},"child_span":{"start":331,"end":345,"token_start":59,"token_end":59,"label":"DRUG"},"color":"#d9fbad","label":"POS3"},{"head":59,"child":61,"head_span":{"start":331,"end":345,"token_start":59,"token_end":59,"label":"DRUG"},"child_span":{"start":351,"end":364,"token_start":61,"token_end":61,"label":"DRUG"},"color":"#d9fbad","label":"POS3"}],"radio":["POS11","POS21","POS31"],"answer":"accept"}
{"text":"Captopril in combination with HYZ significantly reduced BP compared with controls but T replacement increased BP and coronary collagen deposition in spite of HYZ and captopril treatment .","paragraph":"<h3><u>Testosterone increases blood pressure and cardiovascular and renal pathology in spontaneously hypertensive rats.</u></h3>The objective of this paper was to test the hypothesis that testosterone (T) raises blood pressure (BP), which is associated with increased coronary adventitial collagen, whereas the hemodynamic force of BP increases the coronary media:lumen ratio. Five treatment groups of spontaneously hypertensive rat (SHR) were established (n = 8-10 per group): controls; <b style='color:Tomato;'><i>hydralazine</i></b> (HYZ); castration; castration + HYZ; and castration + HYZ + T + <b style='color:Tomato;'><i>captopril</i></b>. At 12 weeks of age, the castrate + HYZ group was divided so that the mean BP was the same in both groups (162 mmHg). Both groups continued to receive HYZ treatment; however one group received T implants. Also, at 12 weeks of age the castrate + HYZ + T + <b style='color:Tomato;'><i>captopril</i></b> group received T implants. BP in the HYZ group was reduced compared with controls (192 mmHg vs 218 mmHg, p < 0.01). Castration lowered BP to 170 mmHg (p < 0.01) compared with controls. However, T implants increased BP by 15 mmHg (p < 0.02) in the castrate + HYZ group and by 44 mmHg in the castrate + HYZ + <b style='color:Tomato;'><i>captopril</i></b> group (p < 0.01). <b style='color:MediumOrchid;'><i>Captopril</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HYZ</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>BP</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>controls</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>T</i></b> <b style='color:DodgerBlue;'><i>replacement</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>BP</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>coronary</i></b> <b style='color:DodgerBlue;'><i>collagen</i></b> <b style='color:DodgerBlue;'><i>deposition</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>spite</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>HYZ</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>captopril</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Captopril","start":0,"end":9,"id":0,"ws":true},{"text":"in","start":10,"end":12,"id":1,"ws":true},{"text":"combination","start":13,"end":24,"id":2,"ws":true},{"text":"with","start":25,"end":29,"id":3,"ws":true},{"text":"HYZ","start":30,"end":33,"id":4,"ws":true},{"text":"significantly","start":34,"end":47,"id":5,"ws":true},{"text":"reduced","start":48,"end":55,"id":6,"ws":true},{"text":"BP","start":56,"end":58,"id":7,"ws":true},{"text":"compared","start":59,"end":67,"id":8,"ws":true},{"text":"with","start":68,"end":72,"id":9,"ws":true},{"text":"controls","start":73,"end":81,"id":10,"ws":true},{"text":"but","start":82,"end":85,"id":11,"ws":true},{"text":"T","start":86,"end":87,"id":12,"ws":true},{"text":"replacement","start":88,"end":99,"id":13,"ws":true},{"text":"increased","start":100,"end":109,"id":14,"ws":true},{"text":"BP","start":110,"end":112,"id":15,"ws":true},{"text":"and","start":113,"end":116,"id":16,"ws":true},{"text":"coronary","start":117,"end":125,"id":17,"ws":true},{"text":"collagen","start":126,"end":134,"id":18,"ws":true},{"text":"deposition","start":135,"end":145,"id":19,"ws":true},{"text":"in","start":146,"end":148,"id":20,"ws":true},{"text":"spite","start":149,"end":154,"id":21,"ws":true},{"text":"of","start":155,"end":157,"id":22,"ws":true},{"text":"HYZ","start":158,"end":161,"id":23,"ws":true},{"text":"and","start":162,"end":165,"id":24,"ws":true},{"text":"captopril","start":166,"end":175,"id":25,"ws":true},{"text":"treatment","start":176,"end":185,"id":26,"ws":true},{"text":".","start":186,"end":187,"id":27,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":30,"end":33,"token_start":4,"token_end":4,"label":"DRUG"},{"start":166,"end":175,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11055476/","_input_hash":-1679930929,"_task_hash":983882790,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":0,"child":4,"head_span":{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":30,"end":33,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Targeted therapy was administered to match the P1K3CA , c-MET , and SPARC and COX2 aberrations with sirolimus+ crizotinib and abraxane+ celecoxib .","paragraph":"<h3><u>Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.</u></h3>Despite advances in molecular medicine over recent decades, there has been little advancement in the treatment of osteosarcoma. We performed comprehensive molecular profiling in two cases of metastatic and chemotherapy-refractory osteosarcoma to guide molecularly targeted therapy. ### Patients And Methods Hybridization capture of >300 cancer-related genes plus introns from 28 genes often rearranged or altered in cancer was applied to >50 ng of DNA extracted from tumor samples from two patients with recurrent, metastatic osteosarcoma. The DNA from each sample was sequenced to high, uniform coverage. Immunohistochemical probes and morphoproteomics analysis were performed, in addition to fluorescence in situ hybridization. All analyses were performed in CLIA-certified laboratories. Molecularly targeted therapy based on the resulting profiles was offered to the patients. Biomedical analytics were performed using QIAGEN's Ingenuity\u00ae Pathway Analysis. ### results In Patient #1, comprehensive next-generation exome sequencing showed MET amplification, PIK3CA mutation, CCNE1 amplification, and PTPRD mutation. Immunohistochemistry-based morphoproteomic analysis revealed c-Met expression [(p)-c-Met (Tyr1234/1235)] and activation of mTOR/AKT pathway [IGF-1R (Tyr1165/1166), p-mTOR [Ser2448], p-Akt (Ser473)] and expression of SPARC and COX2. <b style='color:DodgerBlue;'><i>Targeted</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>match</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>P1K3CA</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>c-MET</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>SPARC</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>COX2</i></b> <b style='color:DodgerBlue;'><i>aberrations</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>sirolimus+</i></b> <b style='color:MediumOrchid;'><i>crizotinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>abraxane+</i></b> <b style='color:MediumOrchid;'><i>celecoxib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In Patient #2, aberrations included NF2 loss in exons 2-16, PDGFR\u03b1 amplification, and TP53 mutation. This patient was enrolled on a clinical trial combining targeted agents tem<b style='color:Tomato;'><i>sirolimus</i></b>, <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b>, to match NF2, PDGFR\u03b1 and TP53 aberrations. Both the patients did not benefit from matched therapy. ### conclusions Relapsed osteosarcoma is characterized by complex signaling and drug resistance pathways. Comprehensive molecular profiling holds great promise for tailoring personalized therapies for cancer. Methods for such profiling are evolving and need to be refined to better assist clinicians in making treatment decisions based on the large amount of data that results from this type of testing. Further research in this area is warranted.","tokens":[{"text":"Targeted","start":0,"end":8,"id":0,"ws":true},{"text":"therapy","start":9,"end":16,"id":1,"ws":true},{"text":"was","start":17,"end":20,"id":2,"ws":true},{"text":"administered","start":21,"end":33,"id":3,"ws":true},{"text":"to","start":34,"end":36,"id":4,"ws":true},{"text":"match","start":37,"end":42,"id":5,"ws":true},{"text":"the","start":43,"end":46,"id":6,"ws":true},{"text":"P1K3CA","start":47,"end":53,"id":7,"ws":true},{"text":",","start":54,"end":55,"id":8,"ws":true},{"text":"c-MET","start":56,"end":61,"id":9,"ws":true},{"text":",","start":62,"end":63,"id":10,"ws":true},{"text":"and","start":64,"end":67,"id":11,"ws":true},{"text":"SPARC","start":68,"end":73,"id":12,"ws":true},{"text":"and","start":74,"end":77,"id":13,"ws":true},{"text":"COX2","start":78,"end":82,"id":14,"ws":true},{"text":"aberrations","start":83,"end":94,"id":15,"ws":true},{"text":"with","start":95,"end":99,"id":16,"ws":true},{"text":"sirolimus+","start":100,"end":110,"id":17,"ws":true},{"text":"crizotinib","start":111,"end":121,"id":18,"ws":true},{"text":"and","start":122,"end":125,"id":19,"ws":true},{"text":"abraxane+","start":126,"end":135,"id":20,"ws":true},{"text":"celecoxib","start":136,"end":145,"id":21,"ws":true},{"text":".","start":146,"end":147,"id":22,"ws":false}],"spans":[{"start":100,"end":110,"token_start":17,"token_end":17,"label":"DRUG"},{"start":111,"end":121,"token_start":18,"token_end":18,"label":"DRUG"},{"start":126,"end":135,"token_start":20,"token_end":20,"label":"DRUG"},{"start":136,"end":145,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26510912/","_input_hash":84312616,"_task_hash":1485475965,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":17,"child":18,"head_span":{"start":100,"end":110,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":111,"end":121,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":20,"child":21,"head_span":{"start":126,"end":135,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":136,"end":145,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":[],"answer":"accept"}
{"text":"Aspirin in antiinflammatory doses has been associated with gastrointestinal bleeding , and the bleeding potential of even 75 mg aspirin has been established .","paragraph":"<h3><u>Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis.</u></h3>Low-dose <b style='color:Tomato;'><i>aspirin</i></b> has been recommended for primary and secondary prevention of myocardial infarction and for the maintenance of aortocoronary bypass patency. Doses as low as 75 mg/day significantly lessen the risk of stroke or death in patients who experience cerebrovascular and ischemic events. <b style='color:MediumOrchid;'><i>Aspirin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>antiinflammatory</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>gastrointestinal</i></b> <b style='color:DodgerBlue;'><i>bleeding</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>bleeding</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>even</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:MediumOrchid;'><i>aspirin</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>established</i></b> <b style='color:DodgerBlue;'><i>.</i></b> I assessed the role of low-dose <b style='color:Tomato;'><i>aspirin</i></b> in gastrointestinal bleeding by combining the results of nine studies that dealt with the prevention of ischemic, thromboembolic, or cerebrovascular events. The combination of the results showed that the occurrence of bleeding was 1.5 times higher in patients treated with low-dose <b style='color:Tomato;'><i>aspirin</i></b> in doses of 75-325 mg/day as compared with placebo (odds ratio 1.52; 95% CI 1.32-1.75). The monthly probability of gastrointestinal bleeding per 1,000 patients treated with low-dose <b style='color:Tomato;'><i>aspirin</i></b> ranged between 0 and 2.1.","tokens":[{"text":"Aspirin","start":0,"end":7,"id":0,"ws":true},{"text":"in","start":8,"end":10,"id":1,"ws":true},{"text":"antiinflammatory","start":11,"end":27,"id":2,"ws":true},{"text":"doses","start":28,"end":33,"id":3,"ws":true},{"text":"has","start":34,"end":37,"id":4,"ws":true},{"text":"been","start":38,"end":42,"id":5,"ws":true},{"text":"associated","start":43,"end":53,"id":6,"ws":true},{"text":"with","start":54,"end":58,"id":7,"ws":true},{"text":"gastrointestinal","start":59,"end":75,"id":8,"ws":true},{"text":"bleeding","start":76,"end":84,"id":9,"ws":true},{"text":",","start":85,"end":86,"id":10,"ws":true},{"text":"and","start":87,"end":90,"id":11,"ws":true},{"text":"the","start":91,"end":94,"id":12,"ws":true},{"text":"bleeding","start":95,"end":103,"id":13,"ws":true},{"text":"potential","start":104,"end":113,"id":14,"ws":true},{"text":"of","start":114,"end":116,"id":15,"ws":true},{"text":"even","start":117,"end":121,"id":16,"ws":true},{"text":"75","start":122,"end":124,"id":17,"ws":true},{"text":"mg","start":125,"end":127,"id":18,"ws":true},{"text":"aspirin","start":128,"end":135,"id":19,"ws":true},{"text":"has","start":136,"end":139,"id":20,"ws":true},{"text":"been","start":140,"end":144,"id":21,"ws":true},{"text":"established","start":145,"end":156,"id":22,"ws":true},{"text":".","start":157,"end":158,"id":23,"ws":false}],"spans":[{"start":0,"end":7,"token_start":0,"token_end":0,"label":"DRUG"},{"start":128,"end":135,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7560825/","_input_hash":-1674945343,"_task_hash":1558867634,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"EURAMOS-1 results do not support the addition of ifosfamide and etoposide to postoperative chemotherapy in patients with poorly responding osteosarcoma because its administration was associated with increased toxicity without improving event-free survival .","paragraph":"<h3><u>Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.</u></h3>We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (\u226510% viable tumour) improved event-free survival in patients with high-grade osteosarcoma. ### methods EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation. Patients were randomly assigned (1:1) to receive either postoperative cisplatin, <b style='color:Tomato;'><i>doxorubicin</i></b>, and <b style='color:Tomato;'><i>methotrexate</i></b> (MAP) or MAP plus <b style='color:Tomato;'><i>ifosfamide</i></b> and <b style='color:Tomato;'><i>etoposide</i></b> (MAPIE) using concealed permuted blocks with three stratification factors: trial group; location of tumour (proximal femur or proximal humerus vs other limb vs axial skeleton); and presence of metastases (no vs yes or possible). The MAP regimen consisted of cisplatin 120 mg/m ### findings Between April 14, 2005, and June 30, 2011, 2260 patients were registered from 325 sites in 17 countries. 618 patients with poor response were randomly assigned; 310 to receive MAP and 308 to receive MAPIE. Median follow-up was 62\u00b71 months (IQR 46\u00b76-76\u00b76); 62\u00b73 months (IQR 46\u00b79-77\u00b71) for the MAP group and 61\u00b71 months (IQR 46\u00b75-75\u00b73) for the MAPIE group. 307 event-free survival events were reported (153 in the MAP group vs 154 in the MAPIE group). 193 deaths were reported (101 in the MAP group vs 92 in the MAPIE group). Event-free survival did not differ between treatment groups (hazard ratio [HR] 0\u00b798 [95% CI 0\u00b778-1\u00b723]); hazards were non-proportional (p=0\u00b70003). The most common grade 3-4 adverse events were neutropenia (268 [89%] patients in MAP vs 268 [90%] in MAPIE), thrombocytopenia (231 [78% in MAP vs 248 [83%] in MAPIE), and febrile neutropenia without documented infection (149 [50%] in MAP vs 217 [73%] in MAPIE). MAPIE was associated with more frequent grade 4 non-haematological toxicity than MAP (35 [12%] of 301 in the MAP group vs 71 [24%] of 298 in the MAPIE group). Two patients died during postoperative therapy, one from infection (although their absolute neutrophil count was normal), which was definitely related to their MAP treatment (specifically <b style='color:Tomato;'><i>doxorubicin</i></b> and cisplatin), and one from left ventricular systolic dysfunction, which was probably related to MAPIE treatment (specifically <b style='color:Tomato;'><i>doxorubicin</i></b>). One suspected unexpected serious adverse reaction was reported in the MAP group: bone marrow infarction due to <b style='color:Tomato;'><i>methotrexate</i></b>. ### interpretation <b style='color:DodgerBlue;'><i>EURAMOS-1</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>do</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>support</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ifosfamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>postoperative</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>poorly</i></b> <b style='color:DodgerBlue;'><i>responding</i></b> <b style='color:DodgerBlue;'><i>osteosarcoma</i></b> <b style='color:DodgerBlue;'><i>because</i></b> <b style='color:DodgerBlue;'><i>its</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>associated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>without</i></b> <b style='color:DodgerBlue;'><i>improving</i></b> <b style='color:DodgerBlue;'><i>event-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The results define standard of care for this population. New strategies are required to improve outcomes in this setting. ### funding UK Medical Research Council, National Cancer Institute, European Science Foundation, St Anna Kinderkrebsforschung, Fonds National de la Recherche Scientifique, Fonds voor Wetenschappelijk Onderzoek-Vlaanderen, Parents Organization, Danish Medical Research Council, Academy of Finland, Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, Federal Ministry of Education and Research, Semmelweis Foundation, ZonMw (Council for Medical Research), Research Council of Norway, Scandinavian Sarcoma Group, Swiss Paediatric Oncology Group, Cancer Research UK, National Institute for Health Research, University College London Hospitals, and Biomedical Research Centre.","tokens":[{"text":"EURAMOS-1","start":0,"end":9,"id":0,"ws":true},{"text":"results","start":10,"end":17,"id":1,"ws":true},{"text":"do","start":18,"end":20,"id":2,"ws":true},{"text":"not","start":21,"end":24,"id":3,"ws":true},{"text":"support","start":25,"end":32,"id":4,"ws":true},{"text":"the","start":33,"end":36,"id":5,"ws":true},{"text":"addition","start":37,"end":45,"id":6,"ws":true},{"text":"of","start":46,"end":48,"id":7,"ws":true},{"text":"ifosfamide","start":49,"end":59,"id":8,"ws":true},{"text":"and","start":60,"end":63,"id":9,"ws":true},{"text":"etoposide","start":64,"end":73,"id":10,"ws":true},{"text":"to","start":74,"end":76,"id":11,"ws":true},{"text":"postoperative","start":77,"end":90,"id":12,"ws":true},{"text":"chemotherapy","start":91,"end":103,"id":13,"ws":true},{"text":"in","start":104,"end":106,"id":14,"ws":true},{"text":"patients","start":107,"end":115,"id":15,"ws":true},{"text":"with","start":116,"end":120,"id":16,"ws":true},{"text":"poorly","start":121,"end":127,"id":17,"ws":true},{"text":"responding","start":128,"end":138,"id":18,"ws":true},{"text":"osteosarcoma","start":139,"end":151,"id":19,"ws":true},{"text":"because","start":152,"end":159,"id":20,"ws":true},{"text":"its","start":160,"end":163,"id":21,"ws":true},{"text":"administration","start":164,"end":178,"id":22,"ws":true},{"text":"was","start":179,"end":182,"id":23,"ws":true},{"text":"associated","start":183,"end":193,"id":24,"ws":true},{"text":"with","start":194,"end":198,"id":25,"ws":true},{"text":"increased","start":199,"end":208,"id":26,"ws":true},{"text":"toxicity","start":209,"end":217,"id":27,"ws":true},{"text":"without","start":218,"end":225,"id":28,"ws":true},{"text":"improving","start":226,"end":235,"id":29,"ws":true},{"text":"event-free","start":236,"end":246,"id":30,"ws":true},{"text":"survival","start":247,"end":255,"id":31,"ws":true},{"text":".","start":256,"end":257,"id":32,"ws":false}],"spans":[{"start":49,"end":59,"token_start":8,"token_end":8,"label":"DRUG"},{"start":64,"end":73,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27569442/","_input_hash":1532611365,"_task_hash":-785120694,"_session_id":"drug_drug_pilot_split2c-dadnyo","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":49,"end":59,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":64,"end":73,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG10"],"answer":"accept"}
